Press CTRL + F from keyboard to search
| No | TEST CODE |
TEST NAME | Method | SPECIMEN | TEMP. | Performing | Usage |
| 414 | 9206RFX | (ANA Blot) ANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGEN (Anti MI,Anti KU,SMITH ABS, nRNP/SM,SS-A (Ro) , SS-B (La), Anti Histone Abs, Anti Centromerem abs, SCL-70 IGG,JO1 – IGG Abs,PM-Scl ,PCNA,nucleosomes,ribosomal P-protein & AMA M2) | IMMUNO FLUORESCENT ASSAY/ IMMUNOBLOT |
SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS OR SHIPPED) | India | ANA is useful in the diagnosis of patients with autoimmune diseases such as SLE, Mixed connective tissue disease, Rheumatoid arthritis, Sjogren’s syndrome, Progressive systemic sclerosis and CREST syndrome. The incidence of low titre ANA positivity increases with age in normal individuals. many drugs like Hydralazine and Procainamide may induce ANA production. |
| 415 | 8825 | 1,25 DIHYDROXY VITAMIN D | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C 14 days ; >14 days -20°C | India | 1,25Dihydroxy vitamin D plays a primary role in the maintenance of calcium homeostasis. A part of circulating 25hydroxy vitamin D is converted to 1,25dihydroxy form in the kidneys. Patients who present with hypercalcemia, hyperphosphatemi a and low PTH may suffer from unregulated conversion of vitamin D from monohydroxy to dihydroxy form as is seen in granulomatous diseases like Sarcoidosis and nutritionally induced Hypervitaminosis D. |
| 416 | 3311 | 17-ALPHA HYDROXYPROGESTERONE (NEONATAL SCREENING) | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 days) | India | 17 OHP is elevated in patients with Congenital Adrenal Hyperplasia. |
| 417 | 3190 | 17-ALPHA-HYDROXYPROGESTERONE | ENZYME IMMUNO ASSAY | SERUM | F | India | 17 OHP along with Cortisol and Androstenedione constitutes the best screening test for Congenital adrenal hyperplasia caused by either 11 or 21 hydroxylase deficiency. It is also useful to evaluate females with hirsutism and infertility. |
| 418 | 9353 | 17-HYDROXYPROGESTERONE (17-OHP) > 1 MONTH | FEIA | Dried blood spots | Ambient | India | To screen for, detect, and monitor treatment for congenital adrenal hyperplasia (CAH); sometimes to help rule out other conditions with similar symptoms |
| 419 | 3313 | 17-KETOSTEROIDS,URINE | CHROMATOGRAPHY / SPECTROPHOTOMETRY | URINE 24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION.( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY.) | 2-8°C (15 days) | India | 17ketosteroids (17KS) are derived from adrenal cortex and testes and are excreted in the urine. These are metabolites of adrenal and gonadal androgenic steroids. In men, 6070% & in women nearly 100% of these are produced in the adrenal cortex. They are useful in evaluating gonadal and adrenal disorders. |
| 420 | 6027F | 1p/19q Deletions, FISH | FISH | BIOPSIES SOULD BE FIXED FOR 24-48 HOURS IN 10% BUFFERED FORMALIN & EMBEDDED IN PARAFFIN. TISSUE SHOULD BE 4 MICRONS THICK & PLACED ON POSITIVELY CHARGED SLIDES. 3 SLIDES / SAMPLES CONTAINING MALIGNANT TISSUE. * TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* clinical details in specified format | A | India | Oligodendroglioma tumors exhibit simultaneous deletions of 1p and 19q in two thirds of cases. These deletions have been associated with a favorableresponse to chemotherapy with long survival. |
| 421 | 8823L | 25 HYDROXY VITAMIN D GOLD, LCMS | LCMSMS | 1] Require SERUM sample (to be collected in plain tube not in gel tube) preferably fasting upto 12-14 hrs. 2] Doctors Name and Contact details+ Clinical history of the patient is mandatory. 3] Sample should to be stored to refrigerate or freeze immediately. |
Refrigerated/Frozen | India | LCMS/MS is the gold standard technique for accurate quantification of vitamin D2 & D3. It also measures 3 epi 25 hydroxy vitamin D3 to increase accuracy of the |
| 422 | 9952 | 5-HYDROXY INDOLE ACETIC ACID | ENZYME IMMUNOASSAY | 24HRS URINE TO BE STRICTLY COLLECTED IN 15ML OF 6N HCL. * WHILE COLLECTING 24HRS URINE SPECIMEN, THE CONTAINER SHOULD BE KEPT IN DARK THROUGHOUT THE COLLECTION. TO AVOID EXPOSURE TO LIGHT, THE 20ML ALIQUOT FROM THE COLLECTED 24HRS URINE SAMPLE HAS TO BE WRAPPED IN ALUMINUM FOIL.DO NOT CONSUME AVOCADOS, BANANAS,COFFEE, PLUMS, PINEAPPLE, TOMATOES, WALNUTS AS WELL AS SOME MEDICATIONS(e.g. ASPIRIN, CORTICOTROPIN, MAO INHIBITORS, PHENAZETIN, CATECHOLAMINES, RESERPIN, NICOTIN) 48HRS PRIOR TO THE COLLECTION OF THE SPECIMEN.MENTION CLINICAL DETAILS(PATIENT CLINICAL HISTORY, CT SCAN,USG & MEDICATION OF THE PATIENT ON THE REQ FORM.. | FROZEN STRICTLY | India | 5HIAA is a major metabolite of Serotonin excreted in urine. Normally 13% of dietary Tryptophan is metabolized to serotonin but in patients with Intestinal Carcinoid syndrome, as much as 60% Tryptophan is converted to Serotonin. |
| 423 | 1674BB | ABCD3 | FLOW CYTOMETRY | WB- EDTA | WB- HEPARIN | WB / SMEARS + CLINICAL HISTORY(WB to reach within 48 hrs) | A | India | CD3 is an antigen expressed by T lymphocytes. There are two subpopulations of CD3 positive cells in the peripheral blood the T helper cells (CD3/CD4) and the T suppressor cells (CD3/CD8). |
| 424 | 7833 | ABPA MINI panel(Allergic bronchopulmonary aspergillosis) | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | To detect ASPERGILLUS. FUMIGATUS – SPECIFIC IGG] and ALLERGEN – ASPERGILLUS FUMIGATUS in serum to aid in diagnosis of Allergic bronchopulmonary aspergillosis |
| 425 | 7869 | ABPA SCREEN (TOTAL IGE, SPECIFIC IGE AF) | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Screening test for Allergic bronchopulmonary aspergillosis. To MEASURE Total IgE AND TO DETECT ALLERGEN – ASPERGILLUS FUMIGATUS in serum |
| 426 | 5110N | ABSOLUTE NEUTROPHIL COUNT | AUTOMATED CELL COUNTER / MICROSCOPY | WB-EDTA + DIRECT BLOOD SMEAR | A | India | Absolute neutrophil count is increased in infections, a variety of inflammatory disorders, cytokine therapy and some myeloid neoplasms. Neutropenia can be seen with various medications, including chemotherapy, toxins, bone marrow replacement (eg., metastatic tumor, granulomas), myelodysplastic syndromes, autoimmune disorders, and congenital disorders. Generally, the degree of neutropenia defines the patient’s risk of infection. |
| 427 | 1336 | ACETONE, URINE | CHEMICAL ANALYSIS | URINE -RANDOM URINE WITHOUT PRESERVATIVE | 2-8°C (3 days); F (>3 days) | India | • Ketone levels are increased in patients with starvation, anorexia, vomiting and fever. Blood ketone levels are used as markers to determine the severity of acute illness. • Presence of ketones in blood and urine (ketoacidosis) are indicative of type 1 diabetes. Ketone levels are used to monitor the insulin dosage in type 1 diabetes patients. The development of ketonuria within 24 hours after insulin withdrawal usually indicates a poor response to the oral hypoglycemic agents. • Ketone bodies help in differentiating Diabetic ketoacidosis and Hyperglycemic Hyperosmolar Syndrome (absence of significant ketoacidosis). During pregnancy, early detection of ketonuria is essential because ketoacidosis is a factor associated with intrauterine death. |
| 428 | 5559 | ACHR-ACETYL CHOLINE RECEPTOR ANTIBODIES(SERUM,EIA) | EIA | SERUM FROZEN | F | India | #N/A |
| 429 | 1464BA | ACID FAST BACILLI CULTURE ( BLOOD & / BONE MARROW) | BACTEC METHOD | BLOOD/ BONE MARROW INOCULATED IN MYCO F LYTIC BACTEC BOTTLE | A | India | Rapid automated culture allows the early recovery of Mycobacteria within 7 days as compared to conventional culture which takes 46 weeks. Identification of Mycobacteria helps in proper selection of Antitubercular drugs. |
| 430 | 1464EP | ACID FAST BACILLI CULTURE: MGIT | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | ANY SPECIMEN of Non-Pulmonary Origin (except Blood & Bone marrow) IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE / SWABS NOT ACCEPTED | R | India | To help diagnose Mycobacterium tuberculosis complex and drug susceptibility testing if positive |
| 431 | 1465 | ACID FAST BACILLI CULTURE: MGIT(WITHOUT IDENTIFICATION) | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | ANY SPECIMEN (EXCEPT BLOOD/BONEMARROW) IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE /SWABS ARE NOT ACCEPTED | R | India | To help diagnose Mycobacterium tuberculosis complex |
| 432 | 2419 | ACID FAST BACILLI STAIN AND CULTURE | CULTURE- LJ | ANY SPECIMEN (EXCEPT BLOOD/BONEMARROW) IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE /SWABS ARE NOT ACCEPTED | R | India | To help diagnose the infection caused by Mycobacterium Tuberculosis complex |
| 433 | 1464S | ACID FAST BACILLI, STAIN & MGIT CULTURE (3 SAMPLES) | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | SPUTUM/ URINE- STERILE CONTAINER | R | India | To help diagnose the infection caused by Mycobacterium Tuberculosis complex |
| 434 | 1464U | ACID FAST BACILLI, STAIN & MGIT CULTURE (5 SAMPLES) | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | SPUTUM/ URINE- STERILE CONTAINER | R | India | To help diagnose the infection caused by Mycobacterium Tuberculosis complex |
| 435 | 5901 | ACTIVATED PROTEIN C RESISTANCE | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C *(DOUBLE CENTRIFUGED PLASMA)* with CLINICAL HISTORY | F (To be F immediately at -20°c & transported in dry ice) | India | Vitro test for detection of defects of the Protein C pathway. |
| 436 | 9315 | ACTIVE VITAMIN B12 (HOLOTRANSCOBALMIN) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (3days), > 3 DAYS (- 20°C_ | India | Vitamin B12 (cobalamin) in serum is bound to two proteins: transcobalamin (TC) and haptocorrin (HC). The transcobalaminvit amin B12 complex is called holotranscobalami n (HoloTC). HoloTC contains the biologically available cobalamin as only HoloTC promotes the uptake of cobalamin by all cells via specific receptors. In comparison, approximately 80% of the cobalamin carried by HC is considered metabolically inert because no cellular receptors exist, with the exception of receptors found in the liver. The shorter circulating halflife of HoloTC compared to holohaptocorrin (HoloHC) makes a decrease of HoloTC one of the earliest markers of cobalamin deficiency. |
| 437 | 7756 | ACUTE HEPATITIS VIRUS EVALUATION I (HCV ABS, HEV IgM, HBsAg, HAV IgM, HBcore IgM) | Chemiluminescent Microparticle Immunoassay (CMIA) / ENZYME IMMUNOASSAY | SERUM | 2-8°C (7 days) ,>7 days -20°C | India | Acute Viral Hepatitis is a systemic infection affecting the liver predominantly. Hepatitis A , B, C & E are common causes of Acute Viral Hepatitis producing clinically similar illnesses ranging from asymptomatic to fatal acute infections. Subclinical persistent infections of Hepatitis B & C virus may progress to Chronic liver disease with Cirrhosis and even Hepatocellular carcinoma. |
| 438 | 7755 | ACUTE HEPATITIS VIRUS EVALUATION II (HCV ABS, HEV IgM / IgG, HBsAg, HAV IgM, HBeAg, HBeAb) | Chemiluminescent Microparticle Immunoassay (CMIA) / ENZYME IMMUNOASSAY | SERUM | 2-8°C (7 days) ,>7 days -20°C | India | Acute Viral Hepatitis is a systemic infection affecting the liver predominantly. Hepatitis A , B, C & E are common causes of Acute Viral Hepatitis producing clinically similar illnesses ranging from asymptomatic to fatal acute infections. Subclinical persistent infections of Hepatitis B & C virus may progress to Chronic liver disease with Cirrhosis and even Hepatocellular carcinoma. |
| 439 | 7757 | ACUTE HEPATITIS VIRUS EVALUATION III (HSV IgM, CMV IgM, EBV (EA) IgG, VZV IgM) | Enzyme Linked Immnunosorbent assay /Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (2 days) ,>2 days -20°C | India | Viral diseases due to Cytomegalovirus, Herpes simplex, Varicella zoster and Epstein barr virus may share certain clinical features with Viral hepatitis and cause elevations in serum aminotransferase levels. Less commonly serum bilirubin levels may also rise. |
| 440 | 1047 | ACUTE MYELOID LEUKEMIA (AML) PANEL (CD7, CD19, CD13, CD14, CD15, CD33, CD34, CD117, CD41, CD61, GLYCOPHORIN A, HLA-DR) | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS DIRECT SMEARS + CLINICAL HISTORY (MANDATORY) | A | India | To help diagnose ACUTE MYELOID LEUKEMIA |
| 441 | 3131 | ADENOSINE DEAMINASE (ADA) | SPECTROPHOTOMETRY | SERUM, PLEURAL FLUID, ASCITIC FLUID/PERITONEAL FLUID, CSF, PERICARDIAL FLUID, SYNOVIAL FLUID & OTHER BODY FLUIDS (EXCEPT URINE, SPUTUM, STOOL,SEMENS & MENSTRUAL BLOOD). + CLINICAL HISTORY MANDATORY | F | India | This assay is useful for evaluation of severe combined Immunodeficiency syndrome and Hemolytic anemia of obscure cause. ADA is increased in cases of Tuberculosis in approximaterly 20% of cases. |
| 442 | 9921I | ADENOVIRUS IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 days); -20°C (>5 days) | India | A four-fold or greater increase in Adenovirus specific IgG titre, between acute and convalescent sera taken 1-3 weeks apart, can be considered diagnostic for infection. |
| 443 | 9924I | ADENOVIRUS IgM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 days); -20°C (>5 days) | India | Presence of IgM indicates recent infection by Adenovirus |
| 444 | 7589 | ADENOVIRUS PCR | POLYMERASE CHAIN REACTION | SWABS: (ORAL, EYE, NASAL) / RESPIRATORY FLUIDS | A | India | This test is a broad based DNA PCR assay targeting conserved regions (including all serotypes) for detection of Adenovirus from various clinical specimens. |
| 445 | 8718 | ADH-ANTI DIURETIC HORMONE (VASOPRESSIN), PLASMA | ELISA | Plasma EDTA FROZEN | F | India | Increased ADH is seen in hypovolemia, hypertension,severe physical stress (eg. trauma, pain, prolonged mechanical ventilation, surgery),SIADH (syndrome of inappropriate ADH secretion), Central nervous system tumours or infection and pneumonia. Decreased levels of ADH are noted in diabetes insipidus and psychogenic water intoxication. Plasma ADH levels, especially below 1.62 pg /ml need to be correlated with clinical findings and other associated tests like plasma & urine osmolality, serum electrolytes and renal function tests for diagnosis & characterisation of Diabetes insipidus. |
| 446 | 9938RD | ADRB2 GENOTYPING FOR B-2-AGONIST RESPONSIVENESS | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Responsiveness ADRB2 gene on chromosome 5q31- 33, has been linked to asthma pheno-types. SNPs and/ or haplotypes in the ADRB2 gene have been associated with the response to inhaled ß- 2 -agonists, asthma severity and other asthma- related phenotypes. Due to temporal changes in the clinical status of patients (such as viral infections and allergy exposures) as well as due to the recognized genetic variability between individuals, there are complexities in the treatment and management of Asthma patients. Recently research based genotypic test for predicting the response to the short acting ß- 2 -agonists have been shown to be useful for identifying patients for earlier intervention with anti-inflammatory agents as an alternative to regularly scheduled ß- 2 -agonists. |
| 447 | 9951U | ADRENALIN URINE | ENZYME IMMUNOASSAY | 24HRS URINE (Preservative:15 – 20ML 6N HCL) . (The patient should not consume Vitamin B, COFFEE AND BANANAS, 48hrs prior to the collection of the specimen.It is advisable to discontinue all medications, alpha methyldopa, MAO & COMT Inhibitors as well as medications related to Hypertension should be discontinued atleast 72 hrs prior to specimen collection.If medications takenshould be STrictly on the advise of the referring physician, the same should be mentioned.Please freeze the specimen immediately after collection. CLINICAL DETAILS(Patient’s clinical history, CT SCAN , USG & MEDICATION MANDATORY) mention 24 hrs urine volume | F FROZEN STRICTLY | India | Adrenalin measurements are indicated in autonomic neuropathy. The concentrations of Adrenalin and its metabolites in urine are of clinical interest especially in The diagnosis of pheochromocytoma, neuroblastoma and ganglioneuroma.K53 |
| 448 | 9951P | ADRENALIN, PLASMA | ENZYME IMMUNOASSAY | THE BLOOD SAMPLE (EDTA) SHOULD BE STORED AT 2-8 DEGREE CELCIUS UNTIL CENTRIFUGED TO SEPARATE THE PLASMA WITHIN 2 HOURS AFTER BLOOD COLLECTION.DO NOT CONSUME VITAMIN B ,COFFEE, BANANAS, ALPHA -METHYDOPA,MOA AND COMT INHIBITORSAS WELL AS MEDICATION RELATED TO HYPERTENSION FOR AT LEAST 72 HRS PRIOR TO THE COLLECTION OF THE SPECIMEN.MENTION CLINICAL DETAILS(PATIENT CLINICAL HISTORY, CT SCAN,USG & MEDICATION) OF THE PATIENT ON THE REQ FORM.. | Separated Plasma to be send FROZEN STRICTLY | India | The concentrations of adrenalin and its metabolites are of clinical interest especially in the diagnosis of pheochromocytoma, neuroblastoma and ganglioneuroma. |
| 449 | Z161K | ADRENOCORTICOTROPIC HORMONE (ACTH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK (Site of biopsy & Clinical details mandatory)MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Aids in the classification of pituitary adenomas and neoplasms with ectopic hormone production |
| 450 | 3103 | ADRENOCORTICOTROPIC HORMONE (ACTH) STIMULATION TEST – 1 HOUR | CHEMILUMINESCENCE | 250ug Synacthen IM/IV 3 Serum Samples Collected 1/2 hr. apart Basal (before drug) , 30min, 60min (Freeze the specimen immediately after separation) + Clinical History | 2-8°C (48 hrs); F (>48 hrs) | India | The ACTH stimulation test measures the functional integrity of the adrenal glands and their sensitivity to ACTH stimulation. The test also indirectly assesses hypothalamic and pituitary function. |
| 451 | AM5654 | AFB SUSCEPTIBILITY : Amikacin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Amikacin |
| 452 | CA5654 | AFB SUSCEPTIBILITY : Capreomycin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Capreomycin |
| 453 | CLO5654 | AFB SUSCEPTIBILITY : CLOFAZIMINE | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for CLOFAZIMINE |
| 454 | ET5654 | AFB SUSCEPTIBILITY : Ethambutol | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Ethambutol |
| 455 | EH5654 | AFB SUSCEPTIBILITY : Ethionamide | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Ethionamide |
| 456 | IS5654 | AFB SUSCEPTIBILITY : Isoniazid | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Isoniazid |
| 457 | KA5654 | AFB SUSCEPTIBILITY : Kanamycin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Kanamycin |
| 458 | LV5654 | AFB SUSCEPTIBILITY : Levofloxacin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Levofloxacin |
| 459 | LZ5654 | AFB SUSCEPTIBILITY : LINEZOLID | BACTEC MGIT-960 METHOD | CULTURE | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for LINEZOLID |
| 460 | MX5654 | AFB SUSCEPTIBILITY : MOXIFLOXACIN | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for MOXIFLOXACIN |
| 461 | OF5654 | AFB SUSCEPTIBILITY : Ofloxacin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Ofloxacin |
| 462 | PA5654 | AFB SUSCEPTIBILITY : PAS | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for PAS |
| 463 | PY5654 | AFB SUSCEPTIBILITY : Pyrazinamide | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Pyrazinamide |
| 464 | RF5654 | AFB SUSCEPTIBILITY : RIFABUTIN | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for RIFABUTIN |
| 465 | RI5654 | AFB SUSCEPTIBILITY : Rifampicin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for RIFAMPICIN |
| 466 | ST5654 | AFB SUSCEPTIBILITY : Streptomycin | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for Streptomycin |
| 467 | 1464R2 | AFB SUSCEPTIBILITY, BACTEC : 10 DRUG PANEL | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test: STREPTOMYCIN ISONIAZID RIFAMPICIN ETHAMBUTOL PYRAZINAMIDE SENSITIVE RAHULK1509 PARA-AMINO SALICYLIC ACID ETHIONAMIDE KANAMYCIN OFLOXACIN CIPROFLOXACIN CAPREOMYCIN AMIKACIN LEVOFLOXACIN RIFABUTIN LINEZOLID etc. |
| 468 | 1464R3 | AFB SUSCEPTIBILITY, BACTEC : 13 DRUG PANEL | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test |
| 469 | 1464R1 | AFB SUSCEPTIBILITY, BACTEC : 5 DRUG PANEL | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test |
| 470 | 1490 | AFB SUSCEPTIBILITY, BACTEC : SIRE PANEL | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test |
| 471 | 5649 | AFB SUSCEPTIBILITY, BACTEC : SIREP PANEL | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test |
| 472 | 1464RGM | AFB DRUG SENSITIVITY: MIC TEST FOR RAPID GROWING NON-TUBERCULOUS MYCOBACTERIA (NTM) | MICRO BROTH DILUTION | PURE FRESHLY SUB-CULTURED RAPID GROWING NTM ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Rpid growing Non-Tuberculous Mycobacteria Drug susceptibility test |
| 473 | 9950 | AFB RAPID GENOTYPIC TEST (MDR-TB) (Note: This test is not applicable for MOTT) | PCR- HYBRIDISATION | Sputum/BAL/ MTB Culture Specimen | A/R | India | for molecular detection of drug resistance and detect all the known mutations responsible for drug resistance. |
| 474 | MX5655 | AFB SUSCEPTIBILITY MOXIFLOXACIN (2.0 MCG/ML) | BACTEC MGIT-960 METHOD | PURE FRESHLY SUB-CULTURED M. TUBERCULOSIS ISOLATE (ISOLATE IDENTIFICATION REPORT FROM THE REFERRING LAB IS MANDATORY | R | India | Mycobacterium Tuberculosis complex (MTC) Drug susceptibility test for MOXIFLOXACIN (2.0 MCG/ML) |
| 475 | 9957 | AFB TB SECOND LINE DRUG, GENOTYPIC ASSAY (Note: This test is not applicable for MOTT) | PCR – REVERSE PROBE HYBRIDIZATION | SPUTUM / BAL /MTB CULTURE (SPECIMENS OF PATIENTS WITH AFB SMEAR LESS THAN 1+ ARE NOT ACCEPTABLE) | A | India | This test detects mutations in: a) gyrA gene (G88A/C, A90V, S91P, D94A/N/Y/G/H) responsible for resistance to fluoroquinolones like ofloxacin and moxifloxacin b) rrs gene (A1401G, C1402T, G1484T) responsible for resistance to Aminoglycosides/Cyclic peptides (viomycin, kanamycin, amikacin and capreomycin) c) embB gene (M306I/V) responsible for resistance to the first-line drug ethambutol • Simultaneous screening of the above mentioned mutations is beneficial for rapid diagnosis and identification of XDR-TB. |
| 476 | 4105S | ALCOHOL (ETHANOL), SERUM | ENZYMATIC/ SPECTROPHOTOMETRY | SERUM (DO NOT USE SPIRIT SWAB WHILE COLLECTING BLOOD SAMPLE. USE NON ALCOHOL GERMICIDAL SOLUTION TO CLEANSE THE SKIN AND STERILE DRY SPONGES SHOULD BE USED TO COVER THE VENIPUNCTURE SITE. THE SERUM SHOULD BE IMMEDIATELY TRANSFERRED IN A CAPPED AND SEALED CONTAINER & SHIPPED TO SRL,MUMBAI IN REFRIGERATED CONDITION). CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (3 days); F (>3 days) | India | To determine if a person has consumed ethanol and to measure the level of ethanol in order to detect and evaluate impairment, intoxication, or overdose in serum |
| 477 | 4105U | ALCOHOL (ETHANOL), URINE | ENZYMATIC/ SPECTROPHOTOMETRY | URINE- RANDOM SEND TO SRL MUMBAI WITHIN 24HRS OF COLLECTION IN A CAPPED AND SEALED CONTAINER.(CLINICAL HISTORY + AGE & GENDER IS MANDATORY). | 2-8°C (14 days) | India | To determine if a person has consumed ethanol and to measure the level of ethanol in order to detect and evaluate impairment, intoxication, or overdose |
| 478 | 1391D | ALDOLASE | SPECTROPHOTOMETRY | SERUM (REFRIGERATED SERUM SPECIMENS TO REACH SRL MUMBAI WITHIN 24HRS, OR TO BE SENT FROZEN) (CLINICAL HISTORY + AGE & GENDER IS MANDATORY). | F | India | Elevated values are found in muscle disease such as Duchenne muscular dystrophy, dermatomyositis, polymyositis and limb girdle dystrophy. Aldolase level also increases in myocardial infarction in a time pattern similar to aspartate aminotransferase. Elevations may also be seen with gangrene prostate tumors, trichinosis, some carcinomas metastatic to the liver, some chronic leukemias, some blood dyscrasias and delirium tremens. |
| 479 | 3105 | ALDOSTERONE | RADIO IMMUNOASSAY | SERUM (Age, Gender, Clinical & Treatment history Required if patient is on Spirolactone or ACE inhibitors) | 2-8°C (48 hrs); F (>48 hrs) | India | Investigation of primary aldosteronism (eg, adrenal adenoma/carcinoma and adrenal cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potassium loading, cardiac failure with ascites, pregnancy, Bartter syndrome) |
| 480 | 3104U | ALDOSTERONE 24 HR,URINE | CLIA | Specimen required 24hrs urine. No preservative.24hrs urine volume should be mentioned on request form.During urine collection, the 24hrs urine container should be kept in the cold condition. | Frozen | India | Investigation of primary aldosteronism (eg, adrenal adenoma/carcinoma and adrenal cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potassium loading, cardiac failure with ascites, pregnancy, Bartter syndrome) from urine specimen |
| 481 | Z209K | ALK-1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | A subset of anaplastic large-cell lymphomas show overexpression of anaplastic lymphoma kinase (ALK-1) protein, resulting from a translocation involving the ALK1 gene. The abnormal ALK-1 expression can be in a nuclear and cytoplasmic distribution. Overexpression of ALK-1 protein is also useful in the diagnosis of lung adenocarcinoma and inflammatory myofibroblastic tumor. |
| 482 | 3996 | ALKALINE PHOSPHATASE ISOENZYMES (BONE FRACTION) | SPECTROPHOTOMETRY | 10 -12 HRS FASTING SERUM + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | 2-8°C (7 days) | India | ALP isoenzyme studies indicate whether the total ALP is increased on the basis of contributions from liver, bone, intestinal and/or placental fractions. |
| 483 | 8035 | ALKALINE PHOSPHATASE ISOENZYMES ELECTROPHORESIS | ELECTROPHORESIS | FASTING SERUM | STRICTLY REFRIGERATED | India |
Liver Isoenzymes : There are two liver isoenzymes, L1 and L2. L1 is increased in some non – malignant diseases (Such as cholestasis, cirrhosis, viral hepatitis and in various biliary and hepatic pathologies). It is also increased in malignancies with hepatic metastasis, in cancer of the lungs and digestive tract and in lymphoma. The L2 fraction exists in healthy subjects at low concentration (< 8 IU/L). An increase of L2 may occur in cholestasis and biliary diseases and in malignancies ( e.g., breast, liver, lung, prostate, digestive tract ) with liver metastasis. Bone Isoenzyme : The bone fraction is interpreted with respect to age. Increase seen in : • Breast cancer with bone or liver metastasis, Osteosarcoma and lymphoma with or without metastasis • Rheumatismal diseases, hyperparathyroidism, Paget disease and rachitism. • Transient hyperphoshatasemia in infancy that is associated with a particular liver fraction . • In such case the total ALP is highly elevated (> 2000 IU/L). • When associated with an increase of other fraction (e.g. L1, L2) it may indicate malignancy of rectum, Lung and prostate (with bone and liver metastasis). Intestinal Isoenzymes : They are absent in about 60% of normal subjects and when present are less than 14% . Placental Isoenzyme : Exists as P1 (90%) and P2 (10%). It is found during pregnancy & in some malignant diseases, e.g.:- ovarian cancers, sarcomas, pancreatic & stomach cancers. Increase can be also due to heavy smoking. |
| 484 | 4008F | ALL FISH PANEL: BCR/ABL t(9:22) + TEL/AML t(12:21) + MLL 11q rearrangement | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [Please mention the clinical history, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | To detect following translocations in ALL patient: BCR/ABL t(9:22) + TEL/AML t(12:21) + MLL 11q rearrangement |
| 485 | 3111 | ALLERGEN – Acacia Tree Pollen (Latin Name:Acacia longifolia ; Indian Name: Babool) inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 486 | 3101 | ALLERGEN – ALMOND inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 487 | 3050 | ALLERGEN – ALTERNARIA ALTERNATA/TENIUS inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 488 | 4073 | ALLERGEN – ANIMAL DANDER PANEL (Cat dander, Horse dander, Cow dander, Dog dander,Guinea pig epithelium,Mouse epithelium) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 489 | 3210 | ALLERGEN – APPLE inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 490 | 3053 | ALLERGEN – ASPERGILLUS FUMIGATUS inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 491 | 3383 | ALLERGEN – BAINGAN (ALLERGEN AUBERGINE) (Common Names:Eggplant ,Brinjal ; Indian Name:Baingan) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy test |
| 492 | 3087 | ALLERGEN – BANANA inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 493 | 3330 | ALLERGEN – BEEF | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 494 | 3162 | ALLERGEN – Bermuda Grass Pollen(Latin Name:Cynodon dactylon ; Indian Name: Dhoobghass) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 495 | 3335 | ALLERGEN – BLUE MUSSEL | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 496 | 3341 | ALLERGEN – BRAZIL NUT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 497 | 3083 | ALLERGEN – CABBAGE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 498 | 3051 | ALLERGEN – CANDIDA ALBICANS | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 499 | 3213 | ALLERGEN – CARROT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 500 | 3056 | ALLERGEN – CASEIN | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 501 | 3085 | ALLERGEN – CASHEW | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 502 | 3047 | ALLERGEN – CAT DANDER/EPITHELIUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 503 | 3096 | ALLERGEN – CAULIFLOWER | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 504 | 7768 | ALLERGEN – CEPHALOSPORIN MIX ANTIBIOTIC (SERUM) | ELISA | SERUM | F | India | Allergy test |
| 505 | 3057 | ALLERGEN – CHEESE CHEDDAR | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 506 | 3178 | ALLERGEN – CHERRY | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy test |
| 507 | 3388 | ALLERGEN – Chick Pea(Common Names: Garbanzo bean, Bengal Gram;Indian Name:Kabuli Chana) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy test |
| 508 | 3118 | ALLERGEN – CHICKEN FEATHERS | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 509 | 3063 | ALLERGEN – CHICKEN MEAT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 510 | 3055 | ALLERGEN – CLADOSPORIUM HERBARUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 511 | 3153 | ALLERGEN – Cocklebur Weed Pollen (Latin Name:Xanthium commune;Indian Names:Bichha,Kutta,Chirchitta ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 512 | 3059 | ALLERGEN – COCKROACH | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 513 | 3108 | ALLERGEN – COCOA | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 514 | 3060 | Allergen – Coconut | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 515 | 3331 | ALLERGEN – CODFISH | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 516 | 3199 | ALLERGEN – COFFEE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 517 | 3161 | ALLERGEN – Common Ragweed Pollen (Latin Name:Ambrosia elatior;Close to Parthenium-Congress Grass) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 518 | 3117 | ALLERGEN – Common Silver birch Tree Pollen( Latin Name:Betula verrucosa) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 519 | 1404 | ALLERGEN – COMPREHENSIVE ALLERGY PANEL – ADULT (Phadia Top Adult, LiST Of Allergens Include:Milk, Soybean, Cheese, Almond, Coconut, Wheat, Egg White, Chicken, Cod Fish, Shrimp, Tuna, Salmon, D.Ptteronyssinus, D.Farinae, Cockroach, House DuST Greer , Mugwort, English Plantain, Lambs Quarter, Alder, Birch, Cat Epithelium, Dog Dander, Cladoprorium, Aspergillus, Candida, Common Ragweed, Cultivated Rye, Velvet) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 520 | 3093 | ALLERGEN – CORN | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 521 | 3390 | ALLERGEN – Cottonwood Tree Pollen (Latin Name: Populus deltoides) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 522 | 3130 | ALLERGEN – COWDANDER | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 523 | 3068 | ALLERGEN – CRAB | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 524 | 3233 | ALLERGEN – Cultivated rye Grass Pollen (Latin Name:Secale cereale ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 525 | 3042 | ALLERGEN – DOG DANDER/EPITHELIUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 526 | 3033 | ALLERGEN – DUST PANEL (HouseduST- Greer, Cockroach, D.Farinae, D.Pteronyssinus) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 527 | 3376 | ALLERGEN – ECZEMA/GIT (Non-veg & Veg) PANEL -Hollister-Stier Labs., Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blatella germanica,Milk, Wheat, Rice, Soybean, Potato, Onion,Tomato ,Peanuts, Egg White,Egg yolk, Cod Fish, Shrimp, Chicken, Mutton (Lamb) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 528 | 3375 | ALLERGEN – ECZEMA/GIT (Veg) PANEL – Hollister-Stier Labs., Dermatophagoides pteronyssinus, Dermatophagoides farinae,Blatella germanica(Cockroach), Milk ,Wheat, Rice, Soybean, Potato, Onion,Tomato , Peanuts, ] | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 529 | 3043 | ALLERGEN – EGG WHITE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 530 | 3076 | ALLERGEN – EGG YOLK | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 531 | 3389 | ALLERGEN – Elm Tree Pollen( Latin Name: Ulmus americana ; Indian Name:Papdi Chibil) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 532 | 3159 | ALLERGEN – English plantain Weed Pollen (Latin Name:Plantago lanceolata ;Common Name:Ribwort) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 533 | 3119 | ALLERGEN – Eucalyptus Tree Pollen (Indian Names:Nilgiri,Safeda) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy test |
| 534 | 3386 | ALLERGEN – Extended Eczema Panel -Milk,Wheat,Rice,Peanut,Soyabean,ChickPea,Cashew Nut,Coconut,Banana,Brinjal,Lemon,Spinach,Tomato,White Bean,Cod Fish,Shrimp,Chicken,Mutton,Egg White,D.Ptyerossinus,Cockroach,Cat dander, Dog dander,Cladosporium herbarum, Aspergillus fumigatus, | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 535 | 3405 | ALLERGEN – Extended Rhinitis/Asthma panel –Adult{ Bermuda Grass, Johnsson Grass,Meadow Grass, Cocklebur , Common Pigweed , Common ragweed,Mugwort, Goosefoot, English Plantain, Acacia, Oak, Elm,Cotton Wood ,Eucalyptus, Mesquite, Mulberry , Alder,Dermatophagoides farinae, Dermatophagoides pteronyssinus , Cockroach,Cat dander, Dog dander,Cladosporium herbarum, Aspergillus fumigatus. | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 536 | 3404 | ALLERGEN – Extended Rhinitis/Asthma panel –Child { Bermuda Grass, Johnsson Grass, Cocklebur, Common Pigweed, Common ragweed, Mugwort ,Goosefoot, Rape seed, Oak, Cotton Wood, Eucalyptus, Mesquite, Mulberry, Alder, Dermatophagoides pteronyssinus, Cockroach, Cat dander, Dog dander, Cladosporium herbarum, Aspergillus fumigatus, Egg white, Milk, CodFish, Wheat, Peanut,Soyabean, Hosue dust Hollistier | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 537 | 3221 | ALLERGEN – FIG | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy test |
| 538 | 4012 | ALLERGEN – FLEXI ALLERGY PANEL – (Select Any 10 Allergen from available inhouse Allergen list) | ImmunoCAP Specific IgE inhouse allergen | serum | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 539 | 4010 | ALLERGEN – FLEXI ALLERGY PANEL – (Select Any 5 Allergen from available inhouse Allergen list) | ImmunoCAP Specific IgE inhouse allergen | serum | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 540 | 2109 | ALLERGEN – FLEXI ALLERGY PANEL – 2 ( Select Any 29 Allergens from available inhouse Allergen list) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 541 | 2179 | ALLERGEN – FLEXI ALLERGY PANEL – 3 (Select Any 19 Allergen from available inhouse Allergen list) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 542 | 4081 | ALLERGEN – FOOD PANEL – FRUITS 1 ( Apple, Banana, Pear,Peach,Orange,Pineapple,Mango) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 543 | 4087 | ALLERGEN – FOOD PANEL – FRUITS 2 (Kiwi,Strawberry,Melon,Peach,Lemon,Orange) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 544 | 4082 | ALLERGEN – FOOD PANEL – NUTS AND SEEDS ( Peanut, Cashew nut ,Pista, Hazel nut, Brazil nut, Almond, Coconut ,Sesame seed,Rape seed) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 545 | 4083 | ALLERGEN – FOOD PANEL – VEG 2 (Wheat,Rice,Garlic,Tomato,Potato,Onion,Lemon,Mustard,Sesame seed,Chick pea) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 546 | 4085 | ALLERGEN – FOOD PANEL – VEG 3 (Tomato, Yeast, Garlic, Onion) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 547 | 3031 | ALLERGEN – FOOD PANEL 2 (Codfish, Tuna, Shrimp, Blue Mussel, Salmon | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 548 | 3075 | ALLERGEN – FOOD PANEL 7 (Egg White,Fish, Milk, Rice, Peanut, Soyabean) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 549 | 4090 | ALLERGEN – FOOD PANEL -LEAFY VEGETABLES (Spinach,Celery,Lettuce,Cabbage) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 550 | 4084 | ALLERGEN – FOOD PANEL MEATS (Chicken,Mutton,Pork,Beef) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 551 | 4086 | ALLERGEN – FOOD PANEL- VEGETABLES (Brinjal,Cabbage,Carrot,Cauliflower,Green pepper,Corn, Mushroom,Spinach,Tomato,Potato) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 552 | 4091 | ALLERGEN – FOOD PANEL-PULSES (Lentil, Chickpea, White bean,Green pea,Soyabean) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 553 | 4092 | ALLERGEN – FOOD PANEL-SEAFOOD (Codfish, Tuna, Shrimp, Blue Mussel, Salmon, Crab, Lobster) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 554 | 3064 | ALLERGEN – GARLIC | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 555 | 3065 | ALLERGEN – GLUTEN | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 556 | 3354 | ALLERGEN – Golden Rod Weed Pollen (Latin Name:Solidago virgaurea) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 557 | 3353 | ALLERGEN – Goosefoot Weed Pollen (Latin Name: Chenopodium album;Common Name:Lamb’s Quarters ; Indian Name:Bathua ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 558 | 3229 | ALLERGEN – Grapefruit (Latin Name:Citrus paradisi ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 559 | 4093 | ALLERGEN – GRASS POLLENS PANEL (Bermuda Grass,Cultivated rye,Johnson Grass,Meadow fescue,Common Ragweed ,Timothy Grass,Velvet Grass) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 560 | 3058 | ALLERGEN – Green PEA | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 561 | 3097 | ALLERGEN – Green pepper(Latin Name:Piper nigrum) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 562 | 3349 | ALLERGEN – Grey alder Tree Pollen (Latin Name: Alnus incana) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 563 | 3127 | ALLERGEN – GUINEA PIG EPITHELIUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 564 | 3340 | ALLERGEN – HAZEL NUT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 565 | 3148 | ALLERGEN – HELMENTHISPORIUM HALODES | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy test |
| 566 | 3133 | ALLERGEN – Honey Bee Venom (Latin name: Apis mellifera) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 567 | 3137 | ALLERGEN – HORSE DANDER | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 568 | 3044 | ALLERGEN – HOUSE DUST GREER | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 569 | 3379 | ALLERGEN – HOUSE DUST HOLLISTIER | ImmunoCAP Specific IgE inhouse allergen | serum | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 570 | 3036 | ALLERGEN – House dust mite-Dermatophagoides pteronyssinus | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy test |
| 571 | 3173 | ALLERGEN – House dust mite-Dermatophagoieds farinae | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 572 | 3164 | ALLERGEN – Johnson Grass Pollen(Latin name:Sorghum halepense ; Indian Name: Jowar) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 573 | 3088 | ALLERGEN – KIWI FRUIT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 574 | 3332 | ALLERGEN – LAMB (MUTTON) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 575 | 3203 | ALLERGEN – LEMON | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 576 | 3373 | ALLERGEN – Lentil ( Common Indian Name: Masur Dal) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy Test |
| 577 | 3200 | ALLERGEN – LETTUCE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 578 | 3336 | ALLERGEN – LOBSTER | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 579 | 3207 | ALLERGEN – Malt (Latin Name:Hordeum vulgare ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 580 | 3054 | ALLERGEN – MANGO | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 581 | 3168 | ALLERGEN – Meadow fescue Grass pollen(Latin name: Festuca elatior) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 582 | 8127 | ALLERGEN – MELALEUCA | IMMUNOCAP | SERUM | FROZEN | India | Allergy Test |
| 583 | 3209 | ALLERGEN – MELON | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 584 | 3398 | ALLERGEN – MesquiteTree Pollen (Latin Name:Prosopis juliflora ; Indian Name: Pahadi Keekar) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 585 | 3037 | ALLERGEN – MILK | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 586 | 3034 | ALLERGEN – MOLD PANEL (P. notatum,C. herbarum,A.fumigatus,C. albicans,A.tenius,M. racemosus,Trichophyton) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 587 | 3129 | ALLERGEN – MOSQUITO AEDES | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 588 | 3138 | ALLERGEN – MOUSE EPITHELIUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 589 | 3052 | ALLERGEN – MUCOR RACEMOSUS | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 590 | 3160 | ALLERGEN – Mugwort Weed Pollen (Latin Name: Artemisia vulgaris ;Indian Names:Barna,Sita Bani,Bano) inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 591 | 3391 | ALLERGEN – Mulberry Tree Pollen (Latin Name:Morus alba; Indian Name:Shahtoot) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 592 | 3201 | ALLERGEN – MUSHROOM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 593 | 3208 | ALLERGEN – MUSTARD | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 594 | 3157 | ALLERGEN – Nettle Weed Pollen (Latin Name: Urtica dioica ;Common Name: Stinging Nettle) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 595 | 1425 | ALLERGEN – NON VEG PANEL (Chicken Meat, Codfish, Salmon, Tuna, Shrimp, Blue Mussel,Egg white, Egg yolk, Lamb) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 596 | 3351 | ALLERGEN – Oak Tree Pollen (Latin Name: Quercus alba) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 597 | 3219 | ALLERGEN – OAT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 598 | 3211 | ALLERGEN – ONION | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 599 | 3030 | ALLERGEN – ORANGE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 600 | 1430 | ALLERGEN – OUTDOOR PANEL ( Common Ragweed, Golden Rod, English Plantain, Alder, Birch, Lambs Quarter, Nettle) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 601 | 5006 | ALLERGEN – PADIATRIC PANEL (EGG WHITE, MILK, SOYABEAN, WHEAT, HOUSE DUST) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 602 | 3135 | ALLERGEN – PARROT FEATHERS | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 603 | 3205 | ALLERGEN – PEACH | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 604 | 3077 | ALLERGEN – PEANUT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 605 | 3086 | ALLERGEN – PEAR | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 606 | 4009 | ALLERGEN – PECAN NUT | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 607 | 3015 | ALLERGEN – PENICILLIUM NOTATUM | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 608 | 4430 | ALLERGEN – PHADIATOP ADULT (INDIVIDUALS ABOVE 5 YEARS) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 609 | 4432 | ALLERGEN – PHADIATOP INFANT (INDIVIDUALS BELOW 5 YEARS) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 610 | 3385 | ALLERGEN – Pigweed Pollen (Latin Name: Amaranthus retroflexus;Indian Names:Kaantewali Chauli) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 611 | 3081 | ALLERGEN – PINEAPPLE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 612 | 3202 | ALLERGEN – PISTACHIO | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 613 | 3333 | ALLERGEN – PORK | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 614 | 3107 | ALLERGEN – POTATO | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 615 | 3329 | ALLERGEN – RABBIT APITH | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 616 | 3400 | ALLERGEN – Rape Seed(Common Names:Canola, Oilseed Rape; Indian Name: Sarson) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 617 | 3239 | ALLERGEN – Red Kidney Beans inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 618 | 1428 | ALLERGEN – RHINITIS/ASTHMA INDOOR INHALANTS PANEL (Aspergillus,Mucor,Alternaria Candida, House Dust, D.Farinae, D.Pteronyssinus, Cockroach, Cat Epithelium, Dog Dander) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 619 | 3377 | ALLERGEN – RHINITIS/ASTHMA PANEL – Ambrosia elatior(Common Ragweed), Penicillium notatum, Aspergillus fumigatus, Mucor racemosus, Candida albicans(yeast), Dermatophagoides farinae(House dust mite), Dermatophagoidespteronyssinuse(House dust mite), Greer labs(house dust), Hollistier-Stier labs(House dust), Blatella germanica(Cockroach) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 620 | 3038 | ALLERGEN – RICE | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 621 | 3343 | ALLERGEN – SALMON | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 622 | 3092 | ALLERGEN – SESAME SEED | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 623 | 3067 | ALLERGEN – SHRIMP | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 624 | 3169 | ALLERGEN – SILK | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 625 | 3061 | ALLERGEN – SOYBEAN | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 626 | 3225 | ALLERGEN – SPINACH | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 627 | 3106 | ALLERGEN – STRAWBERRY | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 628 | 3346 | ALLERGEN – Sweet vernal grass(Latin Name: Anthoxanthum odoratum) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 629 | 3167 | ALLERGEN – Timothy Grass Pollen( Latin Name:Phleum pratense ) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 630 | 3212 | ALLERGEN – TOMATO | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 631 | 4095 | ALLERGEN – TREE POLLENS PANEL (Acacia,Eucalyptus,Elm,Mesquite,Mulberry,Cottonwood,Common Silver Birch) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 632 | 3141 | ALLERGEN – TRICHOPHYTON | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 633 | 3342 | ALLERGEN – TUNA | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 634 | 4433 | ALLERGEN – Vanilla inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 635 | 1414 | ALLERGEN – VEG PANEL (Almond, Wheat, Coconut, Corn, Peanut, Sesame Seed, Cheese, Milk) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 636 | 3348 | ALLERGEN – Velvet Grass Pollen (Latin Name:Holcus lanatus) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 637 | 3098 | ALLERGEN – WALNUT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 638 | 4096 | ALLERGEN – WEED POLLENS PANEL (Common Ragweed,Cocklebur,Goosefoot,Mugwort,Pigweed,Nettle,Goldenrod,,English plantain) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 639 | 3039 | ALLERGEN – WHEAT | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 640 | 3091 | ALLERGEN – WHITE BEAN | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 641 | 3402 | ALLERGEN – White PineTree Pollen (Latin Name:Pinus strobus) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 642 | 3352 | ALLERGEN – Willow Tree Pollen (Latin Name:Salix caprea) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 643 | 3090 | ALLERGEN – Yeast (Latin name: Saccharomyces cerevisiae , Common Names: Baker’s yeast,Brewer’s yeast) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 644 | 4008 | ALLERGEN -APRICOT | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 645 | 7788 | ALLERGEN- HUMAN INSULIN ,SERUM | ImmunoCAP (Fluoroenzymeimmunoassay) (Specific IgE Test) |
SERUM | F | India | Allergy Test |
| 646 | 8129 | ALLERGEN INDIVIDUAL MARKER, OLIVE (FEIA) | IMMUNOCAP | SERUM | FROZEN | India | Allergy Test |
| 647 | 3236 | ALLERGEN -Papaya inhouse allergen | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 648 | 7775 | ALLERGEN- PENICILLYOL G, (ANTIBIOTIC), SERUM | ImmunoCAP (Fluoroenzymeimmunoassay) (Specific IgE Test) |
SERUM | F | India | Allergy Test |
| 649 | 7776 | ALLERGEN- PENICILLYOL V, (ANTIBIOTIC), SERUM | ImmunoCAP (Fluoroenzymeimmunoassay) (Specific IgE Test) |
SERUM | F | India | Allergy Test |
| 650 | 7772 | ALLERGEN, CIPROFLOXACIN ANTIBIOTIC (SERUM) | ELISA | SERUM | F | India | Allergy Test |
| 651 | 7773 | ALLERGEN-ACTH, SERUM | ImmunoCAP (Fluoroenzymeimmunoassay) (Specific IgE Test) |
SERUM | F | India | Allergy Test |
| 652 | 7770 | ALLERGEN-AMOXICILLIN (ANTIBIOTIC), (SERUM) | ELISA | SERUM | F | India | Allergy Test |
| 653 | 7771 | ALLERGEN-AMPICILLIN (ANTIBIOTIC), (SERUM) | ELISA | SERUM | F | India | Allergy Test |
| 654 | 3366 | ALLERGEN-BASIL | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 655 | 9310 | ALLERGEN-BAY LEAF | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 656 | 3342I | ALLERGEN-BLACK PEPPER | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 657 | 3341I | ALLERGEN-CHILLI PEPPER | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 658 | 1408 | ALLERGEN-COMPREHENSIVE ALLERGY PANEL – INFANCY (Phadia top infant, Individual Allergens: Milk, Soybean, Peanut,(Egg Yolk), Almond, Wheat, Corn, Cat Epithelium, Dog Dander, Rabbit Epithelium, Cultivated Rye, English Plantain, D. Pteronyssinus, D. Farinae, House DuST, Cockroach, Aspergillus, Candida, Caesin, Potato,Egg white) | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 659 | 3365 | ALLERGEN-FENNEL | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 660 | 9307 | ALLERGEN-OREGANO | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 661 | 9308 | ALLERGEN-PAPRIKA | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 662 | 9309 | ALLERGEN-PARSLEY | CHEMILUMINESCENCE | SERUM | R/F | India | Allergy Test |
| 663 | 2710 | Allergic bronchopulmonary aspergillosis (ABPA) Panel | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Allergy Test |
| 664 | 7777 | ALLERGY – DRUGS PANEL (IMMUNOCAP) (SERUM) | ImmunoCAP (Fluoroenzymeimmunoassay) (Specific IgE Test) |
SERUM | F | India | Allergy Test |
| 665 | 7818 | ALLERGY PANEL | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy Test |
| 666 | 5967 | ALLERGY PANEL FLEXI-3 | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy Test |
| 667 | 4904 | ALLERGY SCREENING PANEL – 1 | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy Test |
| 668 | 4522B | ALPHA 2- MACROGLOBULIN | NEPHELOMETRY | 12 -14 HRS FASTING SERUM (LIPEMIC SAMPLE SHOULD BE AVOIDED)+ CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Alpha2Macroglo bulin is produced in the liver. Increased concentrations are associated with patients with some Chronic liver diseases, Nephrotic syndrome, and Diabetes. Decreased concentrations are associated in patients with Pancreatitis, Rheumatoid arthritis and Multiple myeloma. |
| 669 | RD1433 | Alpha-1 Antitrypsin, Genotyping | PCR-SEQUENCING | EDTA WHOLE BLOOD+CLINICAL HISTORY | Ambient | India | More than 40 phenotypes of AAT exist. The inherited deficiency seen most often as the ZZ, SS & SZ phenotypes is associated with Neonatal hepatitis & Infantile cirrhosis. In adults these phenotypes are associated with chronic lung disease including Emphysema & Chronic bronchitis. |
| 670 | Z072K | ALPHA-1-ANTITRYPSIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Alpha-1-Antitrypsin (AAT) is useful in the study of inherited AAT deficiency, benign and malignant hepatic tumors and yolk sac carcinoma. |
| 671 | 1512D | ALPHA-1-ANTITRYPSIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Congenital deficiency of AAT is associated with early lung disease, Neonatal hepatitis and Infantile cirrhosis. |
| 672 | Z071K | ALPHA-FETOPROTEIN / LIVER CANCER MONITOR (IHC) |
IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Aids in the identification of yolk sac tumors and hepatocellular carcinoma |
| 673 | 3109F | ALPHA-FETOPROTEIN / LIVER CANCER MONITOR | CHEMILUMINESCENCE | BODY FLUID ( Age+Sex+Clinical history ) | R | India | This is a useful assay for follow up management of patients undergoing cancer therapy specially for testicular tumors, ovarian tumors and Hepatocellular carcinoma. It is often used in conjunction with Human Chorionic Gonadotropin (HCG) test. |
| 674 | 3109C | ALPHA-FETOPROTEIN / LIVER CANCER MONITOR, CSF | CHEMILUMINESCENCE | BODY FLUID ( Age+Sex+Clinical history ) | R | India | An adjunct in the diagnosis of central nervous system (CNS) germinomas and meningeal carcinomatosis. Evaluating germ-cell tumors, including testicular cancer metastatic to the CNS in conjunction with beta-human chorionic gonadotropin measurement. An adjunct in distinguishing between suprasellar dysgerminomas and craniopharyngiomas. A supplement to cerebrospinal fluid cytologic analysis |
| 675 | 7747 | Alternaria alternata – specific IgG | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | To detect IgG antibodies to Alternaria alternata |
| 676 | 9148U24 | ALUMINIUM, 24 HR URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). AFTER SHAKING THE CAN TAKE ALQUOT (10-20 ml) URINE IN METAL FREE SCINTILLATION WHITE BOTTLE AVAILABLE FROM SRL (NO PRESERVATIVE). | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Estimation of urinary Aluminium levels is useful in patients with compromised renal function who are undergoing occasional dialysis to support their reduced renal function |
| 677 | 9148 | ALUMINIUM, PLASMA | GFAAS WITH ZEEMAN CORRECTION | COLLECT WHOLE BLOOD IN SPECIAL TRACE ELEMENT BD, K2 EDTA VACCUTAINER AVAILABLE FROM SRL DO NOT SEPERATE PLASMA | 2-8°C (7 DAYS); SENDING WHOLE BLOOD SAMPLES UNDER COLD CONDITIONS (2-8°C) IS MANDATORY | India | This is the preferred test for routine Aluminium screening. It is specially useful for monitoring Aluminium toxicity in patients undergoing dialysis. It also helps to monitor metallic prosthetic implant ware. Aluminium overload leads to accumulation in brain and bone. Brain deposition has been implicated as a cause of dialysis dementia. |
| 678 | 9148U | ALUMINIUM, URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN METAL FREE (10-20 ML) SCINTILLATION WHITE BOTTLE AVAILABLE FROM SRL (NO PRESERVATIVE). VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Estimation of urinary Aluminium levels is useful in patients with compromised renal function who are undergoing occasional dialysis to support their reduced renal function |
| 679 | 1102 | AMA (ANTI MITOCHONDRIAL ANTIBODIES) WITH TITRE (Reflex to end titre to all positive cases) | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS OR SHIPPED) | India | Mitochondrial antibody is present in approximately > 90% patients with Primary Biliary Cirrhosis. This assay is not useful for indicating the prognosis of the disease or monitoring the course of the disease. |
| 680 | 4631 | AMINO ACIDS, PLASMA | Method : Capillary Gas Chromatography Mass Spectrometry | Instruction: 1. Specimen requirement : 4.0 ml Heparinized Plasma (Reqd. Clinical History, Age & Gender of the patient) 2. Transport & Storage temperature : Frozen |
FROZEN | India | This assay is used for evaluating patients with possible Inborn errors of metabolism. It may also aid in evaluation of endocrine disorders, liver diseases, muscle diseases, neoplastic diseases, neurological disorders, nutritional disturbances, renal failure and burns. |
| 681 | 4631U24 | AMINO ACIDS,24HRS URINE | Gas Chromatography Mass Spectrometry | Transport & Storag Transport & Storage temperature : FrozenInstruction: 1. Specimen requirement : a. 20.0 ml Urine aliquot from 24hrs urine sample, in sterile container (Reqd. Clinical History, Age & Gender of the patient).Mention 24hrs urine volume on the request form temperature. |
FROZEN | India | This assay is used for evaluating patients with possible Inborn errors of metabolism. It may also aid in evaluation of endocrine disorders, liver diseases, muscle diseases, neoplastic diseases, neurological disorders, nutritional disturbances, renal failure and burns. |
| 682 | 4631U | AMINO ACIDS,RANDOM URINE | Gas Chromatography Mass Spectrometry | Specimen requirement : a. 20.0 ml random urine sample, in sterile container (Reqd. Clinical History, Age & Gender of the patient)n requirement : |
FROZEN | India | This assay is used for evaluating patients with possible Inborn errors of metabolism. It may also aid in evaluation of endocrine disorders, liver diseases, muscle diseases, neoplastic diseases, neurological disorders, nutritional disturbances, renal failure and burns. |
| 683 | 9975U24 | AMINOLEVULINIC ACID,URINE 24 hrs | ION EXCHANGE CHROMATOGRAPHY /SPECTROPHOTOMETRY | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION. TO BE PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARKED COLOURED BOTTLE. ( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY) | 2-8°C (4DAYS); F (1 MONTH) | India | Delta Amino levulinic Acid shows a marked increase in cases of Porphyrias during an acute attack. The levels fall to normal after the acute episode except in cases of Acute intermittent porphyria and Hereditary coproporphyria. |
| 684 | 9975 | AMINOLEVULINIC ACID,URINE RANDOM | ION EXCHANGE CHROMATOGRAPHY /SPECTROPHOTOMETRY | RANDOM URINE WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION.TO BE PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARKED COLOURED BOTTLE. ( PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY) | 2-8°C (4DAYS); F (1 MONTH) | India | Delta Amino levulinic Acid shows a marked increase in cases of Porphyrias during an acute attack. The levels fall to normal after the acute episode except in cases of Acute intermittent porphyria and Hereditary coproporphyria. |
| 685 | 4007F | AML FISH PANEL: PML Ra Ra t(15:17) + Inv 16 + AML1/ETO t(8:21) | FISH | WB OR BONE MARROW – SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | To detect followign translocations in AML patient: PML Ra Ra t(15:17) + Inv 16 + AML1/ETO t(8:21) |
| 686 | 7900 | AML PANEL – Karyotyping Reflex to FISH | CELL CULTURE/FISH | BONE MARROW/WB WB (≥70% blast cell) SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY IN SPECIFIED FORMAT,(CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF IN SPECIMEN COLUMN | A | India | In acute myeloid leukemia, the karyotype of the leukemic cell is the most powerful predictor of treatment outcome. |
| 687 | 4303 | AML with C KIT(FLT3+NPM1+C KIT) | PCR – Sequencing | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | c-kit mutations have been reported as a novel adverse prognostic factor of acute myeloid leukemia |
| 688 | 9303 | AML with Normal Cytogenetics (FLT3, NPM1, CEBPA) | PCR – Sequencing | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | This panel may be used for Risk stratification in AML / ALL. The recommended tests as below: AML: BCRABL, PMLRARA, AMLETO, INV16, NPM1, FLT3. ALL: BCRABL, MLLAF9, MLLAF4, MLLENL, t(12;21),t(l;19). |
| 689 | 6008F | AMLI / ETO t(8:21) | FISH | WB OR BONE MARROW – SODIUM HEPARIN. SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | The (8;21) translocation occurs in approximately 5% of AML & is usually associated with a high rate of complete remission and longer overall survival in AML subtype M2. |
| 690 | 4811 | AMYLOID A (SERUM, NEPHELOMETRY) | NEPHELOMETRY | SERUM | FROZEN/REFRIGERATED | India | The determination of SAA is useful for diagnosing inflammatory processes, assessing their activity as well as monitoring these processes and their treatment. |
| 691 | 1360 | ANC COMBO – ANTENATAL PROFILE & TPC (CBC, Blood Group, Glucose Fasting, Urinalysis, HIV 1 & 2, Abs, Hepatitis B,VDRL,TPC) | AUTOMATED CELL COUNTER/ SPECTROPHOTOMETRY / DIPSTICK & MICROSCOPY/ CHEMILUMINESCENCE /CMIA/FLOCCULATION | 10-12 HRS FASTING PLASMA – FLUORIDE , URINE FASTING, SERUM FASTING, EDTA (W.B ) + 2 SMEARS + (AGE & GENDER IS MANDATORY) | EDTA WB : Ambient 2-8°C (<48 HRS); F (> 48 HRS); FLUORIDE PLASMA : 2-8°C (3 DAYS); URINE : 2-8°C( 24 HRS) | India | Antenatal tests are important tools for protecting the health of a pregnant woman and her child. Various tests are performed over the course of pregnancy to determine if the mother has any health conditions that may interfere with normal development of the fetus or if the fetus has any health conditions that may affect the baby’s quality of life. These tests help to identify factors requiring special care. |
| 692 | 9207RFX | ANCA POSITIVE REFLEX MPO, PR3 ANTIBODIES | IFA /FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (1 week); -20°C (longer)/ FOR MPO, PR3 2-8°C (2 DAYS); -20°C (> 2 DAYS) | India | To help detect, diagnose, and sometimes monitor certain forms of systemic vasculitis (an autoimmune disorder that causes inflammation of blood vessels) |
| 693 | 3113 | ANDROSTENEDIONE | CHEMILUMINESCENCE | FASTING ,SERUM TO BE DRAWN BEFORE 1200 NOON. (AGE+GENDER+CLINICAL HISTORY REQUIRED ) | 2-8°C (24 hrs); F ( >24 hrs) | India | This assay is useful in the diagnosis and differential diagnosis of Hyperandrogenis m. It is a crucial sex steroid precursor. In conjunction with other androgenic precursors, it is used in the diagnosis / monitoring of Congenital Adrenal Hyperplasia. It is also useful in diagnosis of Premature adrenarche. |
| 694 | 5832F1 | ANEUPLOIDY SCREENING-2 PROBES, FISH AMNIOTIC FLUID | FISH | AMINOTIC FLUID + DULY FILLED AMNIOTIC FLIUD TRF + CLINICAL HISTORY. CONSENT FORM – GWITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN SHOULD REACH US IN 24 HRS AFTER COLLECTION IN STERILE CONDITION. | A | India | To detect aneuploidy of 13, 18, 21, X, and Y |
| 695 | 3114D | ANGIOTENSIN CONVERTING ENZYME (ACE) | SPECTROPHOTOMETRY | SERUM + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | 2 – 8°C (1 MONTH) | India | This assay is used for evaluation of patients with suspected Sarcoidosis. ACE activity reflects the severity of Sarcoidosis showing 68% positivity in stage I of the disease, 86% in stage II and 91% in stage III. There is a marked decrease in ACE activity in patients of Sarcoidosis on Prednisone therapy. It may also be increased in Gaucher disease, Leprosy, Psoriasis, Amyloidosis and Histoplasmosis. |
| 696 | 9124 | ANTENATAL CHECK | AUTOMATED CELL COUNTER / AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS) / MANUAL (MODIFIED WESTERGREN) / SPECTROPHOTOMETRY / DIPSTICK & MICROSCOPY/Chemiluminescent Microparticle Immunoassay (CMIA) | SERUM+ EDTA WB + citrate black top +SMEAR+ 10-12 HRS FASTING PLASMA – FLUORIDE, URINE FASTING + (AGE & GENDER IS MANDATORY) | A, FLUORIDE PLASMA : 2-8°C (3 DAYS); URINE : 2-8°C( 24 HRS) | India | Antenatal tests are important tools for protecting the health of a pregnant woman and her child. Various tests are performed over the course of pregnancy to determine if the mother has any health conditions that may interfere with normal development of the fetus or if the fetus has any health conditions that may affect the baby’s quality of life. These tests help to identify factors requiring special care. |
| 697 | 5069 | ANTI BULLOUS PEMPHIGOID ANTIBODY 180(ANTI BP 180) | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) | SERUM | FROZEN | India | Initial screening test in the diagnosis of bullous pemphigoid |
| 698 | 5070 | ANTI BULLOUS PEMPHIGOID ANTIBODY 230 (ANTI BP 230) | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) | SERUM | FROZEN | India | Initial screening test in the diagnosis of bullous pemphigoid. |
| 699 | 1202 | ANTI CENTROMERE ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Centromere antibodies occur primarily in patients with CREST syndrome but may also be seen in some patients with Primary biliary cirrhosis, Rheumatoid arthritis and LE. This assay is used as an aid in the diagnosis of CREST syndrome and for evaluating patients with clinical presentation compatible with Systemic sclerosis. |
| 700 | 3885 | ANTI Dnase B | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | DNase B antibody is useful in patients with Group A streptococcal infection. It may persist for as long as 3 months. Comparison of the titres of acute and convalescent specimens is useful for diagnosis of Group A streptococcal infection. |
| 701 | 1177I | ANTI EPIDERMAL / PEMPHIGUS ANTIBODY | IFA | SERUM | FROZEN | India | Autoantibodies are directed against the keratinocyte cell surface in patients with Pemphigus vulgaris. Approximately 50% of patients with Bullous pemphigoid express autoantibodies directed against the basement membrane of stratifed squamous epithelium. |
| 702 | 1287 | ANTI GLIADIN II- IGA (DGP) ANTIBODIES | FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2days); -20°C (>2 days) | India | anti-Gliadin antibodies are the earliest serological markers to diagnose celiac disease. |
| 703 | 1135I | ANTI GLOMERULAR BASEMENT MEMBRANE IgG ANTIBODIES (ANTI GBM) | FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2days); -20°C (>2 days) | India | GBM antibody mediated Glomerulonephritis and Goodpastures syndrome occur with bimodal age distribution mainly in males. This assay is useful for evaluating patients with rapid onset renal failure or pulmonary hemorrhage. It also aids in the diagnosis of Goodpastures syndrome. |
| 704 | 1203 | ANTI HISTONES ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Histone antibody is present in 8095% patients with Drug induced SLE, 2050% patients with Idiopathic SLE and infrequently in patients with other autoimmune connective tissue diseases. |
| 705 | 4834 | ANTI HUMAN TISSUE TRANSGLUTAMINASE ANTIBODY (IgG) | EIA | Serum | Frozen | India |
-Evaluating patients suspected of having celiac disease, including patients with compatible clinical symptoms, patients with atypical symptoms, and individuals at increased risk (family history, previous diagnosis with associated disorder, positivity for HLA DQ2 and/or DQ8
-Screening test for dermatitis herpetiformis, in conjunction with endomysial antibody test -Monitoring adherence to gluten-free diet in patients with dermatitis herpetiformis and celiac disease |
| 706 | 3191 | ANTI INSULIN ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (48 hrs), F (> 48 hrs) | India | Insulin antibody is useful in assessing lower titers of autoantibody in diabetic patients, detecting insulin autoantibody in prediabetics and other autoimmune disorders. |
| 707 | 1166 | ANTI ISLET CELL ANTIBODY | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (FEWDAYS); -20°C (LONGER) | India | Islet cell Antibody measurement is a sensitive means to assess risk and predict onset of Type 1 Diabetes. |
| 708 | 1166T | ANTI ISLET CELL ANTIBODY WITH TITRE | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (FEWDAYS); -20°C (LONGER) | India | An early detection of circulating ICA is important in order to identify the individuals in the general population, the siblings and families of IDDM patients, who are at a higher risk of developing this disease because of their genetic predisposition to diabetes. There is a direct correlation between the antibody titre and severity of autoimmune process. |
| 709 | 4908 | ANTI MAG (MYELIN ASSOCIATED GLYCOPROTEIN) AB | Indirect Immunofluorescence | Serum | Frozen | India | Detection of MAG antibodies is associated with demyelinating sensorimotor neuropathies associated with multiple sclerosis, inflammatory neuropathies, and motor neuron diseases |
| 710 | 2244 | ANTI NMDA RECEPTOR ENCEPHALITIS IGG ANTIBODIES | IMMUNO FLUORESCENT ASSAY | SERUM OR CSF + CLINICAL HISTORY | 2-8°C / REFRIGERATED | India | Auto antibodies against glutamate receptors (NMDA type) are specific markers for anti glutamate receptor type encephalitis. This is an inflammatory encephalopathic autoimmune disease and still widely under diagnosed. This is frequently associated with ovarian and testicular teratomas. |
| 711 | 1180 | ANTI OVARY ANTIBODIES | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (ONE WEEK); -20°C (LONGER) | India | The test is used to detect anti ovarian antibodies of IgG, IgM and IgA class in patients with premature ovarian failure. |
| 712 | 1180T | ANTI OVARY ANTIBODIES TITRES | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (ONE WEEK); -20°C (LONGER) | India | The test is used to detect anti ovarian antibodies of IgG, IgM and IgA class in patients with premature ovarian failure.The presence of granular fluorescence in cytoplasm of the theca cells in follicle area indicates the presence of anti ovarian antibodies with reactivity at 1 :10 titer while absence of fluorescence in cytoplasm of theca cells indicate sample is negative for antiovarian antibodies. Quantitative evaluation is done on the basis of titers. |
| 713 | 1101 | ANTI PARIETAL CELL ANTIBODY (APCA) | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (FEWDAYS); -20°C (LONGER) | India | Parietal cell antibodies are found in 70– 90% patients with Pernicious anemia, 50% individuals with Gastric atrophy without pernicious anemia and upto 15% of unselected adult population. This assay is useful for evaluating patients suspected of having Pernicious anemia or immune meditated deficiency of vitamin B12 with or without Megaloblastic anemia. |
| 714 | 1101T | ANTI PARIETAL CELL ANTIBODY (APCA) WITH TITRE | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (FEWDAYS); -20°C (LONGER) | India | Mitochondrial antibody is present in approximately > 90% patients with Primary Biliary Cirrhosis. This assay is not useful for indicating the prognosis of the disease or monitoring the course of the disease. |
| 715 | 1080A | ANTI PHOSPHOLIPID SYNDROME PANEL (Lupus Anticoagulant Screen, Cardiolipin IgG & IgM ABS, Anti-phospholipid IgG & IgM Abs) | CLOT BASED & ENZYME IMMUNOASSAY | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C + SERUM (R) + CLINICAL HISTORY+ H/O ORAL ANTI COAGULANT (PT. SHOULD BE OFF ANTICOAGULATION FOR 7 DAYS) *(DOUBLE CENTRIFUGED PLASMA)* | Lupus : Frozen (F immediately at -20°c & transported in dry ice) / A | India | This test is used to diagnose Antiphospholipid syndrome in patients with recent miscarriage, pulmonary hypertension, nonvegetative |
| 716 | 1111 | ANTI SACCHAROMYCES CEREVISIAE (ASCA), IgA ANTIBODIES | FLUOROENZYME IMMUNOASSAY(FEIA) | SERUM | Frozen -20°C) | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondaryinfection. Paired acute and convalescent specimens that exhibit a significant change in titer are useful to confirm clinical diagnosis of infection |
| 717 | 1108 | ANTI SACCHAROMYCES CEREVISIAE (ASCA), IgG ANTIBODIES | FLUOROENZYME IMMUNOASSAY(FEIA) | SERUM | F( -20°C) | India | Antibodies to Saccharomyces cerevisiae are found in approximately 75% patients with Crohn’s disease, 15% patients with Ulcerative colitis and 5% of healthy population. This assay helps in distinguishing between Ulcerative colitis & Crohn’s disease in patients suspected of inflammatory bowel disease. |
| 718 | 3303 | ANTI SOLUBLE LIVER ANTIGEN | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS) | India | These antibodies are highly specific for Autoimmune hepatitis (AIH) and are present in 30% of cases. In 15% of AIH cases, SLA is the only detectable antibody. This test is specially important in those patients who are negative for all other autoantibodies. |
| 719 | 5225 | ANTI SPERM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | F( -20°C) | India | Sperm antibodies are associated with some cases of infertility. In couples with abnormal post coital tests, 24% males and 35% females exhibit sperm antibodies. These antibodies interfere with the binding of sperm head with zona pellucida of the egg. |
| 720 | 5951 | ANTI THROMBIN III ACTIVITY( Functional) | CHROMOGENIC ASSAY | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C + CLINICAL HISTORY*(DOUBLE CENTRIFUGED PLASMA) | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | This is the recommended screening test for antithrombin assay. This assay is useful to diagnose acquired or congenital antithrombin deficiency. It is also used to monitor treatment of antithrombin deficiency disorders including infusion of antithrombin therapeutic concentrate. |
| 721 | 5952 | ANTI THROMBIN III ANTIGEN | Immuno Turbidiometry | CITRATED PLASMA(PLATELET POOR) + CLINICAL HISTORY | F | India | Antithrombin III antigen is an inhibitor of several coagulation factors. Patients with low concentrations of Antithrombin Antigen may have a hereditary or acquired prothrombotic state. The Antigenic test differentiates a Type I from Type II deficiency. |
| 722 | 2245 | ANTI VGKC ANTIBODY | IMMUNOFLUORESCENT ASSAY | SERUM / CSF + CLINICAL HISTORY |
2-8°C / REFRIGERATED | India | Serum VGKC antibody have been detected in peripheral nervous system disease specifically associated with the clinical spectrum of acquired neuromyotonia (NMT) and crampfasciculatio n syndrome (CFS), and disorders of the central nervous system, including Morvan syndrome, epilepsy and limbic encephalitis (LE). |
| 723 | 1000 | ANTI-AQUAPORIN-4 / NMO ANTIBODIES (ANTI NEUROMYELITIS OPTICA), | IMMUNO FLUORESCENT ASSAY | SERUM/ CSF + CLINICAL HISTORY | 2-8°C / REFRIGERATED | India | Neuromyelitis Optica is an inflammatory autoimmune disease causing demyelination of the central nervous system with degradation of the insulating sheath of at least one optical nerve (Neuritis nervi optici) and at the same time or few months later the spinal cord (Myelitis). Highly specific serum autoantibody markers are found very frequently in NMO, while they are not detected in Multiple sclerosis (MS) or healthy subjects. |
| 724 | 1236 | ANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGNES(ANA Blot)ANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGEN OR (Anti MI,Anti KU,SMITH ABS, nRNP/SM,SS-A (Ro) , SS-B (La), Anti Histone Abs, Anti Centromerem abs, SCL-70 IGG,JO1 – IGG Abs,PM-Scl ,PCNA,nucleosomes,ribosomal P-protein & AMA M2) (ENA Profile) |
IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | This is a quantitative assay for quantifying specific IgG autoantibodies against Extractable Nuclear Antigens in human serum. It aids in the diagnosis of certain Systemic Rheumatic diseases |
| 725 | 4186 | Anti-ECP (ANTI–EOSINIPHIL CATIONIC PROTEIN) | ImmunoCAP | SERUM | 2-8°C (1 WEEK); -20°C (>1 WEEK) | India | ECP levels are predictive of exercise induced asthma and the propensity to develop a late asthmatic reaction (LAR). ECP levels increase after allergen exposure and these increases are reduced after immunotherapy. Serum ECP measurements may be used to monitor anti-asthma treatment and help optimize drug dosing. |
| 726 | 1260 | ANTI-GLIADIN II- IGG (DGP) ANTIBODIES | FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2days); -20°C (>2 days) | India | Ingestion of Gliadin peptides contained in wheat, rye and barley induce immune mediated inflammation of small intestine in genetically susceptible individuals with Gluten sensitive enteropathy / Celiac disease. This disease is more common in first and second degree relatives of patients with Celiac disease, individuals with Down Syndrome, Turner syndrome, Williams syndrome, Selective IgA deficiency and Autoimmune disorders. Usage of Deamidated molecule increases the specificity and sensitivity of the assay. |
| 727 | 1295I | ANTI-MPO ANTIBODIES (Anti-Myleoperoxidase Antibodies) | FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2days); -20°C (>2 days) | India | Myeloperoxidase or perinuclear antinuclear cytoplasmic antibody is useful to detect several types of Systemic necrotising vasculitis such as Microscopic polyarteritis and Crescentic glomerulonephritis . pANCA is found commonly in Churg Strauss syndrome and 50% of patients with Ulcerative colitis. |
| 728 | 1100 | ANTI-NUCLEAR AB-IFA, HEP2, SERUM | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS OR SHIPPED) | India | ANA is useful in the diagnosis of patients with autoimmune diseases such as SLE, Mixed connective tissue disease, Rheumatoid arthritis, Sjogren’s syndrome, Progressive systemic sclerosis and CREST syndrome. The incidence of low titre ANA positivity increases with age in normal individuals. Many drugs like Hydralazine and Procainamide may induce ANA production. |
| 729 | 4601 | ANTI-PHOSPHOLIPASE A2 RECEPTOR (PLA2R) IGG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (14 DAYS); -20°C (>14 DAYS) | India | This assay detects autoantibodies against phospholipase A2 receptors (PLA2R) which is useful in diagnosis of Primary membranous glomerulonephritis (pMGN). MGN is the most frequent kidney disorder with nephrotic syndrome. Autoantibodies of class IgG against PLA2R are highly specific for the diagnosis of primary MGN and can be detected in the serum of up to 70 to 75% patients. |
| 730 | 1296I | ANTI-PR3 ANTIBODIES | FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2days); -20°C (>2 days) | India | PR3 or cANCA antibody is often seen in Wegener’s granulomatosis, a necrotising granulomatous vascular disease typically involving the respiratory |
| 731 | 1110 | ANTI-THYROGLOBULIN ANTIBODIES (aTG) | CHEMILUMINESCENCE | SERUM | 2-8°C (48 hrs); F (>48 hrs) | India | High levels of anti-Thyroglobulin antibodies are seen in sera of patients with thyroid disorders such as Chronic Lymphocytic (Hashimoto””s) Thyroiditis (76 – 100%), Primary Myxedema (72%), Hyperthyroiditis (33%), Colloid Goitre (8%) & Adenomata (28%).Positive thyroid autoantibody levels in patients with high-normal or slightly elevated serum thyrotropin levels predict the future development of more profound hypothyroidism. Low titers of thyroid autoantibodies may be observed in the absence of autoimmune or other thyroid diseases and are considered a nonspecific finding. |
| 732 | 4185 | Anti-Tryptase | ImmunoCAP | SERUM | 2-8°C (1 WEEK); -20°C (>1 WEEK) | India | Tryptase is a dominant protein component of the secretory granules of human mast cells. This assay is useful for assessing mast cell activation as a result of anaphylaxis or allergen challenge. It is also used to assess patients with Systemic mastocytosis or Mast cell activation syndrome. |
| 733 | 7898 | APA (PHOSPHOLIPID) – IGA (SERUM, EIA) | EIA | SERUM | F | India | To help investigate the presence of blood clots or an unexpectedly prolonged PTT (partial thromboplastin time), especially if you have had recurrent miscarriages; as part of an evaluation for antiphospholipid syndrome (APS); sometimes to help diagnose or evaluate an autoimmune disorder |
| 734 | 4640 | APLA TOTAL (Lupus Anticoagulant Screen, Cardiolipin IgG & IgM Abs, Beta 2 Glycoprotein IgG & IgM Abs) | CLOT BASED & ENZYME IMMUNOASSAY | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C *(DOUBLE CENTRIFUGED PLASMA)* + SERUM (R) + CLINICAL HISTORY+ H/O ORAL ANTI COAGULANT (PT. SHOULD BE OFF ANTICOAGULATION FOR 7 DAYS) | F (To be F immediately at -20°c & transported in dry ice) /2-8°C (3 DAYS), >3DAYS -20°C | India | To help diagnose antiphospholipid syndrome (APS); to help diagnose the cause of an unexplained blood clot (thrombotic episode or venous thromboembolism); to help determine the cause of recurrent miscarriages in women |
| 735 | RD1408 | APO E GENOTYPING | PCR-SEQUENCING | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | The APOE*4 allele (E4) is associated with an increased risk of developing late onset Alzheimer’s disease. Individuals who are homozygous for the APOE*2 allele (E2/E2) have an increased risk of developing Type III hyperlipidemia. |
| 736 | 1899 | APOLIPOPROTEIN – E | NEPHELOMETRY | 12 -14 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Can be used as a parameter for the screening of Type III hyperlipoproteinaemias and atherosclerosis |
| 737 | 1901D | APOLIPOPROTEIN A-I | NEPHELOMETRY | 12 -14 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Apolipoprotein A1 is the primary protein associated with HDL Cholesterol. Increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B is the primary protein associated with LDL Cholesterol and increased levels are associated with increased risk of cardiovascular disease. The ratio of these two correlates with the risk of cardiovascular disease. |
| 738 | 1903D | APOLIPOPROTEIN B | NEPHELOMETRY | 12 -14 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Apolipoprotein A1 is the primary protein associated with HDL Cholesterol. Increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B is the primary protein associated with LDL Cholesterol and increased levels are associated with increased risk of cardiovascular disease. The ratio of these two correlates with the risk of cardiovascular disease. |
| 739 | 1900 | APOLIPOPROTEIN EVALUATION [Apolipo A-1, Apolipo B, Lipoprotein (a) ] | NEPHELOMETRY | 12 -14 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -30 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Apolipoprotein A1 is the primary protein associated with HDL Cholesterol. Increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B is the primary protein associated with LDL Cholesterol and increased levels are associated with increased risk of cardiovascular disease. The ratio of these two correlates with the risk of cardiovascular disease. |
| 740 | 9141U24 | ARSENIC, 24 HR URINE | HGAAS WITH D2 CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). 24 HRS VOLUME SHOULD BE COMPULSORILY SPECIFIED . FIRST SHAKE THE CAN AND TAKE THE 10-20 ML ALIQUOT IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED THE MEASUREMENT OF URINE VOLUME SHOULD BE DONE BEFORE ALIQUOTING. | 2-8°C (5 days); F (> 5 – 30days) | India | Arsenic is widely distributed in the earth’s crust. It is used in some pesticides and industrial applications. Organic forms of Arsenic are normally present in certain food types. Inorganic Arsenic is carcinogenic to humans. This assay helps in the diagnosis of Arsenic intoxication. |
| 741 | 9141 | ARSENIC, BLOOD | GFAAS WITH ZEEMAN CORRECTION | IMPROVE/BD, SRL EDTA VACCUTAINER, WHOLE BLOOD | 2-8°C (7 DAYS); F (> 7 – 30DAYS) | India | Arsenic is widely distributed in the earth’s crust. It is used in some pesticides and industrial applications. Organic forms of Arsenic are normally present in certain food types. Inorganic Arsenic is carcinogenic to humans. This assay helps in the diagnosis of Arsenic intoxication. |
| 742 | 9141U | ARSENIC, URINE SPOT | HGAAS WITH D2 CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (> 5 – 30DAYS) | India | Arsenic is widely distributed in the earth’s crust. It is used in some pesticides and industrial applications. Organic forms of Arsenic are normally present in certain food types. Inorganic Arsenic is carcinogenic to humans. This assay helps in the diagnosis of Arsenic intoxication. Since blood concentrations of Arsenic are elevated only for a short time after exposure, hence urine Arsenic is the preferred method of screening for Arsenic exposure. |
| 743 | 1709 | ASKA-SKELETAL (STRIATED)MUSCLE ANTIBODY,(SERUM IF) | IMMUNO FLUORESCENE ASSAY | SERUM | R / F | India | Autoantibodies directed against contractile elements of striated muscle are found in 30% adult patients with Myasthenia gravis (MG) and 80% cases of Thymoma in association with MG. The antibodies may also be detected in Lambert Eaton Myasthenic syndrome (5%), Small cell lung carcinoma (5%), Breast carcinoma, Autoimmune liver disorders and patients on Dpenicillamine (25%). |
| 744 | 1106 | ASMA (ANTI SMOOTH MUSCLE ANTIBODIES) WITH TITRE (Reflex to end titre to all positive cases) | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS OR SHIPPED) | India | This assay is useful for evaluating patients with chronic liver disease in whom the diagnosis of Chronic active autoimmune hepatitis is suspected. It may also be positive in Primary biliary cirrhosis, Chronic viral hepatitis and Alcoholic hepatitis. |
| 745 | 2327 | ASPERGILLUS FUMIGATES DNA DETECTOR | PCR-SEQUENCING | SPUTUM / CSF / FLUIDS / TISSUES + CLINICAL HISTORY | A | India | This test detects and identifies Aspergillus fumigatus DNA directly from clinical specimens |
| 746 | 3261 | ASPERGILLUS. FUMIGATUS-SPECIFIC IgG | ImmunoCAP(FLUOROENZYME IMMUNOASSAY) | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | In vitro test for the quantitative measurement of Aspergillus specific IgG antibodies in human serum or plasma. |
| 747 | RD1478 | ASS1 GENE MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Confirmation of abnormal newborn-screen test results suggestive of CTNL1. – Diagnostic testing for individuals with clinical and/or biochemical evidence of CTNL1 – Carrier testing for the reproductive partner of an individual affected with, or known to be a Carrier of,CTNL1 |
| 748 | Z413K | ATRX (D5) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 749 | DT5102 | AUTOGEN (Blood Lympho. Culture, Lupus Anti Coagulant Screen, Cardiolipin Antibodies & Anti Phospholipid Antibodies) | CELL CULTURE FOR CHROMOSOMAL ANALYSIS, CLOT BASED & ENZYME IMMUNOASSAY | FASTING, CITRATED PLASMA – AT MINUS 20° C + SERUM, FOR CHROMOSOMAL ANALYSIS WB- SODIUM HEPARIN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY*(DOUBLE CENTRIFUGED PLASMA) | F/A/A/A | India | Chromosome analysis helps in the diagnosis of a wide variety of congenital conditions. It helps in the identification of congenital chromosome abnormalities like Aneuploidy (Trisomy / Monosomy) & structural chromosome abnormalities. Testing for Phospholipid antibodies is indicated in cases of unexplained arterial / venous thrombosis, pregnancy with unexplained fetal deaths, spontaneous abortions, presence of unexplained cutaneous circulatory disturbance like Livido reticularis and presence of Systemic rheumatic disease like LE. This test is also used in cases of unexplained thrombocytopenia, Hemolytic anemia & Non-bacterial thrombotic endocarditis. Lupus Anticoagulants are heterogenous IgG or IgM autoantibodies which interfere with phospholipid dependent in vitro coagulation tests, particularly Activated Partial Thromboplastin Time (APTT). These antibodies are associated with thrombosis (arterial & venous), recurrent abortions, neurological & neuropsychiatric disorders. Cardiolipin antibodies are useful in identifying patients with an increased risk of thrombosis, recurrent spontaneous abortions and phospholipid antibody syndrome. Cardiolipin antibody may be elevated in patients with SLE and related autoimmune disorders. |
| 750 | 2246 | AUTOIMMUNE ENCEPHALITIS PANEL | IMMUNOFLUORESCENT ASSAY | SERUM / CSF + CLINICAL HISTORY |
2-8°C / REFRIGERATED | India | Autoantibodies against neuronal surface antigens are found in patients with autoimmune encephalopathies . |
| 751 | 4895 | AUTOIMMUNE HEPATITIS MINI (ANCA , SLA) | ANCA ( IFA), SLA (ELISA) | Serum | 2-8°C (3 DAYS);-20°C (>3 DAYS) | India | To diagnose AUTOIMMUNE HEPATITIS |
| 752 | 1019A | AUTOIMMUNE HEPATITIS PANEL-1 (ANA, SMA, AMA, LKM-1) | IMMUNOFLUOROSCENCE ASSAY/ Enzyme Linked Immnunosorbent assay | SERUM | R | India | This assay is useful for evaluating patients suspected with Chronic Autoimmune Hepatitis (CAH) or Primary Biliary Cirrhosis (PBC). Positive results for ASMA are consistent with the diagnosis of CAH. Presence of LKM antibodies with or without ASMA is consistent with Autoimmune hepatitis Type 2. Presence of AMA is consistent with PBC. |
| 753 | 1019B | AUTOIMMUNE HEPATITIS PANEL-2 (ANCA , SLA) | IMMUNOFLUOROSCENCE ASSAY, Enzyme Linked Immnunosorbent assay | SERUM (R)+ SERUM (F) | R/F | India | To diagnose AUTOIMMUNE HEPATITIS. |
| 754 | 4894 | AUTOIMMUNE HEPATITIS TOTAL (ANA, SMA, AMA, LKM-1) | For LKM-Enzyme Immunoassay | Serum | 2-8°C (48 hrs); -20°C (>48 hrs) | India | To diagnose AUTOIMMUNE HEPATITIS; |
| 755 | 7906 | AVIAN ANTIGEN HP PANEL (PIGEON+IGG AF) | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | This test detects Aspergillus specific IgG antibodies and pigeon serum protein IGG ( feather and droppings) |
| 756 | 1212M | BACTEC BLOOD CULTURE – (YEAST & FUNGI) | BACTEC FLUORESCENT METHOD | INOCULATED BACTEC BOTTLE (MYCOSIS) | A | India | Rapid automated cultures can identify organisms from sterile sites much earlier and with increased sensitivity as compared to conventional cultures .Only when Yeast is identified, antibiotic sensitivities are performed. |
| 757 | 1212AF | BACTEC BLOOD CULTURE (AEROBIC & FUNGAL) | BACTEC, VITEK | AEROBIC AND MYCOSIS BACTEC BOTTLE | A | India | To check for the presence of a systemic infection; to detect and identify bacteria in the blood (AEROBIC & FUNGAL) |
| 758 | 1195M | BACTEC CULTURE, BODY FLUID -(YEAST & FUNGI) | BACTEC FLUORESCENT METHOD | BODY FLUID- STERILE CONTAINER / INOCULATED BACTEC BOTTLE (MYCOSIS) | A | India | Common organisms causing infections are S.aureus, Pseudomonas aeruginosa, S.pneumoniae, Enterobacteriaece ae, Streptococcus & certain Gram negative bacilli. On identification of the organism, antibiotic susceptibilities are performed that aid in selection of appropriate antibiotic for treatment. |
| 759 | 9208RFX | BACTERIAL ANTIGEN (5) DETECTION IF NEGATIVE REFLEX TO CSF BACTERIAL CULTURE | BACTEC CULTURE/ LATEX PARTICLE AGGLUTINATION | CSF | A | India | Detection of following five bacterial antigen: HAEMOPHILUS INFLUENZAE TYPE B ANTIGEN, NEISSERIA MENINGITIDIS ANTIGEN STREPTOCOCCUS PNEUMONIAE ANTIGEN ESCHERICHIA COLI K1 ANTIGEN, STREPTOCOCCUS GROUP B ANTIGEN. CSF Culture is done if above antigens are negative |
| 760 | 9601 | BACTERIAL ANTIGEN DETECTION (5 ANTIGENS) | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | Streptococcus Group B and E.coli K1 are the two most common causes of Neonatal sepsis while in older age group the commonest isolates are H. influenzae Type B, S. pneumoniae and N.meningitidis A, B, C, Y and W135. Early identification of these infecting agents helps in providing patients with appropriate antibiotic therapy. |
| 761 | 9601C | BACTERIAL ANTIGEN DETECTION, CSF (5 ANTIGENS) | LATEX PARTICLE AGGLUTINATION | CSF | 2-8°C (FEW HRS); -20°C (LONGER) | India | Streptococcus Group B and E.coli K1 are the two most common causes of Neonatal sepsis while in older age group the commonest isolates are H. influenzae Type B, S. pneumoniae and N.meningitidis A, B, C, Y and W135. Early identification of these infecting agents helps in providing patients with appropriate antibiotic therapy. |
| 762 | 9883 | BACTERIAL MENINGITIS MULTIPLEX PCR (H. Influenzae, N. Meningitidis, S.Pnemoniae) | MULTIPLEX POLYMERASE CHAIN REACTION | CSF/THROAT SWAB | A | India | This assay is useful for the detection of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae |
| 763 | 9886 | BACTERIAL PNEUMONIA PANEL (Mycoplasma Pneumoniae, S.Pneumoniae, Chlamydia Genus) | POLYMERASE CHAIN REACTION | SWAB (THROAT SWAB / NASOPHARYNGEAL SWAB) / RESPIRATORY SECRETIONS / BAL | F | India | This assay is useful for the detection of Mycoplasma pneumoniae, Streptococcus pneumoniae and Chlamydia Genus |
| 764 | 7618 | B-Acute Lymphoblastic Leukemia MRD | FLOW CYTOMETRY | 2 ml bone marrow should be collected in both EDTA (lavender top) and Heparin tubes (green top). Sample should be transported at ambient temperature (DO NOT FREEZE) and should reach laboratory preferably within 24 hrs of collection. Filled history sheet, initial Immunophenotyping report/data and Flow Cytometry scatter plots reported at the time of diagnosis/presentation shall be sent along with sample. | A | India | Detection of Minimal Residual Disease (MRD) in Acute lymphoblastic leukemia predicts outcome. This assay can identify patients at higher/lower risk of relapse. Detection of MRD is important for risk assessment and stratification of therapy |
| 765 | 4068 | B-CAROTENE,SERUM | Spectrophotometry | INSTRUCTION: FASTING SERUM (BLOOD TO BE COLLECTED IN RED TOP VACUTAINER TUBE) IN PLASTIC VIAL, WRAPPED IN ALUMINIUM FOIL. PLEASE FORWARD CLINICAL DETAILS ALONG WITH THE SPECIMEN. | FROZEN | India | Carotenes are precursors of Vitamin A and highest levels are found in individuals ingesting large amounts of carrots. Moderate elevations are seen in patients with Diabetes mellitus, Myxedema, Hyperlipidemia and Chronic Nephritis. Decreased levels are seen in nutritional deficiencies including Anorexia nervosa, Malabsorption and Steatorrhea. Individuals with Lycopenemia show normal carotene levels. |
| 766 | Z271K | B-CATENIN | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | identification of β-Catenin protein. Beta Catenin is useful in the diagnosis of Desmoid type Fibromatosis and in the differential diagnosis of spindle cell lesions. β-Catenin is also expressed in a wide range of other neoplasms. |
| 767 | 9907 | B-CELL GENE REARRANGEMENT | POLYMERASE CHAIN REACTION/ FRAGMENT ANALYSIS | EDTA BONE MARROW / EDTA WHOLE BLOOD / PARAFFIN BLOCK+CLINICAL HISTORY | A / A / A | India | A reactive, benign Bcell proliferation is characterized by polyclonal expansion of Bcells whereas a malignant process is often characterized by a clonal expansion of a predominant Bcell population. In conjunction with histopathology study of lymph nodes, bone marrow and other tissue types, the detection of a clonal immunoglobulin heavy chain gene rearrangement by polymerase chain reaction (PCR) is intended as an aid in the diagnosis of malignant Bcell lymphoma. |
| 768 | Z014K | BCL-2 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY. IF TISSUE RECD. , THEN TISSUE PROCESSING WILL BE CHARGED. | A | India | B-cell lymphoma 2 (BCL2) was the first of the translocation-associated proteins to be identified in lymphoma. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease progression. BCL2 is also expressed in a wide range of other neoplasms. |
| 769 | Z254K | BCL-6 ONCOPROTEIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | bcl6 is a transcriptional regulator gene whose expression is seen in approximately 68% of ALK positive Anaplastic Large cell Lymphomas (ALCL). It is also expressed in Follicular lymphomas, Diffuse Large B cell Lymphomas, Burkitt Lymphomas and majority of Reed Sternberg cells in Nodular lymphocyte predominant Hodgkin Lymphoma. |
| 770 | 5834 | BCR/ abl Gene rearrangement (PHILADELPHIA CHROMOSOME) | CELL CULTURE | BONE MARROW OR WB SODIUM HEPARIN + CLINICAL HISTORY.SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | The Ph chromosome causing the BCR/ABL fusion, is present in approximately 95% of CML and 2530% of ALL cases. |
| 771 | 5351 | BCR-ABL 1 KINASE DOMAIN MUTATION ANALYSIS | NESTED PCR SEQUENCING | WHOLE BLOOD-EDTA/ BONE MARROW EDTA TRANSPORT AT COLD ( 2-8°C), (SPECIMEN TO REACH US WITHIN 48 HRS)+CLINICAL HISTORY) | COLD (2-8 OR FROZEN (-20°C))/ 2-8°C) | India | Evaluating patients with CML and Philadelphia chromosome positive B-cell ALL receiving TKI, therapy, who are apparently failing treatment. |
| 772 | 6001F | BCR-abl t(9:22) (Philadelphia Chromosome) | FISH | WB OR BONE MARROW – SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS AFTER COLLECTION.. [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | The Ph chromosome causing the BCR/ABL fusion, is present in approximately 95% of CML and 2530% of ALL cases. |
| 773 | 1720 | BETA 2 GLYCOPROTEIN IGG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (14 DAYS), >14 DAYS -20°C | India | Anti Beta 2 Glycoprotein 1 (Beta 2GP1) antibodies are independent risk factor for thrombosis in autoimmune diseases and complications of pregnancy. Presence of these antibodies can also be helpful in the diagnosis of Antiphospholipid syndrome. |
| 774 | 1719 | BETA 2 GLYCOPROTEIN IGM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (14 DAYS), >14 DAYS -20°C | India | Anti Beta 2 Glycoprotein 1 (Beta 2GP1) antibodies are independent risk factor for thrombosis in autoimmune diseases and complications of pregnancy. Presence of these antibodies can also be helpful in the diagnosis of Antiphospholipid syndrome. |
| 775 | 1058 | BETA CROSSLAPS (BETA CTX) (CTx-1) | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History |
FROZEN: UP TO 3 MONTHS | India | BetaCrosslaps is released into the bloodstream during bone resorption and serves as a specific marker for the degradation of mature type I collagen. It can be used to monitor antiresorptive therapy; treatment response is demonstrated as early as three months in contrast to Bone mineral density which may take two years to produce reliable results. |
| 776 | 3143U | BETA-2-MICROGLOBULIN | CHEMILUMINESCENCE | URINE (First void the urinary bladder, then drink a large glass of water and collect a URINE sample within 1 hour). Clinical History | 2-8°C (48 hrs); F (>48 hrs) | India | This assay is useful for evaluating prognosis of Multiple myeloma. It is also used for the evaluation of Renal tubular disorders where serum levels are low but urine levels are high. |
| 777 | Z073K | BETA-HUMAN CHORIONIC GONADOTROPIN, (BETA hCG) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY. IF TISSUE RECD., THEN TISSUE PROCESSING WILL BE CHARGED. | A | India | Human Chorionic Gonadotropin (HCG) is a glycoprotein, which is secreted in large quantities by normal trophoblasts. It is present only in trace amounts in nonpregnant urine and sera but rises sharply during pregnancy. HCG is composed of two nonidentical, noncovalently linked polypeptide chains designated as the alphaand Betasubunits. The alphasubunit of HCG is nearly identical to that of thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). A germ cell tumor which is positive for cytokeratin, placental alkaline phosphatase (PLAP), and HCG but negative for EMA and AFP is probably a choriocarcinoma. |
| 778 | 3184C | BETA-HUMAN CHORIONIC GONADOTROPIN, CSF (BETA hCG) | CHEMILUMINESCENCE | CSF | R/F | India | Beta hCG CSF is evaluated to calculate CSF : Serum ratios to monitor presence of Cerebral Metastasis, response to treatment as also tumour recurrence amongst patients with gonadal tumors. This ratio is generally of significance in males with nonseminomatous Testicular Tumours. CSF:Serum ratio is greater than 1:60 and ratios less than 1:40 are suspicious for presence of cerebral metastasis. |
| 779 | 8161 | BIOFIRE PNEUMONIA PLUS PANEL | Multiplex RT PCR (FDA approved) |
Sputum/Endotracheal Secretion /BAL Fluid in sterile container | STRICTLY REFRIGERATED | India | N/A |
| 780 | 8055 | BIOFIRE BLOOD PANEL | Multiplex RT PCR (FDA approved) |
Positive culture Bactec bottle | ambient | India | N/A |
| 781 | 8056 | BIOFIRE CSF PANEL | Multiplex RT PCR (FDA approved) |
CSF Sample in Sterile,leakproof, screw tight Container. | STRICTLY REFRIGERATED | India | N/A |
| 782 | 8057 | BIOFIRE GI PANEL | Multiplex RT PCR (FDA approved |
Stool, Rectal Swab : Sample in Sterile, leakproof, screw tight Container. | STRICTLY REFRIGERATED | India | N/A |
| 783 | 8054 | BIOFIRE RESPIRATORY PANEL | Multiplex RT PCR | Nasopharyngeal/Swab/Throat Swab Swab in Viral Transport Medium.
Sputum/BAL/Endotracheal Secretion in Sterile ,leakproof, screw tight Container. |
STRICTLY REFRIGERATED | India | N/A |
| 784 | 1528 | BIOPSY & IMMUNOFLUORESCENT ASSAY; (HISTOPATH + IgG + IgA + IgM + C-3 + C1q + FIBRINOGEN ON TISSUE) | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + 10% FORMALIN FIXED TISSUE (HP) + CLINICAL HISTORY | A | India | Histopathological diagnosis of specimen including immunofluroscent assay ( IGG, IGA, IGM, C3, c1q and fIbrinogen on tissue ) |
| 785 | 1509 | BIOPSY (BONE HISTOPATHOLOGY) | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN + SITE OF BIOPSY + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of bone specimen with final interpretation |
| 786 | 1509P | BIOPSY (BONE HISTOPATHOLOGY) – PHOTO | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN+ SITE OF BIOPSY+ CLINICAL DETAILS . RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Bone biopsy staining with enclosed photo |
| 787 | 1507 | BIOPSY (LARGE TISSUE / SPECIMEN) | HISTOPATHOLOGY | TISSUE IN 10%FORMALIN+ SITE OF BIOPSY SPECIMEN + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation. |
| 788 | 1511 | BIOPSY (MEDIUM TISSUE / SPECIMEN) | HISTOPATHOLOGY | TISSUE IN 10%FORMALIN+ SITE + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation |
| 789 | P0002 | BIOPSY (PHOTO) – IFA | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN+ SITE OF BIOPSY + CLINICAL DETAILS RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | IFA of given specimen with enclosed photo |
| 790 | 1502P | BIOPSY (SKIN HISTOPATHOLOGY) -(PHOTO) | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN- SMALL + CLINICAL HISTORY | A | India | Histopathological processing of specimen with final interpretation (skin) |
| 791 | 1502 | BIOPSY (SKIN HISTOPATHOLOGY) | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN – SMALL + CLINICAL HISTORY | A | India | Histopathological processing of specimen with final interpretation (skin). |
| 792 | 1500 | BIOPSY (SMALL TISSUE BIOPSY / SPECIMEN) | HISTOPATHOLOGY | TISSUE FIXED IN 10% FORMALIN+ SITE OF BIOPSY + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation; |
| 793 | 1500P | BIOPSY (SMALL TISSUE BIOPSY / SPECIMEN) (PHOTO) | HISTOPATHOLOGY | TISSUE + SITE OF BIOPSY + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation’ |
| 794 | 1528P | BIOPSY KIDNEY & IMMUNOFLUORESCENT ASSAY; (HISTOPATH + IgG + IgA + IgM + C-3 + C1q + FIBRINOGEN ON TISSUE ) | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + 10% FORMALIN FIXED TISSUE (HP) + CLINICAL HISTORY | A | India | Histopathological diagnosis of specimen including immunofluroscent assay ( IGG, IGA, IGM, C3,c1q and fIbrinogen on tissue) |
| 795 | P0001 | BIOPSY(PHOTO) – SINGLE (HP) | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN+ SITE OF BIOPSY + CLINICAL DETAILS RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation: |
| 796 | 1519 | BIOPSY; BRAIN BIOPSY WITH SPECIAL STAINS (PTAH & RETICULIN) | HISTOPATHOLOGY | TISSUE FIXED IN 10% BUFFERED FORMALIN + SITE OF BIOPSY + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: CT/MRI PLATES OR REPORT-PLATES ARE PREFFERED. | A | India | Histopathological processing of specimen with final interpretation of brain specimen with two special stains (PTAH & RETICULIN) |
| 797 | Z202K | BIOPSY; H&E SLIDE FOR REVIEW (MORE THAN 2 SLIDES / PARAFFIN BLOCKS) | HISTOPATHOLOGY | PARAFFIN BLOCK / SLIDE + CLINICAL HISTORY + SITE OF BIOPSY | A | India | H&E SLIDE/ block FOR REVIEW (MORE THAN 2 SLIDES) |
| 798 | Z201K | BIOPSY; H&E SLIDE FOR REVIEW (UPTO 2 SLIDES / PARAFFIN BLOCKS) | HISTOPATHOLOGY | PARAFFIN BLOCK / SLIDE + CLINICAL HISTORY + SITE OF BIOPSY | A | India | H&E SLIDE/ block FOR REVIEW (UPTO 2 SLIDES ) |
| 799 | 1533 | BIOPSY; MUSCLE BIOPSY WITH SPECIAL STAINS (MASSON TRICHOME) | HISTOPATHOLOGY | TISSUE FIXED IN 10% BUFFERED FORMALIN + SITE OF BIOPSY + CLINICAL DETAILS (EMG STUDIES, LAB. INVESTIGATIONS, DISTRIBUTION OF MUSCLE WEAKNESS) | A | India | STAINS CONNECTIVE TISSUE / MUSCLE |
| 800 | 1532 | BIOPSY; NERVE BIOPSY WITH SPECIAL STAINS (LUXOL FAST & GBS) | HISTOPATHOLOGY | TISSUE FIXED IN 10% BUFFERED FORMALIN + SITE OF BIOPSY + CLINICAL DETAILS (EMG NERVE CONDUCTION STUDIES, MOTOR / SENSORY LOSS, & SEGMENT INVOLVED) | A | India | Histopathological processing of nerve biopsy with final interpreatation including special stain (LUXOL FAST & GBS |
| 801 | 1534 | BIOPSY; RENAL BIOPSY WITH SPECIAL STAINS (PAS, GMS & OTHER AS REQUIRED FOR EX: CONGORED IN AMYLOIDOSIS) | HISTOPATHOLOGY | TISSUE FIXED IN 10% BUFFERED FORMALIN + SITE OF BIOPSY + CLINICAL DETAILS. RENAL FUNCTION TESTS, INCLUDING 24 HRS URINE PROTEIN. | A | India | This test is useful for evaluation of patients with undiagnosed kidney disease. It helps in following the course of therapy or disease progression. It also diagnoses disease caused by immune mechanisms. Biopsy of transplanted kidney is particularly important in determination of acute rejection, infection or recurrent disease. |
| 802 | 9359 | BIOTINIDASE (BIOT) > 1 MONTH | Colorimetry/FEIA | Dried blood spots | Ambient | India | Preferred test for diagnosing biotinidase deficiency |
| 803 | 9300 | BIOTINIDASE, SERUM | Spectrophotometric | SERUM | FROZEN | India | Biotinidase deficiency is an autosomal recessive disoder caused by mutations in the biotinidase gene. Age of onset and clinical phenotype vary depending on the amount of residual Biotinidase activity. The combined incidence of profound and partial Biotinidase deficiency is 1 in 61000. The carrier frequency in the general population is 1 in 120. This assay is used for diagnosing biotinidase deficiency. It is also useful for follow up testing for certain Organic acidurias. |
| 804 | RD1470 | BK VIRUS DNA QUANTITATIVE | Real time PCR | EDTA WHOLE BLOOD/RANDOM URINE.SPECIMEN COLLECTION INSTRUCTIONS: EDTA WHOLE BLOOD/ RANDOM URINE.SAMPLE SHOULD REACH SRL, MUMBAI WITHIN 24HRS OF COLLECTION. | REFRIGERATED | India | This test is useful for the detection of BK virus which is linked to Transplant associated Nephropathy. The virus disseminates to the kidneys and urinary tract where it persists for the life of the individual. Approximately 80% of the population contains a latent form of this virus, which manifests in cases of immunosuppressio n. |
| 805 | 5814F | BLOOD LYMPHO CULTURE BY FISH (Detects only five chromossomes -Down’s syndrome,ambigious genetalia etc.) | FISH | WB-HEPARIN + FAMILY HISTORY+DETAILED PHYSICAL FEATURES.SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. | A | India | Chromosome analysis helps in the diagnosis of a wide variety of congenital conditions. It helps in the identification of congenital chromosome abnormalities like Aneuploidy (Trisomy / Monosomy) & structural chromosome abnormalities. |
| 806 | 1515SF | BODY FLUID FOR CYTOLOGY | CYTOLOGY | FLUID ( Clinical history required )please mention date and time drawn | A – FLUIDS | India | Screening of body fluids and other body discharges by Papanicoloau staining helps in the early detection of malignancies. |
| 807 | 1014 | BOH PANEL (LUPUS ANTICOAGULANT ASSAY, Antiphospholipid Evaluation, TORCH IgG & IgM 10 Parameter, ANA, TSH, Factor V Leiden (optional, if required will be charged additionally, EDTA WB required. | CLOT BASED & ENZYME IMMUNOASSAY/IFA/CHEMILUMINECENCE | DOUBEL CENTRIFUGED PLASMA CITRATE(F)+SERUM(R)+CLINICAL HISTORY+H/O ORAL ANTICOAGULANT | Lupus : Frozen (F immediately at -20°c & transported in dry ice) R/F | India | Autoimmune conditions manifest with fetal loss and thrombosis and are significantly related to bad obstetric history.Antiphospholipid syndrome (APS) is a major reproductive complication in women, which is characterized by recurrent fetal loss, thrombosis, and thrombocytopenia in association with Anticardiolipin antibodies (aCL). Presence of Anticardiolipin antibodies interferes in very early pregnancy at the stage of fetal implantation, by impeding normal reproductive event. It has been reported that 8-42% of recurrent pregnancy loss is due to the presence of these autoantibodies. Torch panel – To detect certain infectious diseases that can cause birth defects in a newborn; sometimes to screen pregnant women for these infections. |
| 808 | 4638 | BOH TOTAL (TORCH IgG & IgM 10 Parameter, TSH, Lupus Anticoagulant Screen, Cardiolipin IgG & IgM Abs, Beta 2 Glycoprotein IgG & IgM Abs) | CLOT BASED & ENZYME IMMUNOASSAY/ CHEMILUMINECENCE | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C *(DOUBLE CENTRIFUGED PLASMA)* + SERUM (R) + CLINICAL HISTORY+ H/O ORAL ANTI COAGULANT (PT. SHOULD BE OFF ANTICOAGULATION FOR 7 DAYS) | F (To be F immediately at -20°c & transported in dry ice) /2-8°C (3 DAYS), >3DAYS -20°C TORCH DAILY 3 AM, 15.30 PM TSH DAILY (MON – SAT) 1600 HRS and | India | Torch panel – To detect certain infectious diseases that can cause birth defects in a newborn; sometimes to screen pregnant women for these infections. Autoimmune conditions manifest with fetal loss and thrombosis and are significantly related to bad obstetric history.Antiphospholipid syndrome (APS) is a major reproductive complication in women, which is characterized by recurrent fetal loss, thrombosis, and thrombocytopenia in association with Anticardiolipin antibodies (aCL). Presence of Anticardiolipin antibodies interferes in very early pregnancy at the stage of fetal implantation, by impeding normal reproductive event. It has been reported that 8-42% of recurrent pregnancy loss is due to the presence of these autoantibodies. Anti Beta 2 Glycoprotein 1 (Beta 2GP1) antibodies are independent risk factor for thrombosis in autoimmune diseases and complications of pregnancy. |
| 809 | 9214RFX | BONE MARROW ASPIRATION REFLEX WITH MPO | MICROSCOPY+ CYTOCHEMISTRY SPECIAL STAINS | BONE MARROW SMEAR + PERIPHERIAL SMEAR + CLINICAL HISTORY | A | India | Diagnose a disease or condition involving the bone marrow or blood cells Determine the stage or progression of a disease Check iron levels and metabolism Monitor treatment of a disease Investigate a fever of unknown origin Bone marrow biopsy and aspiration may be used for many conditions. These include: Anemia |
| 810 | 1054 | BONE MARROW ASPIRATION SMEARS | MICROSCOPY | BONE MARROW SMEAR + PERIPHERIAL SMEAR + CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | Examination of Bone Marrow is required for further workup of hematological abnormalities observed in peripheral blood, staging for bone marrow involvement by metastatic tumors, assessment of infectious disease processes including fever of unknown origin and in the evaluation of metabolic storage diseases. |
| 811 | 1500BM | BONE MARROW BIOPSY | HISTOPATHOLOGY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Bone Marrow Aspiration Report Mandatory). | A | India | #N/A |
| 812 | 9222RFX | BONE MARROW REFLEX TO LAP | MICROSCOPY + CYTOCHEMISTRY SPECIAL STAINS | BONE MARROW SMEAR + PERIPHERIAL SMEAR + CLINICAL HISTORY | A | India | Diagnose a disease or condition involving the bone marrow or blood cells Determine the stage or progression of a disease Check iron levels and metabolism Monitor treatment of a disease Investigate a fever of unknown origin Bone marrow biopsy and aspiration may be used for many conditions. These include: Anemia Blood cell conditions in which too few or too many of certain types of blood cells are produced, such as leukopenia, leukocytosis, thrombocytopenia, thrombocytosis, pancytopenia and polycythemia Cancers of the blood or bone marrow, including leukemias, lymphomas and multiple myeloma Cancers that have spread from another area, such as breast, into the bone marrow Hemochromatosis with LAP score |
| 813 | 4052 | BORDETELLA PERTUSSIS IGG (SERUM,EIA) | EIA | SERUM | FROZEN/REFRIGERATED | India | To detect IgG antibodies to B. pertussis |
| 814 | RD1317 | BRAF V600E Mutation | Real Time PCR | PARAFFIN BLOCK Tissue embedded in Paraffin block + CLINICAL HISTORY | A | India | BRAF mutation is found in a variety of cancers. Patients exhibiting these mutations benefit from BRAF inhibitors. |
| 815 | 1519K | BRAIN BIOPSY WITH CUSTOM IHC | Histopathology + IHC | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & CT/MRI Report/Plates/Images Mandatory) . | A | India | #N/A |
| 816 | RD1421 | BRCA 1 & 2 GENETIC TEST – BREAST CANCER | Next Generation Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | A test that detects some of the mutations in the BRCA gene which is linked to breast cancer. This assay is useful for screening family members of known Breast cancer patients. |
| 817 | 1692 | BREAST CA PANEL (ER, PGR, HER2/neu, KI-67) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN FOR 24-48 HRS/ PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING.* TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* | A | India | ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her2/neu expression shows responsiveness to Herceptin therapy. |
| 818 | 1811 | BREAST CANCER PROGNOSIS TUMOR PROFILE #5A (ER, PGR, HER 2-neu, , EGFR, DNA PLOIDY) | IMMUNOHISTOCHEMISTRY / FLOW CYTOMETRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK (SITE OF BIOPSY & CLINICAL DETAILS MANDATORY)MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED TIME AND DURATION OR FIXATION SHOULD BE MENTION ON TRF | A | India | BREAST CANCER PROGNOSIS TUMOR PROFILE: (ER, PGR, HER 2-neu, , EGFR, DNA PLOIDY) |
| 819 | 1816 | BREAST CANCER PROGNOSIS TUMOR PROFILE #6A (ER, PGR, DNA PLOIDY, EGFR, HER 2neu, KI -67, , P53) | IMMUNOHISTOCHEMISTRY / FLOW CYTOMETRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK (SITE OF BIOPSY & CLINICAL DETAILS MANDATORY)MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED TIME AND DURATION OR FIXATION SHOULD BE MENTION ON TRF | A | India | BREAST CANCER PROGNOSIS TUMOR PROFILE: (ER, PGR, DNA PLOIDY, EGFR, HER 2neu, KI -67, , P53) |
| 820 | 1831K | BREAST EVALUATION PANEL (ER, PGR, HER2/neu) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN FOR 24-48 HRS/ PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING.* TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* | A | India | ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her2/neu expression shows responsiveness to Herceptin therapy. |
| 821 | 1531 | C 1 Esterase Functional | ENZYME IMMUNOASSAY | SERUM / EDTA PLASMA | FROZEN | India | C1 esterase is decreased in Angioedema. The inherited form is usually diagnosed in the first two decades of life. The acquired form affects primarily adults with autoimmune or lymphoproliferative disorders. Approximately 15% of patients with Hereditary angioedema have a normal concentration of the protein but it is dysfunctional. |
| 822 | 1218T | C DIFFICILE TOXIN A/B: RAPID TEST | RAPID ENZYME IMMUNOASSAY | STOOL in sterile leak proof Container | R if specimen with in 24 hrs of collection. If received >24 hrs from collection then required F at -20 deg C | India | Clostridium difficile is a bacterial pathogen that causes Pseudomembran ous colitis and antibiotic associated diarrhoea. It produces toxins A & B which are enterotoxins. A positive result is considered presumptive evidence of Clostridium diffcile infection. |
| 823 | RD1450 | C.diptheria Toxin A and B PCR | PCR | THROAT SWAB IN STUARTS TRANSPORT MEDIUM, PURE CULTURE ISOLATES | AMBIENT | India | This test is detects both the A and the B subunits of the diphtheria toxin gene. |
| 824 | RD1309 | C0NNEXIN 26 MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Cx26 testing can help to identify the cause of the hearing loss as well as can predict the prognosis of the hearing loss (most Cx26 hearing loss does not worsen). It can also help with treatment decisions (most Cx26 hearing loss responds well to hearing aids and/or cochlear implants). In addition, identifying Cx26 mutations as the cause of a person’s hearing loss will reduce the need to perform other clinical tests. Furthermore, a positive test result can assure the family that no other problems associated with a syndromic form of hearing loss will develop. Testing can also help predict the likelihood that future children in the family will be born with hearing loss. |
| 825 | 1526 | C3, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA +CLINICAL HISTORY | A | India | to help monitor the activity of autoimmune diseases and immune complex-related diseases |
| 826 | 1554 | C4C | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 827 | 1500CD | C4d IMMUNOFLOURESCENCE | IMMUNO FLUORESCENT ASSAY | KIDNEY TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | useful method to detect antibody-mediated rejection in situ. |
| 828 | 3121F | CA 125 / OVARIAN CANCER MONITOR | CHEMILUMINESCENCE | FLUID ( Clinical history required ) | R | India | CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in patients under treatment for ovarian cancer. |
| 829 | Z057K | CA 125 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | CA125 reacts with most epithelial ovarian neoplasms of serous, endometrioid, clear cell and undifferentiated types. CA125 is a useful tumor marker for ovarian carcinomas; however, CA125 has also been described in other neoplasms such as seminal vesicle and anaplastic lymphomas. No reactivity has been shown for mucinous ovarian tumors. |
| 830 | Z111K | CA 19-9 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Gastrointestinal carcinomas are positive, as well as transitional cell carcinomas of the bladder, endometrial adenocarcinomas, thyroid papillary, gallbladder carcinomas and lung carcinomas, including adenocarcinomas, bronchoalveolar cell carcinomas, squamous and small cell carcinomas. |
| 831 | 4117 | CA 72.4 | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History |
2-8°C (30 days); F (3 MONTHS) | India | CA 72.4 is most useful as a marker for Gastrointestinal cancer, but blood levels may be increased in other malignancies like Lung cancer and nonmalignant disorders involving Gastrointestinal tissues. |
| 832 | 9143U24 | CADMIUM, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) AFTER SHAKING THE TAKE THE ALIQUOT IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTTLE BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F (>5 – 30DAYS) | India | This assay is useful in detecting exposure to Cadmium, a toxic heavy metal leading to kidney damage. Breathing the fumes of Cadmium vapours leads to Chronic emphysema. The commonest source of cadmium exposure is from spray painting of organic based paints and also from tobacco smoke. The latter leads to reproductive toxicity in both males and females. |
| 833 | 9143 | CADMIUM, BLOOD | GFAAS WITH ZEEMAN CORRECTION | IMPROVE/BD, SRL EDTA WHOLE BLOOD | 2-8°C (7 DAYS); F (>7 – 30DAYS) | India | This assay is useful in detecting exposure to Cadmium, a toxic heavy metal leading to kidney damage. Breathing the fumes of Cadmium vapours leads to Chronic emphysema. The commonest source of cadmium exposure is from spray painting of organic based paints and also from tobacco smoke. The latter leads to reproductive toxicity in both males and females. |
| 834 | 9143U | CADMIUM, URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 – 30DAYS) | India | This assay is useful in detecting exposure to Cadmium, a toxic heavy metal leading to kidney damage. Breathing the fumes of Cadmium vapours leads to Chronic emphysema. The commonest source of cadmium exposure is from spray painting of organic based paints and also from tobacco smoke. The latter leads to reproductive toxicity in both males and females. |
| 835 | 3126 | CALCITONIN | CHEMILUMINESCENCE | SERUM ( CLINICAL HISTORY REQUIRED ) | FROZEN: UP TO 2 WEEKS | India | Calcitonin is a hormone secreted by parafollicular C cells of thyroid gland. This assay is useful for the diagnosis and follow up of Medullary carcinoma thyroid, as an adjunct to diagnosis of Multiple Endocrine Neoplasia Type II and Familial Medullary thyroid carcinoma. It is occasionally used in the diagnosis and followup of Islet Cell tumors. |
| 836 | Z171K | CALCITONIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | The IHC demonstration of calcitonin is important: (1) For identification of early or microscopic medullary thyroid cancer (MTC), (2) To identify an MTC in the absence of amyloid deposits, (3) To distinguish non-typical forms of MTC (e.g., predominantly spindle cell or small cell patterns) from anaplastic carcinoma or malignant lymphoma, (4) To differentiate MTC with microfollicular or papillary patterns from thyroid follicular and papillary neoplasms and (5) To identify C-cell hyperplasia in association with hypercalcemia of diverse etiologies. |
| 837 | Z223K | CALPONIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | The expression of calponin is restricted to smooth muscle cells. Two isoforms of calponin exist with molecular weights of 34kDa and 29kDa. Expression of the 29kDa form is primarily restricted to muscle of the urogenital tract. Calponin also labels myoepithelial cells and can be useful in distinguishing in situ from infiltrating breast carcinoma. |
| 838 | 9980 | CALPROTECTIN | FLUOROENZYME IMMUNOASSAY | STOOL | 2-8°C (2days); -20°C (>2 days) | India | Calprotectin is a neutrophilic marker specific for inflammation in the gastrointestinal tract. It is elevated in cases of infections, postinfectious Inflammatory Bowel Syndrome (IBS) & NSAID Enteropathy. Fecal calprotectin is used to differentiate IBD from IBS, to monitor treatment in IBD & to determine patients to be referred for endoscopy and / or colonoscopy. |
| 839 | RD1476 | CALR GENE MUTATIONS | PCR-SEQUENCING | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY in specified format | A | India | Somatic mutations in the calreticulin gene (CALR) are detected in peripheral blood in 6585% of Essential thrombocythemia (ET) and Primary myelofibrosis (PMF) patients that are JAK2 and MPL mutation negative. |
| 840 | Z058K | CALRETENIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Calretinin is the most specific and reproducible positive marker of epithelial mesothelioma. |
| 841 | 5704 | CAMPYLOBACTER SPECIES CULTURE | CULTURE | RECTAL BIOPSY, STOOL IN TRANSPORT MEDIA (TRANSPORT MEDIA MANDATORY),BODY FLUID/BLOOD INOCULATED IN BACTEC BOTTLE (AEROBIC PLUS ) | R | India | To detect camplobacter species in the given specimen |
| 842 | 4907 | CANASSIST BREAST | IHC + Machine learning | IHC Performed blocks | 0 | India | N/A |
| 843 | 2330 | CANDIDA ALBICANS ANTIBODIES | INDIRECT HAEMAGGLUTINATION | SERUM | 2-8°C (24 HRS); -20°C (>24 HRS) | India | Identification and sensitivity testing is important for various Candida species like C.albicans, C.parapsilosis, C.glabrata, C.guilliermondii and C.krusei as these species show variable sensitivity profile to antifungal drugs |
| 844 | 2331 | CANDIDA ALBICANS DNA DETECTOR | PCR-SEQUENCING | SPUTUM / CSF / FLUIDS / TISSUES + CLINICAL HISTORY | A | India | This assay is useful for the detection on Candida albicans which is the major cause of invasive candidiasis. It is most frequently isolated pathogen from the blood of postoperative and immunocompromi sed patients. |
| 845 | 4116 | CARBAMAZEPINE( TEGRETOL) | CHEMILUMINESCENCE | SERUM ( TREATMENT HISTORY REQUIRED ) FOR THERAPEUTIC LEVELS SAMPLE SHOULD BE COLLECTED JUST BEFORE ORAL DOSE. FOR TOXIC LEVELS COLLECTION SHOULD BE 4-8 HOURS POST DOSE | 2-8°C (48 hrs); F (>48 hrs) | India | To detect therapeutic and toxic range of CARBAMAZEPINE |
| 846 | 4521 | CARBOHYDRATE DEFICIENT TRANSFERRIN (CDT) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (> 7 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | CDT has also proven successful in monitoring drinking status in patients under alcohol treatment. |
| 847 | 3258F | CARCINOEMBRYONIC ANTIGEN (CEA) | CHEMILUMINESCENCE | BODY FLUID ( Clinical history required ) | R | India | CEA values are important in diagnosis, status assessment and monitoring in cancers of breast, gastrointestinal tract, liver, pancreas, lungs, ovaries and prostate. |
| 848 | Z043K | CARCINOEMBRYONIC ANTIGEN (CEA) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Incresaed levels of CEA are found in patients with primary Colorectal carcinoma and other malignancies like Medullary thyroid carcinoma and Carcinoma of breast, GI tract, liver, lung, ovarian, pancreatic and prostate. Serial monitoring of CEA should begin prior to therapy to establish a baseline for evaluating possible recurrence. Levels generally return to normal within 1 to 4 months after removal of tumor. Smokers show a higher baseline level of CEA. |
| 849 | 3258C | CARCINOMBRYONIC ANTIGEN (CEA), CSF | CHEMILUMINESCENCE | CSF( Clinical history required ) | R | India | It is used for detecting meningeal carcinomatosis, intradural or extradural infiltration, or brain parenchymal metastasis from adenocarcinoma or squamous-cell carcinoma |
| 850 | 3370 | CARDIOLIPIN IGA ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (3 DAYS) ,>3DAYS -20°C | India | These antibodies are important as a diagnostic marker for a disorder called the “anti phospholipid syndrome”(APS). |
| 851 | RD1486 | CARDIONEXT PANEL | Next Generation Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | To assess heart health |
| 852 | 3304 | CATECHOLAMINES, PLASMA | ENZYME IMMUNOASSAY | THE BLOOD SAMPLE (EDTA)SHOULD BE STORED AT 2-8 DEGREE CELCIUS UNTIL CENTRIFUGED TO SEPARATE THE PLASMA WITHIN 2 HOURS AFTER BLOOD COLLECTION. KEEP AWAY FROM HEAT OR DIRECT SUN LIGHT.DO NOT CONSUME VITAMIN B ,COFFEE, BANANAS, ALPHA -METHYDOPA,MOA AND COMT INHIBITORSAS WELL AS MEDICATION RELATED TO HYPERTENSION 72 HRS PRIOR TO THE COLLECTION OF THE SPECIMEN.MENTION CLINICAL DETAILS(PATIENT CLINICAL HISTORY, CT SCAN,USG & MEDICATION) OF THE PATIENT ON THE REQ FORM.. | F FROZEN STRICTLY | India | Less than three fold elevations of catecholamine levels are observed in individuals with essential hypertension. Greater than three fold levels of catecholamines of persistent or of episodic nature are observed in pheochromocytoma. Drug related variance in catecholamine levels are seen in individuals on alpha methly dopa, methanamine mandelate and labetol. Discontinuation of these medications one week prior to catecholamine assay ensures accuracy of results. Interference in catecholamine assay due to synthetic catecholamine analyses e.g. isoproterenol and isoetharine needs correlation with clinical inputs. |
| 853 | 3304U | CATECHOLAMINES, URINE | ENZYME IMMUNOASSAY | 24HRS URINE (Preservative:15 – 20ML 6N HCL) . (The patient should not consume Vitamin B, COFFEE AND BANANAS, 48hrs prior to the collection of the specimen.It is advisable to discontinue all medications, alpha methyldopa, MAO & COMT Inhibitors as well as medications related to Hypertension should be discontinued atleast 72 hrs prior to specimen collection.If medications takenshould be STrictly on the advise of the referring physician, the same should be mentioned.Please freeze the specimen immediately after collection. CLINICAL DETAILS(Patient’s clinical history, CT SCAN , USG & MEDICATION MANDATORY) mention 24 hrs urine volume | FROZEN STRICTLY | India | This assay is useful in the diagnosis of Pheochromocytom a and Paraganglioma. It is also used as an auxillary test to Vanil Mandelic Acid & Homovanilic Acid determination in the diagnosis and followup of patients with Neuroblastoma and related tumors. |
| 854 | 9211RFX | CBC REFLEX TO LAP | AUTOMATED CELL COUNTER +MICROSCOPY + CYTOCHEMISTRY SPECIAL STAINS | EDTA WB +FRESH PERIPHERAL SMEARS (AIR DRIED) + CLINICAL HISTORY | A | India | To determine your general health status; to screen for, diagnose, or monitor any one of a variety of diseases and conditions that affect blood cells, such as anemia, infection, inflammation, bleeding disorder or cancer. LAP score test is used to differentiate Chronic Myeloid Leukemias from Leukemoid reaction and Polycythemia vera from secondary causes of erythrocytosis. |
| 855 | 1602 | CCD3 | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | It is expressed by mature T-lymphocytes and by a subset of thymocytes. |
| 856 | 1604 | CCD79A | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | B Lymphoid cell marker |
| 857 | Z219K | CD 10 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD10, also known as Common Acute Lymphocytic Leukemia Antigen (CALLA), is expressed in early lymphoid progenitors and normal germinal center cells. It is almost always present on the surface of precursor B-lymphoblastic and Burkitt lymphomas and much less frequently on precursor T-lymphoblastic leukemia-lymphoma. Many follicular lymphoma and some diffuse large B-cell lymphomas, along with multiple myeloma are positive. CD10 is also present on breast myoepithelial cells, bile canaliculi, fibroblasts and with especially high expression on the brush border of kidney and gut epithelial cells. CD10 is also a good marker of endometrial stomal sarcoma. |
| 858 | Z244K | CD 138 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Positive staining in tumors includes myeloma, primary effusion lymphoma. CD138 negative staining comprises mature B-cells and lymphomas (even plasmacytoid lymphomas). Many carcinomas also express CD138. |
| 859 | Z224K | CD 1a | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | CD1a is expressed on cortical thymocytes, Langerhans cells, and dendritic cells. It is absent on mature peripheral blood T-cells, but cytoplasmic expression is detected on activated T-lymphocytes. CD1a is found on a subset of T-lymphoblastic lymphoma-leukemia and cases of Langerhans cell histiocytosis. |
| 860 | Z248K | CD 56 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD56 recognizes two proteins of the neural cell adhesion molecule, the basic molecule expressed on most neuroectodermally-derived cell lines, tissues and neoplasms (e.g. retinoblastoma, medulloblastomas, astrocytomas, and neuroblastomas). It is also expressed on some mesodermally-derived tumors (rhabdomyosarcoma) and on natural killer cells. CD56 can be used as a marker for NK cell neoplasms. Some benign and malignant plasma cells are also positive. CD56 is often positive in neuroendocrine carcinomas |
| 861 | Z268K | CD 7 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | CD7 is expressed on the majority of immature and mature T-lymphocytes and T-cell leukemia. It is also found on natural killer cells, and a small subpopulation of normal and malignant B-cells. CD7 antibody can be useful for detection of T-cell leukemias and myeloid leukemias. CD7 expression is often lost in mycosis fungoides. |
| 862 | Z249K | CD 79A | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. |
| 863 | Z247K | CD 8 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD8 is a T-cell marker for the detection of cytotoxic/suppressor T-cells. CD8 is also detected on NK cells, most thymocytes, a subpopulation of null cells, and bone marrow cells. This antibody is useful in evaluating T-cell lymphomas. |
| 864 | 1676BC | CD10 (CALLA) | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM-HEPARIN+DIRECT SMEAR+FLUID SMEAR + CLINICAL HISTORY | A | India | Prognostic ALL marker |
| 865 | 1673 | CD103 | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Hairy cell marker |
| 866 | Z117K | CD117 / C-KIT | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Abnormal expression of cKit has been implicated in pathogenesis of myeloid leukemias. cKit expression has also been demonstrated in solid tumors including gastrointestinal stromal tumor (GIST), melanomas, breast carcinomas and small cell lung carcinoma. C-Kit is indicated as an aid in the differential diagnosis of GIST. Accurate assessment of CD117 protein expression using cKIT testing is a critical factor in the diagnosis of GIST and is becoming increasingly important in clinical management, including the use of imatinib mesylate (Gleevec®) therapy. |
| 867 | 1675BN | CD11c-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | In diseased, cells, CD11c is detected on acute myeloid leukemia (AML)-M4 and M5, hairy cell leukemia, lymphoplasmacytic lymphoma (81%), small lymphocytic lymphoma (SLL), splenic lymphoma, Langerhans cell histiocytosis, sinus histiocytosis, psoriatic skin lesions, and some follicular lymphomas. |
| 868 | 1674BI | CD13 PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | CD13 is a zinc-binding aminopeptidase expressed on the surface of myeloid precursors, mature granulocytic/monocytic cells and basophils. |
| 869 | 1674BJ | CD14 PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | CD14 stains normal macrophages/monocytes, granulocytes (weak), Langerhans cells, dendritic cells, and B cells. Positive staining in diseased cells comprises B-cell chronic lymphocytic leukemia (B-CLL), follicular center cell lymphoma, diffuse large B cell lymphoma (DLBCL), and acute myeloid leukemia (AML)-M4/M5. |
| 870 | Z030K | CD15 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Myeloid cell marker |
| 871 | 1674BK | CD15 PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | It is present on granulocytes, including neutrophils and eosinophils, and to a lesser degree on monocytes. CD15 is also expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is useful in the identification of Hodgkin lymphoma. CD15 is occasionally expressed in large cell lymphomas of both B- and T- phenotypes. |
| 872 | 1674BL | CD16+56-PERCENT + ABSOLUTE COUNTS | FLOW CYTOMETRY | WB- EDTA | WB- HEPARIN | WB / SMEARS + CLINICAL HISTORY(WB TO REACH WITHIN 48 HRS) | A | India | Pan B cell marker |
| 873 | 1675BS | CD19/KAPPA-PERCENT | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM-HEPARIN+DIRECT SMEAR+FLUID SMEAR + CLINICAL HISTORY | A | India | Pan B cell marker |
| 874 | 1675BT | CD19/LAMBDA-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Pan B cell marker |
| 875 | 1675BU | CD19/Tdt-PERCENT | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM-HEPARIN+DIRECT SMEAR+FLUID SMEAR + CLINICAL HISTORY | A | India | CLL segregation marker |
| 876 | 1675BA | CD19-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Pan B cell marker |
| 877 | Z022K | CD20 (PAN-B CELL) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Pan B cell marker |
| 878 | 1675BB | CD20-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Pan B cell marker |
| 879 | Z034K | CD21 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CLL segregation marker |
| 880 | 1677BD | CD22-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Pan B cell marker |
| 881 | Z261K | CD23 (IHC) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Hairy cell / NHL marker |
| 882 | 1677BC | CD23-PERCENT | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM-HEPARIN+DIRECT SMEAR+FLUID SMEAR + CLINICAL HISTORY | A | India | CLL segregation marker |
| 883 | 1674BM | CD25-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Hairy cell / NHL marker |
| 884 | 1675BC | CD2-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Pan T cell marker |
| 885 | Z023K | CD3 (PAN-T CELL) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Pan T cell marker |
| 886 | 1674BY | CD3/CD16+56-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Natural Killer cells |
| 887 | 1674BX | CD3/CD19-PERCENT | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM-HEPARIN+DIRECT SMEAR+FLUID SMEAR + CLINICAL HISTORY | A | India | The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage.CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. |
| 888 | 1674BU | CD3/CD4-ABSOLUTE | FLOW CYTOMETRY | WB-EDTA / HEPARIN + SMEAR (WB TO REACH WITHIN 48 HRS) | A | India | The test is performed to confirm the T cell lymphoma and also during the treatment and after the treatment of the T cell lymphoma. |
| 889 | 1674BZ | CD3/HLA-DR PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. To determine the expression of HLA-DR |
| 890 | Z029K | CD30 (KI-1 ANTIGEN) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | It is expressed in activated B-, T- and NK cells. Positive staining is seen in infectious mononucleosis, lymphocytes infected with HIV, HTLV-1, EBV, HHV8 or hepatitis B, Reed-Sternberg cells, anaplastic large cell lymphomas (90%), lymphomatoid papulosis, peripheral T-cell lymphomas, and embryonal cell tumors. |
| 891 | Z212K | CD31 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | This marker is highly restricted to endothelial neoplasms among all tumors of the soft tissue and its sensitivity is excellent. 100% of angiosarcomas and hemangiomas are CD31 positive. However, Kaposi’s sarcoma (KS) is labeled more consistently by CD34 than by CD31. CD31 has also been used as a prognostic marker measuring tumor angiogenesis. CD31 also stains histiocytes. |
| 892 | 1674BO | CD33 PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | CD33 is a useful marker to identify cells of myeloid and monocytic lineage, leukemias and myeloproliferative neoplasms derived from these cells.N/A |
| 893 | Z211K | CD34 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD34, a single chain transmembrane glycoprotein, is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and endothelial cells. CD34 antibody labels many gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, solitary fibrous tumor and a subset of sarcomas. CD34 staining has been also used to measure angiogenesis. |
| 894 | 1674BQ | CD38-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Plasma cell / prognostic CLL marker |
| 895 | 1659 | CD4 (LYMPHOCYTE SUBSET PERCENTAGE AND ABSOLUTE COUNT) | FLOW CYTOMETRY | EDTA WB ONLY (SAMPLE TO REACH LAB WITHIN 48 HOURS.) |
A | India | Helper T cell marker |
| 896 | Z025K | CD4 (T-Helper cell) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD4, a single chain transmembrane glycoprotein, is found on a T-cell subset (helper/inducer). It is also present on a variety of monocyte-derived cells, including Langerhans and other dendritic cells. The CD4 epitope is absent from immature thymocytes and is expressed during T-cell development. Precursor T-lymphoblastic lymphomas are therefore variable in their expression of CD4, but most mature T-cell lymphomas are positive, with the exception of aggressive NK-cell leukemia, extranodal NK-cell lymphoma, gamma delta T-cell lymphomas, and enteropathy-type T-cell lymphoma. |
| 897 | 1657B | CD4/CD8 (Lymphocyte Enumeration STudy-T Cells (%CD3,%CD4,%CD8,ABS CD3,ABS CD4,ABS CD8)) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 48 HRS) | A | India | This assay is helpful in enumerating the percent and absolute cell counts of T and B lymphocyte subsets in whole blood. |
| 898 | 1676BA | CD41 PERCENT | FLOW CYTOMETRY | EDTA +HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | Used to platelet-specific glycoproteins – platelet glycoprotein Iib |
| 899 | Z024K | CD43 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD43 (leukosialin, sialophorin, or leukocyte sialoglycoprotein) is a cell surface glycoprotein that is expressed on all thymocytes, T-cells, and cells of myeloid lineage. CD43 antibody can be useful in the diagnosis of T-cell lymphoma and a subset of B-cell lymphoma. CD43 expression in lymphomas is highly correlated with CD5; thus, most T-cell malignancies and a group of small lymphocyte B-cell malignancies (CLL/SLL, mantle cell lymphoma, and prolymphocytic leukemia (PLL)) are often positive, whereas follicular lymphoma is rarely positive. CD43 is also positive in about 50% of cases of Burkitt lymphoma. |
| 900 | Z021K | CD45 [Also called as LEUCOCYTE COMMON ANTIGEN (LCA)] | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD45 is expressed on hematopoietic cells (human leukocytes, including lymphocytes, monocytes, and eosinophils), but is absent on normal and malignant non-hematopoietic tissues. |
| 901 | 1676BB | CD45-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | CD45 is expressed on hematopoietic cells (human leukocytes, including lymphocytes, monocytes, and eosinophils), but is absent on normal and malignant non-hematopoietic tissues. |
| 902 | Z213K | CD5 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD5, a transmembrane protein, is found on most thymocytes and immature peripheral T-cells. It stains normal B-cells of mantle zone of spleen and lymph nodes, B-cells in peritoneal and pleural cavities, and almost all T-cells. In a fetus, most B-cells in spleen and cord blood are CD5 positive. It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma. |
| 903 | 1675BP | CD5/CD19-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. |
| 904 | 1675BD | CD5-PERCENT | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma. |
| 905 | 1677BE | CD61 PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | This antibody is useful in detecting neoplastic platelet precursors, normal platelets, and most cases of megakaryocytic leukemias. |
| 906 | Z026K | CD68 IHC, TISSUE/PARAFFIN BLOCK | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CD68 is an antibody directed against lysosomes. It is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, lamina propria of the gut, lung alveoli, and bone marrow. This antibody reacts with myeloid precursors and peripheral blood granulocytes. It shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with true histiocytic neoplasia. It also stains granular cell tumors and some cases of melanoma, renal cell carcinoma, and pleomorphic sarcoma. Tumors of lymphoid origin are usually not stained. |
| 907 | 1674BF | CD7- PERCENT | FLOW CYTOMETRY | EDTA and HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | CD7 is expressed on the majority of immature and mature T-lymphocytes and T-cell leukemia. It is also found on natural killer cells, and a small subpopulation of normal and malignant B-cells. CD7 antibody can be useful for detection of T-cell leukemias and myeloid leukemias. CD7 expression is often lost in mycosis fungoides. |
| 908 | 1351G | CDC CROSSMATCH | SEROLOGY | SODIUM HEPARIN WB OF DONOR & SERUM OF PATIENT.(SAMPLE IS TO BE COLLECTED AT LEAST AFTER 3 DAYS OF LAST DIALYSIS. CROSS MATCH SAMPLE IS TO BE COLLECTED AFTER THREE WEEKS OF LAST BLOOD TRANSFUSION. MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) APPLICABLE FOR SOLID ORGAN TRANSPLANT ONLY (LIVER & KIDNEY) | COLD PACK | India | HLA match shows the basic compatibility between two individuals for transplant. Cross match detects the precise reaction between the serum of patient and the cells of donor in presence of complements. |
| 909 | Z260K | CDX2 (IHC) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CDX2 is an intestinespecific transcription factor that regulates both proliferation and differentiation in intestinal epithelial cells. It plays an important role in triggering cells towards the phenotype of differentiated villus enterocytes as well as in the maintenance of the phenotype. It exclusively marks nuclei of colonic epithelial cells and colorectal cancers on formalinfixed, paraffinembedded tissue sections. |
| 910 | 7478 | CEBPA MUTATION DETECTION | PCR-SEQUENCING | EDTA WHOLE BLOOD/EDTA BONE MARROW + CLINICAL HISTORY | A | India | Mutation of CEBPA has been linked to good outcome in both adult and pediatric Acute myeloid leukemia patients |
| 911 | 7798 | CELIAC FLEXI 2 PANEL | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | To help diagnose celiac disease |
| 912 | 7799 | CELIAC FLEXI 3 PANEL | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | To help diagnose celiac disease |
| 913 | 1073 | CELIAC PROFILE (Ttg IgA ABS, Gliadin IgG & IgA ABS) | Enzyme Linked Immnunosorbent assay , FLUOROENZYME IMMUNOASSAY | SERUM | 2-8°C (2 days) ,>2 days -20°C | India | To help diagnose celiac disease |
| 914 | 7767 | CELIAC TISSUE BIOPSY | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | To help diagnose celiac disease |
| 915 | 7793 | CELIAC TISSUE BIOPSY PLUS | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | To help diagnose celiac disease |
| 916 | 1783 | CELL BLOCK PREPARATION FOR FLUID (ONLY BLOCK PREPARED) | CYTOLOGY | BODY FLUIDS OR ASPIRATES + SITE OF COLLECTION+ CLINICAL HISTORY &/OR RADIOLOGICAL FINDGS. | R FLUIDS /ASPIRATES, IF FLUID SENT WITHIN 24 HRS. FOR MORE THAN 24 HRS, MIX EQUAL PROPORTION OF FLUID WITH 50% ALCOHOL |
India | CELL BLOCK PREPARATION FOR FLUID |
| 917 | 1784 | CELL BLOCK PREPARATION FOR FLUID WITH IHC MARKERS STUDY | CYTOLOGY | BODY FLUIDS OR ASPIRATES + SITE OF COLLECTION+ CLINICAL HISTORY &/OR RADIOLOGICAL FINDGS. | R FLUIDS /ASPIRATES, IF FLUID SENT WITHIN 24 HRS. FOR MORE THAN 24 HRS, MIX EQUAL PROPORTION OF FLUID WITH 50% ALCOHOL |
India | CELL BLOCK PREPARATION FOR FLUID WITH IHC MARKERS STUDY |
| 918 | 1782 | CELL BLOCK PREPARATION FOR FLUID WITH REPORTING | CYTOLOGY | BODY FLUIDS OR ASPIRATES + SITE OF COLLECTION+ CLINICAL HISTORY &/OR RADIOLOGICAL FINDGS. | R FLUIDS /ASPIRATES, IF FLUID SENT WITHIN 24 HRS. FOR MORE THAN 24 HRS, MIX EQUAL PROPORTION OF FLUID WITH 50% ALCOHOL |
India | CELL BLOCK PREPARATION FOR FLUID WITH REPORTING |
| 919 | 1516D | CERULOPLASMIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (> 7 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Ceruloplasmin is an acute phase protein and a transport protein for copper. It is decreased in Wilson’s disease, an autosomal recessive disorder. Low levels may also occur in Menkes syndrome which is a genetic defect in copper absorption. |
| 920 | 1599 | CH 50 COMPLEMENT TOTAL SERUM | ELISA | SERUM | R | India | This assay is useful for the detection of individuals with an ongoing immune process. It should be used as a screening test for congenital complement deficiencies. Low levels are seen during infections, disease exacerbation in known cases of SLE and in patients with immune complex diseases like Glomerulonephritis . Undetectable levels indicate possibility of a complement component deficiency. |
| 921 | 8761 | CHICKEN POX (VARICELLA ZOSTER VIRUS (VZV) IgG ANTIBODIES) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Varicella Zoster virus (VZV) is a herpes virus causing Chickenpox as a primary infection & Herpes zoster due to reactivation of latent infection. A positive IgG result indicates exposure to VZV and immunity. |
| 922 | 8766 | CHICKEN POX (VARICELLA ZOSTER VIRUS (VZV) IgM ANTIBODIES) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Varicella Zoster virus (VZV) is a herpes virus causing Chickenpox as a primary infection & Herpes zoster due to reactivation of latent infection. This assay is useful for diagnosing acute phase infection with VZV. Negative results in suspected early VZV infection should be followed by serial testing 23 weeks apart. |
| 923 | 2492 | CHIKUNGUNYA IgM – RAPID | IMMUNOCONCENTRATION | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS) | India | CHIKUNGUNYA IgM ANTIBODIES RAPID Chikungunya fever is an acute viral infection characterized by a rapid transition from health to illness that includes severe arthralgia and fever. The incubation period ranges from 1 to 12 days. Fever rises abruptly to as high as 40°C and is often accompanied by shaking chills. Arthralgia is poly-articular, favoring the small joints and sites of previous injuries, and is most intense on arising. These symptoms may last for from 1 week to several months and are accompanied by myalgia. Headache, photophobia, retro-orbital pain, sore throat with objective signs of pharyngitis, nausea and vomiting also occur in this setting. The disease is self-limiting. There is no specific treatment or vaccine for Chikungunya; patients are only given symptomatic or supportive treatment. Test Utility: Clinical diagnosis of Chikungunya is confirmed by detection of anti-CHIK-IgM antibody. Antibodies usually become detectable, 5 days after onset of disease. Other methods include detection of CHIK nucleic acids in serum by RT-PCR test; or isolation of Chikungunya virus. Acute or viraemic phase serum samples collected within 2 to 4 days of onset have yielded positive virus isolates and detection of viral nucleic acids. The current test is a qualitative immuno concentration based rapid assay for the detection of IgM antibodies to Chikungunya. It is recommended that all positive specimens be retested with a confirmatory test. Limitations: Comment: A negative result may occur if the quantity of Anti- Chikungunya IgM present in the specimen is below the detection limit of the assay, or the antibodies that are detected are not present during the stage of disease when the specimen is collected. Certain specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results. Hence all results should be interpreted in conjunction with clinical findings and patient history. It is recommended that all positive specimens be retested with a confirmatory test. |
| 924 | 2491 | CHIKUNGUNYA IgM ANTIBODY, SERUM | Enzyme Linked Immnunosorbent assay | SERUM + CLINICAL HISTORY (DETAILS OF FEVER, SYMPTOMS ETC.) | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Chikungunya virus is transmitted by the bite of Aedes aegypti mosquito leading to Dengue like symptoms. However no hemorrhagic manifestations are seen. Absence of IgM antibody does not exclude the possibility of Chikungunya infection. |
| 925 | 7630 | CHIKUNGUNYA RNA PCR | Real Time PCR | SERUM / PLASMA EDTA | Frozen | India | Chikungunya virus is transmitted by the bite of Aedes aegypti mosquito leading to Dengue like symptoms. However no hemorrhagic manifestations are seen. PCR assay detects the presence of Chikungunya virus much earlier than the appearance of IgM antibodies. |
| 926 | RD1453 | CHIMERISM (Post -transplant) | STR Analysis | EDTA WHOLE BLOOD AND SWAB – RECIPIENT (ALONG WITH PREVIOUS ACCESSION NUMBER PRE-TRANSPLANT REPORT). IF PRE- TRANSPLANT TEST NOT PERFORMED AT SRL, DONOR WHOLE BLOOD REQUIRED | Ambient | India | Patients with hematopoietic cell infusions for the purpose of engraftment like bone marrow transplant recipients should have their blood or bone marrow monitored for an estimate of the percentage of donor and recipient cells. The presence of both types of cells (Chimerism) or donor cells alone is an indicator of transplant success. |
| 927 | RD1452 | CHIMERISM (Pre transplant, Donor and recipient) | STR Analysis | EDTA Whole Blood Donor + EDTA Whole Blood Recipient | Ambient | India | o Post-transplant monitoring of donor/recipient origin of white blood cells in peripheral blood and/or marrow. o Assessing risk of prognosis due to graft rejection and recurrence of disease. o Evaluating donor/recipient cells in patients with inadequate marrow function. o Determining if malignancy is a recurrence from recipient cells or a new occurrence from donor cells. o Differentiating donor cell populations in recipients who have received multiple transplants. |
| 928 | 7437 | CHLAMYDIA DNA DETECTOR | POLYMERASE CHAIN REACTION | URINE / GENITAL SWAB/URETHRAL SWAB/EYE SWAB | A/R/F | India | Chlamydia trachomatis is the most common sexually transmitted bacterial infection. Upto 70% of women and 30% of men may be asymptomatic. Infection can lead to tubal pregnancy, pelvic inflammatory disease and infertility |
| 929 | 9405 | CHLAMYDIA PNEUMONIAE ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 days), >5 days- 20 °C | India | Quantitative detection of CHLAMYDIA PNEUMONIAE ANTIBODIES |
| 930 | 9410 | CHLAMYDIA PNEUMONIAE IgA ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 days), >5 days- 20 °C | India | Quantitative detection of IgA ANTIBODIES to CHLAMYDIA PNEUMONIAE |
| 931 | 9408 | CHLAMYDIA PNEUMONIAE IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 days), >5 days- 20 °C | India | Quantitative detection of IgG ANTIBODIES to CHLAMYDIA PNEUMONIAE |
| 932 | 9409 | CHLAMYDIA PNEUMONIAE IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 days), >5 days- 20 °C | India | Quantitative detection of IgM ANTIBODIES to CHLAMYDIA PNEUMONIAE |
| 933 | 7438 | CHLAMYDIA SPECIATION | PCR Sequencing | URINE / GENITAL/ URETHRAL SWAB/EYE SWAB /FLUID | A/R | India | Chlamydia species are known to infect the urogenital, ocular, respiratory, CNS, reproductive, cardiovascular (endocarditis) and musculoskeletal systems. Currently 4 species of Chlamydia are recognized; C. pneumoniae, C. trachomatis, C. psittaci and C.pecorum. Speciation is of paramount clinical importance, as it helps to distinguish asymptomatic and symptomatic infection and can prove useful for evaluation of reactive arthritis possible due to Chlamydia infection. |
| 934 | 5061 | CHLAMYDIA TRACHOMATIS – IGA | EIA | Serum | Frozen | India | Quantitative detection of IgA ANTIBODIES to CHLAMYDIA TRACHOMATIS |
| 935 | 9404 | CHLAMYDIA TRACHOMATIS ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Quantitative detection of CHLAMYDIA TRACHOMATISANTIBODIES |
| 936 | 9406 | CHLAMYDIA TRACHOMATIS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Quantitative detection of IgG ANTIBODIES to CHLAMYDIA TRACHOMATIS |
| 937 | 9411 | CHLAMYDIA TRACHOMATIS IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | Quantitative detection of IgM ANTIBODIES to CHLAMYDIA TRACHOMATIS |
| 938 | 9147U24 | CHROMIUM, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). 24 HRS VOLUME SHOULD BE COMPULSARILY SPECIFIED . FIRST SHAKE THE CAN AND TAKE THE 10-20 ML ALIQUOT. THE MEASUREMENT OF URINE VOLUME SHOULD BE DONE AFTER ALIQUOTING.IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CULTURE BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | This assay is used for screening occupational exposure to Chromium and for monitoring metallic prosthetic implant ware. Chromium concentrations are increased in patients with metallic joint prosthesis. Chromium is principally excreted in the urine, hence urine levels correlate better with exposure. |
| 939 | 9147 | CHROMIUM, BLOOD | GFAAS WITH ZEEMAN CORRECTION | BD SRL SODIUM HEPARIN VACCUTAINER, WHOLE BLOOD | 2-8°C (7DAYS); FROZEN (>7 -30 DAYS) | India | This assay is used for screening occupational exposure to Chromium and for monitoring metallic prosthetic implant ware. Chromium concentrations are increased in patients with metallic joint prosthesis. |
| 940 | 9147S | CHROMIUM, SERUM | GFAAS WITH ZEEMAN CORRECTION | BD RED TOP VACCUTAINER, CENTRIFUGE, SEPARATE SERUM | 2-8°C (7DAYS); FROZEN (>7 -30 DAYS) | India | This assay is used for screening occupational exposure to Chromium and for monitoring metallic prosthetic implant ware. Chromium concentrations are increased in patients with metallic joint prosthesis. |
| 941 | 9147U | CHROMIUM, URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | This assay is used for screening occupational exposure to Chromium and for monitoring metallic prosthetic implant ware. Chromium concentrations are increased in patients with metallic joint prosthesis. Chromium is principally excreted in the urine, hence urine levels correlate better with exposure. |
| 942 | RD1516 | CHROMO750K | Microarray | AMNIOTIC FLUID / CVS IN STERILE SALINE/EDTA WHOLE BLOOD + CLINICAL HISTORY | ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | N/A |
| 943 | Z081K | CHROMOGRANIN A | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Chromogranin is present in several elements of the diffuse neuroendocrine system (DNES), including anterior pituitary, thyroid perifollicular C cells, parathyroid chief cells, pancreatic islet cells, intestinal enterochromaffin cells and tumors derived from these cells. Chromogranin immunoreactivity was also seen in thymus, spleen, lymph nodes, fetal liver, neurons, the inner segment of rods and cones, the submandibullar gland and the central nervous system. This marker is useful in evaluating neuroendocrine tumors |
| 944 | 3951 | CHROMOGRANIN A | RADIO IMMUNOASSAY | SERUM ( CLINICAL HISTORY REQUIRED ) | 2-8°C (24 HRS); F (>24 HRS) | India | Chromogranin A is the first line test for diagnosing Carcinoid tumors. It is used as a followup test for treated cases of Carcinoid tumors. It is useful as an adjunct in the diagnosis of other Neuroendocrine tumors including Pheochromocytom a, Pituitary adenomas and functioning & nonfunctioning Islet cell and Gastrointestinal APUD tumors. |
| 945 | RD1515 | CHROMOOPTIMA | Microarray | AMNIOTIC FLUID / CVS IN STERILE SALINE/EDTA WHOLE BLOOD + CLINICAL HISTORY | ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | N/A |
| 946 | RD1518 | CHROMOPOC | Microarray | IST TRIMESTER – CHORIONIC VILLI; 2ND OR 3RD TRIMESTER – PLACENTAL VILLI (PLEASE SEND CLINICAL HISTORY IN SPECIFIED FORMAT IF NONE OF THESE ARE AVAILABLE, THEN A SMALL PIECE OF FOETAL SKIN (THIGH, STOMACH, ARMS) Don’t send full fetus to the dept. It will not be acceptable. |
ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | N/A |
| 947 | 1609 | Chronic lympho-proliferative disorder panel (WITH INCLUSION OF CD200) | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY(MANDATORY) | A | India | The Leukemia evaluation employs cell surface markers to aid in the diagnosis and characterisation of neoplasms of hematopoietic origin. Results are useful in the differential diagnosis, therapeutic monitoring and detection of relapses of these neoplasms. |
| 948 | 1024 | CHRONIC FATIGUE SYNDROME PANEL (CBC, ESR, Random Glucose, Creatinine, Calcium, Magnesium, Electrolytes, ALT, HBsAg, HIV, HCV, ANA, TSH, Folic Acid, Urinalysis, Food Allergy (Wheat, Milk, Peanut) | AUTOMATED CELL COUNTER, AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS) / MANUAL (MODIFIED WESTERGREN) ,Chemiluminescent Microparticle Immunoassay (CMIA), Chemiluminescence, ImmunoCAP Specific IgE inhouse allergen, SPECTROPHOTOMETRY, IMT, DIPSTICK & MICROSCOPY | EDTA WHOLE BLOOD +CITRATE WHOLE BLOOD BLACK TOP + RANDOM FLORIDE PLASMA+RANDOM URINE+FASTING URINE+SERUM FROZEN + (AGE & GENDER IS MANDATORY) + DIRECT SMEARS. (Folic Acid: Folates are light sensitive. Minimize exposure to light during sample handling and storage). |
FLUORIDE PLASMA : (2-8°C 3 DAYS); SERUM : 2-8°C (2 DAYS), F (> 2DAYS); URINE : 2-8°C(24 HRS) | India | Chronic fatigue syndrome (CFS) is a disorder characterized by persistent and unexplained fatigue resulting in severe impairment in Daily functioning. Besides fatigue most patients with CFS report concomitant symptoms such as pain, cognitive dysfunction, psychiatric illness and unrefreshing sleep. CFS is seen world wide with higher prevalence in females & adult prevalence rate varying between 0.2 0.4 % . Laboratory tests help to exclude disorders causing fatigue e.g. endocrine disorders, neoplasm, heart failure etc |
| 949 | 8425 | CITRATE, URINE 24 H ENZYMATIC | Enzymatic | 24HRS URINE SAMPLE (BEFORE STARTING THE COLLECTION, 10ML OF 6N HCL PRESERVATIVE SHOULD BE ADDED TO THE 24HRS URINE COLLECTION CONTAINER). MENTION AGE, GENDER, 24HRS URINE VOLUME AND CLINICAL DETAILS ON THE REQUISITION FORM. | FROZEN(STABILITY:4 DAYS) | India | Citrate binds to calcium and inhibits kidney stone formation. Thus low levels of citrate may lead to kidney stones and is the most important risk factor of kidney stone formation in children. The treatment includes increasing urinary citrate excretion. |
| 950 | RD1444 | C-KIT GIST | PCR – SEQUENCING | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | AMBIENT | India | cKit mutations are associated with shorter survival and higher relapse risk following standard AML therapy in AML Patients. It also confirms diagnosis of Systemic Mastocytosis where patients without the D816V pathogenic variation are sensitive to the tyrosine kinase inhibitor Imatinib mesylate (Imatinib). |
| 951 | RD1308 | C-KIT MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | cKit mutations are associated with shorter survival and higher relapse risk following standard AML therapy in AML Patients. It also confirms diagnosis of Systemic Mastocytosis where patients without the D816V pathogenic variation are sensitive to the tyrosine kinase inhibitor Imatinib mesylate (Imatinib). |
| 952 | 7748 | Cladosporium herbarum – Specific IgG | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | Detection of IgG to Cladosporium herbarum |
| 953 | 8882 | CLASS I ANTIBODY DETECTION (PRA %) | LUMINEX BASED | RECIPIENT SERUM IN PLAIN VIAL | Cold | India | The test detects the specifically HLA class I antibodies in sensitized patients. |
| 954 | 8883 | CLASS II ANTIBODY DETECTION (PRA %) | LUMINEX BASED | RECIPIENT SERUM IN PLAIN VIAL | Cold | India | The test detects the specifically HLA class II antibodies in sensitized patients. |
| 955 | 6024F | CLL PANEL by FISH (13q14.3, 17p13.1, 11q22.3 deletions and Trisomy 12) | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | To aid in the diagnosis, lineage assignment, subclassification, and response to treatment of hematologic malignancies. |
| 956 | RD1430 | Clostridium Difficile Real Time PCR | Real Time PCR | STOOL | FROZEN/COLD | India | C. difficile testing may be ordered when a person hospitalized for more than three days has frequent watery stools, abdominal pain, fever, and/or nausea during or following a course of antibiotics or following a recent gastrointestinal surgery. Testing may be ordered for outpatients when someone develops these symptoms within 68 weeks after taking antibiotics, several days after chemotherapy, or when a person has a chronic gastrointestinal disorder |
| 957 | 2412A | CLOSTRIDIUM TOXIN A / B | ENZYME IMMUNO ASSAY | STOOL | A/R | India | Clostridium difficile is a bacterial pathogen that causes Pseudomembran ous colitis and antibiotic associated diarrhoea. It produces toxins A & B which are enterotoxins. A positive result is considered presumptive evidence of Clostridium diffcile infection. |
| 958 | 1603 | cmPO | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | Myeloid cell marker |
| 959 | 1614 | cmPO / CCD79A / CCD3 | FLOW CYTOMETRY | WB- EDTA /BM-EDTA / WB- HEPARIN /BM-HEPARIN / FLUIDS IN EDTA /HEPARIN/SMEARS + CLINICAL HISTORY | A | India | Multiparametric flow cytometry analysis of intracellular expression of MPO, or cCD79A or CD3 molecule in hematopoetic neoplasiais used for the identification and characterisation of myelogenous lineage differentiation (i.e cMPO+CD79a-CD3-) or B-cells lineage differentiation (i.e. cMPO-cCD79a+CD3-) or T-cells lineage differentiation (cMPO-CD79a-cCD3+) of hematopoietic acute malignancies. |
| 960 | 7576 | CMV Viral Load | Real Time PCR | EDTA PLASMA /EDTA WHOLE BLOOD/TISSUE | EDTA PLASMA – A/R/F, EDTA WHOLE BLOOD/TISSUE -A/R | India | Quantitative CMV PCR testing gives the clinician a “viral load” value useful for monitoring antiviral therapy and possibly identifying patients at risk for CMV disease. |
| 961 | 9149U | COBALT URINE SPOT URINE | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Cobalt is widely distributed in the environment and used in the manufacture of hard alloys which are component of joint prosthesis devices. Cobalt salts are also used in the glass and pigment industry. This assay is used to detect Cobalt toxicity and to monitor metallic prosthetic implantware. |
| 962 | 9149U24 | COBALT, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson’s disease, Menkes disease, Primary Biliary Cirrhosis and Indian childhoodcirrhosis. Urinary copper concentrations are also used to monitor patients on chelation therapy. |
| 963 | 9149 | COBALT, BLOOD | GFAAS WITH ZEEMAN CORRECTION | BD, SRL EDTA VACCUTAINER, WHOLE BLOOD | 2-8°C (7DAYS); | India | Cobalt is widely distributed in the environment and used in the manufacture of hard alloys which are component of joint prosthesis devices. Cobalt salts are also used in the glass and pigment industry. This assay is used to detect Cobalt toxicity and to monitor metallic prosthetic implantware. |
| 964 | 9149S | COBALT, SERUM | ICPMS | BD RED TOP VACCUTAINER AVAILABLE FROM SRL MUMBAI, CENTRIFUGE, SEPARATE SERUM IN MULTIPURPOSE VIAL AVAILABLE FROM SRL MUMBAI, PERCOLATE, DO NOT USE PIPETE | 2-8°C (28DAYS); F (28 DAYS) | India | Cobalt is an integral component of vitamin B12. It is found in most foods and is readily absorbed from the gastrointestinal tract. Cobalt concentrations may be increased in individuals with deteriorating orthopedic implants. Cobalt chloride is used in the treatment of some refactory anemias, including sickel cell anemia but its use has decreased. Cobalt is used in treating cancer of oral cavity, pharynx and lyranx, rhabdomyosarcoma, carcinoma of penis, and radio senstive but wide-spread tumors. Cobalt is not highly toxic, but large enough doses will produce adverse clinical manifestations. Acute symptoms are pulmonary edema, allergy, nausea, vomiting, hemorrhage, and renal failure. Chronic symptoms include pulmonary syndrome, skin disorders, and thyroid abnormalities. |
| 965 | 4550 | COLORECTAL CANCER PANEL (KRAS, NRAS & BRAF) | PCR Sequencing/PyroSequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS | A | India | To detect following mutation KRAS, NRAS & BRA |
| 966 | RD1507 | COLORECTAL CANCER PROFILER NEXT | Next Generation Sequencing/PCR Fragment Analysis | EDTA WHOLE BLOOD AND PARAFFIN BLOCK + CLINICAL HISTORY | AMBIENT | India | Targeted mutation test is designed to cover hotspot mutations of 22 unique genes. The assay utilizes sequencing of DNA targets allowing detection of > 1,800 cancer related mutations as supported by Cosmic Database, with a very low input DNA material. The assay is useful for : identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously, identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies and for identifying mutations that may help determine prognosis for patients with solid tumors. |
| 967 | RD1465 | COMMON MUTATION PANEL mtDNA (MELAS 1, MERRF,NARP,LHON, KSS MT DNA MUTATION) | PCR Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | This common mutation panel tests more common mitochondrial disorders including: MELAS (Mitochondrial Encephalomyopathy with Lactic Acidosis, and Stroke-like episodes), MERRF (Myoclonic Epilepsy with Ragged Red Fibers), NARP (Neuropathy, Ataxia, and Retinitis Pigmentosa), LHON (Leber Hereditary Optic Neuropathy) and Kearns-Sayre syndrome (KSS). |
| 968 | 1555 | COMPLEMENT C1q | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | immunofluorescence is a technique used in the laboratory to diagnose diseases of the skin, kidney, and other organ systems. |
| 969 | 1501D | COMPLEMENT PROTEIN CONCENTRATION (C3) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | C3 is an acute phase reactant. Decreased levels are seen in patients with SLE, Endocarditis and DIC. Congenital deficiency of C3 increases the risk of recurrent bacteremia. This assay is useful for the diagnosis of C3 deficiency and for investigation of a patient with an undetectable Total complement (CH50) level. |
| 970 | 1504D | COMPLEMENT PROTEIN CONCENTRATION (C4) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | C4 is critical to activation of classical pathway. Decreased levels are seen in patients with SLE, Immune Complex disease and Hereditary angioedema. Congenital deficiency of C4 increases the risk of recurrent bacteremia especially S.pneumoniae. This assay is useful in the diagnosis of C4 deficiency and for investigation of a patient with an undetectable Total complement (CH50) level. |
| 971 | 1209C | COMPREHENSIVE CORONARY RISK PROFILE (Extended Coronary Risk Profile, Homocysteine) | SPECTROPHOTOMETRY/ CHEMILUMINESCENCE/ NEPHELOMETRY | 12-14 HOURS FASTING SERUM + SERUM/ PLASMA- EDTA + (AGE & GENDER IS MANDATORY) | F; 2-8°C (2 DAYS); F (> 2 DAYS) | India | This panel also includes nonlipid markers of cardiovascular disease. The nonlipid factors contributing to cardiovascular disease are genetic mutations, inflammation, coagulation disorders, infection and autoimmune disease. |
| 972 | MGEN002 | Comprehensive Dystonia Panel | 0 | 0 | 0 | India | #N/A |
| 973 | 5040M | COMPREHENSIVE MYELOMA PROTEIN PANEL | ELECTROPHORESIS/ IMMUNOELECTROPHORESIS/NEPHELOMETRY | 10 -12 HRS FASTING SERUM (CLINICAL HISTORY, AGE & GENDER IS MANDATORY ) AVOID LIPEMIC & HEMOLYSED SPECIMEN | 2-8°C (7 DAYS) | India | This asay is useful for screening of Monoclonal gammopathies in the general population. These gammopathies may be seen in a wide spectrum of diseases like Multiple myeloma (MM), Macroglobulinemia , Plasma Cytoma, B cell lymphomas, disorders of monoclonal protein structure and certain premalignant conditions like MGUS. It can also help in assessing risk of progression of MGUS to MM. |
| 974 | 3328IJ | COMPREHENSIVE NEONATAL SCREENING PANEL | MS/MS | A. General Information Collection Time: Collect sample 24 hours AFTER birth up to 1 month of age. (DAY 2-7 REPORTED WITHOUT DISCLAIMER , DAY 8 TO 1 MONTH WITH DISCLAIMER COMMENT) REQUIRE FOLLOWING MADATORY DETAILS: Birth date and time, Sample collection date and time, Age at the time of collection (more than 24 hours), Transfusion details if any with date and time, IV fluid infusion if any with date and time, Feed details (Breast/Bottle/Both Breast and Bottle feed), Status at the time of collection (Normal/Premature/Sick), Gestational age, Birth weight details, Medication if any.Single baby or Twin baby (please specify),Ethnicity (White/Hispanic/Asian/Am.Indian/Af.Amer/Others),Doctors Name and Contact details + Clinical history of the patient. B. Sample Acceptability: Special Instructions: 1. Venous blood from a central line is acceptable (Do NOT apply blood to filter paper through a needle as hemolysed samples are not acceptable). 2. All the requested details on the Newborn Screen Card should be mentioned properly. C. Rejection Criteria |
Storage and Shipping Temperature: Allow blood to dry 3 – 4 hrs before packing. Store/Ship the sample in a ZipLock© or equivalent bag at 2° – 8° C. | India | Various conditions that may be present at birth (congenital) can affect the health and wellness of a newborn. Most of these conditions are rare, though some are more prevalent in certain families or ethnic groups. Disorders range from difficulties processing certain nutrients (metabolic), to problems with hormones (endocrine), to the production of abnormal forms of hemoglobin, the oxygen-carrying protein in red blood cells. Some of these conditions cannot be cured, but many can be managed so that the child can grow and live a relatively normal life.
Newborn screening tests help to identify potentially treatable or manageable congenital disorders within days of birth. Life-threatening health problems, mental retardation, and serious lifelong disabilities can be avoided or minimized if a condition is quickly identified and treated. Newborns can be routinely screened for many of these disorders before leaving the hospital using a few drops of blood. |
| 975 | 3328II | COMPREHENSIVE NEONATAL SCREENING PANEL (Neonatal Screening Panel-1+NBS by MS/MS) |
ENZYME IMMUNOASSAY & MS/MS |
DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth), FOR MS/MS refer test code 3358 | 2-8°C (14 DAYS) |
India | Various conditions that may be present at birth (congenital) can affect the health and wellness of a newborn. Most of these conditions are rare, though some are more prevalent in certain families or ethnic groups. Disorders range from difficulties processing certain nutrients (metabolic), to problems with hormones (endocrine), to the production of abnormal forms of hemoglobin, the oxygen-carrying protein in red blood cells. Some of these conditions cannot be cured, but many can be managed so that the child can grow and live a relatively normal life.
Newborn screening tests help to identify potentially treatable or manageable congenital disorders within days of birth. Life-threatening health problems, mental retardation, and serious lifelong disabilities can be avoided or minimized if a condition is quickly identified and treated. Newborns can be routinely screened for many of these disorders before leaving the hospital using a few drops of blood. |
| 976 | 8012 | COMPREHENSIVE VIRAL FLU PANEL (INFLUENZA A, INFLUENZA B, PARA INFLUENZA, RSV & NOVEL H1N1 VIRUS) | REAL TIME PCR FOR NOVEL H1N1 AND INFLUENZA A; MULTIPLEX RT-PCR FOR INFLUENZA B, RSV AND PARAINFLUENZA | NASAL/THROAT/NASOPHARYNGEAL SWAB IN VTM | F | India | To diagnose following virus: INFLUENZA A, INFLUENZA B, PARA INFLUENZA, RSV & NOVEL H1N1 VIRUS |
| 977 | EGEN006 | Comprehensive Neurology Panel | 0 | 0 | 0 | India | #N/A |
| 978 | RD1438 | COMT GENOTYPING | PCR Sequencing | EDTA WHOLE BLOOD/EDTA PLASMA + CLINICAL HISTORY | Whole Blood (A)/PLASMA (F) | India | CatecholOmethyl transferase (COMT) is involved in phase II (conjugative) metabolism of catecholamines and catechol drugs, such as dopamine, as well as the catecholestrogen s. Schizophrenia patients homozygous for the *2 polymorphism displayed improved cognition following drug treatment |
| 979 | RD1427 | CONNEXIN 30 MUTATION DETECTION | DNA SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | Useful to identify a second mutation in patients who carry a single CX26 mutation and to determine the genetic basis for hearing loss in an affected individual. |
| 980 | 1121T | COOMBS TITRE (Rh ANTIBODY TITRE) | TUBE AGGLUTINATION | SERUM MANDATORY | 2-8°C (48 HRS),>48 HRS -20 °C | India | Indirect Coombs Test is used to identify red blood cell IgG antibodies that can cross the placenta and cause Hemolytic disease of the newborn. |
| 981 | 9202RFX | COPPER REFLEX TO CERULOPLASMIN (CERULOPLASMIN WILL BE PERFORMED IF LOW VALUE OF COPPER) | GFAAS WITH ZEEMAN CORRECTION/NEPHELOMETRY | BD RED TOP VACCUTAINER, CENTRIFUGE, SEPARATE SERUM,( AGE + SEX MANDATORY) +2 ALIQUOT REQUIRED, 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (> 7 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | To measure the amount of copper and ceruloplasmin in the blood; to help diagnose Wilson disease; sometimes to help identify conditions associated with copper deficiencies |
| 982 | 9144U24 | COPPER, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). 24 HRS VOLUME SHOULD BE COMPULSARILY SPECIFIED . FIRST SHAKE THE CAN AND TAKE THE 10-20 ML ALIQUOT IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) THE MEASUREMENT OF URINE VOLUME SHOULD BE DONE AFTER ALIQUOTING. | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson’s disease, Menkes disease, Primary Biliary Cirrhosis and Indian childhoodcirrhosis. Urinary copper concentrations are also used to monitor patients on chelation therapy. |
| 983 | 9144 | COPPER, SERUM | GFAAS WITH ZEEMAN CORRECTION | BD RED TOP VACCUTAINER, CENTRIFUGE, SEPARATE SERUM, AGE + SEX MANDATORY | 2-8°C (7DAYS); F (>7 -30 DAYS) | India | Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson’s disease, Menkes disease, Primary Biliary Cirrhosis and Indian childhood cirrhosis. Copper concentrations increase in acute phase reactions. They decrease in nephrosis, malabsorption and malnutrition. Copper levels are also useful to monitor patients specially pretermnewborns on nutritional supplementation. Results of copper are often interpreted together with ceruloplasmin. |
| 984 | 9144U | COPPER, URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson’s disease, Menkes disease, Primary Biliary Cirrhosis and Indian childhoodcirrhosis.Urinary copper concentrations are also used to monitor patients on chelation therapy. |
| 985 | 1209E | CORONARY RISK PROFILE EXTENDED (E CROP) (CORONARY RISK PROFILE +APOLIPOPROTEIN EVALUATION) | NEPHELOMETRY / SPECTROPHOTOMETRY | SERUM 12-14 HRS FASTING + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (2DAYS); F ( >2 DAYS) | India | This panel tests Lp (a) with other lipid markers of cardiovascular disease. Elevated Lp(a) levels are commonly observed in patients and families with premature coronary heart disease / stroke / cerebrovascular and peripheral vascular disease. |
| 986 | 7535 | COUPLE KARYOTYPING – (PBLC) | CELL CULTURE | WB-HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + FAMILY HISTORY + CLINICAL HISTORY IN SPECIFIED FORMAT + DETAILED PHYSICAL FEATURES + DOCTOR CONTACT NO. (MANDATORY) | A | India | To detect chromosome abnormalities, in order to help diagnose genetic diseases, some birth defects and certain haematologic and lymphoid disorders |
| 987 | 2547I | COXSACKIE ANTIBODY – IGG, SERUM | EIA | SERUM | R/F | India | Coxsackie virus antibodies usually coexist with Echovirus antibodies. Infections commonly seen are Meningitis, Myocarditis and Epidemic pleurodynia. |
| 988 | 2548I | COXSACKIE ANTIBODY – IGM, SERUM | EIA | SERUM | R/F | India | Coxsackie virus antibodies usually coexist with Echovirus antibodies. Infections commonly seen are Meningitis, Myocarditis and Epidemic pleurodynia. |
| 989 | 1158CG | CRYOGLOBULIN-QUALITATIVE | INSPECTION, PHYSICAL (HEATING) | SERUM-AMBIENT ONLY / COLD 2 – 8 DEGREE CELCIUS | A | India | Cryoglobulins are proteins that precipitate spontaneously and reversibly at less than body temperature within 3 days. They are insoluble at 4°C and may aggregate upto 30°C. They have a tendency to fixcomplement and initiate inflammatory reaction. This assay is useful for evaluating patients with Vasculitis, Glomerulonephritis and Lymphoproliferativ e disease. It also helps to evaluate patients with Macroglobulinemia and Myeloma who are symptomatic on exposure to cold. |
| 990 | 9189 | CRYPTOCOCCUS ANTIGEN | IMMUNOCHROMATOGRAPHY | SERUM | 2-8°C -3 days,>3 days: -20°C | India | Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans found commonly in pigeon droppings. The disease affects mainly lungs and CNS. Cryptoccal antigen test is less frequently positive in serum than in CSF. |
| 991 | 9209RFX | CRYPTOCOCCUS ANTIGEN DETECTION IF NEGATIVE REFLEX CSF FUNGAL CULTURE | BACTEC CULTURE /IMMUNOCHROMATOGRAPHY | CSF | A /For CRYPTOCOCCUS ANTIGEN DETECTION : 2-8°C – 3 days,>3 days: -20°C | India | This is the preferred test for diagnosis of Cryptococcal infection. IF NEGATIVE CSF FUNGAL CULTURE IS DONE |
| 992 | 9189C | CRYPTOCOCCUS ANTIGEN, CSF | IMMUNOCHROMATOGRAPHY | CSF | 2-8°C -3 days,>3 days: -20°C | India | Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans found commonly in pigeon droppings. The disease affects mainly lungs and CNS. This is the preferred test for diagnosis of Cryptococcal infection. |
| 993 | 9188 | CRYPTOCOCCUS NEOFORMANS DNA DETECTOR | PCR-SEQUENCING | SPUTUM / CSF / FLUIDS / TISSUES+ CLINICAL HISTORY | A | India | Infection with C. neoformans is termed cryptococcosis. Most infections with C. neoformans occur in the lungs. However, fungal meningitis and encephalitis, especially as a secondary infection for AIDS patients, are often caused by C. neoformans. This test is useful for the detection of C.neoformans. |
| 994 | 7661 | CRYPTOSPORIDIUM ANTIGEN DETECTION FROM STOOL: RAPID CARD TEST | RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | R | India | Cryptosporidium is an intracellular parasite that causes severe and chronic diarrhoea in patients who are immunocompromi sed. |
| 995 | 4803 | CS PANEL | CLOT BASED | PLASMA-CITRATEDPLATELET POOR PLASMA FROZEN AT -20° C+ CLINICAL history | F | India | To help investigate the cause of a blood clot (thromboembolism), such as a deep vein thrombosis (DVT) or pulmonary embolism (PE); to determine whether you may have a protein C or protein S deficiency |
| 996 | 5198 | CSF,MEASELS (RUBEOLA), IGG ANTIBODIES | EIA | CSF + SERUM SPECIMEN COLLECTION: IT IS MANDATORY TO SEND SERUM ALONG WITH THE CSF SAMPLE. IF NOT RECEIVED WILL BE CREATED AS A PROBLEM SAMPLE. | FROZEN | India | Measles virus is highly contagious particularly infecting children, pregnant women, immunocompromi sed and nutritionally deficient individuals. IgG positivity indicates previous exposure to Rubeola virus or immunity. |
| 997 | 1192 | CULTURE, BETA STREP SCREEN | CULTURE | THROAT SWAB FOR GRP A STREPTOCOCCI,VAGINAL/RECTAL SWAB FOR GRP B STREPTOCOCCI- IN STERILE SCREW CAP VIAL | A | India | to detect and identify beta-streptococci |
| 998 | 1206 | CULTURE, CLOT – SALMONELLA SPECIES | CULTURE | CLOTTED BLOOD IN PLAIN VACUTAINER | A | India | to detect and identify SALMONELLA SPECIES |
| 999 | SP1144 | CUSTOM LEUKEMIA PANEL (FOUR SURFACE MARKERS) | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | The Leukemia evaluation employs cell surface & cytoplasmic markers to aid in the diagnosis and characterisation of neoplasms of hematopoietic origin. Results are useful in the differential diagnosis, therapeutic monitoring and detection of relapses of these neoplasms. |
| 1000 | SP1909 | CUSTOM LEUKEMIA PANEL (SIX SURFACE MARKERS) | FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN/ BM / WB / FLUIDS SMEARS + CLINICAL HISTORY | A | India | CUSTOM LUKEMIA PANEL FOR 6 CD MARKERS (CD 45, CD10, CD 14, CD19, C7 etc) |
| 1001 | Z118K | CYCLIN D1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | It is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator. |
| 1002 | 4314I | CYCLOSPORINE, EDTA/HEPARIN WHOLE BLOOD | LCMSMS | 1] Require EDTA/Heparin Whole Blood to be collected directly in relevant vaccutainers only (Label time of collection and administration of drug),preferably with drug dose. 2] MENTION LEVEL CO or C2 AS IT IS MANDATORY FOR REPORTING ( trough or peak) 3] DOCTOR CONTACT DETAILS AND CLINICAL HISTORY IS MANDATORY |
2-8ºC | India | Cyclosporine is a commonly used immunosuppressiv e drug in patients receiving transplants. Therapeutic drug monitoring is used to optimize dose and avoid toxicity. |
| 1003 | 3938 | CYFRA 21-1 | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History |
2-8°C (4 WEEKS); F (3MONTHS) | India | This is a useful marker in the management of Non Small Cell Carcinoma Lung. It is recommended for therapeutic monitoring and recurrences in an already diagnosed case. It may show positivity in certain cases of Squamous cell carcinoma, Large cell carcinoma and Adenocarcinoma. |
| 1004 | RD1311 | CYP2C19 GENOTYPING | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Genetic polymorphism (mainly CYP2C19*2, CYP2C19*3 and CYP2C19*17) exists forCYP2C19 expression, with approximately 3–5% of Caucasian and 15–20% of Asian populations being poor metabolizers with no CYP2C19 function. This may reduce the efficacy of clopidogrel (Plavix). In patients with an abnormal CYP2C19 variant certain benzodiazepines should be avoided, such as diazepam (Valium), lorazepam (Ativan), oxazepam (Serax), and temazepam (Restoril). |
| 1005 | RD1439 | CYP3A4*22 Genotyping | PCR Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | The CYP3A4*22 allele is associated with reduced CYP3A4 activity, which may result in a better response to lipidlowering drugs, such as simvastatin, atorvastatin, or lovastatin |
| 1006 | RD1446 | CYSTIC FIBROSIS DELTA F508 GENE MUTATION | PCR SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Cystic fibrosis (CF), also known as mucoviscidosis, is a genetic disorder that affects mostly the lungs but also the pancreas, liver, kidneys, and intestine. CF is caused by a mutation in the gene cystic fibrosis transmembrane conductance regulator (CFTR). This test detects the most common mutation, ΔF508 which is a deletion of three nucleotides that results in a loss of the amino acid phenylalanine (F) at the 508th position on the protein. This mutation accountsfor twothirds of CF cases worldwide and 90% of cases in the United States. |
| 1007 | RD1460 | Cystic Fibrosis Extended Mutation Panel | Sanger Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Cystic fibrosis (CF), also known as mucoviscidosis, is a genetic disorder that affects mostly the lungs but also the pancreas, liver, kidneys, and intestine. CF is caused by a mutation in the gene cystic fibrosis transmembrane conductance regulator (CFTR). This test detects the most common mutation, ΔF508 which is a deletion of three nucleotides that results in a loss of the amino acid phenylalanine (F) at the 508th position on the protein. This mutation accountsfor twothirds of CF cases worldwide and 90% of cases in the United States. |
| 1008 | 9816C | CYSTICERCUS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | CSF | 2-8º C (24 Hrs), >24 hrs Frozen | India | Cysticercosis is an infection caused by the larval form of tapeworm Taenia solium. Tapeworm eggs contained in food or water migrate through the intestinal wall to various tissues including brain. Cerebrospinal Cysticercosis can result in seizures. |
| 1009 | 9816S | CYSTICERCUS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (1 week), >1 week- 20 °C | India | Cysticercosis is an infection caused by the larval form of tapeworm Taenia solium. Tapeworm eggs contained in food or water migrate through the intestinal wall to various tissues including brain. Cerebrospinal Cysticercosis can result in seizures. |
| 1010 | Z208 | CYTOCHEMISTRY PANEL FOR LEUKEMIAS (PERIODIC ACID SCHIFF,SUDAN BLACK B and MYELOPEROXIDASE) | CYTOCHEMISTRY SPECIAL STAINS | FRESH, AIR DRIED, UNSTAINED REPRESENTATIVE BONE MARROW ASPIRATE / PERIPHERAL BLOOD SMEARS + CLINICAL HISTORY | A | India | CYTOCHEMISTRY PANEL FOR LEUKEMIAS (PERIODIC ACID SCHIFF,SUDAN BLACK B and MYELOPEROXIDASE) |
| 1011 | 5814B | CYTOGENETICS: BLOOD LYMPHO CULTURE | CELL CULTURE | WB-HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + FAMILY HISTORY + CLINICAL HISTORY IN SPECIFIED FORMAT + DETAILED PHYSICAL FEATURES | A | India | This test is used to detect numerical and structural chromosomal abnormalities in postnatal cases with history of physical abnormalities, IQ/learning related disabilities, delayed/absence of menarche, in individuals with bad obstretic history etc. |
| 1012 | 5823 | CYTOGENETICS: BUCCAL SMEAR FOR BARR BODY ANALYSIS | CELL CULTURE | BUCCAL SMEAR SLIDES+ CLINICAL HISTORY | A | India | The cells is used for the presence of Barr bodies (a mass seen in a normal female sex chromosome). When used for that purpose, the buccal smear test can confirm whether the patient is a male or female. |
| 1013 | 6017F | CYTOGENETICS: DEL 13q | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | del(13q) is detected in 1520% of Multiple myeloma patients by conventional karyotype and in 3352% of cases by FISH analysis. |
| 1014 | 5812 | CYTOGENETICS: FANCONI ANEMIA | KARYOTYPE CELL CULTURE | WB HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY, SPECIMAN OF AGE AND SEX MACTCHED CONTROL SAMPLE IS STRONGLY RECOMMENDED. | A | India | Chromosomes from a patient with a congenital form of bone marrow failure, Fanconi’s anemia (FA), are sensitive to clastogenic agents (chemicals causing DNAbreakage) likeMitomycin C (MMC). The effect of MMC on lymphocytes in culture is used to differentiate reliably between FA patients with chromosome instability andIdiopathic aplastic anemia. |
| 1015 | 5364B | CYTOGENETICS: FRAGILE X CHROMOSOME ANALYSIS | KARYOTYPE CELL CULTURE | WB HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | To help diagnose Fragile X syndrome (FXS) |
| 1016 | 6006F | CYTOGENETICS: HER2/neu | FISH | BIOPSIES SOULD BE FIXED FOR 24-48 HOURS IN 10% BUFFERED FORMALIN & EMBEDDED IN PARAFFIN. TISSUE SHOULD BE 4 MICRONS THICK & PLACED ON POSITIVELY CHARGED SLIDES. 3 SLIDES / SAMPLES CONTAINING MALIGNANT TISSUE. * TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* CLINICAL DETAILS IN SPECIFIED FORMAT | A | India | This assay determines gene amplification status of the invasive component of Breast cancer which has therapeutic implications for the patient regarding Herceptin therapy. |
| 1017 | 6015F | CYTOGENETICS: Inv(16) | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | inv(16) in a case of AML shows intermediate prognosis & helps in identifying known chromosomal anomaly in Myeloid malignancy & also monitoring response to therapy. |
| 1018 | 5800 | CYTOGENETICS: KARYOTYPING CHROMOSOME ANALYSIS IN HEMATOLOGICAL DISORDERS ( Blood cancer or Leukemia) | KARYOTYPE CELL CULTURE | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | This assay detects the presence of an abnormal clone to indicate malignant neoplastic process. It assists in the diagnosis and classification of certain malignant hematological disorders, evaluation of prognosis, monitoring effects of therapy and remission. Bone marrow specimens are preferred over peripheral blood. |
| 1019 | 6018F | CYTOGENETICS: MDS PANEL | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | Myelodysplastic syndrome (MDS) describes a group of clonal hematopoietic disorders resulting in ineffective production of one or more of the myeloid cell lineages which increases the risk for transformation to AML. |
| 1020 | 6019F | CYTOGENETICS: MLL 11q rearrangement | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | Prognostic marker for Acute Lymphoblastic leukemia or Acute Myelogenous leukemia. |
| 1021 | 5815 | CYTOGENETICS: NEONATAL KARYOTYPING (NEWBORN TO ONE MONTH OLD CHILD) | KARYOTYPE CELL CULTURE | WB-HEPARIN SPECIMEN TO REACH US IN 24 – 48 HRS / CORD BLOOD- HEPARIN (If baby is alive)+CLINICAL HISTORY in specified format | A | India | High resolution chromosome analysis is the method of choice in neonates for detecting numerical and structural chromosome aberrations. This assay not only detects extra chromosomes, such as chromosome 21 in Down syndrome, but it also identifies structural chromosome changes, including subtle deletions and additions not identified by conventional Karyotyping techniques. |
| 1022 | 6003F | CYTOGENETICS: PML Ra Ra t(15:17) | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | PML / RARA fusion is associated with a good response to alltransretinoic acid therapy in cases of Acute Promyelocytic Leukemia. |
| 1023 | 5832F | CYTOGENETICS: PRENATAL AMNIOTIC FLUID FISH | FISH | AMINOTIC FLUID + DULY FILLED AMNIOTIC FLIUD TRF + CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN SHOULD REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay determines the chromosomal status of the fetus including Numerical and structural abnormalities. Mosaicism can be ruled out in samples drawn after 15 weeks of gestation. |
| 1024 | 5832K | CYTOGENETICS: PRENATAL AMNIOTIC FLUID KARYOTYPING | KARYOTYPING | AMINOTIC FLUID + DULY FILLED AMNIOTIC FLIUD TRF + CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN SHOULD REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay determines the chromosomal status of the fetus including Numerical and structural abnormalities. Mosaicism can be ruled out in samples drawn after 15 weeks of gestation. |
| 1025 | 5832 | CYTOGENETICS: PRENATAL AMNIOTIC FLUID KARYOTYPING + FISH | KARYOTYPING + FISH | AMINOTIC FLUID + DULY FILLED AMNIOTIC FLIUD TRF + CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN SHOULD REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay determines the chromosomal status of the fetus including Numerical and structural abnormalities. Mosaicism can be ruled out in samples drawn after 15 weeks of gestation. |
| 1026 | 5833F | CYTOGENETICS: PRENATAL CHORIONIC VILLUS BIOPSY FISH | FISH | CHORIONIC VILLUS IN MEDIUM+TRF CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay is useful for the diagnosis of genetic disorders from families in which a known familial mutation/s has been identified previously. It is also useful for screening of carriers amongst individuals at risk for known familial mutations. |
| 1027 | 5833K | CYTOGENETICS: PRENATAL CHORIONIC VILLUS BIOPSY KARYOTYPING | KARYOTYPING | CHORIONIC VILLUS IN MEDIUM, BIOPSY+CLINICAL HISTORY CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay is useful for the diagnosis of genetic disorders from families in which a known familial mutation/s has been identified previously. It is also useful for screening of carriers amongst individuals at risk for known familial mutations. |
| 1028 | 5833 | CYTOGENETICS: PRENATAL CHORIONIC VILLUS BIOPSY KARYOTYPING + FISH (Need to ask the dept for medium) | KARYOTYPING + FISH | CHORIONIC VILLUS IN MEDIUM, BIOPSY IN MEDIUM+CLINICAL HISTORY CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | To identify structural chromosome abnormality |
| 1029 | 5831F | CYTOGENETICS: PRENATAL FETAL CORD BLOOD FISH | FISH | FETAL CORD BLOOD WITH SODIUM HEPARIN +CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | To identify structural chromosome abnormality. |
| 1030 | 5831K | CYTOGENETICS: PRENATAL FETAL CORD BLOOD KARYOTYPING | KARYOTYPING | FETAL CORD BLOOD WITH SODIUM HEPARIN +CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | This assay determines the chromosomal status of the fetus including Numerical and structural abnormalities. Mosaicism can be ruled out in samples drawn between 1820 weeks of gestation. |
| 1031 | 5831 | CYTOGENETICS: PRENATAL FETAL CORD BLOOD KARYOTYPING + FISH | KARYOTYPING + FISH | FETAL CORD BLOOD WITH SODIUM HEPARIN +CLINICAL HISTORY. CONSENT FORM WITH PND REGISTRATION NUMBER MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION | A | India | To identify structural chromosome abnormality. |
| 1032 | 5818 | CYTOGENETICS: PRODUCT OF CONCEPTION (POC) | KARYOTYPING OR FISH | IST TRIMESTER – CHORIONIC VILLI; 2ND OR 3RD TRIMESTER – PLACENTAL VILLI (PLEASE SEND CLINICAL HISTORY IN SPECIFIED FORMAT CHORIONIC VILLI OR HEART BLOOD OR CORD BLOOD IF NONE OF THESE ARE AVAILABLE, THEN A SMALL PIECE OF FOETAL SKIN (THIGH, STOMACH, ARMS) FOR CHROMOSOMAL ANALYSIS/FISH Don’t send full fetus to the dept. It will not be acceptable. |
A/R | India | Chromosomal aneuploidy, the gain or loss of chromosomes, is a major cause of early fetal demise. Trisomy is the most common type of chromosomeabnormality in spontaneous abortions and has been observed for most chromosomes, with 13,18,21, X, and Y being the most common. |
| 1033 | 6021F | CYTOGENETICS: TEL/AMLCYTOGENETICS: | FISH | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | Occurs in only about 3% of adult Acute Lymphoblastic leukemia (ALL) cases, it is the most common genetic rearrangement in Blineage pediatric ALL (25%). |
| 1034 | 5840 | CYTOGENETICS:ACUTE PROMYELOCYTIC LEUKEMIA | KARYOTYPE CELL CULTURE | BONE MARROW OR WB SODIUM HEPARIN SPECIMEN TO REACH US WITH 48 HRS + CLINICAL HISTORY [PLEASE MENTION THE CLINICAL HISTORY, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | It enables in detection of the balanced reciprocal translocation between chromosomes 15 and 17, i.e. t(15;17)(q22;q12). This recurrent chromosomal abnormality along with its variants is associated with AML-M3 or Acute Promyelocytic Leukemia (APL;APML). The diagnosis of this subtype of AML is clinically important to administer Anti-trans-retinoic acid (ATRA) therapy. |
| 1035 | Z259K | CYTOKERATIN – 19 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CK19 labels ductal and glandular epithelia, prostatic epithelia, and non-keratinizing squamous epithelia. This antibody is useful in the diagnosis of breast and cervical carcinoma. CK19 is not expressed in hepatocytes, therefore, antibody to CK19 is also useful in the distinction of liver metastasis from hepatocellular carcinomas. |
| 1036 | Z059K | CYTOKERATIN – 20 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Cytokeratin 20 (CK20) positivity is seen in the majority of adenocarcinomas of the colon, mucinous ovarian carcinomas, transitional cell, and Merkel cell carcinomas, and frequently in adenocarcinomas of the stomach, bile system and pancreas. CK7/CK20 immunostaining patterns may be helpful in separating pulmonary from colonic adenocarcinomas. |
| 1037 | Z221K | CYTOKERATIN – 5/6 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Cytokeratin 5/6 have been found valuable for the distinction between low differentiated squamous cell carcinoma and adenocarcinoma. It labels mesothelioma, and epithelial basal cells in prostate and tonsil. No reactivity with other mesodermally derived tissues, such as muscle and connective tissues, has been observed. Anti-CK 5/6 has also been found useful in the differential diagnosis of atypical proliferations of the breast. |
| 1038 | Z060K | CYTOKERATIN – 7 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Cytokeratin 7 (CK7) antibody reacts with proteins that are found in most ductal, glandular and transitional epithelium of the urinary tract and bile duct epithelial cells. CK7 distinguishes between lung and breast epithelium that stain positive, and colon and prostate epithelial cells that are negative. It also reacts with many benign and malignant epithelial lesions, e.g. adenocarcinomas of the ovary, breast and lung. Transitional cell carcinomas are positive and most prostate cancers are negative. This antibody does not recognize other intermediate filament proteins. |
| 1039 | Z054K | CYTOKERATIN 18 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CYTOKERATIN 18 is typically expressed in simple, nonstratified epithelia. However, CK 18 is also expressed in basal and superficial cells of transitional epithelium, as well as in the luminal/secretory cells of complex epithelia. |
| 1040 | Z053K | CYTOKERATIN 8 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Can be used to differentiate lobular carcinoma of the breast from ductal carcinoma of the breast. it also reacts with a range of malignant cells, including those derived from secretory epithelia, but also some squamous carcinomata, such as spindle cell carcinoma. It is considered useful in identifying microscopic metastases of breast carcinoma in lymph nodes, and in distinguishing Paget’s disease from malignant melanoma. It also reacts with neuroendocrine tumors |
| 1041 | Z045K | CYTOKERATIN-HMW, 34BE12 (SQUAMOUS) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | CK903 (34betaE12) is a high molecular weight cytokeratin present in all squamous epithelium and their carcinomas. This antibody recognizes cytokeratins 1, 5, 10 and 14 that are found in complex epithelia. There has been no reactivity with cells derived from simple epithelia, mesenchymal tumors, lymphomas, melanomas, neural tumors and neuroendocrine tumors. One useful application is the identification of the basal cell layer in prostate tissue in the determination of carcinoma. |
| 1042 | Z046K | CYTOKERATIN-LMW, 35BH11 (NON SQUAMOUS) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Clone 35BH11 reacts exlcusively with cytokeratin 8 which is present in glandular-type epithelia and most carcinomas derived thereof. It is in general not reactive in non-epithelial tissues and cells. |
| 1043 | 7578 | CYTOMEGALOVIRUS COMBI TEST (CMV Viral Load/GCV resistance) | REAL TIME PCR/SEQUENCING | EDTA PLASMA /EDTA WHOLE BLOOD + CLINICAL HISTORY | F/A | India | To diagnose a current, past or reactivated cytomegalovirus (CMV) infection or if it is important to know if you ever had a CMV infection, such as prior to receiving an organ transplant. To detect GCV RESISTANCE BY SEQUENCING |
| 1044 | 7575 | CYTOMEGALOVIRUS DNA DETECTOR | REAL TIME PCR | WB-EDTA / CSF/TISSUE | A | India | This assay is useful for rapid qualitative detection of CMV DNA specially in CMV seronegative patients who receive an organ transplant from a seropositive donor. It is also a useful assay in neonates suspected of acquiring virus in utero. |
| 1045 | 9436 | CYTOMEGALOVIRUS IgG & IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (4DAYS), >4 DAYS- 20 °C | India | CMV is a significant cause of morbidity and mortality specially in organ transplant recipients and immunocompromi sed individuals. It is also responsible for congenital disease of the newborn. Positive CMV IgG results indicate past or current CMV infection. Such individuals are potentially at risk of transmitting CMV infection through different modes. Positive CMV IgM results indicate a recent infection which may be primary or reactivation / reinfection. |
| 1046 | 9432 | CYTOMEGALOVIRUS IGG AVIDITY | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (4DAYS), >4 DAYS- 20 °C | India | CMV is a significant cause of morbidity and mortality specially in organ transplant recipients and immunocompromi sed individuals. It is also responsible for congenital disease of the newborn. Positive IgG levels indicate past or current infection. Single IgG titre should not be used for diagnosis of recent infection. Paired acute and convalescent sera should be tested for seroconversion which is indicative of primary infection or reactivation of latent infection. |
| 1047 | 4420 | D3 HYDROXYBUTYRATE (KETONE BODY), SERUM | Enzymatic | SERUM | F | India | This test can be used for both diagnosis and monitoring of diabetic ketoacidosis. |
| 1048 | 4827 | DCP-DECARBOXY PROTHROMBIN PIVKA-II | CMIA | Serum | Frozen | India | DCP can be elevated in HCC. Conditions such as obstructive jaundice, intrahepatic cholestasis causing chronic decrease in vitamin K, and ingestion of drugs such as warfarin or wide-spectrum antibiotics can result in high concentrations of DCP. |
| 1049 | 3146 | DEHYDROEPIANDROSTERONE (DHEA) | RADIO IMMUNOASSAY | SERUM (CLINICAL HISTORY REQUIRED ) | 2-8°C (24 HRS); F (2 months) | India | This assay is useful for the diagnosis and differential diagnosis of Hyperandrogenis m specially when used in conjunction with measurement of other sex steroids. It is an adjunct in the diagnosis of Congenital adrenal hyperplasia. It is also useful in the diagnosis of Premature adrenarche. |
| 1050 | DT3210 | DENGMAL (Dengue Abs (Rapid), MP, CBC ) | IMMUNOCHROMATOGRAPHY /MICROSCOPY/ AUTOMATED CELL COUNTER | WB-EDTA + SERUM + SMEAR | A ( for dengue abs 2-8 d C upto 3 days and > 3 days: -20 d C ) | India | To help diagnose dengue, malaria parasite |
| 1051 | 7647 | DENGUE DUO ANTIGEN & ANTIBODY TESTS (DENGUE NS1 ANTIGEN ELISA+ DENGUE ANTIBODIES ELISA) | ENZYME IMMUNO ASSAY | SERUM | A/R/F | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondary infection. Paired acute and convalescent specimens that exhibit a signifi specimen tht exhibit a significant change in titer are useful to confirm clinical diagnosis of infection. NS1 antigen is a nonstructural protein found in infected patients from 1st day of fever upto 5 days after the onset of fever. |
| 1052 | 7599R | DENGUE DUO RAPID TEST | IMMUNOCHROMATOGRAPHY | SERUM/ WHOLE BLOOD (EDTA) | 2-8°C -3 days,>3 days: -20°C | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondary infection. Paired acute and convalescent specimens that exhibit a signifi specimen tht exhibit a significant change in titer are useful to confirm clinical diagnosis of infection. NS1 antigen is a nonstructural protein found in infected patients from 1st day of fever upto 5 days after the onset of fever. |
| 1053 | 7648 | DENGUE NS1 ANTIGEN TEST | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2DAYS- 20 °C | India | This test is used for the quantitative detection of Dengue Virus NS1 antigen as an aid to the diagnosis of Acute Dengue infection. NS1 antigen is a nonstructural protein found in infected patients from 1st day of fever upto 5 days after the onset of fever. |
| 1054 | 7602 | DENGUE RNA PCR | REAL TIME PCR | EDTA PLASMA/CSF | F | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondary infection. PCR assay detects the presence of Dengue virus much earlier than the appearance of IgM & IgG antibodies. |
| 1055 | 7600 | DENGUE VIRUS IgG & IgM ANTIBODIES, QUALITATIVE | IMMUNOCHROMATOGRAPHY | SERUM | 2-8°C -3 days,>3 days: -20°C | India | DENGUE VIRUS ANTIBODIES Dengue virus is transmitted by Aedes mosquitoes. It belongs to the genus Flavivirus and has four serotypes, DEN-1, DEN-2, DEN-3, and DEN-4. Infection with one dengue serotype provides lifelong immunity to that virus, but no cross protective immunity to the other serotypes. Human dengue infection causes a spectrum of illnesses ranging from inapparent or mild febrile illness to severe to fatal hemorrhagic disease. WHO classifies dengue infections as primary or secondary. It is believed that patients experiencing a secondary infection with heterologous serotypes have higher risk of complications, including Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). Test Utility: Dengue specific IgM can be detected as early as 5 days after the onset of fever and generally persists for 30-90 days, although detectable levels may be present rarely upto 8 months post-infection. IgM antibody is also produced in secondary and tertiary dengue infections, although the response in some secondary and probably most tertiary infections is low level and transient. Dengue IgG levels usually start rising at the end of 1st week in primary infection and persists for months and sometimes for life. Patients with primary dengue infections usually are IgM positive & IgG negative with higher IgM concentrations, whereas patients with secondary infections are usually both IgG and IgM positive with higher IgG concentrations. Limitations: A negative result may occur if the quantity of antibody present in the specimen is below the detection limit of the assay, or the antibody is not present during the stage of disease when the specimen is collected. Positive results obtained with single serum samples are only provisional and do not necessarily indicate current dengue infection, but point to an infection in the previous 2 to 3 months. Patients suffering from other flavivirus infections (Tick-borne encephalitis virus, Japanese encephalitis virus etc) may give a false positive dengue test due to presence of cross reactive epitopes. Hence all results should be interpreted in conjunction with clinical findings and patient history. If clinically indicated, it is recommended to recheck positive specimens with a confirmatory test (M antibody Capture ELISA). |
| 1056 | 7601 | DENGUE VIRUS IgG ANTIBODIES, | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2DAYS- 20 °C | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondaryinfection. Paired acute and convalescent specimens that exhibit a significant change in titer are useful to confirm clinical diagnosis of infection |
| 1057 | 7646 | DENGUE VIRUS IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2DAYS- 20 °C | India | Dengue Hemorrhagic Fever and Dengue Shock Syndrome are caused by infection of RNA Flavivirus transmitted by a mosquito vector. This test differentiates between Primary and Secondaryinfection. Paired acute and convalescent specimens that exhibit a significant change in titer are useful to confirm clinical diagnosis of infection |
| 1058 | Z093K | DESMIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Antibody to desmin reacts with striated (skeletal and cardiac) as well as smooth muscle cells. Anti-desmin antibody is useful in identification of tumors of myogenic origin. It reacts with leiomyosarcomas (smooth muscle) as well as rhabdomyosarcomas (striated muscle). |
| 1059 | 3896 | DIC PROFILE (PT, APTT, TT, Fibrinogen, FDP, D- DIMER, Platelet count) | CLOT BASED / LATEX AGGLUTINATION / AUTOMATED CELL COUNTER | FASTING, CITRATED PLATELET POOR PLASMA – AT MINUS 20° C, WB- EDTA – (A), BLOOD SMEAR – (A) * (DOUBLE CENTRIFUGED PLASMA)* | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) / A | India | Disseminated Intravascular Coagulation (DIC) is a clinicopathological condition in which there is activation of coagulation and fibrinolysis systems resulting in simultaneous formation of thrombin and plasmin with consumption of coagulation factors. |
| 1060 | Z218 | DIFFERENTAIL DIAGNOSIS OF MEDIASTINAL MASS | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help classify mediastinal mass |
| 1061 | 6022F | DI-GEORGE SYNDROME (22q deletion) | FISH | HEPARIN WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | Deletions in 22q11.2 have been associated with several disorders including DiGeorge syndrome (DGS) and Velocardiofacial syndrome (VCFS). |
| 1062 | 1548H | DIGOXIN (lanoxin) | CHEMILUMINESCENCE | SERUM DRAWN 8HRS POST ADMISISTRATION (TREATMENT HISTORY REQUIRED) | 2-8°C (48 hrs); F (>48 hrs) | India | Digoxin is widely prescribed for the treatment of Congestive heart failure and disturbances of cardiac rhythm. Equilibrium of serum and tissue Digoxin levels occurs at 6 to 8 hours, hence blood specimens should be drawn atleast 6 to 8 hours after drug administration. The drug has a narrow therapeutic window which makes monitoring therapy mandatory. Symptoms of toxicity mimic Cardiac arrhythmias for which the drug is originally prescribed. |
| 1063 | 3151 | DIHYDROTESTOSTERONE (DHT) | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (24 HRS), >24 HRS -20°C | India | This assay is useful for monitoring patients receiving 5 alpha reductase inhibitor therapy or chemotherapy. It also helps to evaluate patients with possible 5 Alpha reducatse deficiency. Low levels are seen in patients on 5 Alpha reductase inhibitor therapy and in cases of genetic 5 Alpha reductase deficiency. |
| 1064 | 9964 | DIPTHERIA IGG ABS,SERUM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 days), >2 days- 20 °C | India | The current test is a rapid test for the qualitative detection of IgG Antibodies to DIPTHERIA |
| 1065 | 5400K | DNA PLOIDY & CELL CYCLE ANALYSIS | FLOW CYTOMETRY | PARAFFIN BLOCK ( ONLY BREAST TUMOR ) + CLINICAL HISTORY | A | India | #N/A |
| 1066 | Z272K | DOG-1 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | DOG1 is a cell surface protein of unknown function selectively expressed in gastrointestinal stromal tumors (GIST). Among GIST cases with Kit mutations the DOG1 antibody identified 11% more cases than c-Kit antibody. DOG1 identifies the vast majority of both cKIT negative and Platelet-derived Growth Factor Receptor Alpha (PDGFRA) mutated GIST cases that may still benefit from imatinib mesylate (Gleevec®), an inhibitor of the Kit tyrosine kinase. In addition, DOG1 immunoreactivity is seen in fewer cases of mesanchymal, epithelial tumors and melanomas when compared with cKIT. The use of this highly sensitive and specific novel marker will increase the accuracy of GIST diagnosis. |
| 1067 | 1406 | Dopamine (Plasma,EIA) | EIA | EDTA PLASMA | F | India | To measure the amount of dopamine in blood |
| 1068 | 1406U24 | DOPAMINE, ELISA, 24 HRS URINE | ELISA | 24hrs Urine(Specimen collection instructions:10 ml urine aliquot from collected 24 Hours Urine sample. (Use 10 ml of 6 M HCL Or 10ml of 6M Glacial Acetic Acid as preservative. Mention 24hrs Urine volume on the requisition form) |
FROZEN | India | To measure the amount of dopamine in urine |
| 1069 | 1268FMF | DOUBLE MARKER, SERUM (FMF CERTIFIED) | ELECTROCHEMILUMINESCENCE | SERUM in 2 vials (Clinical Details in specified format, Maternal Date of Birth, Maternal Weight, Maternal Race, Maternal H/O Type I Diabetes Mellitus + Obstetric USG Report between 10 to 13 weeks of gestation+Date of collection) MANDATORY SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] |
2-8°C (8 DAYS); F (> 8 DAYS) |
India | to determine any chromosomal malformation in the foetus. |
| 1070 | 8384 | DPD GENE MUTATIONS (Dihydropyrimidine Dehydrogenase Gene Mutation) | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | The dihydropyrimidine dehydrogenase (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5fluorouracil, capecitabine, and tegafur. Genetic variations within the DPD gene can lead to reduced or absent DPD activity, and individuals who are heterozygous or homozygous for these variations may have partial or complete DPD deficiency; an estimated 0.2% of individuals have complete DPD deficiency. Those with partial or complete DPD deficiency have a significantly increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; examples of |
| 1071 | 4133 | DRUGS OF ABUSE: 5 DRUGS (Opiates, PCP, Cocaine, Cannabinoids, Amphetamine) | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Intended use of this assay is to assist in Drug abuse treatment programs, Pain management clinics. Organ transplantation programs & Psychiatric programs. |
| 1072 | 4132 | DRUGS OF ABUSE: 6 DRUGS (Opiates, PCP, Cocaine, Cannabinoids, Amphetamine, Barbiturates) | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Intended use of this assay is to assist in Drug abuse treatment programs, Pain management clinics. Organ transplantation programs & Psychiatric programs |
| 1073 | 4131 | DRUGS OF ABUSE: 9 DRUGS (Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Cannabinoids, Opiates, Phencyclidine, Methamphetamine, Methodone) |
FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Intended use of this assay is to assist in Drug abuse treatment programs, Pain management clinics. Organ transplantation programs & Psychiatric programs. |
| 1074 | 4134U | DRUGS OF ABUSE: AMPHETAMINE | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Amphetamines are sympathomimetic amines that stimulate the CNS and supress appetite. They are a common cause of drug abuse. This assay confirms drug exposure of Amphetamines and its metabolites. |
| 1075 | 4135U | DRUGS OF ABUSE: BARBITURATES | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | This assay is useful in detecting drug abuse to Barbiturates which are commonly used as “Downers” to induce sleep after Amphetamine or Cocaine induced “High”. As most Barbiturates are fast acting, their presence indicates use within the past 3 days except Phenobarbital which has a longer half life and its presence in urine indicates drug usage within the last 30 days. |
| 1076 | 4136U | DRUGS OF ABUSE: BENZODIAZEPINES | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Benzodiazepine group are drugs of abuse with a half life varying from 2 to 50 hours . The longest half life of 20 to 50 hours is seen with the Diazepam group. The duration of effect varies from 4 to 12 hours. |
| 1077 | 4137U | DRUGS OF ABUSE: CANNABINOIDS | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | The principal psychoactive cannabinoid is delta – 9 tetrahydrocannabi nol (THC) which is released slowly from tissue storage sites. Infrequent smokers may test positive for 2 to 5 days after last Marijuana / Hashish use; Chronic smokers may test positive even 3 to 4 weeks after abstinence. False positive result may be seen with Ketoconazole. |
| 1078 | 4140 | DRUGS OF ABUSE: COCAINE | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Cocaine is widely used by recreational drug abusers. This assay detects and confirms drug abuse involving cocaine. Presence of cocaine or its metabolite Benzoylecgonine in urine indicates use within the past 4 days. Since the half life of cocaine is 6 hrs, it will be present in urine 1 day after last use. |
| 1079 | 4130 | DRUGS OF ABUSE: METHAMPHETAMINE | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Methamphetamine is a prescription drug for weight loss as it has anorectic effect. It is also used in the treatment of Narcolepsy, Attention deficit disorder & Minimal brain dysfunction. As it has a stimulant effect, these drugs are commonly used illicitly and abused. |
| 1080 | 4152 | DRUGS OF ABUSE: METHAQUOLONE | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Methaqualone is a sedative hypnotic drug used illegally as a recreational drug. It is detectable in urine for 46 days after use. |
| 1081 | 4138U | DRUGS OF ABUSE: OPIATES | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Opiates are natural or synthetic drugs that have morphine like action used primarily for relief of pain. This assay detects the presence of opiates in urine and gives the sum of unconjugated and conjugated forms of the parent drug. |
| 1082 | 4139 | DRUGS OF ABUSE: PHENCYCLIDINE (PCP) | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Phencyclidine (Angel dust) is a drug of abuse with stimulant, depressant, hallucinogenic and analgesic properties. It can be self administered by smoking, nasal insufflation, intravenous injection or oral ingestion. |
| 1083 | 4148 | DRUGS OF ABUSE: PROPOXYPHENE | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | Propoxyphene is a prescription drug for the relief of pain and is structurally related to Methadone. Drug overdose mainly affects the brain causing euphoria as well as analgesia, stupor, respiratory depression and coma. The half life of Propoxyphene is 824 hrs. This assay helps to monitor compliance and assess toxicity. |
| 1084 | 4101 | DRUGS OF ABUSE: TETRAHYDROCANNABINOL | FLOW CHROMATOGRAPHIC IMMUNOASSAY | URINE + CLINICAL HISTORY | A (8HRS); 2- 8° C (3 DAYS);F (>3 DAYS) | India | The principal psychoactive cannabinoid is delta – 9 tetrahydrocannabi nol (THC) which is released slowly from tissue storage sites. Infrequent smokers may test positive for 2 to 5 days after last Marijuana / Hashish use; Chronic smokers may test positive even 3 to 4 weeks after abstinence. False positive result may be seen with Ketoconazole. |
| 1085 | 4810 | DSA (DONOR SPECIFIC ANTIBODIES) | LUMINEX BASED | RECIPIENT SERUM & DONOR WB IN ACD VIAL | Cold | India | The assay detects only Anti HLA antibodies against HLA class I & HLA class II antigens. |
| 1086 | 1199 | DsDNA (Reflex to end titre for all positive cases) | INDIRECT IMMUNOFLUROSCENT ASSAY. | SERUM | F | India | dsDNA Antibody is detected in patients with active SLE and approximately 20% of patients with Mixed connective tissue disease. |
| 1087 | 2481 | DUCHENNE / BECKER MUSCULAR DYSTROPHY (This test is not intended for carrier detection. thus, specimens from males only would be accepted) | MULTIPLEX POLYMERASE CHAIN REACTION | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Duchenne and Becker Muscular Dystrophy (DMD & BMD) are Xlinked neuromuscular diseases of childhood resulting from a defect in the dystrophin gene. Deletion of one or more exons in the dystrophin gene may cause DMD/BMD. This assay detects deletions in all 79 exons of the dystrophin gene in both males & females. |
| 1088 | RD1473 | DUCHENNE MUSCULAR DYSTROPHY (DMD) CARRIER TEST | Multiplex ligation-dependent probe amplification (MLPA) | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Duchenne and Becker Muscular Dystrophy (DMD & BMD) are Xlinked neuromuscular diseases of childhood resulting from a defect in the dystrophin gene. Deletion of one or more exons in the dystrophin gene may cause DMD/BMD. This assay detects deletions in all 79 exons of the dystrophin gene in both males & females. |
| 1089 | 7667 | E.COLI O157 ANTIGEN DETECTION | RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | < 72 hrs of collection – R. >72 hrs from collection – F at -20 deg C | India | Entero hemorrhagic E Coli (EHEC) VT 1 & VT 2 infection presents with a wide spectrum of clinical manifestations, including asymptomatic carrier state, non bloody diarrhea , hemorrhagic colitis and hemolytic uremic syndrome. |
| 1090 | 7665 | E.HISTOLYTICA ANTIGEN DETECTION | RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | < 72 hrs of collection – R. >72 hrs from collection – F at -20 deg C | India | The current test is a rapid test for the qualitative detection of Entamoeba histolytica in stool samples. |
| 1091 | Z258K | EBV-LMP – 1 (ANTI-EPSTEIN-BARR VIRUS, LMP) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | This antibody reacts strongly with Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with some EBV-associated neoplasms, particularly EBV-associated Hodgkin lymphoma. |
| 1092 | Z121K | E-CADHERIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | It stains positively in glandular epithelium, as well as adenocarcinomas of the lung, G.I. tract and ovary. It is useful in distinguishing adenocarcinoma from mesothelioma. It is also positive in some thyroid carcinomas. Breast carcinomas with ductal and lobular features show two staining patterns: (1) complete or almost complete lack of membrane staining in lobular carcinomas and (2) uniform membrane expression throughout the tumor in ductal carcinomas. Immunohistochemical detection of ECadherin expression can be a useful diagnostic tool for the differentiation of ductal and lobular carcinomas of the breast. |
| 1093 | 1409 | ECHINOCOCCUS DETECTION | MICROSCOPIC DETECTION – SCOLICES | HYDATID CYST FLUID | A/R | India | Echinococcus granulosus infects dogs and other canines as a definitive host. Man is an intermediate host. Cystic Hydatid disease often affects liver, but other organs may also be involved. |
| 1094 | 1279 | ECHINOCOCCUS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (7 days), >7 days- 20 °C | India | Echinococcus granulosus infects humans as intermediate hosts leading to Cystic Hydatid disease that affects liver as well as other organs. |
| 1095 | 6016F | EGFR Gene AMPLIFICATION | FISH | MALIGNANT TISSUE BIOPSIES FIXED FOR 24-48HRS IN 10% BUFFERED FORMALIN AND EMBEDDED IN PARAFFIN. [PLEASE MENTION THE CLINICAL HISTORY IN SPECIFIED FORMAT, BLOOD PICTURE (CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF] | A | India | EGFRdependent signaling is involved in cancer cell proliferation, apoptosis, angiogenesis, invasion and metastasis. Targeting the EGFR is a valuable molecular approach in cancer therapy. |
| 1096 | RD1405 | EGFR Mutation Detection (IF TISSUE RECEIVED; TISSUE PROCESSING WILL BE CHARGED SEPERATELY.) | PyroSequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS | A | India | Patients positive for EGFR mutations benefit from Tyrosine kinase inhibitors (Gefitinib). This assay detects insertions / deletions in codons 19 and 20. It also detects the most common mutations in codons 18, 19, 20 and 21. |
| 1097 | 1503 | ELECTRON MICROSCOPY – TISSUE | ELECTRON MICROSCOPY | KIDNEY BIOPSY OR MUSCLE BIOPSY IN 3% GLUTARALDEHYDE.IT IS MANDATORY TO SENT HISTOPATHOLOGY DIAGNOSIS REPORT ALONG WITH THE SAMPLE(IF NOT GIVEN, WILL BE CREATED AS A PROBLEM SAMPLE) | ON COLD PACK | India | This test analyzes parenchymal tissues at very high magnifications and is critical in diagnosing certain diseases where pathological features are not discernible under light microscopy. TEMs find application in diagnostic pathology, cancer research, virology, materials science as well as pollution, nanotechnology,and semiconductor research. The high magnification of the electron microscope enables observations not possible by light microscopy, and electron microscopy is considered to be an essential component of human diagnostic renal pathology, neuromuscular pathology, and is a useful tool in difficult cases in oncosurgical pathology . |
| 1098 | 6028F | EML-4 ALK Translocation by FISH | FISH | TISSUE/PARAFFIN BLOCK+CLINICAL HISTORY IN SPECIFIED FORMAT | AMBIENT | India | The ALK-EML4 rearrangement has been identified in 3% to 5% of NSCLC with the majority in adenocarcinoma and younger male patients who were light or nonsmokers |
| 1099 | 1181 | ENDOMYSIAL ANTIBODY IgA, SERUM | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (ONE WEEK); -20°C (LONGER) | India | Circulating IgA endomysial antibodies (EMA) are present in 70 to 80% patients with Celiac disease and Dermatitis herpetiformis. This assay is useful in the evaluation of these diseases. It also monitors adherence to Gluten free diet. The titre generally corelates well with the severity of Gluten sensitive enteropathy. |
| 1100 | 1181T | ENDOMYSIAL ANTIBODY IgA, SERUM WITH TITRE | IMMUNO FLUORESCENT ASSAY | SERUM | 2-8°C (ONE WEEK); -20°C (LONGER) | India | Circulating IgA endomysial antibodies (EMA) are present in 70 to 80% patients with Celiac disease and Dermatitis herpetiformis. This assay is useful in the evaluation of these diseases. It also monitors adherence to Gluten free diet. The titre generally corelates well with the severity of Gluten sensitive enteropathy. |
| 1101 | 7929 | ENDOMYSIAL ANTIBODY IGG (SERUM,IMMUNOFLUORESCENCE) | IFA | SERUM | F | India | To help diagnose celiac disease |
| 1102 | 8441 | ENTAMOEBA HISTOLYTICA ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (7 days), >7 days- 20 °C | India | Entamoeba histolytica is a parasitic protozoan that can infect the digestive tract and occasionally other tissues. Antibody IgG is useful in differentiating Amoebiasis from other causes of liver cysts and pancreatic infection. This is the most sensitive and specific test for Invasive amoebiasis. The test indicates current or previous infection. This test is less sensitive in noninvasive disease. |
| 1103 | 3525 | ENTEROQUICK (Bactec Blood Culture + Rapid Thyphi IgM ) | IMMUNOCHROMATOGRAPHY/BACTEC FLUORESCENT METHOD | SERUM/ BLOOD INOCULATED BACTEC BOTTLE (AEROBIC PLUS ) | A, FOR RAPID TYPHI IgM 2-8°C (24 hrs),> 24 hrs 20 °C | India | To help diagnose Enteric fever |
| 1104 | RD1464 | Enterovirus real time PCR | Multiplex PCR | CSF + CLINICAL HISTORY | FROZEN | India | Enteroviruses are positivesense RNA viruses in the Picornaviridae family. The normal site of enterovirus replication is the gastrointestinal tract where the infection is typically subclinical. However, in a proportion of cases, the virus spreads to other organs, causing systemic manifestations, including mild respiratory disease (eg, the common cold); conjunctivitis; hand, foot, and mouth disease; aseptic meningitis; myocarditis; and acute flaccid paralysis. Collectively, enteroviruses are the most common cause of upper respiratory tract disease in children. In addition, the enteroviruses are the most common cause of central nervous system (CNS) disease; they account for almost all viruses recovered in culture from spinal fluid. |
| 1105 | Z005K | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY. TISSUE PROCESSING CHARGES APPLICABLE INCASE SAMPLE RECEIVED IS TISSUE | A | India | Epidermal Growth Factor Receptor (EGFR) overexpression can occur in a variety of tumor types, including breast, prostate, ovarian, brain, lung and predominantly squamous cell carcinomas. Tumors that express EGFR are associated with a poor prognosis and a shorter disease-free survival. Most colon carcinomas will show expression of EGFR in more than 1% of the invasive tumor cells. Patients whose tumor expresses EGFR are eligible for cetuximab therapy although the response to therapy is independent of the intensity or percentage of cells staining. |
| 1106 | MGEN001 | Epileptic encephalopathy gene panel | 0 | 0 | 0 | India | #N/A |
| 1107 | Z049K | EPITHELIAL MEMBRANE ANTIGEN (EMA) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Epithelial Membrane Antigen (EMA) antibody stains normal and neoplastic cells from various tissues, including mammary epithelium, sweat glands and squamous epithelium. Hepatocellular carcinoma, adrenal carcinoma and embryonal carcinomas are consistently EMA negative, therefore, keratin positivity with negative EMA favors one of these tumors. EMA is frequently positive in meningioma, which can be useful when distinguishing it from other intracranial neoplasms, e.g. Schwannomas. The absence of EMA can also be of value since negative EMA is characteristic of tumors such as adrenal carcinoma, seminomas, paraganglioma and hepatoma. |
| 1108 | 2066 | EPSTEIN BARR VIRUS ANTIBODIES TETRA PANEL {(EBV (VCA) IgG, EBV(VCA) IgM),EBV(EA) IgG] (INFECTIOUS MONONUCLEOSIS) &EBV (NA) IgG | Enzyme Linked Immnunosorbent assay/Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a self limiting disease in children and young adults. Infection with EBV can cause Lymphoproliferativ e disorders including tumors. VCAIgG appears approximately 10 weeks after initial infection and persists for life.VCA IgM appears approximately 4–6 weeks after initial infection and declines after about 3 months. |
| 1109 | 2126EG | EPSTEIN BARR VIRUS EARLY ANTIGEN IgG ANTIBODIES, EBV (EA) (INFECTIOUS MONONUCLEOSIS) | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a selflimiting disease in children and young adults. Infection with EBV can cause lymphoproliferative disorders including tumors. Early Antigen D Antibody appears approximately 1 month after infection and typically is transient lasting only 12 months. Persistently elevated levels suggest reactivation or persistence of EBV infection. |
| 1110 | 2266EG | EPSTEIN BARR VIRUS NUCLEAR ANTIGEN IgG ANTIBODIES, EBV (NA) (INFECTIOUS MONONUCLEOSIS) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (7 DAYS), >7 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a self limiting disease in children and young adults. Infection with EBV can cause Lymphoproliferativ e disorders including tumors. VCA IgG appears approximately 10 weeks after initial infection and persists for life. |
| 1111 | 2266EM | EPSTEIN BARR VIRUS NUCLEAR ANTIGEN IgM ANTIBODIES, EBV (NA) (INFECTIOUS MONONUCLEOSIS) | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a self limiting disease in children and young adults. Infection with EBV can cause Lymphoproliferativ e disorders including tumors. VCA IgM appears approximately 4 6 weeks after initial infection and declines after about 3 months. |
| 1112 | 2116EG | EPSTEIN BARR VIRUS VIRAL CAPSID ANTIGEN IgG ANTIBODIES, EBV (VCA) (INFECTIOUS MONONUCLEOSIS) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (7 DAYS), >7 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a self limiting disease in children and young adults. Infection with EBV can cause Lymphoproliferativ e disorders including tumors. VCA IgG appears approximately 10 weeks after initial infection and persists for life. |
| 1113 | 2116EM | EPSTEIN BARR VIRUS VIRAL CAPSID ANTIGEN IgM ANTIBODIES, EBV (VCA) (INFECTIOUS MONONUCLEOSIS) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8º C (7 DAYS), >7 DAYS- 20 °C | India | Primary infection by EBV causes Infectious mononucleosis, usually a self limiting disease in children and young adults. Infection with EBV can cause Lymphoproliferativ e disorders including tumors. VCA IgM appears approximately 4 6 weeks after initial infection and declines after about 3 months. |
| 1114 | 2136 | EPSTEIN-BARR VIRUS (EBV) DNA PCR | NESTED POLYMERASE CHAIN REACTION | EDTA WB | A/R | India | Epstein Barr virus (EBV) is the causative agent of Infectious mononucleosis (Glandular fever), Burkitt’s lymphoma and Nasopharyngeal carcinoma. Symptoms of Infectious mononucleosis are fever, sore throat and swollen lymph glands. It may involve spleen or liver also. EBV associated central nervous system (CNS) disease is most commonly associated with Primary CNS Lymphoma inpatients with AIDS. CNS infection may also be detected in immunocompetent patients. |
| 1115 | 1160 | ERYTHROPOIETIN (EPO Level) | CHEMILUMINESCENCE | SERUM / PLASMA-HEPARIN (IT IS IMPORTANT TO COLLECT SAMPLES AT A CONSISTENT TIME OF DAY. MORNING SAMPLES TAKEN BETWEEN 7:30 AM AND 12:00 NOON HAVE BEEN RECOMMENDED). CLINICAL HISTORY REQUIRED. | 2-8°C (7 days); F (2 Months) | India | EPO is a hormone produced in the kidneys that regulates red cell production. The levels vary inversely with hematocrit. This assay is useful as an aid in distinguishing between primary and secondary Polycythemia. It also differentiates between appropriate secondary Polycythemia (High altitude, pulmonary disease, tobacco use) and inappropriate secondary Polycythemia (tumors). The assay helps to identify candidates for EPO replacement therapy (Chronic renal failure). The assay evaluates patients undergoing EPO replacement therapy who demonstrate inadequate hematopoeitic response. |
| 1116 | 2381 | ESCHERICHIA COLI K1 ANTIGEN | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | The current test is a rapid test for the qualitative detection of ESCHERICHIA COLI K1 ANTIGEN |
| 1117 | 2381C | ESCHERICHIA COLI K1 ANTIGEN | LATEX PARTICLE AGGLUTINATION | CSF IN PLAIN VACUTAINER / STERILE VIAL | 2-8°C (FEW HRS); -20°C (LONGER) | India | The current test is a rapid test for the qualitative detection of ESCHERICHIA COLI K1 ANTIGEN |
| 1118 | 3156 | ESTRIOL, UNCONJUGATED | CHEMILUMINESCENCE | SERUM (CLINICAL HISTORY REQUIRED) | 2-8°C (7 days); F (3 months) | India | Free Estriol is a biochemical marker of second trimester screening for Down syndrome and Trisomy 18. It is a marker of fetal demise and helps in assessing preterm labor risk. |
| 1119 | 1830K | ESTROGEN RECEPTOR & PROGESTERONE RECEPTOR, | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN FOR 24-48 HRS/ PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING.* TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* | A | India | The primary indication to assess ER in breast cancer is to predict response to hormonal therapies such as tamoxifen, other selective estrogen receptor modulators (SERMs) and aromatase inhibitors. Hormone receptor tests determine if an invasive breast cancer is positive for estrogen and progesterone receptors, helping to guide treatment. |
| 1120 | Z001K | ESTROGEN RECEPTOR (ER) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | The estrogen receptor assay is routinely performed on breast carcinomas and certain other tumors in the body to assess responsiveness to hormone therapy and prognosis. |
| 1121 | 3886 | ESTRONE(E1) | RADIO IMMUNOASSAY | SERUM FASTING | 2-8°C (24 HRS); F (3 months) | India | Estrone estimation is performed for the diagnosis and work-up of precocious and delayed puberty in females, and, to a lesser degree, in males. It is also used for diagnosis and work-up of suspected disorders of sex steroid metabolism, such as, aromatase deficiency and 17 alpha-hydroxylase deficiency. Serum estrogen estimation is useful as an adjunct to clinical assessment, imaging studies and bone mineral density measurement in the fracture risk assessment of postmenopausal women, and, to a lesser degree, older men. It is also used as an aid in monitoring low-dose female hormone replacement therapy in post-menopausal women and also monitoring antiestrogen therapy (eg, aromatase inhibitor therapy). |
| 1122 | 7165 | EVEROLIMUS, EDTA/HEPARIN WHOLE BLOOD | LCMSMS | 1] Require EDTA/Heparin Whole Blood to be collected directly in relevant vaccutainers only. [Label with time of collection and administration of drug, preferably with drug dose.] 2] DOCTOR CONTACT DETAILS AND CLINICAL HISTORY IS MANDATORY |
2-8ºC | India | This assay helps to evaluate patient compliance & adjust dose while minimizing toxicity. |
| 1123 | 1234 | EXTRACTABLE NUCLEAR ANTIGEN (ANCEA, SS-A, SS-B, U1SNRNP, SCL-70) | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | This is a quantitative assay for quantifying specific IgG autoantibodies against Extractable Nuclear Antigens in human serum. It aids in the diagnosis of certain Systemic Rheumatic diseases. |
| 1124 | 9893 | FACTOR II (PROTHROMBIN) MUTATION DETECTION | PCR Sequencing | WB- EDTA + CLINICAL HISTORY | A/R | India | The prothrombin G20210A mutation is the second most common inherited predisposition to hypercoagulability. Heterozygous prothrombin G20210A mutation is associated with a 2 to 6 fold increased lifetime relative risk of VTE. This risk is further increased in combination with pregnancy and OCP use. |
| 1125 | 9894 | FACTOR V MUTATION DETECTION | PCR-SEQUENCING | WB- EDTA + CLINICAL HISTORY | A/R | India | Factor V Leiden Mutation is a point mutation that causes resistance of Factor V degradation by Activated Protein C. This mutation is associated with increased risk of venous thrombosis. This assay is used in patients with clinically suspected Thrombophilia and family history of Factor V Leiden mutation. |
| 1126 | Z097K | FACTOR VIII | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | This test is useful to evaluate a prolonged APTT. The most common form of Hemophilia is caused by deficiency of Factor VIII. Hemophilia A is an X linked disorder affecting between 1 in 5000 to 10000 males. |
| 1127 | 1957 | FACTOR XIII ACTIVITY(Qualitative) | CLOT SOLUBILITY | FASTING, CITRATED PLATELET POOR PLASMA – AT MINUS 20° C *(DOUBLE CENTRIFUGED PLASMA)*+ CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | Diminished Factor XIII levels may cause a bleeding disorder. Absent Factor XIII activity may be associated with spontaneous intracranial hemorrhage. |
| 1128 | 7828 | FACTOR XIII QUANTITATIVE ASSAY | Chromogenic | Platelet Poor Citrated plasma | F | India | To detect Factor XIII deficiency |
| 1129 | 1553 | FIBRINOGEN | IMMUNOFLOURESCENCE | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | immunofluorescence is a technique used in the laboratory to diagnose diseases of the skin, kidney, and other organ systems. |
| 1130 | 4208 | FIBRINOGEN DEGRADATION PRODUCTS (FDP) (SEMI QUANTITATIVE) | LATEX PARTICLE AGGLUTINATION | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C*(DOUBLE CENTRIFUGED PLASMA)* | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | In DIC both thrombin and plasmin are generated. The breakdown products of fibrin clots and fibrinogen include DDimer and FDP. These analytes are also elevated when the coagulation and fibrinolytic systems are activated. |
| 1131 | 4511 | FIBROMETER ALD | NEPHELOMETRY/Hematology/Enzyme Linked Immunoassay | 10-12 HRS FASTING SERUM (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) + CITRATED PLASMA + EDTA WB AND CITRATE WB (LIGHT BLUE TOP) CLINICAL HISTORY + (DOB, SAMPLE COLLECTION DATE, AGE & GENDER IS MANDATORY). ALL SAMPLES MUST BE COLLECTED SIMULTANEOUSLY ON SAME DAY AND SAME TIME. | EDTA whole blood & Citrated whole blood-Ambient Rest all frozen SERUM (F) | India | FibroMeter™ Alcohol package serves as a surrogate marker of liver fibrosis in terms of stage and quantification, in patients with Alcohol-related Liver Disease. |
| 1132 | 4512 | FIBROMETER NAFLD | SPECTROPHOTOMETRY/Hematology/Enzyme Linked Immunoassay | SERUM 10-12 HRS FASTING (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) +FASTING PLASMA FLOURIDE + CITRATED PLASMA + EDTA WB AND CITRATE WB (LIGHT BLUE TOP) (DOB, SAMPLE COLLECTION DATE, AGE, WEIGHT & GENDER IS MANDATORY) ALL SAMPLES MUST BE COLLECTED SIMULTANEOUSLY ON SAME DAY AND SAME TIME. | EDTA whole blood & Citrated whole blood-Ambient Rest all frozen, SERUM (F) | India | FibroMeter™ NAFLD package serves as a surrogate marker of liver fibrosis in terms of stage and quantification, in patients with Metabolic Steatosis. |
| 1133 | 4512V | FIBROMETER VCTE | SPECTROPHOTOMETRY/ NEPHELOMETRY | 10-12 HRS FASTING SERUM (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) CLINICAL HISTORY + (FIBROSCAN REPORT , DOB, SAMPLE COLLECTION DATE, AGE & GENDER IS MANDATORY). ALL SAMPLES MUST BE COLLECTED SIMULTANEOUSLY ON SAME DAY AND SAME TIME. | SERUM (F) | India | The Echosens FibroMeter profile serves as a surrogate marker of liver fibrosis, cirrhosis, and necro-inflammatory activity. |
| 1134 | 4590 | FIBROMETER VIRUS | SPECTROPHOTOMETRY/NEPHELOMETRY/Hematology | SERUM 10-12 HRS FASTING (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) + CITRATED PLASMA + EDTA WB AND CITRATE WB (LIGHT BLUE TOP) (DOB, SAMPLE COLLECTION DATE, AGE & GENDER IS MANDATORY).ALL SAMPLES MUST BE COLLECTED SIMULTANEOUSLY ON SAME DAY AND SAME TIME. | EDTA whole blood & Citrated whole blood-Ambient Rest all frozen, SERUM (F) | India | FibroMeter is a blood test used to aid in the evaluation and management of liver fibrosis. This test was specifically designed for patients with chronic viral hepatitis (with or without HIV co-infection). |
| 1135 | 5014 | FIBROSIS-4 SCORE | SPECTROPHOTOMETERY | SERUM (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | SERUM : 2-8°C (7 DAYS), F (> 7 DAYS) | India |
Liver fibrosis stage is an important factor in determining prognosis and need for treatment in patients infected with HCV or HBV viruses, patients with non-alcoholic fatty liver disease (NAFLD) or in Nonalcoholic steatohepatitis (NASH) cases. Liver biopsies are typically used to assess liver fibrosis. FIB-4 (fibrosis-4 score) is a simple non-invasive index for estimating hepatic fibrosis based on a calculation derived from AST, ALT and platelet concentrations, and age. FIB4 score has been developed to predict liver fibrosis in patients with HBV/HCV and it is also useful for estimating liver fibrosis in patients with NAFLD/NASH. • Low fibrosis scores may be appropriate candidates for medical management and may not require liver biopsy if FIB-4 scores continue to stay low. • Severe fibrosis/cirrhosis scores may need liver biopsy for confirmation of cirrhosis unless there are other clinical or imaging signs of progression to end-stage liver disease. |
| 1136 | 9337 | FILARIA IgG/IgM ANTIBODIES | IMMUNOCHROMATOGRAPHY | SERUM/PLASMA (Heparin) or Whole blood heparin | 2-8°C ( 5 days), >5 DAYS (-20ºC) | India | This assay helps in the detection of Microfilaria in the peripheral blood in both lymphatic and non lymphatic filariasis. |
| 1137 | RD1314 | FIP1L1-PDGFRA GENE REARRANGEMENT | NESTED RT-PCR | EDTA WHOLE BLOOD / EDTA BONE MARROW (SPECIMEN TO REACH US WITHIN 48 HRS)+CLINICAL HISTORY | A | India | The FIP1L1PDGFRA fusion gene is present in approximately 10–15% of patients with Hyper Eosinophilic Syndrome who are sensitive to treatment with the tyrosine kinase inhibitor Imatinib. |
| 1138 | 7644 | FISH for 17p (TP53) abnormalities | FISH | BONE MARROW – SODIUM HEPARIN + CLINICAL HISTORY SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | Prognostic marker in patients with Multiple myeloma. |
| 1139 | 7641 | FISH for 20q deletion | FISH | WB OR BONE MARROW – SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | Deletion of the long arm of chromosome 20, del(20q), is a common chromosomal abnormality in hematologic malignancies, observed in 10% of myeloproliferative neoplasms, 4% of myelodysplastic syndromes, and 2% of acute myeloid leukemias ( doi: 10.1182/bloodadvances.2016003129) |
| 1140 | 7643 | FISH for 5q deletion and monosomy/numerical abnormalities of chromosome 5 | FISH | WB OR BONE MARROW – SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | Deletion/monosomy/ /numerical abnormalities of the long arm of chromosome 5, del(5q), is a chromosomal abnormality in hematologic malignancies, observed in myelodysplastic syndromes, leukemias etc |
| 1141 | 7642 | FISH for 7q deletion and monosomy/numerical abnormalities of chromosome 7 | FISH | WB OR BONE MARROW – SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | A | India | Deletion/monosomy/ /numerical abnormalities of the long arm of chromosome 5, del(5q), is a chromosomal abnormality in hematologic malignancies, observed in cystic fibrosis, williams syndrome, leukemias etc |
| 1142 | 5813FF | FISH in sex-mismatched BMT ( This test will be done at Guragaon Lab) | FISH | Whole blood or bone marrow in Heparin tube | A/R | India | Following allogeneic bone marrow transplantation (BMT) careful monitoring of engraftment is important because the reappearance of the abnormal hematopoietic clone. |
| 1143 | 7540 | FLOW CROSSMATCH | FLOW CYTOMETRY | Sodium heparin WB of Donor & serum of Patient & EDTA W BLOOD DONOR(Sample is to be collected at least after 3 days of last dialysis. Cross match sample is to be collected after three weeks of last blood transfusion. Mandatory Documents to be enclosed with the sample are: | Cold pack | India | The flow cytometric lymphocyte crossmatch is a standard technique for evaluating the compatibility of potential kidney transplant recipients and donors. |
| 1144 | 1606 | FLOWCYTOMETRY ACUTE LYMPHOBLASTIC LEUKEMIA PANEL (CD3,CD4,CD5,CD7,CD8,CD10,CD19,CD20,CD22,CD34,IgM, HLA-DR) |
FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS DIRECT SMEARS + CLINICAL HISTORY(MANDATORY) IN SPECIFIED FORMAT | A | India | To help diagnose ACUTE LYMPHOBLASTIC LEUKEMIA |
| 1145 | 1607 | FLOWCYTOMETRY PANEL; MYELOMA PANEL (CD38,CD56,CD19, CYTOPLASMIC KAPPA AND LAMBDA,CD45, CD138) | FLOW CYTOMETRY | EDTA BM / HEP BM / SMEARS + CLINICAL HISTORY | A | India | Clonal restriction / B cell maturity marker |
| 1146 | 5422 | FLOWCYTOMETRY PANEL; NATURAL KILLER CELL EVALUATION (%CD16+56,ABS CD16+CD56) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 48 HRS) |
A | India | Measurement of NK cells is useful in patients of Bad Obstetric History and Recurrent Abortions. It is also useful in the diagnosis of Retinoblastoma, Medulloblastoma, Astrocytomas and Neuroblastomas. |
| 1147 | 1611 | FLOWCYTOMETRY PANEL; NATURAL KILLER PANEL (CD3,CD16,CD56,CD45) | FLOW CYTOMETRY | EDTA – WB / BM / / FLUIDS, HEPARIN WB / BM / FLUIDS + BLOOD / BM SMEARS + CLINICAL HISTORY | A | India | Natural Killer cells |
| 1148 | 1608 | FLOWCYTOMETRY ACUTE LEUKEMIA PANEL (CD10,CD19,CD20,CD22,CD3,CD5,CD7,CD13,CD33,CD34,CD117,HLA DR) +cMPO/cCD3/cCD79a – as per case specific requirement |
FLOW CYTOMETRY | BM / WB- EDTA | BM / WB- HEPARIN | FLUID-EDTA I FLUID-HEPARIN I BM / WB / FLUIDS DIRECT SMEARS + CLINICAL HISTORY (MANDATORY) IN SPECIFIED FORMAT | A | India | To help classify Acute leukemia (ALL, AML etc) |
| 1149 | 7469 | FLT3 MUTATION DETECTION | PCR,SEQUENCING | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | This assay is useful for the qualitative detection of FLT3TKD and FLT3ITD mutations associated with Acute Myeloid Leukemia. |
| 1150 | 8008 | FLU REAL TIME PCR | REAL TIME PCR | NASAL/THROAT/NASOPHARYNGEAL SWAB IN VTM + CLINICAL HISTORY IN SPECIFIED FORMAT | F | India | This test is intended for the detection of Influenza A H1N1 virus (Swine Flu). Real Time PCR assay is based on the detection of 4 targets in the sample namely influenza A, H1 Influenza A, H1 Influenza A ( Subtype H1) & Human RNase P gene which serves as a positive control for the presence of human nucleic acids. |
| 1151 | 4952 | FLUID BETA -2 TRANSFERRIN | IMMUNOFIXATION ELECTROPHORESIS | EAR FLUID/NASAL FLUID,CSF AND SERUM(SPECIMEN SHOULD PREFERABLY REACH SRL,MUMBAI PREFERABLY WITHIN 24HRS OF COLLECTION).IT IS MANDATORY TO SEND SERUM ALONG WITH THE FLUID SAMPLE | STRICTLY IN COLD CONDITION | India | The presence of Beta2 Transferrin in nasal or ear fluid, or in wound drainage following head trauma, surgery or from tumors or congenital malformation, clearly indicates CSF leaking into these passages or fluids creating a pathway for lifethreatening central nervous system infection. |
| 1152 | 7528 | FLUID, ACE | Kinetic Method | CSF | COLD | India | Quantitative measurement of ACE in CSF. Angiotensin Converting Enzyme (ACE) is used in the assessment of neurosarcoidosis. The major sources of ACE are macrophages and epithelial cells. Patients with sarcoidosis display elevated levels of ACE. |
| 1153 | 8225 | FLUORESCENT TREPONEMAL ANTIBODIES (FTA-ABS) | Indirect Immunofluorescence Assay | Serum from 1 SST. Ship refrigerated or frozen.. | Room 6HRS, Refrig- 1 Week, Frozen 2 Weeks | India | #N/A |
| 1154 | 1677BF | FMC7 PERCENT | FLOW CYTOMETRY | EDTA AND HEPARIN WB/BONE MARROW+CLINICAL & TREATMENT HISTORY (SAMPLE TO REACH WITHIN 48 HRS) | A | India | Prognostic CLL / NHL marker |
| 1155 | Z162K | FOLLICLE STIMULATING HORMONE (FSH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | This antibody is used in the identification of FSH in pituitary adenomas. |
| 1156 | RD1442 | FOOD DETECT | Immunochromatography | SERUM | A/R | India | Food allergy test |
| 1157 | RD1306 | FOOD INTOLERANCE TEST | PROTEIN MICROARRAY | SERUM/PLASMA/ETDA WHOLE BLOOD + CLINICAL HISTORY IN SPECIFIED FORMAT | R/R/A | India | Nontoxic reactions to food can be immune mediated (food allergy) or non immune mediated (food intolerance). Intolerance to food may be enzymatic or pharmacological but in certain instances, it is undefined. Such reactions are independent of IgE mediation. Adverse reactions include gastrointestinal, skin & pulmonary. |
| 1158 | RD1325 | FRAGILE X (FMR 1) MUTATION SCREEN | TRIPLET PRIMED PCR FRAGMENT ANALYSIS | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Mutations in the FMR1 gene cause fragile X syndrome. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. This test is used to determine the number of time the CGG triplet is repeated to diagnose Fragile X syndrome. |
| 1159 | 3248FTE | FREE TESTOSTERONE | ENZYME IMMUNO ASSAY | SERUM | F | India | Circulating Testosterone consists of testosterone bound to SHBG and the bioavailable (Free & Bound to Albumin). The latter is biologically active. In men approximately 40% of Total testosterone is albumin bound while in women approximately 20% is albumin bound. |
| 1160 | 3245 | FREE ANDROGEN INDEX | CHEMILUMINESCENCE | SERUM ( AGE+GENDER+LMP+CLINICAL HISTORY REQUIRED) SAMPLE TO BE DRAWN IN THE MORNING HOURS. | 2-8°C (48 HRS); F (>48 HRS) | India | The Androgen index is a ratio of Testosterone & SHBG. It is an indicator of Free Testosterone and has been found to be useful in evaluation of hirsutism. |
| 1161 | 3285 | FREE BETA HCG (FBHCG) | CHEMILUMINESCENCE | SERUM (CLINICAL DETAILS ); LMP DATE REQUIRED | 2-8°C (7 days); F (>7 days) | India | Maternal serum Free beta HCG assessment between 913 weeks, has significant utility in first Trimester Prenatal Screening for Down Syndrome and other chromosomal anomalies. This test also helps in the diagnosis and monitoring of Trophoblastic diseases and certain Testicular tumors where ratio of Free beta HCG to Total HCG is high. Some tumors secrete only free beta HCG andvirtually no Total HCG is detected. |
| 1162 | 3839I | FREE PROTEIN S | IMMUNO TURBIDIMETRY | FROZEN CITRATED PLASMA | FROZEN | India | The congenital deficiencies of PS are classified in three types – Type I deficiencies correspond to reduced antigen levels of both total and FPS. – Type II deficiencies are characterized by a reduced PS activity but with normal antigen levels of both total and FPS. – Type III deficiencies are defined by a reduced antigen level and activity of FPS but the antigen level of total PS remains normal. Acquired FPS deficiencies can be found in several clinical states ; eg inflammatory syndromes due to the increase of C4b-BP, hepatic disorders, nephrotic syndrome, treatments with oral anticoagulants, oral contraceptives, L – asparaginase. FPS levels progressively decrease in pregnancy. The congenital or acquired deficiency of PS increases the risk of thrombo-embolism, owing to a decrease of blood anticoagulant potential. It may produce recurrent thrombotic episodes. |
| 1163 | 3935 | FRUCTOSAMINE | SPECTROPHOTOMETRY | SERUM (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) AVOID LIPEMIC & HEMOLYSED SPECIMEN | 2-8°C (2 WEEKS); F (5 WEEKS) | India | This assay is useful to assess intermediate term glycemic control. Fructosamine reflects glycemic control in diabetic patients over the previous 2 to 3 weeks. High values indicate poor control. |
| 1164 | 5660 | FUNGAL SUSCEPTIBILITY MIC PANEL | BROTH DILUTION | PURE CULTURE OF YEAST | R | India | fungal antibiotic suceptibility test |
| 1165 | 5661 | FUNGAL SUSCEPTIBILITY MIC SINGLE DRUG | BROTH DILUTION | PURE CULTURE OF YEAST | R | India | The fungal susceptibility test is a quantitative test, based on the principle of determination of the minimum inhibitory concentration of antifungal agents using the broth dilution technique. |
| 1166 | 5322B | FUNGUS CULTURE & STAIN (BLOOD)(FUNGUS ID) | FUNGUS IDENTIFICATION- 1)CULTURE 2)IDENTIFICATION OF YEASTS BY GERM TUBE TEST/CHROMOGENIC MEDIA/AUTOMATED IDENTIFICATION SYSTEM & MOLDS BY COLONY MORPHOLOGY & MICROSCOPY | BLOOD INOCULATED IN BACTEC BOTTLE (MYCOSIS) | A | India | To detect and identify fungal organism |
| 1167 | 5322 | FUNGUS CULTURE, STAIN & IDENTIFICATION | FUNGUS IDENTIFICATION- 1)CULTURE 2)IDENTIFICATION OF YEASTS BY GERM TUBE TEST/CHROMOGENIC MEDIA/AUTOMATED IDENTIFICATION SYSTEM & MOLDS BY COLONY MORPHOLOGY & MICROSCOPY | SPUTUM / CSF / FLUID / URINE / ASPIRATE / TISSUE BIOPSY- STERILE CONTAINER, SWABS NOT ACCEPTED | A/R | India | To detect and identify fungal organism |
| 1168 | 5324 | FUNGUS IDENTIFICATION | FUNGUS IDENTIFICATION- 1)CULTURE 2)IDENTIFICATION OF YEASTS BY GERM TUBE TEST/CHROMOGENIC MEDIA/AUTOMATED IDENTIFICATION SYSTEM & MOLDS BY COLONY MORPHOLOGY & MICROSCOPY | PURE CULTURE OF FUNGUS ON AGAR SLANT | R | India | To detect and identify fungal organism |
| 1169 | 9212RFX | G6PD QUALITATIVE REFLEX G6PD QUANTITATIVE ESTIMATION | DYE DECOLORIZATION + SPECTROPHOTOMETRY | WB-EDTA | A & FOR G6PD QUANTITATIVE ESTIMATION (R) | India | To determine whether you have an inherited G6PD deficienc |
| 1170 | 1146QT | G-6-PD, QUANTITATIVE, BLOOD | SPECTROPHOTOMETRY | WB-EDTA ( CLINICAL HISTORY, AGE & GENDER IS MANDATORY) | R | India | G6PD deficiency is a sex linked disorder affecting males whereas females are the carriers. More than 300 variants of G6PD are known, hence deficiency can range from asymptomatic to acute hemolytic episodes. These episodes can be triggered by drugs, ingestion of fava beans, viral and bacterial infections. This assay is useful for evaluation of individuals with Coomb’s negative nonspherocytic hemolytic anemia. |
| 1171 | 1728 | GALACTOMANNAN | Enzyme Linked Immnunosorbent assay | SERUM(Care must be taken not to contaminate the sample with fungal spores and/or bacteria.Trasnport and store samples in sealed tubes, unexposed to air) | 2-8º C (48 HRS), >48 HRS 70 °C | India | Galactomannan (GM) is a polysaccharide component of the Aspergillus cell wall released from growing hyphae. Serum galactomannan can often be detected between 7 to 14 days before other diagnostic clues become apparent. Monitoring of galactomannan levels can potentially allow initiation of presumptive antifungal therapy before lifethreatening infection occurs. The test aids in the diagnosis of Invasive Aspergillosis (IA) and assesses response to therapy |
| 1172 | RD1434 | Galactosemia (GALT) Gene Mutation | PCR Sequencing | WHOLE BLOOD EDTA/BLOOD SPOT | AMBIENT | India | Galactose1phos phate uridylyltransferase (or GALT) is an enzyme responsible for converting ingested galactose to glucose. This test helps in determining the mutation responsible for Galactosemia. |
| 1173 | 2405 | GAMMA INTERFERON (M.tuberculosis Interferon Gamma Release Assay (IGRA) | Enzyme Linked Immnunosorbent assay | WHOLE BLOOD TO BE COLLECTED IN 5 ml BD ENDOTOXIN FREE HEPARIN TUBE PROVIDED BY SRL FROM SUNDAY TO FRIDAY AND TRANSPORTED WITHIN 12 HRS OF COLLECTION. | A | India | Latent tuberculosis infection (LTBI) is a noncommunicabl e asymptomatic condition that persists for many years and may progress to tuberculous disease. The main aim of diagnosing LTBI is to consider medical treatment for preventing the disease. This test is a measure of cell mediated immune response to antigens simulating the mycobacterial proteins. A positive result indicates that mycobacterium tuberculosis infection is likely but further medical & diagnostic evaluation is necessary. This test is usually negative in individuals vaccinated with Mycobacterium bovis BCG. |
| 1174 | 1419 | GARDNERELLA VAGINALIS CULTURE | CULTURE | VAGINAL / CERVICAL SWABS / SECRETIONS IN TRANSPORT MEDIA | A | India | To detect and identify GARDNERELLA VAGINALIS |
| 1175 | 3175 | GASTRIN | CHEMILUMINESCENCE | FASTING SERUM (CLINICAL HISTORY REQUIRED) | FROZEN: UP TO 30 days | India | Gastrin is a peptide hormone produced by mucosal G cells of gastric antrum. Gastrin levels are pathologically increased in Gastrinoma, Gastric outlet obstruction and Hypo / Achlorhydria. This assay is used to investigate patients with Achlorhydria / Pernicious anemia and ZollingerEllison syndrome. The assay is extremely useful in the diagnosis of Gastrinoma. |
| 1176 | 5013 | GASTROENTERITIS SCREENING PANEL | MICROSCOPY/ CULTURE | STOOL SAMPLE | A | India | Adenovirus is one of the commonest causes of severe gastroenteritis in infants and young children. There are 51 Adenovirus serotypes that have been identified. |
| 1177 | Z273K | GATA-3 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | GATA3 is involved in luminal cell differentiation in the mammary gland and appears to control a set of genes involved in the differentiation and proliferation of breast cancer. The expression of GATA3 is associated with the expression of estrogen receptor-alpha (ER) in breast cancer. GATA3 has been shown to be a novel marker for bladder cancer. GATA3 stains almost all of urothelial carcinomas, but stained no prostate or renal carcinomas. |
| 1178 | Z256K | GCDFP-15 (ANTI-HUMAN GROSS CYSTIC DISEASE FLUID PROTEIN-15) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | GCDFP15 is expressed in apocrine epithelia, lacrimal, ceruminous and Moll’s glands, as well as in numerous serous cells of the submandibular, tracheal, bronchial, sublingual and minor salivary glands. It can be of use in the identification of breast carcinoma, salivary duct carcinoma and apocrine epithelia. |
| 1179 | 7577 | GCV RESISTANCE BY SEQUENCING | PCR-SEQUENCING | EDTA PLASMA /EDTA WHOLE BLOOD + CLINICAL HISTORY | F/A | India | UGT1A1 gene polymorphism is associated with Gidlbert syndrome, Crigler Nijjar syndrome and with irinotecan toxicity |
| 1180 | RD1487 | GDNEXT | Next Generation Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | next-generation sequencing can detect genetic abnormalities using less DNA than required for traditional DNA sequencing approaches. |
| 1181 | RD1324UL | GENE EXPERT (XPERT MTB / RIF) | REAL TIME PCR ON GENEXPERT PLATFORM | SPUTUM / BAL | A/R | India | #N/A |
| 1182 | RD1411 | GENETIC DISORDERS: Freidreichs Ataxia mutation analysis | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Friedreich’s ataxia is an autosomal recessive inherited disease that causes progressive damage to the nervous system. It manifests in initial symptoms of poor coordination such as gait disturbance; it can also lead to scoliosis, heart disease and diabetes, but does not affect cognitive function. This test detects expansion of an intronic GAA triplet repeat in the FXN gene which leads to reduced expression of the mitochondrial protein frataxin |
| 1183 | RD1417 | GENETIC DISORDERS; ANGELMANS SYNDROME MS PCR | Methylation Specific – PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | PraderWilli syndrome (PWS) and Angelman syndrome (AS) are clinically distinct neurodevelopment al genetic disorders that map to 15q11q13. The primary phenotypes are attributable to loss of expression of imprinted genes within this region which can arise by means of a number of mechanisms. The most sensitive single approach to diagnosing both PWS and AS is to study methylation patterns within 15q11q13 |
| 1184 | RD1326 | GENETIC DISORDERS; DRPLA Gene analysis | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Dentatorubralpalli doluysian atrophy (DRPLA) is an autosomal dominant spinocerebellar degeneration caused by an expansion of a CAG repeat encoding a polyglutamine tract in the atrophin1 protein.It is also known as Haw River Syndrome and NaitoOyanagi disease. It is characterized by ataxia, choreoathetosis, dementia, and psychiatric disturbance in adults and ataxia, myoclonus, seizures, and progressive intellectual deterioration in children. |
| 1185 | RD1418 | GENETIC DISORDERS; PRADER- WILLI SYNDROME MS PCR | Methylation Specific – PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | PraderWilli syndrome (PWS) and Angelman syndrome (AS) are clinically distinct neurodevelopment al genetic disorders that map to 15q11q13. The primary phenotypes are attributable to loss of expression of imprinted genes within this region which can arise by means of a number of mechanisms. The most sensitive single approach to diagnosing both PWS and AS is to study methylation patterns within 15q11q13 |
| 1186 | RD1410 | GENETIC DISORDERS; RETT SYNDROME DNA SEQUENCING ( MECP2 MUTATION) | DNA SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Genetically, Rett syndrome (RTT) is caused by mutations in the gene MECP2 located on the X chromosome (which is involved in transcriptional silencing and epigenetic regulation of methylated DNA), and can arise sporadically or from germline mutations. In less than 10% of RTT cases, mutations in the genes CDKL5 or FOXG1 have also been found to resemble it. Rett syndrome is initially diagnosed by clinical observation, but the diagnosis is definitive when there is a genetic defect in the MECP2 gene. |
| 1187 | RD1456 | GENETIC DISORDERS; SCA 12 (SPINAL CEREBRAL ATAXIA TYPE-12) | PCR-Fragment analysis | EDTA WHOLE BLOOD | AMBIENT | India | The assay detects CAG repeats in the SCA12 (ATXN12) gene. To help diagnose SPINAL CEREBRAL ATAXIA TYPE-12 |
| 1188 | RD1413 | GENETIC DISORDERS; SCA 2 (SPINAL CEREBRAL ATAXIA TYPE-2) | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Spinocerebellar ataxia (SCA) or also known as Spinocerebellar atrophy or Spinocerebellar degeneration, is a progressive, degenerative genetic disease with multiple types. In SCA 2 there is a CAG trinucleotide repeat in chromosome 12q which gets affected which results in abnormal Ataxin 2 protein production |
| 1189 | RD1414 | GENETIC DISORDERS; SCA 3 (SPINAL CEREBRAL ATAXIA TYPE-3) | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Spinocerebellar ataxia (SCA) or also known as Spinocerebellar atrophy or Spinocerebellar degeneration, is a progressive, degenerative genetic disease with multiple types. In SCA 3 there is a CAG trinucleotide repeat in chromosome 14q which gets affected which results in abnormal Ataxin 3 protein production |
| 1190 | RD1415 | GENETIC DISORDERS; SCA 6 (SPINAL CEREBRAL ATAXIA TYPE-6) | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Spinocerebellar ataxia (SCA) or also known as Spinocerebellar atrophy or Spinocerebellar degeneration, is a progressive, degenerative genetic disease with multiple types. In SCA 6 there is a CAG trinucleotide repeat in chromosome 19p which gets affected which results in abnormal CACNA1A protein. |
| 1191 | RD1416 | GENETIC DISORDERS; SCA 7 (SPINAL CEREBRAL ATAXIA TYPE-7) | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | Spinocerebellar ataxia (SCA) or also known as Spinocerebellar atrophy or Spinocerebellar degeneration, is a progressive, degenerative genetic disease with multiple types. In SCA 7 there is a CAG trinucleotide repeat in chromosome 3p which gets affected which results in abnormal Ataxin 7 protein. |
| 1192 | RD1455 | GENETIC DISORDERS; SCA10 (SPINAL CEREBRAL ATAXIA TYPE-10) | PCR-Fragment analysis | EDTA WHOLE BLOOD | AMBIENT | India | The assay detects ATTCT repeats in the SCA10 (ATXN10) gene. To help diagnose SPINAL CEREBRAL ATAXIA TYPE-10 |
| 1193 | RD1457 | GENETIC DISORDERS; SCA17 (SPINAL CEREBRAL ATAXIA TYPE-17) | PCR-Fragment analysis | EDTA WHOLE BLOOD | AMBIENT | India | The assay detects CAG/CAA repeats in the SCA17 (ATXN17) gene. To help diagnose SPINAL CEREBRAL ATAXIA TYPE-17 |
| 1194 | 9443 | GENETIC DISORDERS; SMA CARRIER DETECTION | MLPA-FRAGMENT ANALYSIS | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | SMA of all types is associated with homozygous mutations in the survival motor neuron 1 gene (SMN1). This test detects homozygous deletion of SMN1 Exon 7 and or Exon 8 which accounts for 95% of SMA. It detects both active and carrier status of the disease. |
| 1195 | 2408 | GENITAL MYCOPLASMA / UREAPLASMA CULTURE | CULTURE | URETHRAL / CERVICAL SWABS,URINE,SEMEN IN TRANSPORT MEDIA | SPECIMEN IN TRANSPORT MEDIA AT RT UP TO 48 HRS; AT 2-8°C UP TO 72 HRS | India | The current test is intended for the culture of genital mycoplasmas,namely M. hominis and U. urealyticum. |
| 1196 | 7663 | GIARDIA LAMBILA ANTIGEN DETACTION FROM STOOL; RAPID CARD TEST | RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | A/R | India | The current test is a rapid test for the qualitative detection of Giardia lamblia in stool samples. |
| 1197 | RD1443 | GIST PDGFRA GENE MUTATIONS | PCR SEQUENCING | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | FIP1L1PDGFRA rearrangement is generally found in Chronic Eosinophilic Leukemia, but the presentation can be as AML, Tlymphoblastic lymphoma, or both simultaneously. Rearrangement is usually cryptic by routine cytogenetics. |
| 1198 | Z084K | GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Glial Fibrillary Acidic Protein (GFAP) is the major protein found in astrocytes and its expression is evidence of astroglial origin and differentiation. Gliomas are the most common cerebral neoplasm in adults and include astrocytomas, oligodendrogliomas and glioblastomas. It can also be demonstrated in ependymal cells, ependymomas, subependyomas, glioblastomas, mixed central nervous system neoplasms and gangliomas. It is detected in immature but not mature oligodendrocytes and neurons. Anti-GFAP antibodies do not cross-react with neurons, fibroblasts or muscle cells. Anti-GFAP antibodies are useful in differentiating primary gliomas from metastatic lesions in the brain and for documenting astrocytic differentiation in tumors outside the central nervous system. |
| 1199 | 4551 | GLIOMA PANEL (1P/19Q, IDH1/2, MGMT) | FISH/Pyrosequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Oligodendroglioma tumors exhibit simultaneous deletions of 1p and 19q in two thirds of cases. These deletions have been associated with a favorableresponse to chemotherapy with long survival. |
| 1200 | RD1419 | Glucose-6 Phospahte Dehydrogenase (G6PD) Gene Mutations | PCR Sequencing | WHOLE BLOOD EDTA | AMBIENT | India | This assay is useful for the detection of mutations in G6PD gene. G6PD deficiency, also known as favism (after the fava bean) is an Xlinked recessive genetic condition that predisposes to hemolysis (spontaneous destruction of red blood cells) and resultant jaundice in response to a number of triggers, such as certain foods, illness, or medication. |
| 1201 | 9357 | GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) > 1 MONTH | FEA | Dried blood spots | Ambient | India | To detect GLUCOSE-6-PHOSPHATE DEHYDROGENASE deficiency |
| 1202 | 3193 | GLUTAMIC ACID DECARBOXYLASE (GAD-65) IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (48 hrs), >48 hrs -20 °C | India | GAD65 antibody is useful to diagnose Insulin dependent Diabetes mellitus (IDDM), to assess risk for development of IDDM, to predictonset of IDDM and risk of development of related endocrine disorders like Thyroiditis. |
| 1203 | 1674BR | GLYCOPHORIN A (ERYTHROID) | FLOW CYTOMETRY | WB- EDTA | BM / WB- HEPARIN | BM / EDTA/ HEPARIN/ FLUIDS/SMEARS + CLINICAL HISTORY | A | India | Erythroid cell marker |
| 1204 | Z278K | GLYCOPHORIN C | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | N/A |
| 1205 | Z274K | GLYPICAN 3 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | A useful marker to differentiate between benign (negative) and malignant (positive) liver diseases (HCCs). |
| 1206 | Z279K | GRANZYM B | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Granzyme B antibody labels activated human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. This marker can be a useful tool for the identification of anaplastic large cell lymphoma, large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, and subcutaneous panniculitic T-cell lymphomas of T or NK phenotype. |
| 1207 | Z163K | GROWTH HORMONE (GH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | This marker is a useful in classification of pituitary tumors and the study of pituitary disease (acromegaly). |
| 1208 | 3183 | GROWTH HORMONE STIMULATION TEST | CHEMILUMINESCENCE | SERUM – RECOMMENDED DOSE INSULIN – 0.1 – 0.15 U/KG , ARGININE 0.5 GM/KG, GLUCAGON 0.03 MG/KG IM ( 5 SAMPLES COLLECTED 30 MINUTES APART, FIRST SAMPLE COLLECTED BEFORE STIMULATING AGENT) | FROZEN: UP TO 2 Months | India | This test is used to demonstrate Growth Hormone deficiency in cases of growth retardation, short stature and Dwarfism. To diagnose Growth hormone deficiency as a cause of retardation, at least two different stimulants should be used on different days for confirmation. Exercise to be used as an initial stimulant followed by any other provocative agent. |
| 1209 | Z275K | H CALDASMON | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | The h-caldesmon is predominantly expressed in smooth muscle and a subset of myoepithelial cells, |
| 1210 | 9981 | H.PYLORI ANTIGEN DETECTION | RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | R | India | This assay aids in the diagnosis of H.pylori infection and monitor response during and post therapy in patients for treatment effectiveness, relapse or eradication. |
| 1211 | 9606 | HAEMOPHILUS INFLUENZAE B ANTIGEN | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | rapid test to detect HAEMOPHILUS INFLUENZAE B ANTIGEN |
| 1212 | 9606C | HAEMOPHILUS INFLUENZAE B ANTIGEN, CSF | LATEX PARTICLE AGGLUTINATION | CSF | 2-8°C (FEW HRS); -20°C (LONGER) | India | rapid test to detect HAEMOPHILUS INFLUENZAE B ANTIGEN in CSF |
| 1213 | 3832 | HAM TEST (ACIDIFIED SERUM LYSIS TEST) | HEMOLYSIS | EDTA WB AND SERUM | A/R | India | PNH is an acquired clonal disorder of hemopoiesis in which patient’s red cells are abnormally sensitive to lysis by normal constituents of plasma. |
| 1214 | 7178 | HANTA VIRUS-IGM, SERUM BY EIA | EIA | SERUM | R/F | India | quantitative test to measure HANTA VIRUS-IGM |
| 1215 | 1519I | HAPTOGLOBIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (> 7 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Haptoglobin is a binding protein for hemoglobin. Low levels are seen in Chronic intravascular hemolysis, regular strenuous exercise and severe liver disease. Increase occurs as an acute phase reaction. This assay is useful for confirmation of Intravascular hemolysis. |
| 1216 | 7375 | HAPTOGLOBIN GENOTYPING | PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | The haptoglobin Hp 1/2 polymorphism has been associated with the prevalence of infections, autoimmune diseases, cardiovascular diseases, and other disorders, thus suggesting a broad clinical significance. The Hp 22 phenotype was over represented in patients with more severe forms of myocardial infarction. This test is useful for genotyping of the Haptoglobin gene |
| 1217 | 2478 | HAV RNA PCR | REVERSE TRANSCRIPTASE PCR | EDTA PLASMA | F | India | This assay is useful for the detection of Hepatitis A virus in the plasma of the patient. |
| 1218 | 9210RFX | HB VARIANT REFLEX WITH RED CELL INDICES (PERFORMED IF HB A2 OR HB F IS ABNORMAL) / SICKLING TEST (PERFORMED IF HB S IS ABNORMAL) | HPLC/ AUTOMATED CELL COUNTER / MICROSCOPY /DEOXYGENATION | WB-EDTA+ BLOOD SMEAR + CLINICAL HISTORY IN SPECIFIED FORMAT+ AGE & SEX | A | India | HB VARIANT detects abnormal forms of haemoglobin that are often inherited and may cause a blood disorder. A sickle cell test is a simple blood test used to determine if you have sickle cell disease (SCD) or sickle cell trait. CBC is done to determine your general health status; to screen for, diagnose, or monitor any one of a variety of diseases and conditions that affect blood cells, such as anemia, infection, inflammation, bleeding disorder or cancer |
| 1219 | 9218RFX | HBeAG NEGATIVE REFLEX TO HBV PRECORE & BASAL CORE MUTATION | Chemiluminescent Microparticle Immunoassay (CMIA)/ COBAS TAQMAN & NESTED PCR SEQUENCING | SERUM + PLASMA EDTA (FROZEN ONLY) | FOR HBEAG TEST —2-8°C (7 DAYS) ,>7 DAYS -20°C, F | India | HBeAG – qualitative determination of the hepatitis B e antigen (HBeAg) in human serum and plasma. hepatitis B e antigen (HBeAg) is used as a marker of active viral proliferation that might lead to active liver damage. HBV PRECORE & BASAL CORE MUTATION- To detect HBV PRECORE & BASAL CORE MUTATION. BCP and PC gene mutations were reported to cause HBeAg-negative chronic hepatitis B infection by affecting HBeAg expression which ultimately leads to HBeAg loss and negativity with a severe form of chronic liver disease progression. Moreover, the presences of such genes change often need long-term HBV therapy that makes patients susceptible to nucleos(t)ide analogues drug resistance gene evolution |
| 1220 | Z280K | HBME-1 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | HBME1 is an anti-mesothelial monoclonal antibody that recognizes an unknown antigen on the microvilli of mesothelioma cells. It stains normal mesothelial cells as well as epithelial mesotheliomas in a thick membrane pattern. This antibody also reacts with some carcinomas showing cytoplasmic immunostaining. |
| 1221 | RD1305 | HBV DRUG RESISTANCE (Lamivudine, Telbivudine, Adefovir, Tenofovir and Entecavir) | NESTED PCR-SEQUENCING | EDTA PLASMA/SERUM + CLINICAL HISTORY | F | India | For detection & genotyping of HBV. The mutations analysed include M204I (YMDD to YIDD), L180M, M204V (YMDD to YVDD), A181 T/V and N236T. These mutations are known to cause resistance to Lamivudine, Telbivudine, Entecavir, Adefovir and Tenofovir. |
| 1222 | 9973 | HBV VIRAL LOAD BY REAL TIME PCR | REAL TIME PCR | SERUM / PLASMA EDTA | F | India | This test is intended for use as an aid in management of HBV infected patients and is not intended for use in the initial diagnosis or confirmation of HBV infection. It aids in assessing viral response to antiviral treatment as measured by changes in plasma HBV DNA levels. |
| 1223 | 8136 | HBV QUANTITATIVE BY COBAS TAQMAN | COBAS TAQMAN | SERUM / PLASMA EDTA | F | India | The viral load provides the direct and reliable estimate of the level of HBV replication. Quantitation of HBV DNA level is important as it serves to be a prognostic marker of HBV infection. It is used for establishing baseline levels in patients before initiation of the therapy and for monitoring therapeutic response and disease progression. A sudden rise in the viral load may indicate emergence of resistant strains during the therapy. |
| 1224 | DT4102 | HCV ALPHA (HCV RNA Quantitative and HCV Genotyping) | PCR SEQUENCING & COBAS TAQMAN | PLASMA- EDTA | F | India | HCV genotyping assay determines the Genotypes 1,2,3,4,5 & 6 and their subtypes in positive cases. HCV genotype 1 is more difficult to treat than Genotypes 2 & 3 and causes more severe liver disease. This test should not be used for screening of blood or blood products or as a diagnostic test to confirm the presence of HCV infection. |
| 1225 | 5968 | HCV COMBO | PCR SEQUENCING & COBAS TAQMAN | PLASMA- EDTA | F | India | This test is done for HCV genotyping and to detect HCV viral load. Viral load is a monitoring test and hence should not be used for screening or diagnostic purpose. |
| 1226 | 9972 | HCV VIRAL LOAD BY REAL TIME PCR | REAL TIME PCR | PLASMA-EDTA | F | India | to detect HCV viral load |
| 1227 | 7516 | HCV4 (HCV RNA Qualitative AND HCV Antibodies) | REAL TIME POLYMERASE CHAIN REACTION/ CMIA | SERUM. FOR ECLIA/ PLASMA-EDTA FOR PCR | F | India | • To detect HCV infection in individuals actively infected during the sero-negative window period. • To detect the infection in immunocompromised individuals & individuals with chronic HCV as there are absence of serological markers. • Can be used as a confirmatory test for individuals who have equivocal serologic evaluations(1). |
| 1228 | 8400 | HDV RNA PCR | REVERSE TRANSCRIPTASE PCR | EDTA PLASMA | F | India | This assay is useful for the detection of Hepatitis D virus in the plasma of the patient. |
| 1229 | 4113 | HE4 (Human Epididymis Protein-4) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (4 DAYS); -20°C (>4 DAYS) | India | HE4 is the tumor marker of choice with high specificity than CA 125 in Ovarian cancer. To improve sensitivity and specificity, an algorithm, ROMA, using both CA125 & HE4 has been suggested to indicate risk of Ovarian malignancy in patients presenting with abdominal masses. |
| 1230 | 3901 | HEALTH KUNDLI-BRIDE/GROOM (ABO Rh Blood Group, VDRL, HBsAg, HIV 1&2 Antibodies, HB Variant Analysis) | Chemiluminescent Microparticle Immunoassay (CMIA)+Flocculation+ Tube Agglutination+HPLC | EDTA-WHOLE BLOOD+SERUM + CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | Routine health checkup for Bride/ Groom |
| 1231 | RD1402 | HEART ENSURE PANEL | PCR-Sequencing | EDTA WHOE BLOOD | AMBIENT/COLD | India | Routine heart health checkup |
| 1232 | 7736 | HELICOBACTER PYLORI IgA ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | Colonization with H.pylori is associated with increased risk of developing gastritis, peptic ulcer disease and gastric malignancies. Antibody IgA may be elevated for years in infected individuals. Following treatment, values generally decrease, but may not become undetectable. |
| 1233 | 7761 | HELICOBACTER PYLORI IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | Colonization with H.pylori is associated with increased risk of developing gastritis, peptic ulcer disease and gastric malignancies. Antibody IgG may not be accompanied by an increase in IgM or IgA antibodies. It may be elevated for years in infected individuals. Following treatment, values generally decrease, but may not become undetectable. |
| 1234 | 7986 | HELICOBACTER PYLORI IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (2 DAYS), >2 DAYS- 20 °C | India | qualitative measurement of IgM class antibodies against HELICOBACTER PYLORI |
| 1235 | 1221DLW | HEMODIALYSIS WATER CULTURE | CULTURE | DIALYSIS WATER/ DIALYSATE/ R. O. WATER IN STERILE LEAK PROOF CONTAINER | R | India | To detect and identify infection causing organism |
| 1236 | 3834 | HEMOGLOBIN VARIANT ANALYSIS | HPLC | WB-EDTA (AGE, CLINICAL HISTORY IN SPECIFIED FORMAT AND CBC(IF PERFORMED) FINDINGS MANDATORY) | A | India | This assay is useful in the diagnosis of Beta Thalassemia. It quantitates the percent of fetal hemoglobin and assists in the diagnosis of disorders with elevated levels of HbF. |
| 1237 | 3897 | HEMOPHILIA PANEL (APTT, FACTOR VIII, FACTOR IX) | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA *- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | Hemophilia A (Factor VIII deficiency) is the most common severe congenital bleeding Xlinked disorder affecting 1:5000 to 10,000 males. Females are usually carriers but canhave Hemophilia A if there is unbalanced Lyonization of the normal Xchromosome, Turner’s syndrome or daughters of an affected male and a carrier female. Hemophilia B / Christmas disease (Factor IX deficiency) is a severe congenital Xlinked bleeding disorder affecting 1:25,000 to 30,000 males. Factor IX activity levels during childhood remain at about 75% of adult levels. |
| 1238 | Z257K | HEPAR-1 [ANTI-HUMAN HEPATOCYTE ) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Recognizes mitochondrial antigen of hepatocytes |
| 1239 | 2463 | HEPATITIS A & B VIRUS EVALUATI0N (HEP A IgG & IgM, HBCORE TOTAL & IgM, HBsABS, HBsAg, HBeABS, HBeAg) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | Acute Viral Hepatitis is a systemic infection affecting the liver predominantly. Hepatitis A , B, C & E are common causes of Acute Viral Hepatitis producing clinically similar illnesses ranging from asymptomatic to fatal acute infections. Subclinical persistent infections of Hepatitis B & C virus may progress to Chronic liver disease with Cirrhosis and even Hepatocellular carcinoma. |
| 1240 | 6014 | HEPATITIS A IGG ANTIBODY | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8º C (3 DAYS), >3 DAYS- 20 °C | India | HAV is a self limiting disease transmitted by the fecaloral route. Anti HAV IgG levels rise quickly once the virus is cleared and may persist for many years. Presence of Anti HAV IgG indicates immunity against the virus. |
| 1241 | 2460 | HEPATITIS A VIRUS IgG & IgM ANTIBODIES | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | rapid test to detect IgG & IgM Antibodies to HEPATITIS A (HAV) |
| 1242 | 2451 | HEPATITIS A VIRUS IgM ANTIBODIES | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | HAV is a self limiting disease transmitted by the fecaloral route. Anti HAV IgM antibodies are detectable by the time symptoms appear, usually 15 45 days after exposure. They fall to undetectable levels by 6 months after HAV infection. |
| 1243 | 2455 | HEPATITIS B E ANTIBODY, SERUM | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 days) ,>7 days -20°C | India | HBeAg is found in early phase of HBV infection and correlates with infectivity. This assay is useful for the diagnosis and monitoring of HBV infectivity. It also determines infection status in chronically HBV infected patients. |
| 1244 | 7658 | HEPATITIS B surface antigen virus ,Qunatitative | CMIA | SERUM | FROZEN/REFRIGERATED | India | This assay is useful for the diagnosis of acute, recent and chronic HBV infection. It also determines the chronic Hepatitis B infection status. It is the first serologic marker to appear in the serum at 6 to 16 weeks following exposure to HBV. It usually disappears 1 to 2 months after the onset of symptoms. Persistence >6 months indicates chronic carrier state or chronic HBV infection. |
| 1245 | Z076K | HEPATITIS B SURFACE ANTIGEN (IHC) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 1246 | 2449 | HEPATITIS B SURFACE ANTIGEN NEUTRALIZATION (WITH CONFIRMATION) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C 14 DAYS) ,>14 DAYS -20°C | India | The detection of HbsAg in human serum or plasma indicates an infection by the Hepatitis B virus. |
| 1247 | 7476 | HEPATITIS B VIRUS ( HBV )PRECORE MUTATION | NESTED PCR SEQUENCING | EDTA PLASMA / SERUM +CLINICAL HISTORY | F | India | Due to limited population specific data, currently this test is meant for research use only. A precore mutant is a variety of hepatitis B virus that does not produce hepatitis B virus e antigen (HBeAg). |
| 1248 | 7475 | HEPATITIS B VIRUS BASAL CORE PROMOTER MUTATION (HBV BASAL) | NESTED PCR SEQUENCING | EDTA PLASMA / SERUM + CLINICAL HISTORY | F | India | The test identifies substitution mutations in the HBV Basal Core Promoter gene np 1762 and 1764 and codon 28 (np 1896) of HBV PreCore gene |
| 1249 | Z077K | HEPATITIS B VIRUS CORE ANTIGEN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Hepatitis B surface antibody targets Hepatitis B Virus Surface Antigen in IHC applications. |
| 1250 | 2457 | HEPATITIS B VIRUS CORE IgM ANTIBODIES | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | This assay is useful for diagnosis of Acute Hepatitis B infection. It identifies Acute HBV infection in the core window period when HBsAg and Anti HBs are negative. It also differentiates between acute and chronic HBV infection in the presence of positive Anti HBc. |
| 1251 | 9890 | HEPATITIS B VIRUS DNA ,QUANTITATIVE (HBV QUANTITATIVE BY COBAS TAQMAN) |
COBAS TAQMAN | PLASMA EDTA/ SERUM | F | India | The viral load provides the direct and reliable estimate of the level of HBV replication. Quantitation of HBV DNA level is important as it serves to be a prognostic marker of HBV infection. It is used for establishing baseline levels in patients before initiation of the therapy and for monitoring therapeutic response and disease progression. A sudden rise in the viral load may indicate emergence of resistant strains during the therapy. Viral load is a monitoring test and hence should not be used for screening or diagnostic purpose. |
| 1252 | 8141 | HEPATITIS B VIRUS DNA DETECTOR, ( HBV ) QUALITATIVE | REAL TIME PCR | SERUM OR PLASMA – EDTA | F | India | HBV PCR has immense diagnostic utility in patients who have inconclusive serology results especially in cases of chronic hepatitis B infection and in HBV carriers. |
| 1253 | 2461 | HEPATITIS B VIRUS EVALUATION (HBCORE TOTAL & IgM, HBsABS, HBsAg) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | This test helps to distinguish acute and chronic infection and assesses recovery from or immunity to Hepatitis B. |
| 1254 | 7474 | HEPATITIS B VIRUS GENOTYPING (HBV GENOTYPING) |
PCR-SEQUENCING | SERUM, EDTA-PLASMA + CLINICAL HISTORY | F | India | This test is useful for the Qualitative detection & Genotyping of 12 High risk genotypes known to be associated with Cervical cancer & 2 Low risk genotypes of HPV which are linked to Genital warts. |
| 1255 | 2456 | HEPATITIS Be VIRUS ANTIGEN | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | HBeAg is found in early phase of HBV infection and correlates with infectivity. This assay is useful for the diagnosis and monitoring of HBV infectivity. It also determines infection status in chronically HBV infected patients. |
| 1256 | 2462 | HEPATITIS Be VIRUS ANTIGEN / ANTIBODY EVALUATION | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | HBeAg is found in early phase of HBV infection and correlates with infectivity. It also determines infection status in chronically HBV infected patients. HBe antibody measurement is useful for recognition of resolution of HBV infection with seroconversion of HBeAg to Anti HBe. This usually indicates loss of infectivity but carrier state may persist. |
| 1257 | 7516A | HEPATITIS C VIRUS (HCV RNA PCR, QUALITATIVE) | REAL TIME POLYMERASE CHAIN REACTION | SERUM FOR CMIA/ PLASMA-EDTA FOR PCR | F | India | This test is useful in diagnosing HCV infection prior to seroconversion, distinguishing active from resolved infection and diagnosing chronic hepatitis carriers who are HCV antibody negative. |
| 1258 | 7473 | HEPATITIS C VIRUS GENOTYPING (HCV GENOTYPING) |
PCR SEQUENCING | PLASMA- EDTA | F | India | HCV genotyping assay determines the Genotypes 1,2,3,4,5 & 6 and their subtypes in positive cases. HCV genotype 1 is more difficult to treat than Genotypes 2 & 3 and causes more severe liver disease. This test should not be used for screening of blood or blood products or as a diagnostic test to confirm the presence of HCV infection. |
| 1259 | 9891 | HEPATITIS C VIRUS RNA QUANTITATIVE (HCV RNA QUANTITATIVE ) |
COBAS TAQMAN | PLASMA- EDTA | F | India | Quantitation of HCV RNA level is important as it serves to be a prognostic marker of HCV infection and is used for establishing baseline levels in patients before initiation of the treatment. It is also useful for monitoring the treatment. |
| 1260 | 7486 | HEPATITIS C VIRUS RNA, QUANTITATIVE | COBAS TAQMAN | PLASMA EDTA | F | India | Quantitation of HCV RNA level is important as it serves to be a prognostic marker of HCV infection and is used for establishing baseline levels in patients before initiation of the treatment. It is also useful for monitoring the treatment. |
| 1261 | 2458 | HEPATITIS DELTA VIRUS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (7 days), >7 days- 20 °C | India | Hepatitis D occurs in patients infected with HBV. Presence of Hepatitis D antibody and HBsAg indicate a coinfection. Patients with Hepatitis D are more likely to develop fulminant hepatitis and chronic hepatitis. |
| 1262 | 2466G | HEPATITIS E VIRUS IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (7 days), >7 days- 20 °C | India | HEV causes an acute self limiting infection. Anti HEV IgG appears within a few days of infection and remains positive for several years. This assay is used for the diagnosis of past HEV infection. |
| 1263 | 2466M | HEPATITIS E VIRUS IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (7 days), >7 days- 20 °C | India | HEV causes an acute self limiting infection. Anti HEV IgM appears within a few days of infection and remains positive upto 6 months. This assay is used for the diagnosis of acute or recent HEV infection. |
| 1264 | 2464 | HEPATITIS G VIRUS RNA | REVERSE TRANSCRIPTASE PCR | EDTA PLASMA | F | India | This assay is useful for the detection of Hepatitis G virus in the plasma of the patient. |
| 1265 | 5011 | HEPATITIS SCREENING PANEL (CBC,SGPT, SGOT, TOTAL BILIRUBIN,DIRECT BILIRUBIN,INDIRECT BILIRUBIN,HBsAg,HAV IgM,HEP E IGM.) | AUTOMATED CELL COUNTER/SPECTROPHOTOMETRY/ELISA/ENZYME IMMUNOASSAY/CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | EDTA WB + DIRECT SMEARS + SERUM 10-12 HRS FASTING (AGE & GENDER IS MANDATORY) AVOID LIPEMIC & HEMOLYSED SPECIMEN | EDTA WB : ambient /R/F, SERUM 2-8°C (2 days); F (> 2 days) |
India | Screening test for hepatitis |
| 1266 | Z004K | HER-2 / neu ONCOPROTEIN (C-ERB B2) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN FOR 24-48 HRS/ PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING.* TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* | A | India | HER2 is an oncogene that is over-expressed in a variety of cancers including some breast carcinomas. |
| 1267 | RD1482 | Hereditary Cancer Panel-Expanded | Next Generation Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | This test analyzes following genes which are associated with hereditary cancer predisposition. APC, ATM, AXIN2, BARD1, BMPR1A, BRIP1, CDC73, CDH1, CDK4, CDKN2A, CDKN2A, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SDHD, SMAD4, STK11, TP53, VHL, XRCC2. These genes are associated with commonly inherited cancers (Ovarian, Endometrial, Colorectal, Gastrointestinal, Pancreatic and Cutaneous Malignant Melanoma) and cancer related syndromes {(Fanconi anemia,Peutz-Jeghers Syndrome,Cowden Syndrome,PTEN Hamartoma Tumor syndrome(PHTS),Bannayan -Riley – Ruvalcaba syndrome,Proteus syndrome,Autism spectrum disorder with macrocephaly,Von Hippel- Lindau Disease,MUTYH – associated polyposis MAP),HNPCC (Hereditary Non – Polyposis Colorectal Cancer),Lynch syndrome,Muir- Torre syndrome,Turcot syndrome,Li- Fraumeni Syndrome,Juvenile Polyposis Syndrome (JPS),HHT,Ataxiatelangiectasia, Louis-Barr syndrome,Familial Adenomatous Polyposis (FAP),Gardner Syndrome and Attenuated FAP (AFAP)}. |
| 1268 | RD1481 | Hereditary Cancer Panel-Next | Next Generation Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | This test analyzes following 32 genes recommended by ACMG(American College of Medical Genetics and Genomics),which are associated with hereditary cancer predisposition. APC,ATM,AXIN2,BRCA1,BRCA2,BARD1,BMPR1A,BRIP1,CDC73,CDH1,CDK4,CDKN2A,CDKN2A, CHEK2,EPCAM,MLH1,MRE11A,MSH2,MSH6,MUTYH,NBN,PALB2,PMS2,PTEN,RAD50,RAD51C,RAD51D,SDHD,SMAD4,STK11,TP53,VHL and XRCC2 These genes are associated with commonly inherited cancers (Breast, Ovarian, Endometrial, Colorectal, Gastrointestinal, Pancreatic and Cutaneous Malignant Melanoma) and cancer related syndromes {(Fanconi anemia,Peutz-Jeghers Syndrome,Cowden Syndrome,PTEN Hamartoma Tumor syndrome(PHTS),Bannayan -Riley – Ruvalcaba syndrome,Proteus syndrome,Autism spectrum disorder with macrocephaly,Von Hippel- Lindau Disease,MUTYH – associated polyposis MAP),HNPCC (Hereditary Non – Polyposis Colorectal Cancer),Lynch syndrome,Muir- Torre syndrome,Turcot syndrome,Li- Fraumeni Syndrome,Juvenile Polyposis Syndrome (JPS),HHT,Ataxiatelangiectasia, Louis-Barr syndrome,Familial Adenomatous Polyposis (FAP),Gardner Syndrome and Attenuated FAP (AFAP)}. |
| 1269 | MGEN009 | Hereditary Pancreatitis gene Panel | 0 | 0 | 0 | India | #N/A |
| 1270 | MGEN005 | Hereditary Spastic Paraplegia | 0 | 0 | 0 | India | #N/A |
| 1271 | 9454 | HERPES SIMPLEX VIRUS 1&2 IGG, ABS | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (4 DAYS), >4 DAYS- 20 °C | India | Herpes Simplex Virus Type 1 (HSV1) infections are acquired through direct person to person contact, most typically by a nongenital route. HSV 2 infections are usually acquired through sexual contact. This assay helps in determining recent exposure as well as previous exposure to HSV Types 1 & 2. |
| 1272 | 7581 | HERPES SIMPLEX VIRUS DNA DETECTOR | REAL TIME PCR | CSF / SERUM/EDTA PLASMA/SWAB | A/R | India | DNA testing is analytically more sensitive specially in patients with Encephalitis, Meningitis and Neonatal infections. Encephalitis is usually due to HSV 1 virus whereas Meningitis is usually due to HSV 2 virus. DNA testing provides reliable means to define the type. |
| 1273 | 9471P | HERPES SIMPLEX VIRUS TYPES 1& 2 IgM ANTIBODIES (COMBINED) | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (4 DAYS), >4 DAYS- 20 °C | India | Herpes Simplex Virus Type 1 (HSV1) infections are acquired through direct person to person contact, most typically by a nongenital route. Recurrent infections are clinically apparent as fever blisters or cold sores. HSV 2 infections are usually acquired through sexual contact. 85% of genital herpes is caused by Type 2 virus and 15% caused by Type 1 virus. This assay helps in determining recent exposure to HSV Types 1 & 2. |
| 1274 | 2116 | HETEROPHILE ANTIBODIES (HA) (INFECTIOUS MONONUCLEOSIS) | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (2 DAYS) ,>2 DAYS -20°C | India | This is a qualitative test for heterophile antibodies to Infectious Mononucleosis. Heterophilic antibodies are associated almost exclusively with Infectious Mononucleosis and EB Virus associated neoplasms. Usually these antibodies develop 3 weeks after infection, but some patients may take as long as 3 months to develop the antibodies. |
| 1275 | RD1459 | HFE gene mutations | PCR Sequencing | EDTA WHOLE BLOOD | AMBIENT | India | Clinical HFEHH is characterized by excessive storage of iron in the liver, skin, pancreas, feet, joints, and testes. This test identifies common mutations such as C282Y, H63D and S65C. |
| 1276 | 1010 | HIRSUTISM EVALUATION PANEL (DHEA, Testosterone (Total and Free), LH, FSH, Sex Hormone Binding Globulin, 17 Hydroxyprogesterone) |
RADIOIMMUNOASSAY/CHEMILUMINECENCE | SERUM (AGE+GENDER TO BE MENTIONED+CLINICAL HISTORY | 2-8°C (24 HRS); F (>24 HRS) | India | Hirsutism is defined as excessive growth of terminal hair in women and children in a distribution similar to that in post pubertal men. True hirsutism which is androgen responsive has to be distinguished from hypertrichosis. Causes can be ovarian, adrenal, endocrine, iatrogenic, familial & idiopathic. |
| 1277 | 1009 | HIRSUTISM SCREENING PANEL (DHEA, Testosterone (Total and Free) | RADIOIMMUNOASSAY/CHEMILUMINECENCE | SERUM (Age+Gender to be mentioned+CLINICAL HISTORY) | 2-8°C (24 hrs); F ( >24 hrs) | India | Dehydroepiandrosterone (DHEA) is a useful marker of adrenal androgen synthesis. Levels of DHEA may be elevated in conditions such as virilizing adrenal adenoma & carcinoma, 21-hydroxylase & 3 beta-hydroxycorticosteroid dehydrogenase deficiencies and in some cases of hirsutism. Testosterone measurements are used mainly for clinical evaluation of hypogonadism in males and hyperandrogenic states in females. |
| 1278 | 8182 | HISTAMINE | ELISA | EDTA PLASMA | FROZEN | India | To help confirm a diagnosis of anaphylaxis, mastocytosis, or mast cell activation |
| 1279 | 9237RFX | HISTOPATH REFLEX TO CUSTOM IHC- BONE BIOPSY | IMMUNOHISTOCHEMISTRY | TISSUE in 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | Histopathological processing of specimen with final interpretation of bone biopsy including IHC when warranted. |
| 1280 | 9244RFX | HISTOPATH REFLEX TO CUSTOM IHC PANEL – OTHERS | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | Histopathological processing of specimen with final interpretation of tissue specimen including IHC when warranted. |
| 1281 | 9239RFX | HISTOPATH REFLEX TO CUSTOM IHC PANEL – PROSTATE | IMMUNOHISTOCHEMISTRY | TISSUE in 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | Histopathological processing of specimen with final interpretation of prostate biopsy including IHC when warranted. |
| 1282 | 9241RFX | HISTOPATH REFLEX TO CUSTOM IHC PANEL -BONE MARROW | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% BUFFERED FORMALIN (SMALL TISSUE) + SITE OF BIOPSY &CLINICAL DETAILS | A | India | Histopathological processing of specimen with final interpretation of bone marrow including IHC when warranted. |
| 1283 | Z009KM | HISTOPATHOLOGY & IHC; COMPLETE DISGNOSIS WITH SPECIAL STAINS & IHC (AS AND WHEN NEEDED) | IMMUNOHISTOCHEMISTRY | PARAFFIN BLOCKS (PLEASE LET US KNOW THE SITE OF BIOPSY & CLINICAL DETAILS) | A | India | #N/A |
| 1284 | 7197 | HISTOPATHOLOGY REVIEW BY DR.ANJALI AMRAPURKAR | Histopathology | Clinical details, site of the tissue, pathology reports along with the specimen will be required. If it is a bone marrow specimen, CBC report will also be required and for bone specimen, will also require MRI & X-Ray of the patient. If the paraffin blocks of the tissue are to be returned back to the client along with the report, a request letter from the referring doctor will be required along with the specimen.Mention the site of biopsy on TRP | Ambient | India | HISTOPATHOLOGY REVIEW BY DR.ANJALI AMRAPURKAR |
| 1285 | DT4202 | HIV MONITOR (Viral Load, CD4 / CD8) | Abbott m2000 , FLOW CYTOMETRY | PLASMA- EDTA (F); WB-EDTA, WB-HEPARIN(WB TO REACH WITHIN 48 HRS) | F/A | India | This test is intended for use as an aid in the management of HIV 1 infected patients and is not intended for use in the initial diagnosis or confirmation of HIV 1 infection. This panel is used to assess patient prognosis and monitor the effect of antiretroviral therapy. |
| 1286 | DT4204 | HIV ROCHE COBAS MONITOR (Viral Load, CD4 / CD8) | COBAS TAQMAN, FLOW CYTOMETRY | PLASMA- EDTA (F); WB-EDTA, WB-HEPARIN (WB TO REACH WITHIN 48 HRS) | F-HIV-1 VIRAL LOAD; CD4/CD8: EDTA A 48 HRS; HEPARIN A 96 HRS | India | Viral Load – to determine the status of the infection and subsequently to monitor the effectiveness of antiretroviral treatment. CD4 / CD8- this test is done to measure the strength of your immune system if you have been diagnosed with human immunodeficiency virus (HIV) infection and to monitor the effectiveness of treatment |
| 1287 | 9885B | HIV-1 DNA DETECTOR,QUALITATIVE | POLYMERASE CHAIN REACTION | WB-EDTA/ACD | A/R | India | This test is intended for use as an aid in the management of HIV 1 infected patients and is not intended for use in the initial diagnosis or confirmation of HIV 1 infection. This test is used to assess patient prognosis and monitor the effect of antiretroviral therapy. |
| 1288 | 9939 | HIV-1 GENOTYPIC RESISTANCE | PCR-SEQUENCING | EDTA-PLASMA + CLINICAL HISTORY | F | India | The high replication rate of HIV 1 coupled with its rapid mutation rate leads to accumulation of mutations, some of which reduce susceptibility to antiretroviral agents. HIV 1 Genotyping identifies mutations in HIV 1 Reverse Transcriptase & Protease genes. Genotyping helps in identifying the mutations associated with resistance and guiding initiation or change of Anti HIV 1 treatment regimens. |
| 1289 | DT4206 | HIV-1 REAL TIME MONITOR | Abbott m2000 , FLOW CYTOMETRY | PLASMA EDTA (F) / *WB- EDTA / HEPARIN (* SAMPLE TO REACH LAB WITHIN 48 HRS) | F+A+A | India | The viral load provides an accurate estimate of the level of HIV replication Quantitation of HIV Viral load is important as it serves to be a prognostic marker of HIV infection and is used for establishing baseline levels in patients before initiation of the therapy and for monitoring the disease progression. |
| 1290 | 9885 | HIV-1 VIRAL Load | Abbott m2000 | PLASMA- EDTA | F | India | 1.The viral load provides an accurate estimate of the level of HIV replication . 2.Quantitation of HIV Viral load is important as it serves to be a prognostic marker of HIV infection . 3.It is used for establishing baseline levels in patients before initiation of the therapy and for monitoring the disease progression 4.A sudden rise in the viral load may indicate emergence of resistant strains during the therapy. |
| 1291 | 9974 | HIV-1 VIRAL LOAD BY REAL TIME PCR | PCR | PLASMA- EDTA | F | India | This test is intended for use as an aid in the management of HIV 1 infected patients and is not intended for use in the initial diagnosis or confirmation of HIV 1 infection. This test is used to assess patient prognosis and monitor the effect of antiretroviral therapy. |
| 1292 | 7101PDK | HIV-1-RNA DETECTION (QUALITATIVE) | Real Time PCR | EDTA PLASMA | FROZEN | India | Qualitative Assay for the detection of human immunodeficiency virus (HIV-1) in human plasma. It is intended for use as an aid in the diagnosis of HIV-1 infection, including acute or primary infection. Presence of HIV-1 RNA in the plasma of patients without antibodies to HIV-1 is indicative of acute or primary HIV-1 infection. |
| 1293 | 9917B | HLA – A FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations. |
| 1294 | 4851B | HLA – A B C DR FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1295 | 4852B | HLA – A B C DR DQ FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations; |
| 1296 | 6150B | HLA – A B DR DUO (PATIENT + DONOR) FOR HSCT | HistoSpot SSO-PCR | Recipient EDTA-Whole Blood, Donor EDTA-Whole Blood | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1297 | 9911B | HLA – B FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1298 | 9913B | HLA – C FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1299 | 9914B | HLA – DQ FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1300 | 4858B | HLA – DR DQ FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1301 | 9915B | HLA – DR FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1302 | 1349G | HLA (A,B,C) | SEROLOGY | SODIUM HEPARIN WB (SAMPLE IS TO BE COLLECTED AT LEAST AFTER 3 DAYS OF LAST DIALYSIS. CROSS MATCH SAMPLE IS TO BE COLLECTED AFTER THREE WEEKS OF LAST BLOOD TRANSFUSION. MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) . APPLICABLE FOR SOLID ORGAN TRANSPLANT ONLY(LIVER & KIDNEY) | COLD PACK | India | HLA (Human Leucocyte Antigen) are hereditary immunogenetic markers employed for detecting compatibility between the two, the patient and donor for transplantation. HLA Class I antigen has A, B and C loci expressed numerically that reflect the hereditary aspect. |
| 1303 | 1706G | HLA (DR/DQ) | SEROLOGY | SODIUM HEPARIN WB (SAMPLE IS TO BE COLLECTED AT LEAST AFTER 3 DAYS OF LAST DIALYSIS. CROSS MATCH SAMPLE IS TO BE COLLECTED AFTER THREE WEEKS OF LAST BLOOD TRANSFUSION. MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) APPLICABLE FOR SOLID ORGAN TRANSPLANT ONLY (LIVER & KIDNEY) | COLD PACK | India | HLA (Human Leucocyte Antigen) are hereditary immunogenetic markers employed for detecting compatibility between the two, the patient and donor for transplantation. HLA Class II antigen has DR and DQ loci expressed numerically that reflect the immunological reaction. It is an important parameter and its matching is essential. |
| 1304 | 4848 | HLA A B C DR DQ DP LOCI | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1305 | 4848B | HLA A B C DR DQ DP LOCI | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1306 | 4852 | HLA A B C DR DQ LOCI | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1307 | 4851 | HLA A B C DR LOCI | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1308 | 9971B | HLA –A B DR FOR HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1309 | 9971GLB | HLA –A B DR FOR HSCT | Luminex | Recipient EDTA-Whole Blood, Donor EDTA-Whole Blood | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1310 | 6150 | HLA A B DR LOCI DUO (Patient + Donor) | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1311 | 9917 | HLA A LOCUS | PCR-SSO | WB-EDTA+ MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1312 | 9911 | HLA B LOCUS | PCR-SSO | WB-EDTA+ MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1313 | 4572 | HLA B*5701 GENOTYPING ABACAVIR HYPERSENSITIVITY, B | PCR SEQUENCING | EDTA Whole Blood. Specimen should reach SRL,Mumbai within 24hrs of collection by Monday 09:00hrs and Wednesday 09:00hrs. | REFRIGERATED(Specimen stability: 5 days ) | India | Presence of HLAB*57:01 is associated with hypersensitivity to Abacavir, a highly effective drug used to treat HIV infection and AIDS. Hypersensitivity reactions usually occur during the first 6 weeks of treatment and include skin rashes, gastrointestinal and respiratory symptoms. Fatalities have also been reported with Abacavir. This allele is also associated with 80 fold increased risk of liver injury when treated with Flucloxacillin. Although the negative predictive value of the test is high, a negative result does not preclude the development of an allergic response to Abacavir and cannot substitute for clinical vigilance whenever Abacavir is administered. |
| 1314 | 1350 | HLA B27 (FLOWCYTOMETRY) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 72 HRS) | A | India | HLA B 27 positivity is associated with Ankylosing spondylosis and other diseases like Reiter’s syndrome, Anterior uveitis, Salmonella/Yersini a/ Psoriatic/ Juvenile Chronic Arthritis, Spondylitis with Inflammatory Bowel Disease. |
| 1315 | 1348 | HLA B27 (PCR) | POLYMERASE CHAIN REACTION | WB-EDTA | A | India | Approximately 8% of the normal population carries the HLA B27 antigen. It is present in Ankylosing spondylitis (89%), Reiter’s syndrome (79%) & Juvenile Rheumatoid arthritis (42%). |
| 1316 | 9913 | HLA C LOCUS | PCR-SSO | WB-EDTA+ MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1317 | 4849B | HLA -DP & DQ for HSCT | HistoSpot SSO-PCR | EDTA-Whole Blood (Recipient or Donor) | R | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1318 | 4849 | HLA DP & DQ LOCUS | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1319 | 4857DP | HLA –DP LOCUS TYPING | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1320 | 4858 | HLA -DQ & DR LOCI TYPING | PCR -SSO | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1321 | 9914 | HLA DQ LOCUS | PCR-SSO | WB-EDTA+ MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1322 | 9920 | HLA DQ Typing | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1323 | 9915 | HLA DR LOCUS | PCR-SSO | WB-EDTA+ MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1324 | 1309 | HLA typing Combo | Serology & PCR | 20ml Whole blood (heparin) and 10ml Whole Blood (EDTA) + SRL TRF of patient + HLA request form for HLA Typing Photo ID Proof of patient/donor (all mandatory) | Sample to be sent in Cool packs | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1325 | 9971GL | HLA-A B DR LOCI | LUMINEX | EDTA WHOLE BLOOD . Mandatory Documents to be enclosed with the sample are:- Completely filled in HLA TRF, Additional TRF, Photo I.D.Proofs of patient & donor ,doctor’s prescription.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1326 | 9971 | HLA-A B DR LOCI | PCR-SSO | EDTA WHOLE BLOOD . MANDATORY DOCUMENTS TO BE ENCLOSED WITH THE SAMPLE ARE:- COMPLETELY FILLED IN HLA TRF, ADDITIONAL TRF, PHOTO I.D.PROOFS OF PATIENT & DONOR ,DOCTOR’S PRESCRIPTION.) | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1327 | 8215 | HLA-A,B,C,DRB1,DQ1 HR-Loci Typing | NGS | EDTA WHOLE BLOOD /BUCCAL SWAB | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1328 | 8217 | HLA-A,B,C,DRB1,DQ1,DPB1 HR-Loci Typing | NGS | EDTA WHOLE BLOOD /BUCCAL SWAB | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1329 | 8216 | HLA-A,B,DRB1 HR-Loci Typing | NGS | EDTA WHOLE BLOOD /BUCCAL SWAB | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1330 | 1675BO | HLA-DR-PERCENT | FLOW CYTOMETRY | WB- EDTA | BM / WB- HEPARIN | BM / FLUIDS- EDTA/HEPARIN /SMEARS + CLINICAL HISTORY | A | India | Detection of many subtypes or “splits” of HLA antigens or alleles. It can routinely define antigens at the allele level, assuring no ambiguity in interpretations |
| 1331 | Z062K | HMB-45 (MELANOMA MARKER) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | HMB45 recognizes a melanoma-specific antigen by reacting with melanoma cells, nevus cells and neonatal melanocytes. HMB45 is expressed on the majority of malignant melanoma cases as well as on tumors of melanocytic differentiation. |
| 1332 | 7561 | HOMA | SPECTROPHOTOMETRY/ CHEMILUMINESCENCE | FASTING FLUORIDE PLASMA WITH FASTING SERUM SIMULTANEOUSLY OF SAME DAY COLLECTION. (AGE & GENDER OF THE PATIENT IS MANDATORY FOR REPORTING) | FLUORIDE PLASMA 2-8°C (3 DAYS) AND SERUM FROZEN ONLY | India | This assay is used to assess risk of developing diabetes and response to treatment with oral hypoglycemic agents. |
| 1333 | 9203RFX | HOMOCYSTEINE REFLEX VIT B12 AND FOLIC ACID (If Homocysteine value is high perform VIT B12 AND FOLIC ACD) | CHEMILUMINESCENCE | SERUM / PLASMA-EDTA – SEPARATE SAMPLE IMMEDIATELY AFTER COLLECTION. FASTING | 2-8°C (48 hrs); F (>48 hrs) | India | To help determine if you are deficient in vitamins B6, B9 (folate) or B12; to determine if you are at increased risk of heart attack or stroke; to monitor those who have heart disease; sometimes to help diagnose a rare inherited disorder called homocystinuria in newborns. IN CASE OF HIGH HOMOCYSTEINE, SERUM VIT B12 AND FOLIC ACID WILL BE PROCESSED AND INNORMAL LEVELS BOTH THE ELEMENTS WILL BE CANCELLED DURING REVIEW OF THE FINAL RESULT. |
| 1334 | 3344U | HOMOCYSTEINE, URINE | QUALITATIVE | URINE, RANDOM + CLINICAL HISTORY MANDATORY | FROZEN | India | Increased homocysteine urine levels may indicate: Vitamin Bdeficiency Chronic kidney failure Homocystinuria (a genetic disorder) Coronary artery disease (CAD) |
| 1335 | 0017LS | HOMOGENTISIC ACID, URINE | QUALITATIVE | URINE, RANDOM. CLINICAL DETAILS OF THE PATIENT IS MANDATORY. | FROZEN | India | It is characterised by urine that slowly darkens on standing due to deficiency leading to accumulation of Homogentisic Acid. |
| 1336 | 1820 | HPV DNA DETECTOR | POLYMERASE CHAIN REACTION | GENITAL SWABS / LBC SAMPLE/ FORMALIN FIXED TISSUE PARAFFIN BLOCKS / CERVICAL/ ORAL SCRAPINGS ON SLIDES -AIR DRIED + CLINICAL HISTORY (AGE & SEX) | A | India | This is a rapid in-vitro qualitative PCR assay for detecting genital infections caused by HPV. Human Papilloma virus subtypes – 6, 11, 42, 43 & 44 are regarded as low risk whereas HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 are regarded as intermediate to high-risk types for development of Cervical carcinoma. This test serves as an adjunct to the PAP smear in the identification of women who may be at increased risk for cervical intraepithelial neoplasia. Useful for detecting HPV in oral scrap/biopsy where PAP test is not applicable. Confirming presence of HPV when PAP test indicates abnormal cellular morphology. |
| 1337 | 1821 | HPV DNA Detector & PAP Smear | POLYMERASE CHAIN REACTION / CYTOLOGY | FIXED UNSTAINED SMEARS (FOR PAP) AND GENITAL SWABS / CERVICAL SCRAPINGS ON SLIDES (FOR HPV-PCR) + SITE OF COLLECTION CLINICAL HISTORY & AGE & SEX |
A | India | This test is used for the Screening, Qualitative detection and Genotyping of 12 high risk genotypes known to be associated with Cervical cancer and 2 low risk genotypes which are linked to Genital warts. |
| 1338 | 1819 | HPV TYPING BY SEQUENCING | PCR-SEQUENCING | LBC SAMPLES/ CERVICAL SWABS / CERVICAL SCRAPINGS / CERVICAL BIOPSY IN STERILE VIAL / PARAFFIN BLOCK + CLINICAL HISTORY | A | India | This test is useful for the Qualitative detection & Genotyping of 12 High risk genotypes known to be associated with Cervical cancer & 2 Low risk genotypes of HPV which are linked to Genital warts. |
| 1339 | 1823 | HPV: HYBRID CAPTURE 2 HIGH RISK HPV DNA TEST | Diagen DNA Hybrid Capture | LBC/THINPREP, SUREPATH, DIGENE CERVICAL SAMPLER | A | India | The link between Human Papillomavirus (HPV) and cervical cancer is now clearly established. The sensitivity for high-risk HPV DNA testing using Hybrid Capture® 2 (HC2) [US FDA & CE-approved] is proven to be significantly higher than any Pap test (cytology) or visual Inspection with acetic acid (VIA) for detection of LSIL and HSIL. HPV DNA testing, in general, determines a patient’s clinical risk for progression to cervical disease or cancer. A negative test result means negligible risk of detecting cervical disease with a 99.7% certainty in the next few years. A positive test result, conversely, indicates the presence of high-risk oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 & 68). Individual HPV types are not reported in this test and can be obtained from a HPV genotyping. A higher cut-off value could indicate presence of a large lesion and severity of disease which can also be confirmed by colposcopy or directed biopsy. Surgical intervention following a positive test result may be taken in conjunction with clinical symptoms, visual examination and histological findings. The HC2 HPV DNA Test can also be used as a post-treatment monitor for patients who undergo ablative therapy by laser, diathermy, or cold knife biopsy, along with clinical symptoms, visual examination and histological findings. |
| 1340 | 7781 | HTLV I & II ANTIBODIES | Chemiluminescent Microparticle Immunoassay (CMIA) | SERUM | 2-8º C (3 DAYS), >3 DAYS- 20 °C | India | HTLVI is associated with adult Tcell Lymphoblastic leukemia and Bcell Chronic Lymphocytic Leukemia. HTLVII is less common and is associated with neoplasias of the CD8 T lymphocytes. HTLV Confirmatory Assay should be interpreted in conjunction with the HTLV Screening Immunoassay. |
| 1341 | 9979 | h-tTG/DGP | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (48 hrs); -20°C (>48 hrs) | India | hTTGDGP Screen is a sensitive and specific screening test for Celiac disease. This test performs simultaneous detection of both IgA & IgG antibodies to a selectively deamidated synthetic peptide (DGP) and human TTG. Even with coexistent IgA deficiency, Celiac |
| 1342 | RD1409 | HUNTINGTON DISEASE MOLECULAR ANALYSIS | PCR / Fragment Analysis | EDTA WHOLE BLOOD + clinical history | AMBIENT | India | Huntington’s disease is a neurodegenerative genetic disorder that affects muscle coordination and leads to mental decline and behavioral symptoms. Less than 26 repeats of nucleotide CAG is normal, 40 or more leads to symptoms while in between 2640 repeats is intermediate |
| 1343 | 7831 | HYPERSENSITIVITY PNEUMONITIS PANEL | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | To detect IgG antibodies to following species: ALTERNARIA ALTERNATE CLADOSPORIUM HERBARUM PENICILLIUM CHRYSOGENUM PIGEON SERUM PROTEIN, FEATHER & DROPPINGS ASPERGILLUS. FUMIGATUS MUCOR RACEMOSUS |
| 1344 | 1020 | IBD SCREENING PANEL (ASCA IgA, ASCA IgG, ANCA) | FLUOROENZYME IMMUNOASSAY(FEIA) / IMMUNOFLOROSCENCE | SERUM | A/R AND STRICTLY FROZEN FOR ASCA IgG & IgA required | India | Antibodies to Saccharomyces cerevisiae are found in approximately 75% patients with Crohn’s disease, 15% patients with Ulcerative colitis and 5% of healthy population. This assay helps in distinguishing between Ulcerative colitis & Crohn’s disease in patients suspected of inflammatory bowel disease. |
| 1345 | Z414K | IDH1 (H09) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 1346 | RD1475 | IDH1 AND IDH2 GENE MUTATIONS | PYROSEQUENCING | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | This test aids in assessing prognosis in glioma (all grades); differential diagnosis of glioma and other neoplastic or reactive lesions in brain tissue. |
| 1347 | 1506D | IgA | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (> 8 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | IgA constitutes 15% of gamma globulins in normal serum. Decreased levels are seen in patients with Congenital deficiencies. Monoclonal elevation of IgA is seen in Multiple myeloma & Primary Systemic Amyloidosis. This assay is useful for detection and monitoring of Monoclonal gammopathies and Primary or Secondary Immune deficiencies. |
| 1348 | 1523P | IgA ON TISSUE – PHOTO | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | IgA DIRECT IMMUNOFLUORESCENCE ASSAY of provided block/ Tissue and enclosed photo of the same. |
| 1349 | 1523 | IgA, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | IgA IMMUNOFLUORESCENCE of tissue. Immunofluorescence (IF) is a technique used in the laboratory to diagnose diseases of the skin, kidney, and other organ systems. |
| 1350 | 1045 | IgA, IgM & IgG IMMUNOGLOBULIN, QUANTITATIVE | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (> 8 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Elevations of IgG, IgA & IgM are due to polyclonal immunoglobulin production. Low levels are seen in patients with Congenital deficiencies. This assay is useful for the detection and monitoring of Monoclonal gammopathies & Immune deficiencies. |
| 1351 | 1675BI | IgD HEAVY CHAIN (SURFACE) | FLOW CYTOMETRY | WB- EDTA | BM / WB- HEPARIN / BM/ EDTA FLUID /HEPARIN FLUID /SMEARS + CLINICAL HISTORY | A | India | IgD molecular weight 185 kD is one of the 5 classes of human immunoglobulins. IgD accounts for less than 1% of the total plasma immunoglobulins. Very high serum IgD concentrations are found in the Multiple myeloma patients. Raised levels are also found in the Hyperimmunoglo bulinemia IgD syndrome (HIDS). |
| 1352 | 3960 | IGF BINDING PROTEIN-3 | CHEMILUMINESCENCE | SERUM (AGE AND GENDER MANDATORY) | 2-8°C (24 HRS) ; F (3 Months) | India | Low IGFBP3 levels are observed in Growth hormone (GH) deficiency / resistance. Elevated levels indicate a sustained overproduction of GH or excessive recombinant human Growth hormone (rhGH) injections. This assay is useful for diagnosing growth disorders and adult GH deficiency. It is also used to monitor rhGH treatment. This test can also be used as an adjunct to IGF1 & GH in the diagnosis and followup of Acromegaly & Gigantism |
| 1353 | 1505D | IgG | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (> 8 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | IgG constitutes 80% of total immunoglobulins in serum. Elevation is seen in polyclonal immunoglobulin production whereas monoclonal elevation characterises Multiple myeloma. This assay is useful for the detection and monitoring of Monoclonal gammopathies & Immune deficiencies. |
| 1354 | 1675BE | IgG HEAVY CHAIN (SURFACE) | FLOW CYTOMETRY | WB- EDTA | BM / WB- HEPARIN | BM / EDTA / HEP FLUIDS/SMEARS + CLINICAL HISTORY | A | India | Clonal restriction / B cell maturity marker |
| 1355 | 1522P | IgG ON TISSUE – PHOTO | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + CLINICAL HISTORY | A | India | IgG DIRECT IMMUNOFLUORESCENCE ASSAY of provided block/ Tissue and enclosed photo of the same. |
| 1356 | 2441 | IgG, CSF | NEPHELOMETRY | CSF+CLINICAL HISTORY (AGE & GENDER IS MANDATORY) FROZEN SPECIMEN IS NOT ACCEPTABLE | 2-8°C (8 DAYS) | India | Concentration of CSF IgG is increased in various infections, inflammatory conditions, neoplastic diseases and active Multiple sclerosis. |
| 1357 | 1522 | IgG, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | IgG IMMUNOFLUORESCENCE of tissue. Immunofluorescence (IF) is a technique used in the laboratory to diagnose diseases of the skin, kidney, and other organ systems. |
| 1358 | 7923 | IGG1 FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | used for the identification of the IgGG1 |
| 1359 | 7924 | IGG2 FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | used for the identification of the IgGG2 |
| 1360 | 7925 | IGG3 FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | used for the identification of the IgGG3 |
| 1361 | 9548C | IGG4 | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -30 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Patients with recurrent infections by encapsulated bacteria often show decreased levels of IgG2 and IgG4. Recurrent respiratory infections with bronchiectasis are often associated with decreased levels of IgG2, IgG3 and IgG4. Elevated IgG4 concentrations often occur in sera from patients with atopic eczema and dermatitis, probably as the result of prolonged antigenic stimulation. In secondary immunodeficiencies such as HIV infection (Stage III & IV) IgG2 and IgG4 levels are often decreased while levels of IgG1 and IgG3 are increased. IgG4 deficiency is often seen in healthy individuals. Slightly lowered concentrations of one or more IgG subclass proteins are not uncommon, and are usually clinically not relevant. |
| 1362 | Z281K | IGG4 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Aids in the identification of IgG4-positive plasma cells in the tissue of patients with systemic autoimmune or allergic manifestations |
| 1363 | 7926 | IGG4 FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | used for the identification of the IgGG4 |
| 1364 | 1508D | IgM | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (> 8 DAYS-90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Measurement of immunoglobulin M is useful in the diagnosis of hereditary and acquired IgM immunodeficiencies. Total IgM evaluates humoral immunity; establishes the diagnosis and monitors therapy in macroglobulinemia of Waldenstrom and Plasma cell myeloma. IgM levels are used to evaluate likelihood of in utero infections or acuteness of infections. |
| 1365 | 1675BG | IgM HEAVY CHAIN (SURFACE) | FLOW CYTOMETRY | WB- EDTA | BM / WB- HEPARIN | BM / FLUIDS/SMEARS + CLINICAL HISTORY | A | India | Clonal restrictionv/ B cell maturity marker |
| 1366 | 1524P | IgM ON TISSUE – PHOTO | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | IgM DIRECT IMMUNOFLUORESCENCE ASSAY of provided block/Tissue and enclosed photo of the same. |
| 1367 | 1524 | IgM, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | IgM IMMUNOFLUORESCENCE of tissue. Immunofluorescence (IF) is a technique used in the laboratory to diagnose diseases of the skin, kidney, and other organ systems. |
| 1368 | RD1428 | IgVH GENE MUTATION | DNA sequencing | BONE MARROW EDTA/WB EDTA) | A | India | This assay is useful to provide an estimate of prognosis (aggressiveness of disease) of Bcell chronic lymphocytic leukemia (BCLL) and to help evaluate treatment options. BCLL with mutated IgVH is typically less aggressive (more slowly progressive) than BCLL with unmutated IgVH. |
| 1369 | P0003 | IHC (PHOTO), TISSUE / PARAFFIN BLOCK | IMMUNOHISTOCHEMISTRY | TISSUE FIXED IN 10%FORMALIN / PARAFFIN BLOCK | A | India | IHC of provided block and enclosed photo of the same |
| 1370 | 5044 | IHC without interpretation -one marker | Immunohistochemistry | Paraffin block | A | India | #N/A |
| 1371 | RD1436 | IL28B Genotyping | PCR Sequencing | WB EDTA/EDTA PLASMA | Ambient/FROZEN | India | IL28B genotype has the strongest predictive value among host factors associated with sustained virologic response. A single nucleotide polymorphism (rs12979860) is strongly associated with a Sustained Virologic Response in HCV genotype 1 infections and to a lesser extent with HCV genotypes 2 & 3. |
| 1372 | 9949 | IL-6 (INTERLUEKIN-6) | ENZYME IMMUNOASSAY | SERUM | FROZEN -20°C | India | IL6 is a protein cytokine that serves as a messenger which activates the immune system against foreign invasion and may help the body against the spread of cancer. |
| 1373 | 1527P | IMMUNO FLUORESCENT ASSAY (IgG + IgA + IgM + C-3 + C1q + FIBRINOGEN ON TISSUE )- PHOTO | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | Histopathological diagnosis of specimen including immunofluroscent assay ( IGG, IGA, IGM, C3,c1q and fIbrinogen on tissue ) |
| 1374 | 1527 | IMMUNO FLUORESCENT ASSAY (IgG + IgA + IgM + C-3 + C1q + FIBRINOGEN ON TISSUE) | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | Histopathological diagnosis of specimen including immunofluroscent assay ( IGG, IGA, IGM, C3,c1q and fIbrinogen on tissue ) |
| 1375 | 3125 | IMMUNOFIXATION ELECTROPHORESIS | IMMUNOELECTROPHORESIS | SERUM (CLINICAL HISTORY, AGE & GENDER IS MANDATORY ) AVOID LIPEMIC & HEMOLYSED SPECIMEN | 2-8°C (7 DAYS); F ( 7 – 30 DAYS) | India | This assay is useful for diagnosing & monitoring patients with Monoclonal gammopathies. Protein electrophoresis alone is not considered an adequate screening test for Monoclonal gammopathies. |
| 1376 | 3125C | IMMUNOFIXATION ELECTROPHORESIS, CSF | IMMUNOELECTROPHORESIS | CSF + CLINICAL HISTORY | 2-8°C (7 DAYS); F ( 7 – 30 DAYS) | India | To help diagnose or monitor conditions that result in abnormal protein production or loss of protein |
| 1377 | 3125U | IMMUNOFIXATION ELECTROPHORESIS, URINE | IMMUNOELECTROPHORESIS | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION) + MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY DETAILS. | 2-8°C (7 DAYS); F ( 7 – 30 DAYS) | India | This assay is useful for diagnosing & monitoring patients with Monoclonal gammopathies. Protein electrophoresis alone is not considered an adequate screening test for Monoclonal gammopathies. |
| 1378 | 3307 | IMMUNOREACTIVE TRYPSINOGEN (NEONATAL SCREENING) | Enzyme Linked Immnunosorbent assay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | This test is intended as a screening method for the measurement of IRT (IMMUNOREACTIVE TRYPSINOGEN ) concentration in newborn blood spot specimens as an aid in the diagnosis of cystic fibrosis. |
| 1379 | 9609I | INFLUENZA VIRUS A IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | qualitative measurement of IgG class antibodies against Influenza virus A |
| 1380 | 9610I | INFLUENZA VIRUS A IgM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | qualitative measurement of IgM class antibodies against Influenza virus A |
| 1381 | 9605I | INFLUENZA VIRUS B IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | qualitative measurement of IgG class antibodies against Influenza virus B |
| 1382 | 9607I | INFLUENZA VIRUS B IgM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8º C (5 DAYS), >5 DAYS- 20 °C | India | qualitative measurement of IgM class antibodies against Influenza virus B |
| 1383 | Z0149K | INHIBIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Inhibin is useful in the diagnosis of Sex cord stromal tumors of ovary and testis. Anti-Inhibin alpha is an antibody against a peptide hormone which has a demonstrated utility in differentiating between adrenocortical tumors and renal cell carcinoma. This antibody stains most adrenal tumors but no cases of renal cell carcinomas (RCC). Sex cord stromal tumors of the ovary, as well as trophoblastic tumors, also demonstrate cytoplasmic positivity with this antibody. |
| 1384 | 3983 | INHIBIN A (DIMERIC) | CHEMILUMINESCENCE | SERUM + CLINICAL HISTORY | 2-8°C (48 HRS); F (>48 HRS) | India | Inhibin A is produced in the placenta and is used with other maternal serum biochemical markers to improve the sensitivity of the screen for Down Syndrome. |
| 1385 | 3339 | INHIBIN B | ENZYME IMMUNOASSAY | SERUM | 2-8°C (24 HRS),>24 HRS -20°C | India | Inhibin B levels are used to assess ovarian reserve and as an aid in the diagnosis & monitoring of Granulosa cell tumors and Mucinous epithelial ovarian tumors. |
| 1386 | 1013 | INHIBIN B, LH, FSH & Prolactin | ENZYME IMMUNOASSAY/ CHEMILUMINESCENCE |
SERUM (Age+Gender to be mentioned+CLINICAL HISTORY) | 2-8°C < 24 HRS) ; F ( > 24 HRS ) | India | Fertility panel |
| 1387 | 3194 | INSULIN LIKE GROWTH FACTOR-1 (IGF-1) | CHEMILUMINESCENCE | SERUM | 2-8°C (24 HRS); F (3 Months) | India | Low IGF1 levels are observed in Growth hormone (GH) deficiency / resistance. Elevated levels indicate a sustained overproduction of GH or excessive recombinant human Growth hormone (rhGH) injections. This assay is useful for diagnosing growth disorders and adult GH deficiency. It is also used to monitor rhGH treatment. This test is also used for diagnosis and followup of Acromegaly & Gigantism. |
| 1388 | 1876 | International Digital Pathology Opinion (HARTFORD) | Digital Pathology | Tissue/Paraffin Block (Site of Biopsy & Clinical details) | A | India | #N/A |
| 1389 | 9919I | INTRINSIC FACTOR IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C ( < 48 hrs) ; F ( > 48 hrs ) | India | Intrinsic Factor, produced by cells lining the stomach, binds vitamin B12 (cyanocobalamin) to facilitate absorption of the vitamin. This antibody impedes the action of Intrinsic Factor as observed in approximately half of the patients who develop Pernicious anemia. |
| 1390 | RD1310 | JAK2 EXON 12 MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | JAK2 exon 12 test detects mutations in entire exon 12 of JAK2 by DNA Sequencing. JAK2 exon 12 testing is recommended in patients with a clinical picture suggestive of polycythemia vera (PV) and who were found to be negative for the JAK2 V617F mutation and in some patients with idiopathic erythrocytosis. |
| 1391 | 8386 | JAK2 V617F MUTATION DETECTION | REAL TIME PCR | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | JAK2 gene mutations are important diagnostic markers for the Myeloproliferative disorder Polycythemia vera (PV). A single mutation (V617F) is found in approximately 95% of cases. Of the PV cases that are V617Fnegative (approximately 5%), most are associated with mutations in a different region of the JAK2 gene within exon 12. Patients with exon 12 mutations present frequently with erythrocytosis as the predominant feature, but without concurrent elevations in the megakaryocytic or granulocytic lineages as seen in V617Fpositive PV. Consequently, many exon 12 positive cases are considered clinically as Idiopathic erythrocytosis. Unlike the V617F mutation that is found in several Myeloproliferative neoplasms (PV, Essential thrombocythemia & Primary myelofibrosis), JAK2 exon 12 mutations are restricted only to cases of PV. WHO (2016) diagnostic algorithm for suspected PV now recommends JAK2 exon 12 mutation screening in patients who present with a suspicion for PV that is V617F negative. |
| 1392 | RD1420 | JAPANESE ENCEPHALITIS VIRUS- RT-PCR | RT-PCR- Sequencing | CSF | F | India | The assay detects presence of JEV in clinical specimen by RT-PCR-Sequencing. JEV detection in CSF confirms infection of the central nervous system with JEV. |
| 1393 | RD1471 | JC VIRUS (QUANTITATIVE) | Real time PCR | CSF/SERUM/EDTA PLASMA/URINE | FROZEN | India | PCR to detect and quantitate BKV DNA in plasma has been considered as a non-invasive way to identify patients at risk for BK nephropathy and to monitor response to therapy. BKV viral load can be tested in renal transplant patients to assess risk for BKV nephropathy. I |
| 1394 | 9937 | JC/BK DNA PCR (QUALITATIVE) | POLYMERASE CHAIN REACTION | EDTA PLASMA,/CSF/ URINE + CLINICAL HISTORY | SERUM/ PLASMA – FROZEN, CSF – REFRIGERATED; OTHERS AMBIENT | India | This assay is useful for the detection of JC and BK virus which are associated with transplants |
| 1395 | 1208 | JO-1 IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Jo1 antibodies are a marker of Polymyositis & occur most commonly in Myositis patients who also have Interstitial lung disease. The antibodies are detected in 50% patients with Interstitial pulmonary fibrosis & Symmetrical polyarthritis |
| 1396 | 9074 | KALA-AZAR | IMMUNOCHROMATOGRAPHY | SERUM | 2-8°C (3 DAYS),>3 DAYS -20 °C | India | To help diagnose Kalazar |
| 1397 | 7921 | KAPPA FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1398 | 1661 | KAPPA FREE LIGHT CHAIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (21 DAYS) | India | This assay in combination with serum protein electrophoresis and immunofixation electrophoresis yields high sensitivity (99%) for the diagnosis of Plasma cell disorders (PCD). Baseline measurement is of major prognostic value and allows quantitative monitoring of patients with oligosecretory PCD. |
| 1399 | Z031K | KAPPA LIGHT CHAIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1400 | 1661U24 | KAPPA LIGHT CHAIN QUANTITATIVE, 24 hrs. URINE | NEPHELOMETRY | 24 HRS URINE SAMPLES WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION+ CLINICAL HISTORY, AGE & GENDER IS MANDATORY (MENTION 24 HRS URINE VOLUME) | 2-8°C (7 DAYS) | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment in urine |
| 1401 | 1661U | KAPPA LIGHT CHAIN QUANTITATIVE, URINE RANDOM | NEPHELOMETRY | RANDOM URINE + CLINICAL HISTORY, AGE & GENDER IS MANDATORY | 2-8°C (7 DAYS) | India | Presence of Immunoglobulin Light Chains, Kappa & Lambda on the cell surface is characteristic of clonal proliferation most often seen in Multiple Myeloma and Lymphoproliferativ e diseases. |
| 1402 | 9245RFX | Karyotyping Reflex to BCR-ABL (FISH). CML and BCR/ABL suspected ALL cases | CELL CULTURE/FISH | BONE MARROW/WB WB (≥70% blast cell) SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY IN SPECIFIED FORMAT, BLOOD PICTURE(CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF IN SPECIMEN COLUMN | A | India | To help diagnose and monitor the treatment of chronic myelogenous leukemia (CML) and a type of B-cell acute lymphoblastic leukemia (ALL) |
| 1403 | Z006K | KI-67 (Proliferating Cells) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | A marker of proliferation in neoplasms |
| 1404 | 1761G | KIDNEY BIOPSY NATIVE | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + 10% NEUTRAL BUFFERED FORMALIN FIXED TISSUE (HP) + CLINICAL DETAILS & RENAL FUNCTION TEST WITH 24 HOURS URINARY PROTEIN VALUE & URIN REPORT. | A | India | Histopathological diagnosis of specimen including immunofluroscent assay and |
| 1405 | 1762G | KIDNEY BIOPSY TRANSPLANT | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + 10% NEUTRAL BUFFERED FORMALIN FIXED TISSUE (HP) + CLINICAL DETAILS & RENAL FUNCTION TEST WITH 24 HOURS URINARY PROTEIN VALUE & URIN REPORT. | A | India | Histopathological diagnosis of specimen including immunofluroscent assay and Immunhistochemistry |
| 1406 | 4162 | Kidney stone analysis by FTIR (TEST IS DONE IN GURGAON LAB) | FTIR | STONE | AMBIENT | India | To determine exact composition of a kidney stone which is useful in determining therapy and dietary management. Most Common renal calculi seen in clinical practice are given as under: Calcium Oxalate Monohydrate and Dihydrate, Uric Acid, Ammonium Hydrogen Urate, Cystine, Carbonate Apatite, Calcium Hydrogen Phosphate, Magnesium Hydrogen Phosphate. |
| 1407 | RD1502 | KINSHIP ANALYSIS | STR Analysis | EDTA WHOLE BLOOD (DONOR AND RECIPIENT) + REQUIRED DOCUMENTATION | AMBIENT | India | Relatedness between individuals and groups can be investigated using DNA markers. A child’s DNA profile is a combination of alleles passed down from the father and mother. This means that relationships can be investigated between alleged family members. |
| 1408 | RD1511 | KINSHIP ANALYSIS | STR Analysis | EDTA WHOLE BLOOD (DONOR AND RECIPIENT) + REQUIRED DOCUMENTATION | AMBIENT | India | Relatedness between individuals and groups can be investigated using DNA markers. A child’s DNA profile is a combination of alleles passed down from the father and mother. This means that relationships can be investigated between alleged family members. |
| 1409 | RD1315 | KRAS codon 61 Mutation Detection | PCR – Sequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | This assay is useful for the detection of KRAS mutations which are associated with shorter progressionfree survival in Colorectal cancers. Codon 12 and codon 13 are more prevalent while codon 61 forms less than 1% of KRAS mutations. |
| 1410 | RD1307 | KRAS MUTATION DETECTION | PYROSEQUENCING | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS | A | India | KRAS mutation testing is recommended prior to initiation of EGFR targeted therapy in Colorectal carcinoma. Absence of detectable KRAS mutation within the tumor suggests that this patient may respond to such therapies. |
| 1411 | 7922 | LAMBDA FITC, IFA | IMMUNO FLUORESCENT ASSAY | TISSUE IN MICHEL’S TRANSPORT MEDIA + CLINICAL HISTORY | A | India | N/A |
| 1412 | 1662 | LAMBDA FREE LIGHT CHAIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (21 DAYS) | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1413 | Z032K | LAMBDA LIGHT CHAIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | useful in establishing clonality of B-cell and plasma cell neoplasms and in amyloidosis. |
| 1414 | 1662U24 | LAMBDA LIGHT CHAIN QUANTITATIVE, 24 hrs. URINE | NEPHELOMETRY | 24 HRS URINE SAMPLES WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION+ CLINICAL HISTORY, AGE & GENDER IS MANDATORY (MENTION 24 HRS URINE VOLUME) | 2-8°C (7 DAYS) | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1415 | 1662U | LAMBDA LIGHT CHAIN QUANTITATIVE, URINE RANDOM | NEPHELOMETRY | RANDOM URINE + CLINICAL HISTORY, AGE & GENDER IS MANDATORY | 2-8°C (7 DAYS) | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1416 | 4063 | LAMOTRIGINE | Homogeneous Enzyme Immunoassay | EDTA Plasma . Trough level (Draw specimen immediately before next scheduled dose or at least 12 hours after last dose.)Mentioned Clinical history/medication details mandatory. | FROZEN | India | Lamotrigine is used in the treatment of Bipolar I disorder and a wide variety of seizures including Primary generalized tonic clonic seizures and Partial seizures. It is also used to treat Migraine, Trigeminal neuralgia and Treatment refractory depression. This assay is used to monitor the blood levels, assess compliance and adjust dosage in patients receiving other anticonvulsant agents which interact pharmacokineticall y with Lamotrigine. |
| 1417 | Z207K | LAP (LEUCOCYTE ALKALINE PHOSPHATASE / NEUTROPHIL ALKALINE PHOSPHATASE (NAP)SCORE) | CYTOCHEMISTRY SPECIAL STAINS | FRESH PERIPHERAL SMEARS AIR DRIED + CLINICAL HISTORY | A | India | high LAP score include blastic and accelerated phases of CML, neutrophilia of infection, polycythaemia vera, leukamoid reaction, Hodgkin lymphoma etc. Decreased scores are seen in CML, PNH with Aplastic anaemia and Heriditary hypophosphatasia. This test is not diagnostic of CML. |
| 1418 | 9316B | LARGE TISSUE / SPECIMEN+SLIDE RETURN | HISTOPATHOLOGY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN+ SITE OF BIOPSY SPECIMEN + CLINICAL DETAILS. RELEVANT RADIOLOGY FINDINGS: X-RAY/CT/MRI REPORT IMAGES (SOFT COPY). | A | India | Histopathological diagnosis of specimen |
| 1419 | 9224RFX | LBC REFLEX TO HPV-PCR- SUREPATH CYTOLOGY [FULLY -AUTOMATED] + HPV-PCR | CYTOLOGY + PCR |
SPECIMEN FIXED IN SUREPATH PRESERVATIVE SOLUTION + CLINICAL HISTORY & AGE / SEX/ LMP |
15 – 30 ºC | India | Cervical cancer screening |
| 1420 | 8033 | LDH- ISOENZYMES BY ELECTROPHORESIS | ELECTROPHORESIS | FASTING SERUM | STRICTLY REFRIGERATED | India | LDH is found in highest concentrations in liver, heart, muscle, kidney, lung & erythrocytes. This assay is useful for investigating a variety of diseases involving these organs. It is also used to monitor changes in tumor burden after chemotherapy. |
| 1421 | 9142U24 | LEAD, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 days); F (>5 -30 days) | India | Elevated urinary Lead concentration is indicative of chronic lead toxicity. Urinary Lead concentrations may be used to monitor detoxification therapy. |
| 1422 | 9142 | LEAD, BLOOD | GFAAS WITH ZEEMAN CORRECTION | IMPROVE/BD, SRL EDTA VACCUTAINER, WHOLE BLOOD +AGE+SEX MANDATORY FOR REPORTING | 2-8°C (7DAYS); F (>7 -30 DAYS) | India | Blood Lead is useful in detecting industrial, dietary and accidental exposure to lead and to monitor detoxification therapy. |
| 1423 | 9142U | LEAD, URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Elevated urinary Lead concentration is indicative of chronic lead toxicity. Urinary Lead concentrations may be used to monitor detoxification therapy. |
| 1424 | 8111 | LEGIONELLA PNEUMOPHILA ANTIGEN DETECTION, URINE | Immunochromatography | SPOT URINE | FROZEN(STABILITY: 4 DAYS) | India | Legionella urinary antigen is useful in conjunction with other laboratory tests in the diagnosis of Legionnaires disease. Known risk factors of this disease are immunosuppressio n, smoking, alcohol and concomitant pulmonary disease. |
| 1425 | 7451 | LEGIONELLA PNEUMOPHILA IGM (SERUM,EIA) | EIA | SERUM | R/F | India | Legionella pneumophila causes pulmonary disease in both normal and immunocompetent hosts leading to Legionnaires disease, Pontiac fever and extra pulmonary infections which are collectively referred to as Legionellosis. |
| 1426 | 1492 | LEISHMANIA DONOVANI (LD) BODIES DETECTION | MICROSCOPY | EDTA / SPLENIC ASPIRATE / BONE MARROW+ SMEAR + CLINICAL HISTORY | A | India | Leishmania donovani causes Kala Azar. Serologic tests may be done in immunosuppresse d patients from endemic areas who show definite clinical findings. Cross reactivity may be seen with Trypanosomiasis, Malaria and Leprosy. |
| 1427 | 2438E | LEPRA SMEAR | MICROSCOPY | SKIN SMEAR | R | India | To detect the aetiological agent of leprosy i.e Mycobacterium leprae |
| 1428 | 4805 | LEPTIN | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C ( 24 HRS.), >24HRS. (-20°C) | India | Leptin is an adipocyte derived hormone that is essential for normal body weight regulation. Leptin production is under neuroendocrine control and the serum concentrations vary directly with the amount of triglycerides stored in adipose tissue depots. |
| 1429 | DT3220 | LEPTOCHEQ | Enzyme Linked Immnunosorbent assay / DARKFIELD MICROSCOPY / UA / DIPSTICK & MICROSCOPY/ SPECTROPHOTOMETRY | SERUM 10- 12 HRS FASTING/ WB-HEPARIN / URINE IN PLAIN VACCUTAINER STERILE. (AGE & GENDER IS MANDATORY) | SERUM : 2-8°C (2 DAYS), F (> 2 DAYS); URINE : 2-8°C(24 HRS) FOR DARKFIELD MICROSCOPY MUST BE AMBIENT, WITHIN 24HRS OF COLLECTION | India | To help diagnose leptospira infection |
| 1430 | 9910 | LEPTOSPIRA DNA PCR | POLYMERASE CHAIN REACTION | WB-EDTA / URINE IN STERILE CONTAINER | A | India | This assay is useful for the detection of Leptospira in blood/urine samples |
| 1431 | 7551 | LEPTOSPIRA IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 days); -20°C (>5 days) | India | Leptospirosis is a zoonotic disease transmitted through soil, food or water contaminated by urine of infected animal. Illness may be self limiting or cause Hepatorenal failure (Weil syndrome). IgG antibodies appear late and may persist for a long time. |
| 1432 | 7621 | LEPTOSPIRA IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 days); -20°C (>5 days) | India | Leptospirosis is a zoonotic disease transmitted through soil, food or water contaminated by urine of infected animal. Illness may be self limiting or cause Hepatorenal failure (Weil syndrome. IgM antibodies appear within 12 weeks after onset of illness and peak at 24 weeks. |
| 1433 | 1674S | LEUKEMIA / LYMPHOMA EVALUATION WITH HISTOPATHOLOGY | IMMUNOHISTOCHEMISTRY & HISTOPATHOLOGY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK (SITE OF BIOPSY & CLINICAL DETAILS MANDATORY)MANDATORY | A | India | To help classify leukemia/ lymphoma |
| 1434 | RD1330 | Leukemia Translocation Panel (Custom 4 markers) | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | The Leukemia evaluation employs cell surface & cytoplasmic markers as a two step process to aid in the diagnosis and characterisation of neoplasms of hematopoietic origin. Results are useful in the differential diagnosis, therapeutic monitoring and detection of relapses of these neoplasms. |
| 1435 | 1625 | LEUKEMIA TRANSLOCATION PANEL 1 (t(1;19) (q23;p13), Inv(16)(p13;q22), t(9;22) (q34;q11), t(4;11) (q21;q23), t(12;21) (p13;q22), t(15;17)(q22;q22), t(8;21)(q22;q22)) | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel detects following seven translocations : t(1; 19) (q23; p13), Inv 16 (p13; q22), t(9; 22) (q34; q11), t(4;11) (q21; q23), t(12; 21) (p13; q22), t(15; 17) (q21; q22), t(8;21) (q22; q22) –Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information regarding appropriate treatment and prognosis. –It provides prognostic information for AML as well as ALL patients |
| 1436 | 1626 | LEUKEMIA TRANSLOCATION PANEL 2 (Inv(16)(p13;q22), t(15;17)(q22;q22), t(8;21)(q22;q22)) | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel targets following three translocations: t(15; 17) (q21; q22), Inv 16 (p13; q22), t(8; 21) (q22; q22) –Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information for appropriate treatment descisions and prognosis. –It provides prognostic information for AML patients i.e. |
| 1437 | 1627 | LEUKEMIA TRANSLOCATION PANEL 3 (t(1;11) (p32;q23), t(1;11) (p21;q23), t(4;11) (q21;q23), t(6;11) (q27;q23), t(9;11) (p22;q23), t(10;11) (p12;q23), t(11;17) (q23;q21), t(11;19) (q23;p13.1), t(11;19) (q23;p13.3), Dup MLL (11q23), t(X;11) (q13;q23)) | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel targets following eleven different translocations. in MLL gene: t(1;11) (p32; q23), t(1;11) (p21; q23), t(4; 11) (q21; q23), t(6;11) (q27; q23), t(9;11)(p22;q23), t(10;11)(p12;q23), Dup MLL (11q23), t(11; 17) (q23; q21), t(11; 19) (q23; p13.1), t(11; 19) (q23; p13.3), t(X;11) (q13; q23) –Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information regarding appropriate treatment and prognosis. –MLL gene rearrangements are associated with an extremely poor prognosis in Acute Lymphoblastic Leukemia (ALL); particularly infant ALL |
| 1438 | 1628 | LEUKEMIA TRANSLOCATION PANEL 4 t(1; 19) (q23; p13), t(9; 22) (q34; q11), t(4;11) (q21; q23), t(1;11) (p32; q23), t(11; 19) (q23; p13.3), t(X;11) (q13; q23) |
MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel detects following six translocations : t(1; 19) (q23; p13), t(9; 22) (q34; q11), t(4;11) (q21; q23), t(1;11) (p32; q23), t(11; 19) (q23; p13.3), t(X;11) (q13; q23) –Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information regarding appropriate treatment and prognosis. –Presence of any of these six translocations indicates poor prognosis for the ALL patients. |
| 1439 | 1624 | LEUKEMIA TRANSLOCATION PANEL 5 t(9; 22) (q34; q11), Dup MLL (11q23), t(11; 17) (q23; q21), | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel detects following three translocations :t(9; 22) (q34; q11), Dup MLL (11q23), t(11; 17) (q23; q21), –Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information regarding appropriate treatment and prognosis. –Presence of any of the three translocations indicates poor prognosis in AML patients |
| 1440 | 1678 | LEUKEMIA TRANSLOCATION PANEL 6 t(1; 19) (q23; p13), t(9; 22) (q34; q11), t(4;11) (q21; q23) and t(12; 21) (p13; q22), | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel detects following four translocations : t(1; 19) (q23; p13), t(9; 22) (q34; q11), t(4;11) (q21; q23) and t(12; 21) (p13; q22). Characterization of fusion gene transcripts in leukemia that result from chromosome translocations provides valuable information regarding appropriate treatment and prognosis. • It provides prognostic information for AML as well as ALL patients |
| 1441 | 5016 | LEUKEMIA TRANSLOCATION PANEL 8 | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | N/A |
| 1442 | 1759 | LEUKEMIA TRANSLOCATIONS – PANEL 7 | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This panel detects following translocations : t(1; 19) (q23; p13), t(9; 22) (q34; q11), t(4;11) (q21; q23), t(1;11) (p32; q23), t(11; 19) (q23; p13.3), t(X;11) (q13; q23), t(12; 21) (p13; q22). Presence of any of six translocations, except t(12; 21) indicates poor prognosis for the ALL patients. In B-ALL cases, t(12;21 is associated with a favourable prognosis. |
| 1443 | 5020 | LEVETIRACETAM | Homogeneous Enzyme Immunoassay | Serum separated from red top vacutainer .Specimen should be collected at Trough level (Before the next dose) | FROZEN | India | To determine the concentration of levetiracetam in the blood to establish an individualized dose; to detect toxicity or verify that you are taking the medication as prescribed (compliance); to monitor during health changes that may affect drug clearance and/or kidney function |
| 1444 | 1613 | LGL PANEL | FLOW CYTOMETRY | WB- EDTA / BM-EDTA / WB- HEPARIN / BM HEPARIN+DIRECT SMEAR+HISTORY | A | India | To help diagnose LARGE GRANULAR LYMPHOBLASTIC LEUKEMIA |
| 1445 | 3446D | LIPOPROTEIN (a) | NEPHELOMETRY | 12 -14 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (> 7 DAYS-30 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | This assay provides additional information on Coronary Heart Disease (CHD) risk in patients known or suspected to be at increased risk based on factors like family history of premature CHD or Stroke, Hypertension, Cigarette smoking, Obesity, Diabetes mellitus, increased levels of LDL and decreased levels of HDL. High levels of Lp(a) increase cardiovascular risk 23 fold. Lp(a) behaves like an acute phase protein and should not be measured during periods of active inflammation and for at least 1 month after Myocardial infarction or Stroke. |
| 1446 | 1284 | LIQUID BASED CYTOLOGY ( SUREPATH CYTOLOGY) |
CYTOLOGY | SPECIMEN FIXED IN SUREPATH PRESERVATIVE SOLUTION + CLINICAL HISTORY, AGE, LMP |
15 – 30 ºC | India | Cervical cancer screening |
| 1447 | 1284P | LIQUID BASED CYTOLOGY ( SUREPATH CYTOLOGY) |
CYTOLOGY | SPECIMEN FIXED IN SUREPATH PRESERVATIVE SOLUTION + CLINICAL HISTORY, AGE, LMP |
15 – 30 ºC | India | Cervical cancer screening |
| 1448 | 1274 | LIQUID BASED CYTOLOGY- PAP SMEAR | CYTOLOGY | IN LBC CONTAINER ( Clinical history required ) |
A | India | Liquid based cytology increases the sensitivity of detection of precancerous cervical lesions. Screening has substantially reduced the mortality rate due to Cervical cancer. Screening guidelines recommend regular PAP testing for all women greater than 21 years of age. At age 30, women who have had 3 normal test results in a row may get screened every 2 to 3 years.Women between 6570 years with no abnormal results in the previous 10 years can stop screening. Women after Total hysterectomy for noncancerous causes do not require screening. |
| 1449 | RD1514 | LIQUID BIOPSY EGFR TRUE | RT PCR | EDTA Plasma( Frozen), +clinical history | FROZEN STRICTLY | India | To detect EGFR mutation |
| 1450 | 4871 | LITHIUM | ION SELECTIVE ELECTRODE | SERUM (10-12 HRS FASTING) AVOID LIPEMIC & HEMOLYSED SPECIMEN. (CLINICAL HISTORY , AGE & GENDER IS MANDATORY) | 2-8°C (24 HRS ); F (>24 HRS – 7 DAYS) | India | This assay is used to monitor therapy of patients with Bipolar disorder including recurrent episodes of Mania and Depression. It is also useful to evaluate toxicity. |
| 1451 | 1115 | LIVER KIDNEY MICROSOME 1 (LKM1) AUTOANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (48 hrs); -20°C (>48 hrs) | India | This antibody can be demonstrated in majority of Autoimmune Hepatitis (AIH) cases like Chronic active hepatitis. This assay is useful for evaluating patients with liver disease of unknown etiology and suspected AIH. |
| 1452 | DT6302 | LIVORHYTHM – 2 | CHEMILUMINESCENCE, ENZYME IMMUNOASSAY | SERUM 2 VIALS | 2-8°C (72 HRS), F (>72 HRS) | India | N/A |
| 1453 | DT6304 | LIVORHYTHM – 4 (HCV RNA {NESTED REVERSE TRANSCRIPTASE PCR}, HCV ABS, HBVDNA PCR, Small tissue biopsy, Special STains, AFB Culture, MYCO3PLEX DNA PCR) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA), ECLIA, REVERSE TRANSCRIPTASE PCR, DNA PCR, FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE , HISTOPATHOLOGY AND SPECIAL STAINS+MICROPARTICLE ENZYME IMMUNOASSAY | PLASMA-EDTA, SERUM, SMALL TISSUE BIOPSY / CORE (NEEDLE) BIOPSY / FINE NEEDLE ASPIRATION BIOPSY IN (A) FORMALIN & (B) NORMAL SALINE, SPECIAL STAINS | F A A | India | N/A |
| 1454 | WI7441C | L-LACTATE, CSF (ONLY FOR WALKIN PATIENT AT SRL GORGAON LAB) | SPECTROPHOTOMETRY | CSF(PLAIN TUBE) + CLINICAL HISTORY | F | India | N/A |
| 1455 | WI7441D | L-LACTATE, PLASMA (ONLY FOR WALKIN PATIENT AT SRL GORGAON LAB) | SPECTROPHOTOMETRY | PLASMA FLUORIDE (BLOOD COLLECTION FROM STASIS FREE VEIN TO BE STORE IN ICE BATH. PLASMA TO BE SEPARATED WITHIN 30 MIN) + (CLINICAL HISTORY , AGE & GENDER IS MANDATORY) | F | India | N/A |
| 1456 | 5000 | LP- PLA2 (PLAC) – CARDIAC RISK MARKER | CLIA | Serum | Frozen | India | 1. Lp-PLA2 test is a blood test that measures the concentration of Lp-PLA2(lipoprotein – associated phospholipase A2 a vascular-specific inflammatory marker implicated in the formation of rupture-prone plaque. 2. Lp-PLA2 is a biomarker providing information on risk for atherosclerotic cardiovascular disease (CVD) independent of traditional cardiovascular risk factors . 3. Lp-PLA2 is produced in the plaque itself.It is vascular specific unlike other inflammatory markers that measure systemic inflammation . 4. The Lp-PLA2 test may be used as a management tool in patients at moderate to high risk for CVD events, such as family of CVD or hypertension ,diabetes, metabolic syndrome and chronic kidney disease and hyperlipidemia . 5. An elevated Lp-PLA2 test may indicate need for more aggressive lipid lowering therapy to reduce the risk of CVD events. |
| 1457 | 4817 | Lung Cancer Panel (EGFR Mutation+EML4 ALK by FISH) | Pyrosequencing/FISH | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS | A | India | Activating mutations in EGFR are present in approximately 1012% of NonSmall cell carcinomas of the lung (Primarily Adenocarcinomas) . EGFR mutation predict a good response to treatment with EGFR inhibitors like gefitinib and erlotinib. ALK rearrangement testing by FISH along with EGFR molecular testing are recommended for recurrent or metastatic cases with histological subtypes of Adenocarcinoma, Large cell carcinoma, or NSCLC NOS (not otherwise specified), and Squamous cell carcinoma in nonsmokers or when biopsy specimens are small. FISH technique is the gold standard for detecting ALK1 gene rearrangements. |
| 1458 | RD1503 | LUNG CANCER PROFILER NEXT | Next Gen Sequencing | PARAFFIN BLOCK +CLINICAL HISTORY | A | India | This test is used for tumor molecular profiling using next generation sequencing |
| 1459 | 5964 | LUPUS ANTICOAGULANT SCREENING PROFILE | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA* 2 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | Lupus Anticoagulants are heterogenous IgG or IgM autoantibodies which interfere with phospholipid dependent in vitro coagulation tests, particularly Activated Partial Thromboplastin Time (APTT). These antibodies are associated with thrombosis (arterial & venous), recurrent abortions, neurological & neuropsychiatric disorders. |
| 1460 | Z164K | LUTEINIZING HORMONE (LH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | used for classification of Pituitary adenomas. |
| 1461 | 2069I | LYME DISEASE (BORRELIA BURGDORFERI IgG) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (7 days ),>7days( -20°C) | India | Lyme disease is transmitted by a tick vector carrying Borrelia burgdorferi. Immunoblot testing qualitatively examines, with high specificity, antibodies in a patient’s specimen. Immunoblot testing is appropriate for confirming a detected EIA or IFA test result. |
| 1462 | 2070I | LYME DISEASE (BORRELIA BURGDORFERI IgM) | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (7 days ),>7days( -20°C) | India | Lyme disease is transmitted by a tick vector carrying Borrelia burgdorferi. Immunoblot testing qualitatively examines, with high specificity, antibodies in a patient’s specimen. Immunoblot testing is appropriate for confirming a detected EIA or IFA test result. |
| 1463 | 1668 | LYMPH0CYTE ENUMERATION, BASIC & NK CELLS (%CD3,%CD4,%CD8,%CD19,%CD16+56,ABS CD3,ABS CD4,ABS CD8,ABSCD19,ABSCD16+56) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 48 HRS) |
A | India | Lymphocyte Enumeration Helper/Inducer(CD3+CD4+) and suppressor(CD3+CD8+) monitors patient T-Cell status. Serial estimation of absolute T-Helper counts is valuable in predicting prognosis of the disease in HIV-infected individuals. The counts are useful in decisions regarding institution of anti-retroviral and prophylactic antibiotic therapy against opportunistic infections. |
| 1464 | 1656B | LYMPHOCYTE ENUMERATION, T- HELPER CELLS (%CD3,%CD4,ABS CD3,ABS CD4) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 48 HRS) | A | India | This test (CD4 counts) is intended for use as an aid in the management and care of HIV patients and is required to assess their candidacy for ART initiation. It is not intended for use in the initial diagnosis or confirmation of HIV infection. |
| 1465 | 1658B | LYMPHOCYTE ENUMERATION, T & B CELLS (%CD3,%CD19,ABS CD3,ABS CD19) | FLOW CYTOMETRY | WB-EDTA + HEPARIN + CLINICAL HISTORY (WB TO REACH WITHIN 48 HRS) |
A | India | Antigenically peripheral blood lymphocytes are of two types, thymus (T) derived & bone marrow (B) derived. The former is involved in cell-mediated immune response, while the latter is responsible for humoral immune response.
Enumeration of CD3 positive lymphocytes & their main subsets (CD4 positive & CD8 positive lymphocytes) is of great clinical significance in evaluation of cell mediated immune status, specially in immune compromised patients, e.g. immune deficiency syndromes. Similarly, enumeration of B (CD19 positive) lymphocytes helps in assessing the humoral immune status of an individual. The number of B-lymphocytes in blood can increase during bacterial infections. Since B-lymphocytes produce immunoglobulins in response to antigenic stimulation, expansion of this population of cells is associated with polyclonal increase in immunoglobulins. |
| 1466 | 1669 | LYMPHOCYTE ENUMERATION, BASIC & HIV -1 ANTIBODIES,HIV ABS, WESTERN BLOT | FLOW CYTOMETRY /IMMUNOBLOT | WB-EDTA + HEPARIN + SERUM (WB TO REACH WITHIN 48 HRS) |
FLOW–A, A/R/F | India | Lymphocyte Enumeration Helper/Inducer(cd3+cd4+) and suppressor(cd3+cd8+) monitors patient T-cell status. Serial estimation of absolute T-helper counts is valuable in predicting prognosis of the disease in HIV-infected individuals. The counts are useful in decisions regarding institution of anti-retroviral and prophylactic antibiotic therapy against opportunistic infections. |
| 1467 | 1671B | LYMPHOCYTE ENUMERATION, BASIC (%CD3,%CD4,%CD8,%CD19,,ABS CD3,ABS CD4,ABS CD8,ABS CD19) | FLOW CYTOMETRY | WB-EDTA + HEPARIN (WB TO REACH WITHIN 48 HRS) |
A | India | Enumeration of helper/inducer (CD3+CD4+) and suppressor (CD3+CD8+) lymphocytes is required to monitor the patient’s cell mediated immune status. Serial estimation of absolute T-helper cell counts is valuable in assessing progression of the disease in HIV-infected individuals. The counts are useful in taking decisions regarding institution of anti-retroviral and prophylactic antibiotic therapy against opportunistic infections. Similarly, enumeration of B (CD19+) lymphocytes helps in assessing the humoral immune status of an individual. The number of B-lymphocytes in blood can increase during bacterial infections. Since B-lymphocytes produce immunoglobulins in response to antigenic stimulation, expansion of this population of cells is associated with polyclonal increase in immunoglobulins |
| 1468 | 5401 | MALE INFERTILITY PANEL, (Testosterone Total, LH, FSH, Prolactin, TSH, Blood Lympho Culture, Anti sperm Antibodies, Urine culture, isolation & Identification + Sensitivity) |
CHEMILUMINESCENCE / ENZYME IMMUNOASSAY/ CELL CULTURE/ CULTURE + SENSITIVITY BY MIC BREAKPOINT | Serum ( Age+ Gender+ Clinical History Required ) **Draw sample between 8 AM to 10AM ,After 3-4 hrs patient has awakened.** WB-HEPARIN SPECIMEN TO REACH US within 48 hrs + FAMILY HISTORY + CLINICAL HISTORY in specified format + DETAILED PHYSICAL FEATURES URINE(Early morning mid stream collection) STERILE CONTAINER |
2-8°C (48 hrs); F ( >48 hrs); F(-20°C); HEPARIN (A); URINE (R) (MANDATORY); | India | To help determine the cause of male infertility |
| 1469 | 9146U24 | MANGANESE 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) ALIQUOT. IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Manganese is a trace element that is an essential cofactor for several enzymes. Environmental sources of Manganese can lead to toxicity. This assay is useful for monitoring manganese exposure & long term parenteral nutrition with manganese supplementation. |
| 1470 | 9146 | MANGANESE BLOOD | GFAAS WITH ZEEMAN CORRECTION | BD, SRL EDTA WHOLE BLOOD | 2-8°C (7 DAYS); F (>7 -30 DAYS) | India | Manganese is a trace element that is an essential cofactor for several enzymes. Environmental sources of Manganese can lead to toxicity. This assay is useful for evaluating central nervous system symptoms similar to Parkinson’s disease in manganese miners and processors. It is also useful for therapeutic monitoring of Cirrhosis, environmental exposure to manganese and nutrition related manganese toxicity. It also helps to evaluate Behcet’s disease. This is the recommended test for monitoring therapy. |
| 1471 | 8424 | MANGANESE SERUM ICPMS | ICPMS | SERUM | R/F | India | To measure hypo or hyper maganese level in serum |
| 1472 | 9146U | MANGANESE SPOT URINE | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Manganese is a trace element that is an essential cofactor for several enzymes. Environmental sources of Manganese can lead to toxicity. This assay is useful for monitoring manganese exposure & long term parenteral nutrition with manganese supplementation. |
| 1473 | 3322 | MAPLE SYRUP URINE DISORDERS (NEONATAL SCREENING) | Enzymatic | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | This assay confirms the presence of Leucine, Isoleucine, Valine & Alloisoleucine for the diagnosis of MSUD. It also aids in the followup of patients with MSUD and |
| 1474 | 1268 | MATERNAL SCREENING (DOUBLE MARKER TEST) 1st Trimester Risk assessment 8 – 13.6 weeks. (FREE BHCG & PAPP-A) |
CHEMILUMINESCENCE | SERUM in 2 vials (Clinical Details in specified format, Maternal Date of Birth, Maternal Weight, Maternal Race, Maternal H/O Type I Diabetes Mellitus + Obstetric USG Report between 10 to 13 weeks of gestation+Date of collection) MANDATORY |
2-8°C (24 hrs); F ( >24 hrs) | India | The Dual Screen test between 913 weeks of pregnancy has significant utility in First trimester Prenatal Screening of Down Syndrome (Trisomy 21), and other chromosomal anomalies. The false positive rate is 5% but the detection of Down Syndrome is as high as 8590%. |
| 1475 | 1275 | MATERNAL SCREENING (QUADRUPLE MARKER TEST) 2nd Trimester Risk assessment, 14 – 22 Weeks. ( AFP, HCG, E3UN & DIA) |
CHEMILUMINESCENCE | SERUM in 2 vials (Clinical Details in specified format, Maternal Date of Birth, Maternal Weight, Maternal Race, Maternal H/O Type I Diabetes Mellitus + Obstetric USG Report between 10 to 13 weeks of gestation+Date of collection) MANDATORY |
2-8°C (48 hrs); F (>48 hrs) | India | The Quadruple test is used for Prenatal Screening of Down Syndrome (Trisomy 21), Edward’s Syndrome (Trisomy 18) and Open Neural Tube Defects. The approximate detection rate with this test is 7580 % with a false positive rate of 5% |
| 1476 | 1278 | MATERNAL SCREENING (SEQUENTIAL INTEGRATED TEST) Phase I (1st Trimester): 10 – 13.6 weeks (FREE BHCG & PAPP – A). Screen Positive cases are offered CVS or Amniocentesis Chromosome analysis, whereas Screen Negative are offered second Trimester Serum test. Phase II (2nd Trimester): 15 – 22 weeks (AFP, HCG, E3UN & DIA). Final risk assessment incorporates First and Second Trimester results. |
CHEMILUMINESCENCE/ KARYOTYPING | SERUM IN 2 VIALS (CLINICAL DETAILS IN SPECIFIED FORMAT, DATE OF BIRTH, MATERNAL WEIGHT, MATERNAL RACE + USG REPORT +DATE OF COLLECTION+LMP DATE) GA: 8- 12 WEEKS CHORIONIC VILLUS IN MEDIUM (MEDIUM WILL BE PROVIDED BY THE LAB), GA: 14-19 AMNIOTIC FLUID CLINICAL HISTORY, CONSENT FORM WITH PND REGISTRATION NUMBER IS MANDATORY. SPECIMEN TO REACH US IN 24 HRS AFTER COLLECTION |
Phase I (1st Trimester): 2-8°C (24 hrs); F (>24 hrs) Phase II (2nd Trimester): 2-8°C (48 hrs); F (>48 hrs) CVS: Ambient Amniotic Fluid |
India | Screening test to detect genetic abnormalities or other defects in developing foetus |
| 1477 | 1277 | MATERNAL SCREENING (STANDARD INTEGRATED TEST) Phase I (1st Trimester) : 10 – 13.6 Weeks. (FREE BHCG & PAPP – A). Phase II (2nd Trimester): 15 – 22 Weeks. (AFP, HCG, E3UN & DIA). Final risk assessment incorporates First and Second Trimester results. |
CHEMILUMINESCENCE | SERUM IN 2 VIALS (CLINICAL DETAILS IN SPECIFIED FORMAT, DATE OF BIRTH, MATERNAL WEIGHT, MATERNAL RACE + USG REPORT BETWEEN 10 TO 13 WEEKS OF GESTATION +DATE OF COLLECTION+LMP DATE) MANDATORY | Phase I (1st Trimester): 2-8°C (24 hrs); F (>24 hrs) Phase II (2nd Trimester): 2-8°C (48 hrs); F (>48 hrs) |
India | Screening test to detect genetic abnormalities or other defects in developing foetus |
| 1478 | 1267 | MATERNAL SCREENING (TRIPLE MARKER TEST) 2nd Trimester Risk assessment, 14 – 22 Weeks. (AFP, HCG & E3UN) |
CHEMILUMINESCENCE | SERUM in 2 vials (Clinical Details in specified format, Maternal Date of Birth, Maternal Weight, Maternal Race, Maternal H/O Type I Diabetes Mellitus + Obstetric USG Report between 10 to 13 weeks of gestation+Date of collection) MANDATORY |
2-8°C (72 hrs); F (> 72 hrs – 15 Days) | India | The Triple Screen test is used for Prenatal Screening of Down Syndrome (Trisomy 21), Edward’s Syndrome (Trisomy 18) and Open Neural Tube Defects. The approximate detection rate with this test is 55–65% with a false positive rate of 5%. |
| 1479 | 8771 | MEASLES IgG & IgM ANTIBODIES | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (7 DAYS); -20°C (>7 DAYS) | India | Measles virus is highly contagious particularly infecting children, pregnant women, immunocompromi sed and nutritionally deficient individuals. IgG positivity indicates previous exposure to Rubeola virus or immunity. IgM positivity indicates recent infection, with Rubeola virus. |
| 1480 | 8776 | MEASLES IgG ANTIBODIES | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (7 DAYS); -20°C (>7 DAYS) | India | Measles virus is highly contagious particularly infecting children, pregnant women, immunocompromi sed and nutritionally deficient individuals. IgG positivity indicates previous exposure to Rubeola virus or immunity. |
| 1481 | 8781 | MEASLES IgM ANTIBODIES | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (7 DAYS); -20°C (>7 DAYS) | India | Measles virus is highly contagious particularly infecting children, pregnant women, immunocompromi sed and nutritionally deficient individuals. IgM positivity indicates recent infection, with Rubeola virus. |
| 1482 | Z253K | MELAN-A | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help diagnose malignant melanoma |
| 1483 | 7002 | MENOPAUSE PLUS PROFILE | LIA, EIA, RIA | 7 SALIVA SAMPLES COLLECTED OVER A 6 DAYS PERIOD •WASH HANDS BEFORE COLLECTION. • SEE INSTRUCTIONS INSIDE TEST KIT FOR DETAILS.ON REQUEST KIT WILL BE PROVIDED BY SRL,MUMBAI | F | India | To Evaluate MENOPAUSE PROFILE |
| 1484 | 9138U24 | MERCURY, 24 HRS URINE | HGAAS | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) ALIQUOT. IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Mercury, a highly toxic metal is present in select industrial environments and in contaminated ocean fish. Urinary measurement is the most reliable way to assess exposure to inorganic mercury. |
| 1485 | 9138 | MERCURY, BLOOD | ICPMS | BD, SRL EDTA VACCUTAINER, WHOLE BLOOD | 2-8°C (15 DAYS); SENDING SAMPLE UNDER COLD CONDITIONS (2-8°C) IS MANDATORY | India | To determine mercury level in blood |
| 1486 | 9138U | MERCURY, URINE SPOT | HGAAS | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | Mercury, a highly toxic metal is present in select industrial environments and in contaminated ocean fish. Urinary measurement is the most reliable way to assess exposure to inorganic mercury. |
| 1487 | 9131 | MERCURY,SERUM ICPMS | ICPMS | SERUM | R/F | India | To determine mercury level in serum |
| 1488 | 3315P | METANEPHRINE-FREE, PLASMA | EIA | EDTA PLASMA .It is mandatory to forward clinical history allow with the sample | FROZEN | India | This assay is useful as a screening test for the presumptive diagnosis of catecholamine secreting Pheochromocytom a & Paragangliomas. Metanephrine and Normetanephrine are 3Methoxy metabolites of Epinephrine and Normetanephrine respectively. These are further metabolized to VMA. This assay may be used as a first order screening test. |
| 1489 | 3317 | METANEPHRINES | ENZYME IMMUNOASSAY | 24HRS URINE (Preservative:15 – 20ML 6N HCL) . (The patient should not consume,Vitamin B, COFFEE AND BANANAS, 48hrs prior to the collection of the specimen.It is advisable to discontinue all medications, alpha methyldopa, MAO & COMT Inhibitors as well as medications related to Hypertension should be discontinued atleast 72 hrs prior to specimen collection.If medications takenshould be STrictly on the advise of the referring physician, the same should be mentioned.Please freeze the specimen immediately after collection. CLINICAL DETAILS(Patient’s clinical history, CT SCAN , USG & MEDICATION MANDATORY) mention 24 hrs urine volume | STRICTLY F | India | This assay is useful as a screening test for the presumptive diagnosis of catecholamine secreting Pheochromocytom a & Paragangliomas. Metanephrine and Normetanephrine are 3Methoxy metabolites of Epinephrine and Normetanephrine respectively. These are further metabolized to VMA. This assay may be used as a first order screening test. |
| 1490 | Z243K | METASTASIS OF UNKNOWN ORIGIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | to classify neoplasms of uncertain origin |
| 1491 | Z232 | METATASTIC TUMOUR BREAST (ER, PgR, Her-2/neu, GCDFP-15) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help diagnose breast tumor metastasis |
| 1492 | 4149 | METHADONE, URINE | Lateral Flow Chromatography Immunoassay. | URINE + CLINICAL HISTORY | A (8HRS); 2- 8º C (3 DAYS);F (>3 DAYS) | India | Methadone is a synthetic opoid used clinically to relieve pain, treat opoid abstinence syndrome and to treat heroin addiction in the attempt to wean patients from illicit drug use. |
| 1493 | 4202 | METHAEMOGLOBIN ESTIMATION | SPECTROPHOTOMETRY | EDTA BLOOD | A | India | Excessive formation of Hi occurs as a result of oxidation of Hb by drugs and chemicals such as phenacetin, sulphonamides, aniline dyes, nitrates and nitrites. Other (rare) types of methemoglobinaemia are caused by inherited deficiency of the enzyme NADH methemoglobin reductase and by rare hemoglobinopathies (e.g. Hb M). Methemoglobin leads to cyanosis which becomes obvious with as little as 15 g/l of Hi, i.e. about 10 %. |
| 1494 | 2124 | METHYLMALONIC ACID, URINE | QUALITATIVE | URINE (RANDOM) | FROZEN | India | The assay is a specific diagnostic marker for methylmalonic acidemias which can be congenital or acquired. The acquired causes are more common and usually found in patients with cobalamine (Vitamin B12) deficiency as a consequence of intestinal malabsorption, impaired digestion or poor diet. Other causes are renal insufficiency, hypovolemia and bacterial overgrowth in small intestine. |
| 1495 | Z245K | MIB-1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with breast carcinoma |
| 1496 | Z218K | MIC2 GENE PRODUCTS, EWING SARCOMA MARKER/Also known as CD99 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help diagnose EWINGS SARCOMA |
| 1497 | 1493 | MICROFILARIA DETECTION | MICROSCOPY | WB-EDTA + SMEAR (MIDNIGHT COLLECTION SPECIMEN PREFERRED) | A | India | Filariasis is a disease resulting from parasitization by thread like of filiform worms called filariae. The embryos circulate in lymphatic tissues and blood as microfilaria leading to Lymphangitis, Lymphadenitis, Elephantiasis and Tropical eosinophilia. |
| 1498 | RD1461 | MICROSATELLITE STABILITY INDEX(MSI ANALYSIS) | PCR Fragment Analysis | EDTA WHOLE BLOOD AND PARAFFIN BLOCK + CLINICAL HISTORY | AMBIENT | India | This panel studies mismatch repair proteins in Hereditary Nonpolyposis Colorectal cancer. |
| 1499 | Z262K | MLH1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Immunohistochemical testing for MLH1expression provides useful prognostic information for the management of colorectal cancer patients. It is also used as routine screening for Lynch syndrome |
| 1500 | RD1447 | MLH1 Hypermethylation | Pyrosequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | AMBIENT | India | Detection of MLH1 hypermethylated alleles |
| 1501 | 5207 | MONSOON ALLERGY PANEL | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | Allergy test |
| 1502 | RD1322 | MPL Mutation Detection | PCR Sequencing | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | Mutations in exon 10 of MPL have been detected in approximately 5% of patients with Primary myelofibrosis (PMF) and Essential thrombocythemia (ET). |
| 1503 | RD1322RFX | MPN Reflex Panel | PCR-SEQUENCING | WB-EDTA/ BONE MARROW-EDTA (Specimen to reach us within 48 hrs)+CLINICAL HISTORY | A/R | India | To help diagnose myeloproliferative neoplasms. |
| 1504 | 7687 | MPN Reflex Panel 1 | PCR-SEQUENCING | WB-EDTA/ BONE MARROW-EDTA (Specimen to reach us within 48 hrs)+CLINICAL HISTORY | A/R | India | To help diagnose myeloproliferative neoplasms |
| 1505 | Z263K | MSH2 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | genetic testing of the tumour DNA to determine whether whether mutation in MSH2 is present. |
| 1506 | Z264K | MSH6 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | genetic testing of the tumour DNA to determine whether whether mutation in MS6 is present. |
| 1507 | 9336 | MISMATCH REPAIR GENE (IHC) or MSI STUDY (MLH-1,MSH-2,MSH-6,PMS-2) |
IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | genetic testing of the tumour DNA to determine whether mutation in MSI is present. |
| 1508 | 9802 | MTHFR MUTATION DETECTION | PCR Sequencing | EDTA Whole Blood + CLINICAL HISTORY | A | India | Homozygous mutation for MTHFR (Methylenetetrahy drofolate reductase) is associated with Hyperhomocystein emia which is an independent risk factor for stroke, MI, peripheral arterial disease and venous thrombosis. Indian studies suggest that heterozygosity for MTHFR C677T is also associated with elevated homocysteine levels. |
| 1509 | 3262 | MUCOR RACEMOSUS -SPECIFIC IgG | ImmunoCAP(FLUOROENZYME IMMUNOASSAY) | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | MUCOR RACEMOSUS IgG antibodies test |
| 1510 | 4573 | Multiple Myeloma MRD Panel | Flowcytometry | BONE MARROW HEPARIN (2 VIALS) To reach lab within 24 hours from collection |
A | India | Detection of Minimal Residual Disease (MRD) in Acute lymphoblastic leukemia predicts outcome. This assay can identify patients at higher/lower risk of relapse. Detection of MRD is important for risk assessment and stratification of therapy. |
| 1511 | 6031F | Multiple Myeloma panel | FISH | BONE MARROW – SODIUM HEPARIN + CLINICAL HISTORY SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | ambient | India | Prognostic marker in patients with Multiple myeloma. |
| 1512 | Z282K | MUM-1 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | MUM1 is a powerful tool for understanding the histogenesis of B-cell lymphomas. MUM1 protein is an excellent marker for Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma in combination with CD30. Furthermore, MUM1 seems to be a marker of prognostic value since it has been found that the expression of MUM1 is associated with the poor prognosis of patients with diffuse large B-cell lymphoma (DLBCL). |
| 1513 | 9711 | MUMPS IgG & IgM ANTIBODIES | Chemiluminescent Immunoassay (CLIA) | SERUM | 2-8°C (9DAYS); -20 TO -70°C (>9 DAYS) | India | This assay is used for the laboratory diagnosis of Mumps virus infection. Absence of detectable IgG antibodies suggests lack of specific immune response to immunization and no previous exposure to the virus. Detection of IgM antibodies supports a clinical diagnosis of recent / acute phase infection with the virus. |
| 1514 | 4065 | MUSK ANTIBODY (SERUM) | RADIO IMMUNOASSAY | SERUM | F | India | MuSK antibodies have been detected in patients with Myasthenia gravis who are seronegative for Acetylcholine receptor antibodies. This assay is used to evaluate patient response to therapies for ongoing management. |
| 1515 | 6029F | MYC gene | FISH | HEPARIN WB / Bone Marrow + + CLINICAL HISTORY SPECIMEN TO REACH US WITHIN 48 HRS AFTER COLLECTION. [Please mention the CLINICAL HISTORY, blood picture (CBC Report) and medication of the patient on the TRF] | ambient | India | The MYCN gene, which encodes the nmyc protein, is a protooncogene with highest expression in the developing brain and insignificant expression in normal adult tissues. Gene amplification is detected in approximately 20% of Neuroblastoma and a variety of other solid tumors including 5% Medulloblastoma, Glioblastoma multiforme, 25% Alveolar rhabdomyosarcom a, 1520% Smallcell lung cancer, 40% Neuroendocrine prostate cancer, and 5% Prostate adenocarcinoma. MYCNamplifications are associated with aggressive disease and/or poor outcome. Detection can be useful to stratify patients for aggressivetreatment. |
| 1516 | 4513 | MYCN Gene amplification Assay | FISH | BLOCKS.PLEASE PROVIDE THE HISTOPATHOLOGY REPORT AND CLINICAL HISTORY ALONG WITH THE BLOCKS. | AMBIENT | India | The MYCN gene, which encodes the nmyc protein, is a protooncogene with highest expression in the developing brain and insignificant expression in normal adult tissues. Gene amplification is detected in approximately 20% of Neuroblastoma and a variety of other solid tumors including 5% Medulloblastoma, Glioblastoma multiforme, 25% Alveolar rhabdomyosarcom a, 1520% Smallcell lung cancer, 40% Neuroendocrine prostate cancer, and 5% Prostate adenocarcinoma. MYCNamplifications are associated with aggressive disease and/or poor outcome. Detection can be useful to stratify patients for aggressivetreatment. |
| 1517 | 2435 | MYCO3PLEX | MULTIPLEX POLYMERASE CHAIN REACTION, MICROSCOPY FLUORESCENT STAIN/ ZIEHL NEELSEN STAIN & MGIT-960+LJ CULTURE METHOD | ANY SPECIMEN OTHER THAN BLOOD IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE (SWABS NOT ACCEPTED) | A UP TO 48 HRS AND R >48 HRS AFTER SPECIMEN COLLECTION | India | N/A |
| 1518 | 2435F | MYCO3PLEX AD WITH FREE ADA | MULTIPLEX POLYMERASE CHAIN REACTION, MICROSCOPY FLUORESCENT STAIN/ ZIEHL NEELSEN STAIN & MGIT-960+LJ CULTURE METHOD/SPECTROPHOTOMETRY | ANY SPECIMEN OTHER THAN BLOOD IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE (SWABS NOT ACCEPTED) | Culture-R /A up to 48 hrs and R >48 hrs after specimen collection F for ADA | India | N/A |
| 1519 | 2435T | MYCO3PLEX AD WITH FREE HISTOPATH | MULTIPLEX POLYMERASE CHAIN REACTION, MICROSCOPY FLUORESCENT STAIN/ ZIEHL NIELSEN STAIN & MGIT-960+LJ CULTURE METHOD | ANY SPECIMEN IN STERILE CONTAINER/ TISSUE IN STERILE NORMAL SALINE, TISSUE + SITE OF BIOPSY + CLINICAL DETAILS (FOR BONE SPECIMENS ALSO SEND XRAY) – SWABS NOT ACCEPTED | Culture R/A up to 48 hrs and R >48 hrs after specimen collection F for ADA | India | N/A |
| 1520 | 1122 | MYCOBACTERIA DETECTION | MICROSCOPY / FLUORESCENT STAIN | ANY SPECIMEN EXCEPT BLOOD, BONE MARROW.SWAB NOT ACCEPTABLE | A/R | India | To help detect Mycobacterium Tuberculosis |
| 1521 | 2401 | MYCOBACTERIUM LEPRAE | POLYMERASE CHAIN REACTION | SKIN SCRAPPING/ SKIN BIOPSY/ NASAL/SKIN SWAB / TISSUE/ SLIDES/BLOCKS | A | KABUL | M. leprae DNA PCR is used for early detection in patients with paucibacillary and indeterminate forms of leprosy. |
| 1522 | 9956 | MYCOBACTERIUM SPECIATION – COMMON | PCR – REVERSE PROBE HYBRIDIZATION | MTB Culture Specimen | A | India | The assay permits identification of M. avium ssp., M. chelonae, M. abscessus, M. fortuitum, M. gordonae, M. intracellulare, M. scrofulaceum, M. interjectum, M. kansasii, M. malmoense, M. peregrinum, M. marinum/ M. ulcerans, M. tuberculosis complex and M. xenopi. |
| 1523 | 9955 | MYCOBACTERIUM SPECIATION – EXTENDED | PCR – REVERSE PROBE HYBRIDIZATION | MTB Culture Specimen | A | India | The assay permits identification of M. simiae, M. mucogenicum, M. goodii, M. celatum, M. smegmatis, M. genevense, M. lentiflavum, M. heckeshornense, M. szulgai/ M. intermedium, M. phlei, M. hemophilum, M. kansasii, M. ulcerans, M. gastri, M. asiaticum and M. shimoidei |
| 1524 | 2402 | MYCOBACTERIUM SPECIATION (AFB SPECIATION) |
PCR – SEQUENCING | CULTURE/ SPUTUM/ BAL/ PUS + CLINICAL HISTORY (SPECIMENS OF PATIENTS WITH AFB SMEAR LESS THAN 1+ ARE NOT ACCEPTABLE) | A | India | This test is designed to identify all known Mycobacterium species in given pure culture or AFB smear (2+) positive specimens. |
| 1525 | 8746 | MYCOPLASMA PNEUMONIAE IgG ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 days); -20°C (>2 days) | India | Mycoplasma pneumoniae is an important respiratory tract pathogen accounting for nearly 20% of all cases of Pneumonia. It most commonly affects children & young adults. IgG antibodies indicate previous immunologic exposure. |
| 1526 | 8746M | MYCOPLASMA PNEUMONIAE IgM ANTIBODIES | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 days); -20°C (>2 days) | India | Mycoplasma pneumoniae is an important respiratory tract pathogen accounting for nearly 20% of all cases of Pneumonia. It most commonly affects children & young adults. Positive IgM results are consistent with acute infection. |
| 1527 | 2434 | MYCOREAL (TB PCR) | REAL TIME PCR | SPUTUM/ BAL/ URINE/ FNAC/ ASCITIC / PLEURAL / CSF FLUIDS/ TISSUE IN STERILE NORMAL SALINE / BONE MARROW-EDTA / PARAFFIN BLOCK (SWABS AND BLOOD SPECIMEN NOT ACCEPTED) | A | India | This is a sensitive PCR assay for the detection of Mycobacterium tuberculosis complex and Non Tuberculous Mycobacteria (NTM). |
| 1528 | 2439 | MYCOtect (TB PCR) | REAL TIME PCR | SPUTUM/ BAL/ URINE/ FNAC/ ASCITIC / PLEURAL / CSF FLUIDS/ TISSUE IN STERILE NORMAL SALINE / BONE MARROW-EDTA / PARAFFIN BLOCK (SWABS AND BLOOD SPECIMEN NOT ACCEPTED) | A | India | To help diagnose an infection caused by Mycobacteria. |
| 1529 | RD1517 | MYD88 GENE MUTATION | REAL TIME PCR | EDTA WHOLE BLOOD / EDTA BONE MARROW/FFPE+ CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | Detection of MYD88 L265P can help establish a diagnosis of lymphoplasmacytic lymphoma (LPL) in patients with typical histologic and flow cytometry findings |
| 1530 | Z210K | MYELOPEROXIDASE (MPO) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | A marker of myeloid lineage |
| 1531 | Z206 | MYELOPEROXIDASE (MPO) STAIN | CYTOCHEMISTRY SPECIAL STAINS | FRESH, UNSTAINED, AIR DRIED PERIPHERAL SMEAR / BONE MARROW ASPIRATE SMEARS + CLINICAL HISTORY | A | India | The main value of a positive myeloperoxidase reaction is in the distinction between acute myelogenous and acute lymphoblastic leukemia. Some individuals have congenital deficiency of neutrophil MPO, wherein all stages of the neutrophil lineage are MPO negative. |
| 1532 | Z246K | MYO-D1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Marker of skeletal muscle differentiation |
| 1533 | 9273 | MYOGLOBIN, URINE (URINE SPOT, ECLIA) | ECLIA | RANDOM URINE | R/F (STABILITY:4 DAYS) | India | To determine whether muscle has been injured; to help diagnose conditions associated with muscle damage; to detect high levels in the urine that can cause kidney damage after extensive muscle damage; sometimes to help determine if you have had a heart attack, although for heart attack detection, this test has been largely replaced by troponin |
| 1534 | RD1484 | MYOTONIC DYSTROPHY TYPE 1 (DM1) | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY in specified format | A | India | DMPK mutation analysis is recommended for an individual with a clinical diagnosis of myotonic dystrophy type 1(DM-1); Carrier identification in individuals with a positive family history of DM-1. Over 98% of myotonic dystrophy cases have an expansion of the DMPK CTG repeat region. Diagnostic testing using PCR and TP-PCR is predicted to detect pathological expansions of the DMPK CTG repeat region with high sensitivity in myotonic dystrophy type 1 (DM1).This assay can determine homozygous expanded repeats by the TPP. |
| 1535 | RD1485 | MYOTONIC DYSTROPHY TYPE 1 (DM1) – PNDT | PCR-SEQUENCING | AMNIOTIC FLUID / CVS IN STERILE SALINE / FETAL BLOOD EDTA+EDTA WHOLE BLOOD FOR BOTH PARENTS + CLINICAL HISTORY | A | India | This assay can determine homozygous expanded repeats by the TPP. |
| 1536 | Z276K | NAPSIN A | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Aids in the identification of primary lung adenocarcinoma |
| 1537 | 7717 | NBS 4 PARAMETERS (TSH,17 ALPHA OHP,IMMUNOREACTIVE TRYPSINOGEN, TOTAL GALACTOSE) | Enzyme Immunoassay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. (CAH, Galactosemia, Thyroid disorders, etc.) |
| 1538 | 7708 | NBS 7 PARA (17OH,BIOT,G6PD,IRT,PHYL,GALAC,TSH) | Enzyme Immunoassay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. (CAH, Galactosemia, G6PD deficiency, PKU, Thyroid disorders, etc.) |
| 1539 | 4464 | NBS 8 PARAMETERS (17 ALPHA OHP, BIOTINIDASE DEFICIENCY,G6PD,IRT,PHENYLALANINE,GALACTOSE,TSH,SICKLE CELL | Enzyme Immunoassay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. (CAH, Galactosemia, G6PD deficiency, PKU, Thyroid disorders, sickle cell etc.) |
| 1540 | 7517 | NBS NEW PANEL(CH, CAH, G6PD, GALACTOSE) | Enzyme Immunoassay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. (CAH, Galactosemia, G6PD deficiency) |
| 1541 | 4604 | NBS PANEL (MORE THAN 1 MONTH) | Colorimetry/FEIA,FEA,FEIA,TMS,FLUORIMETRY | Dried blood spots | Ambient | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. |
| 1542 | 2414 | NEISSERIA GONORRHOEAE CULTURE | CULTURE | PUS /URETHRAL DISCHARGE/VAGINAL SECRETIONS OR URETHRAL/VAGINAL SWABS IN TRANSPORT MEDIUM | A | India | To detect infection caused by NEISSERIA GONORRHOEAE |
| 1543 | 9801 | NEISSERIA GONORRHOEAE DNA PCR | POLYMERASE CHAIN REACTION | URETHRAL/ ENDOCERVICAL SWABS OR URINE | A | India | Neisseria gonorrhoeae (NG) are nonmotile, Gramnegative diplococci, and the causative agent of gonorrheal disease. Gonorrhea is the second most commonly reported bacterial sexually transmitted disease. The majority of urethral infections caused by NG among men produce symptoms that cause them to seek curative treatment, but among women, infections often do not produce recognizable symptoms until complications like pelvic inflammatory disease have occurred. |
| 1544 | 9611 | NEISSERIA MENINGITIDIS A, B, C, Y, W135 ANTIGEN DETECTION | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | To detect infection caused by NEISSERIA MENINGITIDIS and further typing inSERUM |
| 1545 | 9611C | NEISSERIA MENINGITIDIS A, B, C, Y, W135 ANTIGEN DETECTION, CSF | LATEX PARTICLE AGGLUTINATION | CSF | 2-8°C (FEW HRS); -20°C (LONGER) | India | To detect infection caused by NEISSERIA MENINGITIDIS and further typing in CSF |
| 1546 | 5815F | NEONATAL FISH 13 & 21 (2 PROBE) | FISH | WB-HEPARIN SPECIMEN TO REACH US IN 24 – 48 HRS / CORD BLOOD- HEPARIN (IF BABY IS ALIVE)+CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | to help find genetic defects (13 & 21) in a developing baby |
| 1547 | 5815FF | NEONATAL FISH 18,X & Y (3 PROBE) | FISH | WB-HEPARIN SPECIMEN TO REACH US IN 24 – 48 HRS / CORD BLOOD- HEPARIN (IF BABY IS ALIVE)+CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | to help find genetic defects (18, X &Y) in a developing baby |
| 1548 | 5815KF | NEONATAL KARYOTYPE + FISH | Karyotype + FISH | WB-HEPARIN SPECIMEN TO REACH US IN 24 – 48 HRS / CORD BLOOD- HEPARIN (IF BABY IS ALIVE)+CLINICAL HISTORY IN SPECIFIED FORMAT | A | India | to help find genetic defects in a developing baby |
| 1549 | 3320 | NEONATAL SCREENING (Biotinidase) | Enzymatic | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | Biotinidase deficiency is an autosomal recessive disoder caused by mutations in the biotinidase gene. Age of onset and clinical phenotype vary depending on the amount of residual Biotinidase activity. The combined incidence of profound and partial Biotinidase deficiency is 1 in 61000. The carrier frequency in the general population is 1 in 120. This assay is used for diagnosing biotinidase deficiency. It is also useful for follow up testing for certain Organic acidurias. |
| 1550 | 3321 | NEONATAL SCREENING (GLUCOSE-6-PHOSPHATE DEHYDROGENASE) | Enzymatic | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | G6PD deficiency is a sex linked disorder affecting males whereas females are the carriers. More than 300 variants of G6PD are known, hence deficiency can range from asymptomatic to acute hemolytic episodes. These episodes can be triggered by drugs, ingestion of fava beans, viral and bacterial infections. |
| 1551 | 3312 | NEONATAL SCREENING (PHENYLALANINE) | Enzymatic | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | Phenylketonuria (PKU) is the most common autosomal recessive inherited disorder of amino acid metabolism caused by deficiency of enzyme Phenylalanine hydroxylase. This assay is useful for evaluating patients with Hyperphenylalanin emia and monitoring effectiveness of dietary theapy. |
| 1552 | 3309 | NEONATAL SCREENING (TOTAL GALACTOSE) | Enzymatic | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | Galactosemia is an autosomal recessive disorder caused by inability to metabolize galactose which is derived from lactose (milk sugar). The accumulation of galactose can cause feeding problems, vomiting, sepsis, diarrhoea, dehydration and hypoglycemia. Cataracts and mental retardation develop gradually. |
| 1553 | 3308 | NEONATAL SCREENING (TSH) | Enzyme Immunoassay | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | This test should be used only in neonates to screen for thyroid disorders. |
| 1554 | 3328IA | NEONATAL SCREENING PANEL-1 (Immunoreactive Trypsinogen, TSH, Total Galactose, 17-Alpha-Hydroxyprogesterone, Phenylalanine, Biotinidase, Glucose-6-Phosphate Dehydrogenase, Maple Syrup Urine Disease | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The aim of newborn screening is to detect diagnostic markers of treatable disorders in blood spots collected from presymptomatic newborns. Early identification of disorders significantly improves long term prognosis of affected patients, minimizes complications, avoids unnecessary diagnostic testing and identifies families for whom prenatal genetic counselling may be helpful. |
| 1555 | 3328IB | NEONATAL SCREENING PANEL-2 (Immunoreactive Trypsinogen, TSH, 17-Alpha-HydroxyprogeSTerone, Phenylalanine, Glucose-6-Phosphate Dehydrogenase | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. |
| 1556 | 3328IC | NEONATAL SCREENING PANEL-3 (TSH, Phenylalanine) | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. ( Thyroid disorders and PKU) |
| 1557 | 3328ID | NEONATAL SCREENING PANEL-4 (G6PD, TSH, Phenylalanine) | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 DAYS) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. ( Thyroid disorders, G6PD deficiency and PKU) |
| 1558 | MGEN007 | Nephrotic Syndrome Gene Panel | 0 | 0 | 0 | India | #N/A |
| 1559 | 1532K | NERVE BIOPSY WITH NEUROFILAMENT | Histopathology + IHC | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details Mandatory) . | A | India | #N/A |
| 1560 | Z415K | NEUROFILAMENT (2F11) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 1561 | RD1463 | Neuromuscular Disorders mtDNA mutation Panel | PCR Sequencing | EDTA WHOLE BLOOD + CLINICAL HISTORY | AMBIENT | India | Viruses have evolved mechanisms enabling them to easily infiltrate the nervous system. Two main methods of viral entry are transneuronal and hematogenous spread. PCR is frequently used to for rapid identification of specific DNA viruses from the CSF, while Reverse transcriptase PCR is commonly used to identify RNA viruses in the CSF. Viral replication tends to peak early and then decline to undetectable levels in CNS infection. PCR assays have a higher incidence of detecting CNS viral infection. |
| 1562 | EGEN004 | Neuromuscular Disorders Panel | 0 | 0 | 0 | India | #N/A |
| 1563 | Z048K | NEURON SPECIFIC ENOLASE | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help diagnose neuroendocrine neoplasms |
| 1564 | 3328IN | NEW NEONATAL SCREENING PANEL(TSH,Phenylalanine & 17-Alpha-Hydroxyprogesterone) | ENZYME IMMUNOASSAY | DRY BLOOD SPOT with complete CLINICAL HISTORY form including birth date & birth time.(Dried Blood spot should be ideally collected within 3rd and 5th day of life after birth) | 2-8°C (14 days) | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. ( Thyroid disorders, CAH and PKU) |
| 1565 | 3358A | NEWBORN SCREENING FOR ACYLCARNITINE & AMINO ACIDS | MS/MS (Tandem Mass Spectrometry) | A. General Information Collection Time: Collect sample 24 hours AFTER birth up to 1 month of age. (DAY 2-7 REPORTED WITHOUT DISCLAIMER , DAY 8 TO 1 MONTH WITH DISCLAIMER COMMENT) REQUIRE FOLLOWING MADATORY DETAILS: Birth date and time, Sample collection date and time, Age at the time of collection (more than 24 hours), Transfusion details if any with date and time, IV fluid infusion if any with date and time, Feed details (Breast/Bottle/Both Breast and Bottle feed), Status at the time of collection (Normal/Premature/Sick), Gestational age, Birth weight details, Medication if any.Single baby or Twin baby (please specify),Ethnicity (White/Hispanic/Asian/Am.Indian/Af.Amer/Others),Doctors Name and Contact details + Clinical history of the patient. B. Sample Acceptability: Special Instructions: 1. Venous blood from a central line is acceptable (Do NOT apply blood to filter paper through a needle as hemolysed samples are not acceptable). 2. All the requested details on the Newborn Screen Card should be mentioned properly. C. Rejection Criteria |
Ambient | India | The aim of newborn screening is to detect diagnostic markers of treatable disorders in blood spots collected from presymptomatic newborns. Early identification of disorders significantly improves long term prognosis of affected patients, minimizes complications, avoids unnecessary diagnostic testing and identifies families for whom prenatal genetic counselling may be helpful. |
| 1566 | 3358 | NEWBORN SCREENING FOR ACYLCARNITINE & AMINO ACIDS, Dried Blood spot | LCMSMS | A. General Information Collection Time: Collect sample 24 hours AFTER birth up to 1 month of age. (DAY 2-7 REPORTED WITHOUT DISCLAIMER , DAY 8 TO 1 MONTH WITH DISCLAIMER COMMENT) REQUIRE FOLLOWING MADATORY DETAILS: Birth date and time, Sample collection date and time, Age at the time of collection (more than 24 hours), Transfusion details if any with date and time, IV fluid infusion if any with date and time, Feed details (Breast/Bottle/Both Breast and Bottle feed), Status at the time of collection (Normal/Premature/Sick), Gestational age, Birth weight details, Medication if any.Single baby or Twin baby (please specify),Ethnicity (White/Hispanic/Asian/Am.Indian/Af.Amer/Others),Doctors Name and Contact details + Clinical history of the patient. B. Sample Acceptability: Special Instructions: 1. Venous blood from a central line is acceptable (Do NOT apply blood to filter paper through a needle as hemolysed samples are not acceptable). 2. All the requested details on the Newborn Screen Card should be mentioned properly. C. Rejection Criteria |
Storage and Shipping Temperature: Allow blood to dry 3 – 4 hrs before packing. Store/Ship the sample in a ZipLock© or equivalent bag at 2° – 8° C. | India | The screening process is a diagnostic tool used by qualified physicians to assist them in diagnosis of metabolic disorders. |
| 1567 | RD1480 | NF1 GENE MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY in specified format | A | India | To help diagnose Neurofibromatosis Type 1 |
| 1568 | 9150U | NICKEL URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | spot test for nickel level in urine |
| 1569 | 9150U24 | NICKEL, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). 24 HRS VOLUME SHOULD BE COMPULSARILY SPECIFIED . FIRST SHAKE THE CAN AND TAKE THE 10-20 ML ALIQUOT IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) THE MEASUREMENT OF URINE VOLUME SHOULD BE DONE AFTER ALIQUOTING. | 2-8°C (5 DAYS); F (>5 -30 DAYS) | India | To measure nickel level in urine |
| 1570 | 9132 | NICKEL, SERUM BY ICPMS (SERUM) | ICPMS | SERUM | R | India | To measure the nickel level by serum |
| 1571 | 8826 | NICOTINE METABOLITE, URINE |
CHEMILUMINESCENCE | URINE: Collect urine without preservatives ( AGE+GENDER+CLINICAL HISTORY REQUIRED ) | 2-8°C (30 DAYS); F (> 30 DAYS) | India | To measure nicotine level in urine |
| 1572 | 8826S | NICOTINE METABOLITE, SERUM | CHEMILUMINESCENCE | SERUM ( AGE+GENDER+CLINICAL HISTORY REQUIRED ) | 2-8°C (30 DAYS); F (> 30 DAYS) | India | To measure nicotine level in blood |
| 1573 | 2247 | NMDA PLUS (NMDAR + VGKC) | IMMUNO FLUORESCENT ASSAY | SERUM/ CSF + CLINICAL HISTORY | 2-8°C / REFRIGERATED | India | Detection of antibodies to voltage gated potassium channels (VGKC) and NMDAR. To help diagnose immune-mediated encephalitis caused by them. |
| 1574 | 4910S | NMO WITH MOG ANTIBODY PROFILE,SERUM | Immunofluorescence | SERUM | FROZEN | India | • Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis • Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy • Diagnosis of neuromyelitis optica (NMO) • Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease • Diagnosis of ADEM (acute disseminated encephalomyelitis) • Prediction of a relapsing disease course |
| 1575 | RD1458 | NOCARDIA SPECIATION | DNA SEQUENCING | Pure Culture Isolate | A | India | This test is designed to identify all known Nocardia species in given pure culture. |
| 1576 | 1515P | NON-GYNAEC CYTOLOGY & FINE NEEDLE ASPIRATION CYTOLOGY (FNAC), PHOTO |
CYTOLOGY | UNSTAINED FNAC SMEARS OR BODY FLUIDS OR ASPIRATES + SITE OF COLLECTION+ CLINICAL HISTORY &/OR RADIOLOGICAL FINDGS. | A-SMEARS OR R – FLUIDS /ASPIRATES, IF FLUID SENT WITHIN 24 HRS. FOR MORE THAN 24 HRS, MIX EQUAL PROPORTION OF FLUID WITH 50% ALCOHOL |
India | Aspiration cytology from a variety of organ sites is useful in the determination of pathologic states particularly neoplasms & inflammatory conditions. |
| 1577 | 7572 | NON-INVASIVE PRENATAL SCREENING (NIPS) | MPSS-Mass Parallel shotgun Seguencing | Whole Blood(Streck cell-free(black/tan tiger top)glass tube [*2] | Room Temperature | India | For pregnant women, to assess the risk of your developing baby (fetus) having certain chromosome disorders |
| 1578 | 9953P | NORADRENALIN, PLASMA | ENZYME IMMUNOASSAY | THE BLOOD SAMPLE (EDTA)SHOULD BE STORED AT 2-8 DEGREE CELCIUS UNTIL CENTRIFUGED TO SEPARATE THE PLASMA WITHIN 2HOURS AFTER BLOOD COLLECTION.DO NOT CONSUME VITAMIN B ,COFFEE, BANANAS, ALPHA -METHYDOPA,MOA AND COMT INHIBITORSAS WELL AS MEDICATION RELATED TO HYPERTENSION FOR AT LEAST 72 HRS PRIOR TO THE COLLECTION OF THE SPECIMEN.MENTION CLINICAL DETAILS(PATIENT CLINICAL HISTORY, CT SCAN,USG & MEDICATION) OF THE PATIENT ON THE REQ FORM.. | F FROZEN STRICTLY | India | To measure the amount of noradrenalin in blood |
| 1579 | 9953U | NORADRENALIN, URINE | ENZYME IMMUNOASSAY | 24HRS URINE (Preservative:15 – 20ML 6N HCL) . (The patient should not consume Vitamin B, COFFEE AND BANANAS,48hrs prior to the collection of the specimen.It is advisable to discontinue all medications, alpha methyldopa, MAO & COMT Inhibitors as well as medications related to Hypertension should be discontinued atleast 72 hrs prior to specimen collection.If medications takenshould be STrictly on the advise of the referring physician, the same should be mentioned.Please freeze the specimen immediately after collection. CLINICAL DETAILS(Patient’s clinical history, CT SCAN , USG & MEDICATION MANDATORY) mention 24 hrs urine volume | F FROZEN STRICTLY | India | To measure Noradrenalin level in urine |
| 1580 | 7779 | NOR-METANEPHRINE, ELISA, URINE (24 HRS URINE) | ELISA | 24 Hours Urine. Use 10 ml of 6M HCL as Preservative. Mention 24hrs Urine volume on the TRF. Forward 20.0ml of aliquot from the 24hrs Urine sample in frozen condition.Clinical history is mandatory for timely reporting. | F | India | To help diagnose or rule out a rare tumor of the adrenal gland called a pheochromocytoma or a rare tumor outside the adrenal glands called a paraganglioma; these tumors (PPGL) produce excess catecholamines, which are broken down to metanephrines. |
| 1581 | Z027K | NP67 (IHC) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | #N/A |
| 1582 | 7579 | NPM1 MUTATION DETECTION | PCR – SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY/EDTA BONE MARRAOW | A | India | This assay is useful for the qualitative detection of mutations associated with Acute Myeloid Leukemia. |
| 1583 | RD1316 | NRAS exon 1 and 2 Mutation | NESTED PCR – Sequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Determination of NRAS status plays a role in determining the outcome of therapy in colorectal carcinoma. Absence of NRAS mutation within the tumor suggests that the patient may respond to therapy but other mutations such as EGFR, KRAS etc also play a role. |
| 1584 | 1702 | NSE (NEURON SPECIFIC ENOLASE) | ELECTROCHEMILUMINESCENCE | SERUM (Centrifuge blood within 1 hour) [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History |
2-8°C (24 HRS); F (3 MONTHS) | India | This assay is used as a followup marker in patients with NSE secreting tumors of any type. It is an auxillary tool in the diagnosis of Small Cell lung carcinoma (SCLS), Carcinoid tumors, Islet cell tumors & Neuroblastomas. It also helps in the assessment of comatose patients. |
| 1585 | RD1469 | O6-methylguanine methyltransferase (MGMT) promoter | Pyrosequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | AMBIENT | India | In patients with Glioblastoma multiforme, a severe type of brain tumor, the methylation state of the MGMT gene determines whether tumor cells would be responsive to temozolomide; if the promoter is methylated, temozolomide is more effective |
| 1586 | DT8101 | OBEY-CT PANEL I (Glucose F & Glucose PP, T3, T4 & TSH, Triglycerides, Cholesterol, HDL Cholesterol, LDL Cholesterol, VLDL Cholesterol, Cholesterol to HDL Ratio, LDL to HDL Cholesterol Ratio, Creatinine, Total Protein, Electrolytes, Calcium, Phosphorus & Urine Analysis, Uric acid | SPECTROPHOTOMETRY, DIPSTICK & MICROSCOPY/CELL COUNTER/CHEMILUMINESCENCE/IMT | SERUM (12-14HRS FASTING), FLUORIDE PLASMA – FASTING & PP, FASTING URINE, EDTA, MICRO SLIDE + (AGE & GENDER IS MANDATORY) | SERUM 2-8°C (<48 HRS); F (> 48 HRS); FLUORIDE PLASMA : 2-8°C (3 DAYS); SERUM : 2-8°C (2 DAYS), F (> 2 DAYS); URINE :2-8°C(24 HRS) | India | #N/A |
| 1587 | Z277K | OCT-2 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Octamer Binding Transcription Factor 2 (OCT2) is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 stains is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma (both markers expressed). Classical Hodgkin lymphoma stains as BOB1-OCT2+ or BOB1+ OCT2-, while nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) or diffuse large B-cell lymphoma (DLBCL) stains BOB1+ OCT2+. |
| 1588 | 1316 | OLIGOCLONAL BANDS, CSF | ISOELECTRIC FOCUSING WITH IMMUNOFIXATION | CSF & SERUM SAMPLE MUST BE COLLECTED SIMULTANEOUSLY ON SAME DAY AND SAME TIME (FOR PARALLEL TESTING) + (CLINICAL HISTORY, AGE & GENDER IS MANDATORY ). AVOID LIPEMIC & HEMOLYSED SPECIMEN | 2 – 8 °C(1 WEEK), F(1 MONTH) | India | Oligoclonal bands are present in less than 85% of patients with clinically definite Multiple Sclerosis. Ideally serum and CSF should be tested simultaneously to distinguish between production of oligoclonal bands due to peripheral gammopathy from that due to local production in the CNS. Other conditions which show oligoclonal bands are Subacute sclerosing panencephalitis, Inflammatory polyneuropathy, CNS Lupus and Brain tumors. |
| 1589 | RD1499 | ONCOFOCUS-NEXT | Next Generation Sequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | AMBIENT | India | N/A |
| 1590 | 3966 | ORGANIC ACID SCREEN,URINE | Gas Chromatography/Mass spectrometry (GC/MS)-semi quantitative analysis. | RANDOM URINE+ CLINICAL DETAILS AND MEDICATION TO BE PROVIDED ALONG WITH THE SPECIMEN. | F | India | The incidence of Inborn errors of Organic acid metabolism is approximately 1 in 3000 live births but in association with other defects like Amino acid & Urea cycle disorders, the incidence is 1 in 1000 live births. Organic acidurias can be acute life threatening illness in early infancy or unexplained development delays in later childhood. |
| 1591 | 3550 | OSTEOCALCIN (N MID) | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History |
2-8°C (3DAYS); F (3 MONTHS) |
India | Osteocalcin is the most important noncollagen protein in bone matrix. It is a marker of bone osteoblastic activity and is considered indicative of bone turnover rather than bone formation. This assay helps in monitoring and assessing effectiveness of antiresorptive therapy in patients treated for Osteopenia, Osteoporosis and Paget’s disease. It is also used as an adjunct in the diagnosis of medical conditions associated with increased bone turnover like bone metastasis, Primary hyperparathyroidis m & Renal osteodystrophy. |
| 1592 | 1060 | OSTEOMON (BETA CROSSLAPS & TOTAL P1NP) | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration]+ Clinical History | FROZEN: UP TO 3 MONTHS | India | OSTEOPORESIS MONITORING PANEL |
| 1593 | Z0150K | OSTEONECTIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help calssify bone tumors |
| 1594 | 1059 | OSTEOPOROSIS MONITORING (TOTAL P1NP) | ELECTROCHEMILUMINESCENCE | SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] + Clinical History | 2-8°C (5DAYS); F (> 5DAYS- 6 MONTH) | India | P1NP is a marker of osteoblastic activity and is increased in conditions like Paget’s disease, Osteoporosis, Primary / Secondary Hyperparathyroidis m & Osteomalacia. This test is used to monitor effectiveness of therapy, identify noncompliance amongst patients and predict fracture risk. |
| 1595 | 2363 | OVA & PARASITE: COCCIDIA EVALUATION | STAINING: MICROSCOPY | STOOL IN LEAK PROOF CONTAINER | 2-8°C (48 HRS) | India | To demonstrate coccidia ova or parasite |
| 1596 | 2362S | OVA & PARASITE: COMPREHENSIVE EXAMINATION WITH COCCIDIA EVALUATION | CONCENTRATION; MICROSCOPY; STAINING | STOOL IN LEAK PROOF CONTAINER | R | India | To demonstrate coccidia ova or parasite |
| 1597 | 7194 | OVARIAN MALIGNANCY RISK ALGORITHM (ROMA) | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | SERUM (Note:LMP or Pre or Post Menopausal status Mandatory required) | 2-8°C (4 DAYS); -20°C (>4 DAYS) | India | Risk of Ovarian Malignancy algorithm (ROMA) test is used as an aid in assessing the risk of Ovarian cancer in women with a pelvic mass based on patient’s HE4 & CA125 levels and their menopausal status. Women with ROMA levels above their cutoff have an increased risk of Ovarian cancer. ROMA must be interpreted in conjunction with clinical & radiological assessment. |
| 1598 | Z283K | P16 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Aids in the identification of human papilloma virus infectio |
| 1599 | Z008K | p53 (MUTANT WILD TYPE) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | used as a surrogate for mutational analysis in the diagnostic workup of carcinomas of multiple sites including ovarian cancers. |
| 1600 | Z255K | p63 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Aids in identifying squamous, urothelial, or myoepithelial differentiation in tumors |
| 1601 | RD1462 | PAN NEUROTROPIC VIRUS PANEL ( GOLD STANDARD IN DIAGNOSING ASEPTIC MENINGITIS & ENCEPHALITIS | Multiplex PCR | CSF + CLINICAL HISTORY | Frozen | India | To help diagnose ASEPTIC MENINGITIS & ENCEPHALITIS |
| 1602 | 3884 | Pancreatic Elastase Test(Fecal Elastase) | Enzyme Linked Immnunosorbent assay | STOOL | AMBIENT-5 DAYS, 2-8°C (7 DAYS); -20°C (>7 DAYS) | India | Pancreatic elastase remains undegraded during intestinal transit,thus reduced concentration in feces reflects exocrine pancreatic insufficiency caused by Chronic Pancreatitis, Diabetes Mellitus,Cholelithiasis, Cystic Fibrosis, Pancreatic Cancer, Celiac disease etc. It may also be used for monitoring patients on treatment for pancreatic insufficiency |
| 1603 | Z055K | PAN-CYTOKERATIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK (SITE OF BIOPSY & CLINICAL DETAILS MANDATORY) IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | to classify neoplasms of uncertain origin |
| 1604 | 9602 | PANFUNGAL DETECTION & IDENTIFICATION PANEL | PCR SEquencing | SPUTUM / CSF / FLUIDS / TISSUES + CLINICAL HISTORY | A | India | to detect and identify clinically relevant fungal pathogens using species specific probes. |
| 1605 | 9603 | PANFUNGAL DNA DETECTOR | PCR SEquencing | SPUTUM / CSF / FLUIDS / TISSUES + CLINICAL HISTORY | A | India | This assay is useful for the detection of fungi as a causative organism of a disease |
| 1606 | 1479 | PAP DUO + HYBRID | Diagen DNA Hybrid Capture and CYTOLOGY | LBC | A | India | Cervical cancer screening and HPV typing |
| 1607 | 1822 | PAP DUO- SUREPATH CYTOLOGY+ HPV-PCR |
CYTOLOGY/ POLYMERASE CHAIN REACTION | SPECIMEN FIXED IN THINPREP / SUREPATH PRESERVATIVE SOLUTION + CLINICAL HISTORY, AGE, LMP | 15 – 30 ºC | India | Cervical cancer screening and HPV typing |
| 1608 | 9216RFX | PAP SMEAR REFLEX TO HPV DETECTION(DNA DETECTOR) | CYTOLOGY/ POLYMERASE CHAIN REACTION | FIXED UNSTAINED SMEARS (FOR PAP) AND GENITAL SWABS / CERVICAL SCRAPINGS ON SLIDES + CLINICAL HISTORY & AGE & SEX |
A | India | Cervical cancer screening and HPV typing |
| 1609 | 1272 | PAP STAIN | CYTOLOGY | FIXED UNSTAINED SMEARS + CLINICAL HISTORY, AGE, LMP | A | India | Screening with Papanicoloau has substantially reduced the mortality rate due to Cervical cancer. Screening guidelines recommend regular PAP testing for all women greater than 21 years of age. At age 30, women who have had 3 normal test results in a row may get screened every 2 to 3 years.Women between 6570 years with no abnormal results in the previous 10 years can stop screening. Women after Total hysterectomy for noncancerous causes do not require screening. |
| 1610 | 1272P | PAP STAIN [PHOTO] | CYTOLOGY | FIXED UNSTAINED SMEARS + CLINICAL HISTORY, AGE, LMP | A | India | Cervical cancer screening |
| 1611 | 1564I | PARACETAMOL | COLORIMETRY | 1] Require SERUM sample.Mention time of drug dose. 2] Require Doctors Name and Contact details + Clinical history of the patient is mandatory. |
REFRIGERATED | India | To assess the concentration of Paracetamol |
| 1612 | 3861 | PARANEOPLASTIC DISORDER PROFILE ( HUABS, YOABS, RI ABS, PNMA2 ABS, AMPHIPHYSIN ABS) | IMMUNOBLOT | SERUM OR EDTA/HEPARIN/CITRATED PLASMA (CLINICAL HISTORY MANDATORY) | 2-8°C (14 days); -20°C (>14 days) | India | This assay detects antibodies against neuronal antigens in Paraneoplastic syndromes. It is used in the diagnosis of Paraneoplastic neurological autoimmune disorders related to carcinoma of lung, breast, ovary, Thymoma and Hodgkin lymphoma. |
| 1613 | 3305 | PARVOVIRUS B19 DNA PCR | POLYMERASE CHAIN REACTION | EDTA-PLASMA / WB-EDTA / BONE MARROW EDTA | R-WB/BONE MARROW, F-EDTA PLASMA | India | Parvovirus B19 (B19) is the only member of the family Parvoviridae known to be pathogenic in humans. The virus is widespread, and manifestations of infection vary with the immunologic and hematologic status of the host. Infection with B19 occurs early in life and virus is transmitted by respiratory secretions and occasionally by blood products. Infection in adults is sometimes associated with an acute symmetric polyarthropathy that may mimic Rheumatoid arthritis. |
| 1614 | 2067I | PARVOVIRUS B19 IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 DAYS); -20°C (>5 DAYS) | India | Parvovirus B19 is the causative agent of Fifth disease (Erythema infectiosum) which usually produces a mild illness. The virus is also associated with Hydrops fetalis, Aplastic crises and Arthralgia. Detection of IgG antibodies indicates past infection or immunity. IgG antibodies appear soon after onset of illness reaching peak levels by 30 days and may persist for years. |
| 1615 | 2068I | PARVOVIRUS B19 IgM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (5 DAYS); -20°C (>5 DAYS) | India | Parvovirus B19 is the causative agent of Fifth disease (Erythema infectiosum) which usually produces a mild illness. The virus is also associated with Hydrops fetalis, Aplastic crises and Arthralgia. Detection of IgM antibodies indicate recent infection. The antibodies appear soon after onset of illness and peak within 30 days. |
| 1616 | RD1424 | PATERNITY TESTING DUO | STR Analysis | EDTA WHOLE BLOOD + BUCCAL SWAB | AMBIENT | India | To establish the probability of paternity of the Child. |
| 1617 | RD1425 | PATERNITY TESTING TRIO | STR Analysis | EDTA WHOLE BLOOD + BUCCAL SWAB | AMBIENT | India | to help with the classification of genetic variants, including copy number variants. |
| 1618 | Z267K | PAX-5 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | PAX5 gene encodes B cell lineage Specific Activator Protein that is expressed in early but not late stages of B cell differentiation.It is used in the diagnosis of B cell Non Hodgkins Lymphomas & in Hodgkin Lymphoma. |
| 1619 | Z270K | PAX-8 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Aids in the identification of renal cell carcinomas, as well as papillary thyroid carcinomas and tumors of Mullerian origin |
| 1620 | Z010K | PCNA (IHC) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | #N/A |
| 1621 | 4806 | PDGFR PLUS (FIP1L1-PDGFRA GENE REARRANGEMENT AND TEL-PDGR BETA T(5;12) TRANSLOCATION) | Nested RT-PCR | EDTA WB / BONE MARROW EDTA | A | India | To help investigate the cause of hypereosinophilia (HE), a condition with persistent increase in the number of eosinophils, a specific type of white blood cell, or hypereosinophilic syndrome (HES), which is HE with associated tissue or organ damage; to help determine if someone with HE or HES can be treated with a tyrosine kinase inhibitor (TKI) such as imatinib. Identifying patients with chronic myelomonocytic leukemia and other hematologic disorders who may be responsive to imatinib mesylate. Identifying and tracking chromosome abnormalities and response to therapy |
| 1622 | 7749 | Penicillium chrysogenum – Specific IgG | ImmunoCAP | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | to determine IgG against Penicillium chrysogenum |
| 1623 | Z204 | PERIODIC ACID SCHIFF (PAS) STAIN | CYTOCHEMISTRY SPECIAL STAINS | BONE MARROW SMEAR + PERIPHERIAL SMEAR + CLINICAL HISTORY | A | India | to detect glycogen deposits, to demonstrate the thickness of glomerular basement membrane when renal disease is being assessed, is also used to demonstrate hyphae and yeast-forms of fungi in tissue samples. Etc. |
| 1624 | 1560 | PHENOBARBITAL | CHEMILUMINESCENCE | SERUM / PLASMA – EDTA , RESULTS FROM SPECIMEN COLLECTED 2 TO 4 HRS AFTER DOSE CAN BE MISLEADING. (TREATMENT HISTORY REQUIRED) | 2-8°C (48 hrs); F (>48 hrs) | India | Phenobarbitone is a CNS suppressant which has proven to be effective in the control of Generalized & Partial seizures. This assay is useful for monitoring appropriate therapeutic concentration and assessing compliance or toxicity. |
| 1625 | 9355 | PHENYLKETONURIA (PKU) > 1 MONTH | TMS | Dried blood spots | Ambient | India | To help diagnose PHENYLKETONURIA |
| 1626 | 4103 | PHENYTOIN (Dilantin) | CHEMILUMINESCENCE | SERUM / Plasma – EDTA OR HEPARINIZED, Specimen to be collected 4 – 5 hrs after dose. (Treatment history Required) | 2-8°C (48 hrs); F (>48 hrs) | India | Phenytoin is the drug of choice to treat and prevent TonicClonic & Psychomotor seizures. This assay is useful for monitoring appropriate therapeutic concentration and assessing compliance for toxicity. |
| 1627 | 5350 | PHILADELPHIA CHROMOSOME (BCR / abl qualitative) | REAL TIME PCR | BONE MARROW-EDTA/ WB- EDTA (SPECIMENS TO REACH US WITHIN 48 HRS) +CLINICAL HISTORY | A/R | India | BCRABL is a fusion gene formed by the rearrangement of breakpoint cluster region (BCR) on chromosome 22 with the ABL protooncogene on chromosome 9 leading to the formation of Philadelphia chromosome. This rearrangement is seen in almost 95% patients with CML. |
| 1628 | 5350QN | PHILADELPHIA CHROMOSOME (BCR/abl – quantitative) | REAL TIME PCR | WB-EDTA/ BONE MARROW-EDTA (SPECIMEN TO REACH US WITHIN 48 HRS)+CLINICAL HISTORY | A/R | India | BCRABL is a fusion gene formed by the rearrangement of breakpoint cluster region (BCR) on chromosome 22 with the ABL protooncogene on chromosome 9 leading to the formation of Philadelphia chromosome. This rearrangement is seen in almost 95% patients with CML. The Quantitative assay helps in the management of the disease and monitors effect of therapy. |
| 1629 | RD1318 | PHILADELPHIA CHROMOSOME (BCR/ABL BREAKPOINT ANALYSIS) | MULTIPLEX RT-PCR | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A/R – SAMPLE SHOULD REACH WITHIN 48 HRS | India | Aids in detection and discrimination of type of BCR-ABL1 fusion transcripts (major, minor and micro). |
| 1630 | 9892IS | PHILADELPHIA CHROMOSOME (BCR/ABL IS- INTERNATIONAL SCALE) | Real time PCR | WB-EDTA/BONE MARROW EDTA | AMBIENT/ REFRIGERATED | India | This test detects BCR/ABL p210 translocation (exon 2 or exon 3), and the ABL endogenous control |
| 1631 | 9892 | PHILADELPHIA CHROMOSOME (BCR-abl transcript quantification) | REAL TIME PCR | WB- EDTA / BM- EDTA (SPECIMEN TO REACH US WITHIN 48 HRS)+ CLINICAL HISTORY | A/R | India | BCRABL is a fusion gene formed by the rearrangement of breakpoint cluster region (BCR) on chromosome 22 with the ABL protooncogene on chromosome 9 leading to the formation of Philadelphia chromosome. This rearrangement is seen in almost 95% patients with CML. The Quantitative assay helps in the management of the disease and monitors effect of therapy. |
| 1632 | 3260 | PIGEON SERUM PROTEIN, FEATHER & DROPPINGS -SPECIFIC IgG | ImmunoCAP(FLUOROENZYME IMMUNOASSAY) | SERUM | 2-8°C (1 week); -20°C (>1 week) | India | This assay detects antibodies to Pigeon serum proteins, feathers and droppings. |
| 1633 | RD1437 | PIK3CA Gene Mutation | PCR Sequencing | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | AMBIENT | India | Mutations in the PIK3CA gene have been identified in carcinomas arising from colon, breast, ovary, liver, stomach, and lung as well as in Glioblastomas. Identification of the mutation helps in risk stratification and classification. |
| 1634 | Z222K | PIN 4 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | to help diagnose prostatic intraepithelial neoplasia (PIN) and/or prostate carcinoma |
| 1635 | Z239 | PITITUARY LESION HORMONES (Prolactin, Growth hormone, LH, FSH, ACTH,TSH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Classification of pituitary tumors |
| 1636 | 7927 | PLA2R1 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | To help diagnose Idiopathic Membranous Nephropathy |
| 1637 | Z074K | PLACENTAL ALKALINE PHOSPHATASE | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Aids in the identification of germ cell tumors |
| 1638 | 4332P | PLASMA OXALATE | SPECTROPHOTOMETERY | HEPARIN WHOLE BLOOD (CLINICAL HISTORY, AGE & GENDER IS MANDATORY) HEMOLYSED SPECIMEN NOT ACCEPTABLE. | 2-8°C | India | Assessing the body pool size of oxalate. |
| 1639 | 3216 | Plasma RENIN | RADIO IMMUNOASSAY | PLASMA-EDTA (CLINICAL HISTORY REQUIRED)(STANDING/ SUPINE) UPRIGHT POSTURE INDUCES A PROMPT ELEVATION IN PLASMA RENIN ACTIVITY BEGINNING IN 15MINUTES AND PEAKING BETWEEN 60 &120 MINUTES | FROZEN: UP TO 2 WEEKS | India | Renin is a proteolytic enzyme released from juxtaglomerular cells of the kidney. The enzyme cleaves a substrate to produce Angiotensin I which in turn produces Angiotensin II. This metabolite plays a key role in various forms of hypertension. Increased levels are seen in Renal hypertension, Addison’s disease and Secondary hypoaldosteronism . Low levels are detected in Hyporeninemic hypoaldosteronis m and Primary aldosteronism. |
| 1640 | 4069 | PLASMA VERY LONG CHAIN FATTY ACIDS | Stable isotope dilution Gas Chromatography Mass spectrometry | HEPARIN PLASMA | FROZEN | India | To help diagnose X-linked adrenoleukodystrophy (X-ALD) and other peroxisomal disorders. |
| 1641 | RD1432 | Plasminogen Activator Inhibitor-1 (PAI-1) / SERPINE-1, 4G/5G Genotyping | PCR Sequencing | WHOLE BLOOD EDTA | AMBIENT | India | Genetically, Rett syndrome (RTT) is caused by mutations in the gene MECP2 located on the X chromosome (which is involved in transcriptional silencing and epigenetic regulation of methylated DNA), and can arise sporadically or from germline mutations. In less than 10% of RTT cases, mutations in the genes CDKL5 or FOXG1 have also been found to resemble it. Rett syndrome is initially diagnosed by clinical observation, but the diagnosis is definitive when there is a genetic defect in the MECP2 gene. |
| 1642 | 5115 | PLATELET ANTIBODIES (SERUM,IMMUNOFLUORESCENCE) | IMMUNOFLUORESCENCE | SERUM | R/F | India | To help diagnose ITP |
| 1643 | 9905 | PML Ra Ra t(15:17), QUALITATIVE | REAL TIME PCR | WB-EDTA / BONE MARROW (SPECIMEN TO REACH US WITHIN 48 HRS)+CLINICAL HISTORY | A/R | India | Vast majority of cases of Acute Promyelocytic Leukemia (APL) have a translocation t(15;17)(q22;q122 1) which fuses the Promyelocytic gene (PML) on chromosome band 15q22 to the Retinoic acid receptor alpha (RARA) gene at 17q1221. This PML / RARA fusion is associated with a good response to all transretinoic acid therapy. |
| 1644 | 9906 | PML Ra Ra t(15:17), QUANTITATIVE | REAL TIME PCR | WB-EDTA / BONE MARROW (SPECIMEN TO REACH US WITHIN 48 HRS)+CLINICAL HISTORY | A/R | India | Vast majority of cases of Acute Promyelocytic Leukemia (APL) have a translocation t(15;17)(q22;q122 1) which fuses the Promyelocytic gene (PML) on chromosome band 15q22 to the Retinoic acid receptor alpha (RARA) gene at 17q1221. This assay is useful for montoring patients in which t(15;17) (q22;q12) has been detected. |
| 1645 | Z265K | PMS2 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ Site of biopsy and Clinical details MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Evaluation of tumor tissue to identify patients at risk for having hereditary nonpolyposis colon cancer/Lynch syndrome |
| 1646 | 7745S | PNEUMOCYSTIS CARINII DETECTION | SPECIAL STAINS: MICROSCOPY | SPUTUM / BAL RESPIRATORY FLUIDS | A/R/F | India | To help diagnose infection caused by PNEUMOCYSTIS CARINII |
| 1647 | 1672 | PNH (CD55 and CD59) | FLOW CYTOMETRY | EDTA WB + CLINICAL HISTORY | A | India | To help diagnose PNH |
| 1648 | 7669 | PNH TEST ON WHITE BLOOD CELLS [ANTI-CD45, CD14, CD15, CD24 AND CD64 ANTIBODIES, AND FLUOROSCENT AEROLYSIN (FLAER)] |
Flow Cytometry | BLOOD (EDTA) + CLINICAL HISTORY | Ambient (25 Degree Celcius) | India | To help diagnose PNH |
| 1649 | 9219RFX | POC FISH REFLEX TO POC KARYOTYPING | FISH OR CYTOGENETICS | IST TRIMESTER: CHORIONIC VILLI; 2ND OR IIIRD TRIMESTER: PLACENTAL VILLI. PLEASE SEND CLINICAL HISTORY IN SPECIFIED FORMAT- CHORIONIC VILLI OR HEART BLOOD OR CORD BLOOD IF NONE OF THESE ARE AVAILABLE, THEN A SMALL PIECE OF FOETAL SKIN (THIGH, STOMACH, ARMS) FOR CHROMOSOMAL ANALYSIS/FISH Don’t send full fetus ti the dept. |
A/R | India | To identify structural chromosome abnormality |
| 1650 | 4899 | POLLUTION ALLERGY PANEL | ImmunoCAP Specific IgE inhouse allergen | SERUM | 2-8°C (48 hrs), F (>48 hrs) | India | To help diagnose cause of allergy |
| 1651 | 1652 | PORPHOBILINOGEN QUANTITATIVE URINE, 24 HRS | ION EXCHANGE CHROMATOGRAPHY /SPECTROPHOTOMETRY | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION. TO BE PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARKED COLOURED BOTTLE. ( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY) | 2-8°C (7 DAYS); F (1 MONTH) | India | Urinary porphobilinogen is the first step in the diagnosis of Acute intermittent porphyria. An acute attack usually leads to gastrointestinal disturbance and neuropsychiatric disorders. |
| 1652 | 1653 | PORPHOBILINOGEN QUANTITATIVE URINE, Random | ION EXCHANGE CHROMATOGRAPHY /SPECTROPHOTOMETRY | RANDOM URINE WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION.TO BE PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARKED COLOURED BOTTLE. ( PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY) | 2-8°C (7 DAYS); F (1 MONTH) | India | Elevated values of VMA along with other catecholamine metabolites are suggestive of catecholamine secreting tumor like Neuroblastoma, Pheochromocytom a and other Neural crest tumors. VMA levels may also be useful in monitoring patients who are also treated. Elevated levels are suggestive of Pheochromocytoma but not diagnostic. |
| 1653 | 4170 | PORPHOBILINOGEN, URINE | CHEMICAL ANALYSIS | RANDOM URINE WITHOUT PRESERVATIVE TO PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARK COLOURED BOTTLE. (PATIENT AGE, GENDER AND CLINICAL HISTORY DETAILS.) (PATIENT AGE, GENDER AND CLINICAL HISTORY DETAILS.) | 2-8°C (7 DAYS); F (> 7 DAYS) | India | To help diagnose porphyrias |
| 1654 | 9999 | PORPHYRINS SPECIATION, 24HRS URINE | HPLC | 24HRS URINE (NO PRESERVATIVE).COLLECT 24HRS URINE SAMPLE IN BROWN BOTTLE. COURIER THE 25ML OF 24HRS URINE ALIQUOT IN DARK BROWN CONTAINER.MENTION 24HRS URINE VOLUME ON THE REQUISITION FORM. DOCTORS NAME AND CONTACT DETAILS REQUIRED. | F | India | Porphyrias are a diverse group of disorders characterized by accumulation of porphyrins & porphyrinogen. This assay is used in the differential diagnosis of Porphyrias. It is a preferred test during symptomatic period for Acute intermittent porphyria, Hereditary coproporphyria & Variegate porphyria. |
| 1655 | 4516 | PORPHYRINS, 24HRS URINE | ION EXCHANGE CHROMATOGRAPHY /SPECTROPHOTOMETRY | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION. TO BE PROTECT FROM LIGHT, THE URINE SPECIMEN NEEDS TO BE COLLECTED IN A DARKED COLOURED BOTTLE. ( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY IS MANDATORY) | 2-8°C (4 DAYS); F (1 MONTH) | India | To help diagnose and sometimes to monitor porphyrias |
| 1656 | 1550 | PREALBUMIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | To help detect protein-calorie malnutrition and to monitor the effectiveness of parenteral (for example, intravenous) nutrition. |
| 1657 | 1299 | PRE-ECLA | ELECTROCHEMILUMINESCENCE | Serum sample should be collected on Gestational Age > 20 weeks or in between > 20 to 37 weeks – Mandatory. SERUM in 2 vials (Clinical Details in specified format, Maternal Date of Birth, Maternal Weight, Latest Obstetric USG Report ) Mandatory SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] |
2-8°C (2 DAYS); F (> 2 DAYS) |
India | To determine the risk of pre-eclampsia |
| 1658 | 3300 | PREGNANCY ASSOCIATED Plasma PROTEIN-A (PAPP-A) | CHEMILUMINESCENCE | SERUM (Clinical Details ); LMP date required | 2-8°C (24 HRS); F (2 Months) | India | For pregnant women, to assess the risk of your baby having a chromosome disorder, such as Down syndrome (trisomy 21) or Edwards syndrome (trisomy 18) |
| 1659 | RD1492 | PRENAT-NEXT | Next Generation Sequencing | WHOLE BLOOD IN STRECK TUBES + CLINICAL/RISK HISTORY WITH APPROPRIATE DOCUMENTATION. CONTACT LAB FOR DETAILS ON DOCUMENTATION REQUIRED | Ambient | India | To identify structural chromosome abnormality |
| 1660 | 5067 | PRENAT-NGS (PRENATAL SCREENING–NEXT GENERATION) | Next Generation Sequencing | WHOLE BLOOD IN STRECK TUBES + CLINICAL/RISK HISTORY WITH APPROPRIATE DOCUMENTATION. CONTACT LAB FOR DETAILS ON DOCUMENTATION REQUIRED | Ambient | India | To identify structural chromosome abnormality |
| 1661 | 1297 | PRENAT-SCREEN | ELECTROCHEMILUMINESCENCE | SERUM in 2 vials (Clinical Details in specified format, Maternal TRF [Height, B.P. (Right & Left arm), Uterine arterial pressure: Pulsatility Index (Righ & Left) – Mandatory]. Obstetric USG Report between 10 to 13 weeks of gestation+Date of collection) along with patient specifications Mandatory SERUM [Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration] |
2-8°C (2 DAYS); F (> 2 DAYS) |
India | to find out if the fetus might have a genetic birth defect |
| 1662 | 3898 | PRE-OP ROUTINE COAGULATION PROFILE (PT, APTT, Platelet Count, Factor XIII Activity) | CLOT BASED / AUTOMATED CELL COUNTER / MICROSCOPY / CLOT SOLUBILITY | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C + *(DOUBLE CENTRIFUGED PLASMA)* WHOLE BLOOD EDTA + BLOOD SMEAR | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) +A | India | Routine test for couagulation abnormalities/ preoperative coagulation profile |
| 1663 | MGEN008 | Primary Hyperoxaluria Gene Panel | 0 | 0 | 0 | India | #N/A |
| 1664 | Z002K | PROGESTERONE RECEPTOR (PgR) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Guiding decisions on hormonal therapy in patients with breast carcinomas |
| 1665 | Z165K | PROLACTIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Subclassification of pituitary adenomas |
| 1666 | 1539 | PROSTATE SEXTANT BIOPSY |
HISTOPATHOLOGY | TISSUE IN 10%FORMALIN Clinical details and PSA Levels required. . |
A | India | To help diagnose prostatic lesions |
| 1667 | Z041K | PROSTATE SPECIFIC ANTIGEN (PSA) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Marker of glandular epithelium in normal and neoplastic prostate |
| 1668 | 3547 | PROSTATE SPECIFIC ANTIGEN (PSA) FREE & TOTAL | CHEMILUMINESCENCE | SERUM (AGE+SEX+ CLINICAL HISTORY REQUIRED) DO NOT SCHEDULE ANY PROSTATIC EXAMINATION / INSTRUMENTATION ATLEAST FOR 3 DAYS BEFORE BLOOD TEST IS PERFORMED. | 2-8°C (24 hrs); F (3 Months) | India | This assay aids in the early detection of Prostate cancer in males 50 years or older with Total PSA values between 4.0 and 10.0 ng/mL and nonsuspicious digital rectal examination. It also discriminates between Prostate cancer and Benign Prostatic disease. Patients with benign conditions have a higher proportion of Free PSA compared with Prostate cancer. |
| 1669 | 3836 | PROTEIN C ACTIVITY | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA* 2 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | This assay should be used as the initial test for evaluating patients suspected of Congenital Protein C deficiency including those with family history of thrombotic events. It also helps to identify decreased Functional Protein C of acquired origin e.g. due to oral anticoagulant effect, Vitamin K deficiency, Liver disease or DIC. |
| 1670 | 7164 | PROTEIN C ANTIGEN(CITRATED PLASMA, ELFA) | ELFA | Platelet Poor Citrated plasma | FROZEN | India | To help diagnose vitamin K deficiency, oral anticoagulation with coumarin compound, liver disease, DIC and other disorders. |
| 1671 | 9201RFXM | PROTEIN ELECTROPHORESIS REFLEX TO IMMUNOFIXATION | CAPILLARY ELECTROPHORESIS +IMMUNOELECTROPHORESIS | 10 -12 HRS FASTING SERUM (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 DAYS) | India | #N/A |
| 1672 | 1580C | PROTEIN ELECTROPHORESIS, CSF | ELECTROPHORESIS | CSF + (CLINICAL HISTORY, AGE & GENDER IS MANDATORY ). | 2-8°C (7 DAYS) | India | Protein electrophoresis evaluates the major protein fractions and determines if there are deficiencies or excesses as seen with Macroglobulinemia and Multiple Myloma. Immunofixation is useful in characterising M components. |
| 1673 | 1580M | PROTEIN ELECTROPHORESIS, SERUM | CAPILLARY ELECTROPHORESIS | 10 -12 HRS FASTING SERUM (LIPEMIC & HEMOLYSED SAMPLE SHOULD BE AVOIDED) + (CLINICAL HISTORY + AGE & GENDER IS MANDATORY) | 2-8°C (10 DAYS) | India | To help diagnose or monitor conditions that result in abnormal protein production or loss of protein |
| 1674 | 1580U | PROTEIN ELECTROPHORESIS, URINE | ELECTROPHORESIS | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION) + MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY DETAILS. | 2-8°C (7 DAYS) | India | Protein electrophoresis evaluates the presence of monoclonal gammopathy & renal damage in urine. |
| 1675 | 9201RFXU | PROTEIN ELECTROPHORESIS, URINE REFLEX TO IMMUNOFIXATION ELECTROPHORESIS, URINE | ELECTROPHORESIS +IMMUNOELECTROPHORESIS | URINE -24 HOURS WITHOUT PRESERVATIVE & REFRIGERATE DURING COLLECTION) + MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY DETAILS. | 2-8°C (7 DAYS) | India | To help diagnose or monitor conditions that result in abnormal protein production or loss of protein. |
| 1676 | 3837 | PROTEIN S ACTIVITY | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA* 2 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | This assay is used as an adjunct to initial testing based on the results of Protein S antigen assay. It helps in |
| 1677 | 1744 | PSEUDOCHOLINESTERASE | SPECTOPHOTOMETRY | SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C(2 DAYS); F (>2 DAYS) | India | Cholinesterase / Pseudocholinester ase assay is useful for monitoring exposure to Organophosphoru s insecticides. It also monitors patients with liver disease particularly those undergoing liver transplantation. However normal values are seen in Chronic hepatitis, mild Cirrhosis & Obstructive jaundice. |
| 1678 | RD1310RFX | PV Jak2 Reflex Panel | PCR-SEQUENCING | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY in specified format | A | India | To detect mutation in Jak2 |
| 1679 | DT3101 | PYRO-DETECT ( CBC, MP(Smear), MP antigen, ESR, CRP, Urinalysis, Stool Routine, WIDAL, Hepatic Profile, Blood Culture Preliminary & Final) | AUTOMATED CELL COUNTER, MICROSCOPY OF STAINED SMEAR, ,ENZYME CHROMATOGRAPHY, MODIFIED WESTERGREN,SPECTROPHOTOMETRY,NEPHELOMETRY, DIPSTICK & MICROSCOPY, AGGLUTINATION, BACTERIAL CULTURE & BIOCHEMICAL IDENTIFICATION REACTIONS, BACTERIAL | WB-EDTA, PERIPHERAL BLOOD SMEARS HEPARIN WB/WHOLE BLOOD SPS, SERUM 10-12 HRS FASTING, URINE, STOOL (ESR ON SITE) + (AGE & GENDER IS MANDATORY) | EDTA WB :A A R URINE 2-8°C(24 HRS) , SERUM 2-8°C (2 DAYS); F (> 2 DAYS) | India | To determine the cause of pyrexia of unknown origin |
| 1680 | 5062 | PYRUVATE, SERUM | Enzymatic | Serum | Frozen | India | Screening for possible disorders of mitochondrial metabolism |
| 1681 | 4199 | QUANTITATIVE D-DIMER | Immunoturbidometry | Plasma Citrate | Frozen | India | This assay is useful in the diagnosis of intravascular coagulation and fibrinolysis / DIC. It also has negative predictive value in excluding the diagnosis of Pulmonary embolism or Deep vein Thrombosis particularly when this assay is combined with clinical information. DDimer levels are increased in DIC / Intravascular coagulation, recent bleeding, hematoma,trauma, surgical operation and thromboembolism. High levels may also be seen in liver disease and malignancy. |
| 1682 | 4635M | RA TOTAL-(Anti-CCP,ANA,CRP(Quantitative),Rheumatoid factor quantitative) | NEPHELOMETRY/CMIA/EIA | SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | R/ FOR CRP & ASO 2-8°C (7 DAYS); F (3 MONTHS, IF F WITHIN 24 HRS OF COLLECTION). | India | Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. Serum antibodies to Cyclic citrullinated peptides (Anti CCP) are now recognised to be a valuable marker of diagnostic and prognostic significance. ANA’s occur both in systemic and organ specific autoimmune diseases showing positivity in Rheumatoid arthritis. There is incremental value in testing for presence of both Rheumatoid factor (RF) and Anti CCP as some patients with RA are positive for RF but negative for Anti CCP and vice versa. |
| 1683 | 2333 | RAAS SCREENING PANEL (Plasma Renin, Aldosterone) | RADIO IMMUNOASSAY | PLASMA-EDTA & SERUM (CLINICAL HISTORY REQUIRED) (STANDING/ SUPINE) UPRIGHT POSTURE INDUCES A PROMPT ELEVATION IN PLASMA RENIN ACTIVITY BEGINNING IN 15MINUTES AND PEAKING BETWEEN 60 &120 MINUTES | FROZEN: UP TO 2 WEEKS | India | This ratio can be used as a screening test in cases of severe hypertension. The ratio allows detection of cases of Primary Aldosteronism in normokalemic patients. |
| 1684 | 7664R | RAPID FILARIA ANTIGEN DETECTION | IMMUNOCHROMATOGRAPHY | SERUM/PLASMA HEPARIN | 2-8°C (3 days)>3 days -20°C | India | Filariasis is a disease resulting from parasitization by thread like of filiform worms called filariae. The embryos circulate in lymphatic tissues and blood as microfilaria leading to Lymphangitis, Lymphadenitis, Elephantiasis and Tropical eosinophilia. |
| 1685 | 3523 | RBC FOLATE | CHEMILUMINESCENCE | 2 TUBES OF WB-EDTA+CLINICAL HISTORY | ONE EDTA BLOOD SAMPLE TO BE KEPT AT 2-8°C ONLY , FOR SECOND EDTA SAMPLE 2-8°C (24 HRS) AND F (>24 HOURS) | India | Serum folate concentrations are affected by diet whereas RBC folate is a more reliable indicator of folate status. This assay is useful for identification of folate deficiency when serum folate is normal but there is a high clinical suspicion of nutritional deficiency. It is used in the evaluation of individuals with low serum levels of both folate and iron. |
| 1686 | 8881 | RECIPIENT ANTIBODY STATUS (POS/NEG)(PRA SCREEN) | LUMINEX BASED | RECIPIENT SERUM IN PLAIN VIAL | Cold | India | Test is a qualitative test to find out patient’s sensitization against anti-HLA antibodies through previous transplants, transfusions, infections and pregnancy. Test is used for regular follow up of patients waiting for solid organ transplantation and also for post transplant follow up. |
| 1687 | 1253AM | RECURRENT MISCARRIAGE PANEL (Protein C, Protein S, Lupus Antigoagulent, Antiphospholipid Antibody, Serum Homocystein, Anti Thrombin III Activity) [To be ordered with Factor V leiden (# 9894) if required ] which will be charged separately | CLOT BASED / CHEMILUMINESCENCE/CHROMOGENIC ASSAY/ENZYME IMMUNOASSAY | FASTING SERUM /PLASMA (Centrfuge samples and remove SERUM or plasma from red blood cells as soon as possible to ensure accurate measurement.) AND CITRATED PLATELET POOR PLASMA* 2 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA) + CLINICAL HISTORY | HOMOCYSTEINE:2-8°C (48 hrs); F (>48 hrs)A/R/F AND F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | To determine the cause of recurrent miscarriage |
| 1688 | 2365 | REDUCING SUBSTANCES, STOOL | QUALITATIVE CHEMICAL ANALYSIS | STOOL IN LEAK PROOF CONTAINER | A / R | India | To help diagnose lactose intolerance (and some rare metabolic abnormalities) |
| 1689 | RD1441 | RET GENE MUTATIONS | PCR SEQUENCING | EDTA WHOLE BLOOD | A | India | Genetically, Rett syndrome (RTT) is caused by mutations in the gene MECP2 located on the X chromosome (which is involved in transcriptional silencing and epigenetic regulation of methylated DNA), and can arise sporadically or from germline mutations. In less than 10% of RTT cases, mutations in the genes CDKL5 or FOXG1 have also been found to resemble it. Rett syndrome is initially diagnosed by clinical observation, but the diagnosis is definitive when there is a genetic defect in the MECP2 gene. |
| 1690 | 4520 | RETINOL BINDING PROTEIN (RBP) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | This assay is useful for diagnosing Vitamin A deficiency & toxicity and for monitoring therapy. It evaluates persons with intestinal malabsorption of lipids. Vitamin A deficiency can leads to blindness whereas chronic intoxication can affect several organs. Known HIV positive patients with Vitamin A deficiency show increased disease progression and mortality. |
| 1691 | 1500R | RETURN OF PARAFFIN BLOCK / SLIDE | HISTOPATHOLOGY | BLOCK/ SLIDE | A | India | N/A |
| 1692 | 5008 | RHEUMATOID ARTHARITIS PANEL (ANA, RHEUMATOID FACTOR, ANTI CCP) | NEPHELOMETRY | 12 -14 HRS FASTING SERUM (LIPEMIC SAMPLE SHOULD BE AVOIDED) + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. Serum antibodies to Cyclic citrullinated peptides (Anti CCP) are now recognised to be a valuable marker of diagnostic and prognostic significance. ANA’s occur both in systemic and organ specific autoimmune diseases showing positivity in Rheumatoid arthritis. There is incremental value in testing for presence of both Rheumatoid factor (RF) and Anti CCP as some patients with RA are positive for RF but negative for Anti CCP and vice versa. |
| 1693 | 1074 | RHEUMATOLOGY PROFILE – 1 (Rheumatology Profile – 2, DSDNA TITRE) | IMMUNOBLOT / FARR RADIOBINDING ASSAY | SERUM IN 2 VIALS 1 AMBIENT+ 1 REFRIGERATED | A/R/F | India | To help diagnose SLE. |
| 1694 | 1075 | RHEUMATOLOGY PROFILE – 2 (SM ABS, U1SNRNP ABS, SS-A ABS, SS-B ABS) | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. Being a systemic disease, RA can result in a variety of extraarticular manifestations. ANA’s occur both in systemic and organ specific autoimmune disease showing positivity in Rheumatoid arthritis, Scleroderma, Sjogren’s syndrome, Mixed connective tissue disease and CREST syndrome. |
| 1695 | 5017 | RICKETSSIA PCR | Real Time PCR | EDTA Whole Blood. Specimen should reach SRL,Mumbai preferably within 24hrs of collection. | REFRIGERATED | India | To help diagnose a infection caused by Ricketssia |
| 1696 | 4637A | RMP TOTAL (Protein C Activity, FREE PROTEIN S, LUPUS ANTICOAGULANT Factor VIII SCREENING PROFILE, HOMOCYSTEINE, Antithrombin III activity, Anticardiolipin antibody, Factor V Leiden, ANTI ß2 GLYCOPROTEIN 1 IGM/ IGG, FACTOR VIII ACTIVITY) | CLOT BASED/ CHEMILUMINESCENCE/ CHROMOGENIC ASSAY/ ENZYME IMMUNOASSAY/ PCR SEQUENCING | FASTING SERUM, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C *(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY+ EDTA WHOLE BLOOD | FROZEN (To be F immediately at -20°C & transported in dry ice) | India | To assess coagulation abnormalities |
| 1697 | 4571 | ROS-1 GENE REARRANGEMENT BY FISH | FISH | BLOCKS.PLEASE PROVIDE THE HISTOPATHOLOGY REPORT AND CLINICAL HISTORY ALONG WITH THE BLOCKS. | AMBIENT | India | The cros oncogene 1 (ROS1), originally described in Glioblastomas, has been identified as a potential relevant therapeutic target in lung Adenocarcinoma. Crizotinib has shown in vitro activity and early evidence of clinical activity in ROS1rearrang ed tumors. FISH is bettersuited than molecular testing to detect the spectrum of variants of ROS1 gene. It has seven chromosomesdescribed so far in NonSmall Cell Lung Carcinoma (NSCLC). While molecular assays must be designed to individual and unique fusions, FISH detection encompasses all described and asyet undescribed rearrangements. |
| 1698 | Z225 | ROUND CELL TUMOURS (ADULTS) – 2 (HMB45, MPO, S-100P) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Classification of round cell tumors |
| 1699 | 1478 | RPL (RECURRENT PREGNENCY LOSS PANEL) PANEL | CELL CULTURE FOR CHROMOSOMAL ANALYSIS, CLOT BASED & ENZYME IMMUNOASSAY | FASTING, CITRATED PLASMA – AT MINUS 20° C + SERUM, WB- HEPARIN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY*(DOUBLE CENTRIFUGED PLASMA) | F/A/A/A | India | To determine the cause of recurrent pregnancy loss |
| 1700 | 3963 | RSV-Respiratory Syncytial Virus IgG(Serum,EIA) | Immunofluorescence | SERUM | R/F | India | RSV causes an Influenza like illness which is severe in infants, young children and older adults. It is the most common cause of Bronchiolitis & pneumoniae in children below 1 year of age. |
| 1701 | 3964 | RSV-RESPIRATORY SYNCYTIAL VIRUS -IGM (SERUM,EIA) | Immunofluorescence | SERUM | R/F | India | To help diagnose a infection caused by RESPIRATORY SYNCYTIAL VIRUS |
| 1702 | 9434 | RUBELLA IGG AVIDITY | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (4 DAYS); -20°C (>4 DAYS) | India | Avidity test helps in discriminating primary infection & reinfection. Avidity indices less than 30% is an indication of current infection. |
| 1703 | 9217RFX | RUBELLA IGM / IGG +VE REFLEX RUBELLA RNA PCR | Enzyme Linked Immnunosorbent assay + NESTED REVERSE TRANSCRIPTASE PCR | SERUM + EDTA PLASMA / CSF / AMNIOTIC FLUID NASOPHARYNGEAL SWAB | A/R/F + F | India | To help diagnose a infection caused by Rubella |
| 1704 | 9415 | RUBELLA RNA PCR | NESTED REVERSE TRANSCRIPTASE PCR | EDTA PLASMA / CSF / AMNIOTIC FLUID / NASOPHARYNGEAL SWAB | F | India | This assay detects the presence of Rubella virus in the sample provided |
| 1705 | Z061K | S-100 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Aids in the identification of various neoplasms. S-100 expression is seen in cartilaginous tumors, myoepithelial tumors, Schwann cells and neural tumors, Langerhans cell proliferations, benign and malignant melanocytes, clear cell sarcoma, and some carcinomas |
| 1706 | Z217K | S-100 PROTEIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Aids in the identification of various neoplasms. S-100 expression is seen in cartilaginous tumors, myoepithelial tumors, Schwann cells and neural tumors, Langerhans cell proliferations, benign and malignant melanocytes, clear cell sarcoma, and some carcinomas. |
| 1707 | 9442 | SALICYLATE | SPECTOPHOTOMETRY | SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C(2 WEEKS); F (6 MONTHS) | India | To measure the concentration in the blood, to detect and/or monitor an overdose (salicylate poisoning) |
| 1708 | RD1412 | SCA 1 (SPINAL CEREBRAL ATAXIA TYPE-1) | PCR – FRAGMENT ANALYSIS | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | To detect CAG trinucleotide repeats in the SCA1 (ATXN1) gene. |
| 1709 | 4593 | SCA PANEL (SCA TYPE -1,12,2,3,6) | PCR/ Fragment Analysis | EDTA WHOLE BLOOD | A | India | To help diagnose types of Spinocerebellar ataxia |
| 1710 | 1235 | Scl-70 IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Scl70 antibodies are considered to be specific for Scleroderma and are found in nearly 60% of these patients. They are more common in patients with extensive cutaneous involvement and Interstitial pulmonary fibrosis and their presence is a poor prognostic indicator. |
| 1711 | 5003 | SCLERODERMA DIAGNOSTIC PANEL (ANA,U1 Sm RNP,CENTROMERE ABS,SCLERODERMA -70 IgG | IFA/IMMUNOBLOT | SERUM | 2-8°C (3 DAYS); -20°C (>3 DAYS OR SHIPPED) FOR ANA | India | Antibodies to Scl70 (DNA topoisomerase I) are detected in nearly 75% patients with Progressive Systemic Sclerosis (PSS). Patients of Scleroderma with Scl70 antibody positivity are associated with diffuse cutaneous involvement, increased frequency of pulmonary fibrosis and high mortality Centromere antibodies are most often associated with lower frequency of pulmonary fibrosis and mortality although an increased risk for pulmonary hypertension has been observed. |
| 1712 | 1739 | Scrub Typhus Antibody | Immunochromatograpy | SERUM/PLASMA (Heparin/ EDTA/ Sodium citrate) | 2-8°C (3 DAYS); -20°C (>3 DAYS) | India | To help diagnose a infection caused by Scrub Typhus |
| 1713 | 1739E | Scrub Typhus IgM Antibody | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (48 HRS); -20°C >48 HRS) | India | To help diagnose a infection caused by Scrub Typhus |
| 1714 | 7153 | SdLDL; SMALL DENSE LDL | SPECTROPHOTOMETRY | SERUM-12-14 HRS FASTING (AGE & GENDER IS MANDATORY) | F | India | LDL Cholesterol circulates as large buoyant (pattern A), intermediate & dense particles (pattern B). Compared to individuals with pattern A, individuals with pattern B have an increased risk of cardiovascular diseases and may respond more favourably to lipid lowering therapy. |
| 1715 | 9140U | SELENIUM URINE SPOT | GFAAS WITH ZEEMAN CORRECTION | SPOT URINE IN STERILE PLASTIC URINE CONTAINER AVAILABLE FROM SRL (10-20 ml) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (5 DAYS); F ( >5 – 30 DAYS) | India | Selenium is an essential element found in many over the counter vitamin preparations because its antioxidant activity is thought to be anticarcinogenic. Selenium deficiency targets cardiac muscle leading to Cardiomyopathy. This assay is useful for monitoring Selenium replacement therapy specially patients with no functional bowel, on parenteral selenium supplementation. Urine quantitation helps to assess clearance of Selenium. |
| 1716 | 9140U24 | SELENIUM, 24 HRS URINE | GFAAS WITH ZEEMAN CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE) ALIQUOT. IN METAL FREE SCINTILLATION VIAL AVAILABLE OR STERILE URINE CONTAINER BOTH AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F ( >5 – 30 DAYS) | India | Selenium is an essential element found in many over the counter vitamin preparations because its antioxidant activity is thought to be anticarcinogenic. Selenium deficiency targets cardiac muscle leading to Cardiomyopathy. This assay is useful for monitoring Selenium replacement therapy specially patients with no functional bowel, on parenteral selenium supplementation. Urine quantitation helps to assess clearance of Selenium. |
| 1717 | 9140 | SELENIUM, BLOOD | GFAAS WITH ZEEMAN CORRECTION | IMPROVE/BD, SRL EDTA VACCUTAINER, WHOLE BLOOD | 2-8°C (7 DAYS); F ( >7 – 30 DAYS) | India | Selenium is an essential element found in many over the counter vitamin preparations because its antioxidant activity is thought to be anticarcinogenic. Selenium deficiency targets cardiac muscle leading to Cardiomyopathy. This assay is useful for monitoring Selenium replacement therapy specially patients with no functional bowel, on parenteral selenium supplementation. |
| 1718 | 9140S | SELENIUM, SERUM | ICPMS | BD RED TOP VACCUTAINER AVAILABLE FROM SRL MUMBAI, CENTRIFUGE, SEPARATE SERUM IN MULTIPURPOSE VIAL AVAILABLE FROM SRL MUMBAI, PERCOLATE, DO NOT USE PIPETE | 2-8°C (7DAYS); FROZEN (>7 -30 DAYS) | India | To screen for deficiency / toxicity due to selenium |
| 1719 | RD1474 | SEPSISCREEN | PCR-Sequencing | (CSF, BAL, AF, PF, Aspirates & Tissue Biopsy) | AMBIENT | India | To help diagnose sepsis |
| 1720 | 7690 | SEROTONIN | ELISA | SERUM | FROZEN | India | Serotonin concentrations are increased in patients with Carcinoid syndrome. Carcinoid tumors are associated with Multiple Endocrine Neoplasia (MEN) types I & II. These tumors are associated with flushing, diarrhoea, pain and other symptoms. |
| 1721 | 7690U | SEROTONIN ,5-HYDROXY TRYPTAMINE URINE | ENZYME IMMUNOASSAY | Spot Urine or 24 hr urine (no preservative). Mention 24 hrs urine volume on the test requisition form. Specimens should be strictly sent in frozen condition. | FROZEN STRICTLY | India | The diagnosis of a small subgroup of carcinoid tumors that produce predominately 5-hydroxytryptophan (5-HTP), but very little serotonin and chromogranin A. Follow-up of patients with known or treated carcinoid tumors that produce predominately 5-HTP, but very little serotonin and chromogranin A |
| 1722 | 1732 | SERUM FREE LIGHT CHAIN (Free Light Chain Kappa, Free Light Chain Lambda, Kappa/Lambda Ratio) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (21 DAYS) | India | To help detect, diagnose, and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, primary amyloidosis, and related diseases or to monitor the effectiveness of treatment |
| 1723 | 8034 | SERUM LIPOPROTEIN ELECTROPHORESIS | ELECTROPHORESIS | FASTING SERUM | STRICTLY REFRIGERATED | India | To determine abnormal distribution and concentration of lipoproteins in the serum |
| 1724 | 3218 | SEX HORMONE BINDING GLOBULIN (SHBG) | CHEMILUMINESCENCE | SERUM + CLINICAL HISTORY (AGE/GENDER) | 2-8°C (7 DAYS); F (2 Months) | India | This assay is useful for diagnosis and followup of women with signs and symptoms of androgen excess like Polycystic ovarian syndrome and Idiopathic hirsutism. It is an adjunct in monitoring sex steroid and antiandrogen therapy, diagnosis of disorders of puberty / Thyrotoxicosis and diagnosis & followup of Anorexia nervosa. |
| 1725 | 2488 | SICKLE CELL DNA PCR | PCR | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | The genetic disorder is due to the mutation of a single nucleotide, from a GAG to GTG codon on the coding strand. In people heterozygous for HgbS (carriers of sickling haemoglobin), the polymerisation problems are minor, because the normal allele is able to produce over 50% of the haemoglobin. In people homozygous for HgbS, the presence of longchain polymers of HbS distort the shape of the red blood cell from a smooth doughnutlike shape to ragged and full of spikes, making it fragile and susceptible to breaking within capillaries |
| 1726 | 2489 | SICKLE CELL DNA PCR PND | PCR | AMNIOTIC FLUID (2-8 °C) (A) / CVS IN STERILE SALINE / FETAL BLOOD EDTA & WB-EDTA FOR BOTH PARENTS MANDATORY + CLINICAL HISTORY | AMNIOTIC FLUID/ CVS AT 2-8 °C,REST AMBIENT | India | This assay is useful for the detection of GAG to GTG mutation in amniotic fluid/CVS of the fetus for determining the status of the mutation |
| 1727 | 2486 | SICKLE SHORT PROGRAM SICKLE CELL VARIANT ANALYSIS, BLOOD SPOT | HPLC | 3-4 DRIED BLOOD SPOT | A | India | To help diagnose sickle cell variant |
| 1728 | 8884 | SINGLE ANTIGEN BEAD CLASS I (ABC LOCI) | LUMINEX BASED | RECIPIENT SERUM IN PLAIN VIAL | Cold | India | To detect anti HLA IgG antibodies in the patient and allow for a precise, highly sensitive determination of a patient’s antibody profile. |
| 1729 | 8885 | SINGLE ANTIGEN BEAD CLASS II (DR ,DQ & DP LOCI) | LUMINEX BASED | RECIPIENT SERUM IN PLAIN VIAL | Cold | India | To detect anti HLA IgG antibodies in the patient and allow for a precise, highly sensitive determination of a patient’s antibody profile |
| 1730 | 7166 | SIROLIMUS, EDTA/HEPARIN WHOLE BLOOD | LCMSMS | 1] Require EDTA/Heparin Whole Blood to be collected directly in relevant vaccutainers only, [Label with time of collection and administration of drug, preferably with drug dose.] 2] DOCTOR CONTACT DETAILS AND CLINICAL HISTORY IS MANDATORY |
2-8ºC | India | Sirolimus is an immunosuppressa nt drug used either in addition to Cyclosporine or Tacrolimus or as a substitute in patients intolerant to these drugs. This assay monitors Sirolimus concentration during therapy particularly in individuals coadministered CYP3A4 substrates, inhibitors or inducers. The assay helps to evaluate patient compliance, adjust dose to optimize immunosuppressio n while minimizing toxicity. |
| 1731 | 1528S | Skin Biopsy with IFA | IMMUNO FLUORESCENT ASSAY / HP | TISSUE IN MICHEL’S TRANSPORT MEDIA (IFA) + 10% NEUTRAL BUFFERED FORMALIN FIXED TISSUE (HP) + CLINICAL DETAILS & RENAL FUNCTION TEST WITH 24 HOURS URINARY PROTEIN VALUE & URIN REPORT. | A | India | Histopathological processing of specimen with final interpretation (skin). |
| 1732 | 5004 | SLE DIAGNOSTIC PANEL (ANA & DsDNA WITH TITRE) | IMMUNOFLUORESCENT ASSAY | SERUM | R + F | India | To help diagnose SLE |
| 1733 | 7139 | SMALL DENSE LDL COMBO | SPECTROPHOTOMETRY | SERUM-12-14 HRS FASTING (AGE & GENDER IS MANDATORY) | F | India | To measure small dense LDL particles which is associated with an increased risk of coronary artery disease |
| 1734 | 1220 | SMITH (Sm) IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | Smith antibodies are specific for Lupus erythematosus occuring in nearly 30%of these patients. It is a component of extractable nuclear antigens also seen in other connective tissue disorders. This assay is useful for evaluating patients with signs and symptoms of a connective tissue disorder in whom ANA is positive. |
| 1735 | Z092K | SMOOTH MUSCLE ACTIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Identification of cells expressing the alpha-smooth muscle isoform of actin |
| 1736 | RD1504 | SOLID TUMOR DNA PROFILER NEXT | NGS | PARAFFIN BLOCK +CLINICAL HISTORY | A | India | To detect rare mutations and tumor subclones. |
| 1737 | RD1505 | SOLID TUMOR RNA PROFILER NEXT | NGS | PARAFFIN BLOCK +CLINICAL HISTORY | A | India | To detect rare mutations and tumor subclones |
| 1738 | 4523 | SOLUBLE TRANSFERRIN RECEPTOR( sTFR) | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (8 DAYS); F (>8 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | To detect iron deficiency anemia and distinguish it from anemia caused by chronic illness or inflammation |
| 1739 | Z203K | SPECIAL STAINS – ANY ONE (PAS/MUCICARMINE/CONGORED/RETICULIN/AFB/GMS/PRUSSIAN BLUE/MASSON/LUXOL FAST BLUE/ FITE FARRACO/ELASTIC STAIN/GIEMSA/ALCIAN BLUE ) | HISTOPATHOLOGY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK (PLEASE LET US KNOW THE SITE OF BIOPSY & CLINICAL DETAILS) | A | India | STAINS GLYCOGEN & MUCIN |
| 1740 | 9444 | SPERM DNA FRAGMENTATION | INDIRECT ASSAY USING ACRIDINE ORANGE BY FLOW CYTOMETRY | INSTRUCTION: 1. . Semen volume required: 2-3 ml. 2. Temperature and Stability: – 20 degree (Frozen) for 10 days. Specimen should be forwarded to SRL,Mumbai, preferably within 24hrs of collection between Monday 09:00hrs to Friday 09:00hrs, strictly in frozen condition. 3. Sperm count report or any other test related reports , marital status, smoking and any other medical complications if any details required. Preferably 3 days abstinence is mandatory for good results. |
FROZEN | India | To denote abnormal genetic material within the sperm |
| 1741 | MGEN003 | Spinal Muscular Atrophy Gene Panel | 0 | 0 | 0 | India | #N/A |
| 1742 | 8764 | SPINAL MUSCULAR ATROPHY MICRODELETION PCR | PCR SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | SMA of all types is associated with homozygous mutations in the survival motor neuron 1 gene (SMN1). This test detects homozygous deletion of SMN1 Exon 7 and or Exon 8 which accounts for 95% of SMA. |
| 1743 | 8765 | SPINAL MUSCULAR ATROPHY MICRODELETION PCR PNDT | PCR SEQUENCING | EDTA WHOLE BLOOD/AMNIOTIC FLUID/CVS IN STERILE SALINE/FETAL BLOOD (EDTA) – AMNIOTIC FLUID/CVS IN STERILE SALINE/FETAL BLOOD (EDTA) & EDTA WHOLE BLOOD FOR BOTH PARENTS+ CLINICAL HISTORY | ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | SMA of all types is associated with homozygous mutations in the survival motor neuron 1 gene (SMN1). This test detects homozygous deletion of SMN1 Exon 7 and or Exon 8 which accounts for 95% of SMA. It detects both active and carrier status of the disease. |
| 1744 | 9940 | SPORTS GENE TEST (ACTN3 Genotyping) | PCR-SEQUENCING | EDTA WHOLE BLOOD/ BUCCAL SWAB | A | India | To determine genetic predisposition to engage in endurance or power sports. |
| 1745 | 6025F | SRY by FISH | FISH | HEPARIN WHOLE BLOOD | AMBIENT | India | SRY (sex reversal Y) probe detects deletion in Yp11.3 that may be related to gonadal dysgenesis or sex reversal. |
| 1746 | 6030F | SS18 (SYT) Gene Rearrangement FISH | FISH | BIOPSIES SOULD BE FIXED FOR 24-48 HOURS IN 10% BUFFERED FORMALIN & EMBEDDED IN PARAFFIN. TISSUE SHOULD BE 4 MICRONS THICK & PLACED ON POSITIVELY CHARGED SLIDES. 3 SLIDES / SAMPLES CONTAINING MALIGNANT TISSUE. * TIME AND DURATION OF FIXATION SHOULD BE MENTIONED ON THE TRF.* clinical details in specified format | A | India | Synovial Sarcoma accounts for 510% of softtissue sarcomas. They harbor the t(X;18)(p11.2;q11. 2), resulting in the fusion of the SYT gene at 18q11 with either the SSX1 or the SSX2 gene (or, rarely, SSX4), which is a primary cytogenetic anomaly in 90% of the cases. Detection of this translocation is highly specific for Synovial Sarcoma. Breakapart rearrangement assays by FISH have been found more suitable for detection of the t(X;18) in Synovial sarcoma, given the presence of multiple partner loci. |
| 1747 | 1007 | SS-A (Ro) & SS-B (La) IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | SSA/Ro & SSB/La are extractable nuclear antigens. SSA/Ro antibodies occur in patients with Sjogren’s syndrome (90%), Lupus erythematosus (4060%) & Rheumatoid arthritis. SSB/La antibodies occur in patients with Sjogren’s syndrome (60%) &Lupus erythematosus (15%). This assay is useful for evaluating patients with signs and symptoms of connective tissue disorder in whom ANA is positive. |
| 1748 | 1204 | SS-A (Ro) IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | SSA/Ro is an extractable nuclear antigen with antibodies occuring in patients with Sjogren’s syndrome (90%), Lupus erythematosus (4060%) & Rheumatoid arthritis. This assay is useful for evaluating patients with signs and symptoms of connective tissue disorder in whom ANA is positive. |
| 1749 | 1205 | SS-B (La) IgG ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | SSB/La is an extractable nuclear antigen with antibodies occuring in patients with Sjogren’s syndrome (60%) & Lupus erythematosus (15%). This assay is useful for evaluating patients with signs and symptoms of connective tissue disorder in whom ANA is positive. |
| 1750 | 5005 | STD DIAGNOSTIC PANEL (C TRACHOMATIS DNA DETECTOR, HPV DNA DETECTOR, HSV DNA DETECTOR ) | POLYMERASE CHAIN REACTION | SWABS / PARAFFIN BLOCK /SLIDES /CSF,URINE IN STERILE CONTAINER | A/R/F | India | Sexually transmitted diseases (STD) affect adults worldwide and many individuals are at risk for complications. These are the most common of all infectious diseases with >30 infections now being classified as predominantly sexually transmitted or as frequently sexually transmissible. Chlamydial infections & genital Herpes can spread widely even in relatively low risk populations. |
| 1751 | 9223RFX | STOOL ROUTINE REFLEX TO GIARDIA/CRYPTOSPIRA/ROTAVIRUS ANTIGEN | MICROSCOPY + ANTIGEN DETECTION BY RAPID IMMUNOCHROMATOGRAPHY | STOOL IN LEAK PROOF CONTAINER | A/R | India | To help diagnose an infection caused by GIARDIA/CRYPTOSPIRA/ROTAVIRUS |
| 1752 | 2368 | STOOL-HANGING DROP (FOR WALK-IN PATIENTS ONLY) | MICROSCOPY | RICE-WATERY STOOL IN STERILE LEAK PROOF CONTAINER | A | India | A confirmatory test to identify if an organism is motile or non motile |
| 1753 | 9641 | STREPTOCOCCUS GROUP B ANTIGEN | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | Streptococcus Group B is the most common cause of Neonatal Sepsis. Early identification is of considrable value in providing patients with appropriate antibiotic therapy. |
| 1754 | 9641C | STREPTOCOCCUS GROUP B ANTIGEN, CSF | LATEX PARTICLE AGGLUTINATION | CSF | 2-8°C (FEW HRS); -20°C (LONGER) | India | To help diagnose an infection caused by Streptococcus B |
| 1755 | 9636 | STREPTOCOCCUS PNEUMONIAE ANTIGEN | LATEX PARTICLE AGGLUTINATION | SERUM | 2-8°C (FEW HRS); -20°C (LONGER) | India | To help diagnose an infection caused by Streptococcus Pneumonia; |
| 1756 | 9636C | STREPTOCOCCUS PNEUMONIAE ANTIGEN, CSF | LATEX PARTICLE AGGLUTINATION | CSF | 2-8°C (FEW HRS); -20°C (LONGER) | India | To help diagnose an infection caused by Streptococcus Pneumonia. |
| 1757 | 3831 | SUCROSE LYSIS TEST | HEMOLYSIS | EDTA WB | A | India | Screening test for paroxysmal nocturnal hemoglobinuria |
| 1758 | Z205 | SUDAN BLACK STAIN , BLOOD/SMEAR | CYTOCHEMISTRY SPECIAL STAINS | BONE MARROW SMEAR + PERIPHERIAL SMEAR + CLINICAL HISTORY | A | India | Herpes Simplex Virus Type 1 (HSV1) infections are acquired through direct person to person contact, most typically by a nongenital route. HSV 2 infections are usually acquired through sexual contact. This assay helps in determining recent exposure as well as previous exposure to HSV Types 1 & 2. |
| 1759 | 7928 | SV40 | IMMUNO HISTOCHEMISTRY | TISSUE IN 10% NEUTRAL BUFFERED FORMALIN / PARAFIN BLOCK (Site of biopsy, Clinical details & Primary Histopathology Report ) MANDATORY . IF TISSUE RECEIVED, TISSUE PROCESSING WILL BE CHARGED | A | India | Identification of Simian Virus 40 (SV-40) |
| 1760 | Z086K | SYNAPTOPHYSIN BLOCK | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Identification of neuronal tumors and tumors with neuroendocrine differentiation |
| 1761 | 5950T | TACROLIMUS | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) | EDTA WHOLE BLOOD (Labelled with time of collection & administration of drug with transplant history) | 2-8°C (7 days) | India | To determine the level of the drug tacrolimus in your blood in order to establish a dosing regimen, maintain therapeutic levels, and detect toxic levels |
| 1762 | 5950A | TACROLIMUS, EDTA/HEPARIN WHOLE BLOOD | LCMSMS | 1] Require EDTA/Heparin Whole Blood to be collected directly in relevant vaccutainers only [Label with time of collection and administration of drug, preferably with drug dose.] 2] Doctors contact details+clinical historyis mandatory. | 2-8ºC | India | This assay is useful in monitoring whole blood Tarcolimus concentration during therapy particularly in individuals coadministered CYP3A4 substrates, inhibitors or inducers. It helps to evaluate patient compliance and adjust dose while minimizing toxicity. |
| 1763 | 9215RFX | TB CULTURE POSITIVE REFLEX MDR BY PCR SEQUENCING | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & BACTEC MGIT 960 CULTURE + PCR – SEQUENCING | ANY SPECIMEN IN STERILE CONTAINER/ WHOLE BLOOD HEPARIN / TISSUE IN STERILE NORMAL SALINE + PURE AFB CULTURE | R | India | To help diagnose an infection caused by Mycobacteria: |
| 1764 | 1464 | TB CULTURE: ACID FAST BACILLI CULTURE MGIT | FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | ANY SPECIMEN OF PULMONARY ORIGIN IN STERILE CONTAINER/ | R | India | This test includes speciation of Mycobacterium. Rapid automated culture allows the early recovery Mycobacteria within 7 days as compared to conventional culture which takes 46 weeks. |
| 1765 | 2440 | TB PANEL (MYCO3 PCR, ADA, GAMMA INTERFERON) | POLYMERASE CHAIN REACTION / ENZYME IMMUNOASSAY / SPECTROPHOTOMETRY | SERUM, PLEURAL FLUID, ASCITIC FLUID, CSF. FOR GAMMA INTERFERON TO BE COLLECTED FROM SUNDAY TO THRUSDAY IN SPECIAL TBFERON TUBES(3) | FOR ADA TEST SERUM / FLUID SAMPLE : F, A/R FORTBFERON BLOOD TO BE COLLECTED IN TUBES ( TB-NIL, TB ANTIGEN & MITOGEN TUBE) FROM SUNDAY TO FRIDAY AND TRANSPORTED WITHIN 16 HRS OF COLLECTION AT AMBIENT TEMP | India | To help diagnose a infection caused by Mycobacteria |
| 1766 | 2406 | TBFERON (M TUBERCULOSIS IGRA) | Enzyme Linked Immnunosorbent assay | WHOLE BLOOD TO BE COLLECTED IN 5 ml BD ENDOTOXIN FREE HEPARIN TUBE PROVIDED BY SRL FROM SUNDAY TO FRIDAY AND TRANSPORTED WITHIN 12 HRS OF COLLECTION. | A | India | Latent tuberculosis infection (LTBI) is a noncommunicabl e asymptomatic condition that persists for many years and may progress to tuberculous disease. The main aim of diagnosing LTBI is to consider medical treatment for preventing the disease. This test is a measure of cell mediated immune response to antigens simulating the mycobacterial proteins. A positive result indicates that mycobacterium tuberculosis infection is likely but further medical & diagnostic evaluation is necessary. This test is usually negative in individuals vaccinated with Mycobacterium bovis BCG. |
| 1767 | 9506 | TBG (THYROXINE BINDING GLOBULIN) | CHEMILUMINESCENCE | SERUM | 2-8°C (48 hrs); F (>48 hrs) | India | The measurement of TBG can be used to establish the presence of TBG deficiency or excess suggested by abnormal Total serum T4 and T3 concentrations in the presence of normal free levels of these hormones. Definitive documentation of a TBG derangement may avoid unnecessary diagnostic procedures and therapy in individuals with harmless congenital TBG anomalies, and in their relatives. |
| 1768 | 2430 | TBRESIST (Note: This test is not applicable for MOTT) | PCR – SEQUENCING | SPUTUM/ CSF/ BAL/ PLEURAL FLUIDS/ CULTURE (SPECIMENS OF PATIENTS WITH AFB SMEAR LESS THAN 1+ ARE NOT ACCEPTABLE) + CLINICAL HISTORY | A | India | To help diagnose an infection caused by Mycobacteria |
| 1769 | 9909 | T-CELL GENE REARRANGEMENT | POLYMERASE CHAIN REACTION/ FRAGMENT ANALYSIS | BONE MARROW / EDTA WHOLE BLOOD / CLINICAL HISTORY TISSUE EMBEDDED IN PRAFFIN BLOCK OR IN NORMAL SALINE | A / A / A | India | This assay is useful to diagnose a lymphoma, monitor the progress of treatment of lymphoma and measure minimal residual disease (MRD), which can predict the likelihood of recurrence. |
| 1770 | RD1472 | TEL-PDGR BETA T(5;12) TRANSLOCATION | Nested RT-PCR | EDTA WHOLE BLOOD / BONE MARROW- EDTA | A | India | To detect TEL-PDGR BETA T(5;12) TRANSLOCATION seen in Hematolymphoid Neoplasms (CMML) |
| 1771 | 1635B | TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TDT) | FLOW CYTOMETRY | WB-EDTA + HEPARIN + SMEAR + CLINICAL HISTORY | A | India | Precursor cell marker |
| 1772 | 1635M | TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TDT) | FLOW CYTOMETRY | BONE MARROW-HEPARIN + SMEAR / EDTA + HISTORY | A | India | Precursor cell marker |
| 1773 | Z216K | TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TDT) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Classification of leukemias or lymphomas |
| 1774 | 3248FT | TESTOSTERONE, FREE | RADIO IMMUNOASSAY | SERUM (AGE + GENDER TO BE MENTIONED)-SAMPLE TO BE DRAWN IN THE MORNING HRS | 2-8°C (24 HRS); F ( >24 HRS) | India | Circulating Testosterone consists of testosterone bound to SHBG and the bioavailable (Free & Bound to Albumin). The latter is biologically active. In men approximately 40% of Total testosterone is albumin bound while in women approximately 20% is albumin bound. |
| 1775 | 3248 | TESTOSTERONE, FREE/TOTAL | CHEMILUMINESCENCE / RADIOIMMUNOASSAY | SERUM (Age + Gender to be mentioned)-SAMPLE TO BE DRAWN IN THE MORNING hrs | 2-8°C (24 HRS); F ( >24 HRS) | India | Circulating Testosterone consists of testosterone bound to SHBG and the bioavailable (Free & Bound to Albumin). The latter is biologically active. In men approximately 40% of Total testosterone is albumin bound while in women approximately 20% is albumin bound. |
| 1776 | 9963 | TETANUS IgG Antibodies | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 days); -20°C (>2 days) | India | To help diagnose an infection caused by Clostridium Tetani |
| 1777 | 2479 | THALASSEMIA; ALPHA THALASSEMIA MUTATION DETECTION (α3.7, α4.2, αFIL, αSEA, αTHAI ) | MULTIPLEX DNA POLYMERASE CHAIN REACTION | EDTA WHOLE BLOOD+CLINICAL HISTORY | A | India | This assay is useful for the detection of mutations which lead to alpha thalessemia. |
| 1778 | 2480 | THALASSEMIA; ALPHA THALASSEMIA MUTATION DETECTION (α3.7, α4.2, αFIL, αSEA, αTHAI ) PNDT | MULTIPLEX DNA POLYMERASE CHAIN REACTION | AMNIOTIC FLUID / CVS IN STERILE SALINE / FETAL BLOOD EDTA & EDTA WHOLE BLOOD FOR BOTH PARENTS + CLINICAL HISTORY | ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | To detect whether a mentioned mutation is present or not |
| 1779 | 2482 | THALASSEMIA; BETA THALASSEMIA MUTATION DETECTION (IVS1-5 G-C, 619 bp deletion, cd 8/9 + G, IVS1-1 G-T, 41/42 – TTCT) | MULTIPLEX DNA POLYMERASE CHAIN REACTION | EDTA WHOLE BLOOD+ CLINICAL HISTORY | A | India | This test detects 22 most common mutations linked to Beta Thalassemia in India & Middle East. |
| 1780 | 2483 | THALASSEMIA; BETA THALASSEMIA MUTATION DETECTION (IVS1-5 G-C, 619 bp deletion, cd 8/9 + G, IVS1-1 G-T, 41/42 – TTCT) PNDT | MULTIPLEX DNA POLYMERASE CHAIN REACTION | AMNIOTIC FLUID / CVS IN STERILE SALINE / FETAL BLOOD EDTA+EDTA WHOLE BLOOD FOR BOTH PARENTS + CLINICAL HISTORY | ONLY AMNIOTIC FLUID/ CVS AT 2-8 °C; REST A | India | This test detects 5 most common mutations linked to Beta Thalassemia in India & Middle East in the fetus using amniotic fluid or CVS as the sample. |
| 1781 | 9155U24 | THALLIUM, 24 HRS URINE | ICPMS | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL MUMBAI (NO PRESERVATIVE) ALIQUOT IN METAL FREE SCINTILLATION VIAL OR STERILE URINE CONTAINER WITH GREEN CAP BOTH AVAILABLE FROM SRL MUMBAI (NO PRESERVATIVE) VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (28 DAYS); F (28DAYS) | India | To screen for, detect, and monitor excessive exposure to thallium; |
| 1782 | 9155 | THALLIUM, BLOOD | ICPMS | IMPROVE/BD, SRL EDTA WHOLE BLOOD | 2-8°C (28 DAYS); F (28DAYS) | India | To screen for, detect, and monitor excessive exposure to thallium. |
| 1783 | 9155U | THALLIUM, URINE SPOT | ICPMS | SPOT URINE IN METAL FREE SCINTILLATION VIAL (NO PRESERVATIVE) OR STERILE PLASTIC URINE CONTAINER WITH GREEN CAP (NO PRESERVATIVE) BOTH AVAILABLE FROM SRL MUMBAI VACCUTAINER COLLECTION WILL NOT BE ACCEPTED | 2-8°C (28 DAYS); F (28DAYS) | India | To screen for, detect, and monitor excessive exposure to thallium |
| 1784 | 1563I | THEOPHYLLINE, SERUM | PETINIA | 1] Require SERUM sample.Mention time of drug dose. 2] Require Doctors Name and Contact details + Clinical history of the patient is mandatory. |
REFRIGERATED | India | Thallium is a byproduct of lead smelting and is basically used as a rodenticide. High doses lead to Alopecia, Peripheral neuropathy & Renal failure. This assay detects toxic thallium exposure. |
| 1785 | 4210 | THROMBIN TIME | CLOT BASED | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C+ CLINICAL HISTORY(DOUBLE CENTRIFUGED PLASMA)* | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | This assay is useful for identifying the cause of a prolonged PT / APTT / dRVVT tests. Prolonged TT is consistent with the presence of heparin like anticoagulants, hypofibrinogenemi a, dysfibrinogenemia, fibrin degradation products and antibody inhibitors of thrombin. |
| 1786 | 1751M | Thrombocheck Total | CLOT BASED / CHEMILUMINESCENCE/CHROMOGENIC ASSAY/ENZYME IMMUNOASSAY/PCR SEQUENCING | FASTING SERUM AND CITRATED PLATELET POOR PLASMA* 3 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY, EDTA Whole Blood | FROZEN (To be F immediately at -20°c & transported in dry ice) | India | Thrombophilia evaluations are usually performed to assess the need to extend anticoagulation, hence testing should be performed in a steady state, remote from the acute event. Laboratory assays to detect thrombophilic states include highly sensitive and specific test like molecular diagnosis, immunologic and functional assays. Many coagulation factors and inhibitors are affected during acute thrombosis, acute illnesses, inflammatory conditions, pregnancy certain medications. Antithrombin is decreased by heparin and acute thrombosis whereas protein C & S levels are increased during acute thrombosis, but decreased by warfarin. Lupus anticoagulants are also associated with thromboembolic disease states. |
| 1787 | 1253M | THROMBOCHEK PANEL (Protein C, Protein S, Lupus Antigoagulent, Antiphospholipid Antibody, Serum Homocystein, Anti Thrombin III Activity) [To be ordered with Factor V leiden (# 9894)] which will be charged separately | CLOT BASED / CHEMILUMINESCENCE/CHROMOGENIC ASSAY/ENZYME IMMUNOASSAY | FASTING SERUM /PLASMA (Centrfuge samples and remove SERUM or plasma from red blood cells as soon as possible to ensure accurate measurement.) AND CITRATED PLATELET POOR PLASMA* 2 VIALS- AT MINUS 20° C(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | HOMOCYSTEINE:2-8°C (48 hrs); F (>48 hrs),A/R/F AND F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | To help investigate the cause of a blood clot (thrombotic episode); to evaluate a prolonged partial thromboplastin time (PTT); to help determine the cause of recurrent miscarriages, or as part of an evaluation for antiphospholipid syndrome |
| 1788 | 4804 | THROMBOTIC RISK PANEL | CLOT BASED & ENZYME IMMUNOASSAY AND PCR SEQUENCING | PLATELet Poor Citrated plasma + SERUM/EDTA PLASMA AND EDTA WHOLE BLOOD | F (F immediately at -20°c) / A OR R | India | An imbalance between procoagulant system and regulatory mechanisms can cause excessive fibrin production leading to Thrombosis. These imbalances can be genetic or acquired or due to a combination of both leading to excessive fibrin formation at the site of injury with vessel occlusion and thrombus formation. Major risk factor for arterial thrombosis is atherosclerosis while for venous thrombosis, the risk factors include immobility, surgery, malignancy, hormone therapy, obesity and genetic factors. |
| 1789 | DT8100 | THYPROBE (TSH3G – UL, aTG, aTPO, FT4) | CHEMILUMINESCENCE | SERUM ( Age + Gender + Clinical History Required ) Mandatory | 2-8°C (48 hrs); F (>48 hrs) | India | To help diagnose and monitor autoimmune thyroid disorders. |
| 1790 | Z170K | THYROGLOBULIN | IMMUNO HISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY) IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Classification of thyroid carcinoma |
| 1791 | 3251 | THYROGLOBULIN | CHEMILUMINESCENCE | SERUM (CLINICAL HISTORY REQUIRED) | 2-8°C (72 hrs); F (2 Months) | India | This assay is useful as a follow up of patients with differentiated thyroid cancers after thyroidectomy & ablation. It also acts as an aid in determining the presence of thyroid metastasis to lymph nodes. In the absence of significant thyroid remnant, elevated or rising Tg levels are suspicious of recurrent or persistent disease. |
| 1792 | 1016 | THYROID ANTIBODIES (ANTI- THYROID PREOXIDASE abs. (also known as Anti Microsomal abs.) AND ANTI-THYROGLOBULIN ABS) | CHEMILUMINESCENCE | SERUM | 2-8°C (48 HRS); F ( >48 HRS) | India | Measurements of Antithyroid thyroglobulin and Antithyroid peroxidase antibodies are used for the diagnosis of Autoimmune thyroid disease. Positive thyroid autoantibody levels in patients with high normal or slightly elevated thyrotropin levels predicts future development of more profound hypothyroidism. Patients with postpartum thyroiditis with persistently elevated thyroid antibody levels have an increased likelihood of permanent hypothyroidism. |
| 1793 | Z231 | THYROID LESIONS | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Classification of thryoid carcinomas |
| 1794 | 9356 | THYROID STIMULATING HORMONE (TSH) > 1 MONTH | FEIA | Dried blood spots | Ambient | India | To help diagnose thyroid disorders |
| 1795 | Z065K | THYROID TRANSCRIPTION FACTOR- 1 | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | 2-8°C (48 hrs); F (>48 hrs) | India | Thyroid transcription factor 1aids in the classification of carcinomas of unknown origin |
| 1796 | Z166K | THYROID-STIMULATING HORMONE (TSH) | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK + SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | To help diagnose thyroid disorders and to monitor treatment of hypothyroidism and hyperthyroidism |
| 1797 | TISSUE | TISSUE FOR PROCESSING | HISTOPATHOLOGY | TISSUE FIXED IN 10%FORMALIN+ SITE OF BIOPSY + CLINICAL DETAILS (FOR BONE SPECIMENS ALSO SEND X-RAY) | A | India | Processing of biopsy sample for further analysis |
| 1798 | TISSUE1 | Tissue for processing (1block) | Histopathology | Formalin fixed tissue | A | India | Processing of biopsy sample for further analysis |
| 1799 | TISSUE2 | Tissue for processing (3blocks) | Histopathology | Formalin fixed tissue | A | India | Processing of biopsy sample for further analysis |
| 1800 | TISSUE3 | Tissue for processing (7blocks) | Histopathology | Formalin fixed tissue | A | India | Processing of biopsy sample for further analysis |
| 1801 | 2231M | TORCH IgM ANTIBODIES (4 Parameters) | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (4 DAYS); -20°C (>4 DAYS) | India | This panel tests for the common agents causing uterine infection leading to recurrent abortions and transmission from a pregnant woman to the fetus. This assay is useful as an indication of recent acquired / Congenital infection with Toxoplasma, Rubella, CMV & Herpes viruses. |
| 1802 | 2232 | TORCH PCR (Toxoplasma PCR, Rubella PCR, Cytomegalovirus PCR, Herpes Simple Virus PCR) | POLYMERASE CHAIN REACTION | EDTA PLASMA, CSF, AMNIOTIC FLUID, SERUM, NASOPHARYNGEAL SWAB; IF SERUM SENT,EDTA PLASMA IS MANDATORY | F | India | This assay is useful for detection of microorganisms such as Toxoplasma, Rubella, CMV and Herpes simplex particulary in pregnant women |
| 1803 | 5201 | TOTAL BILE ACIDS | SPECTROPHOTOMETRY | SERUM (10-12 HRS FASTING) AVOID LIPEMIC & HEMOLYSED SPECIMEN. (CLINICAL HISTORY , AGE & GENDER IS MANDATORY) | 2-8°C ( 7 DAYS); F ( >7 DAYS – 3 MONTHS) | India | Total bile acids are metabolized in the liver and can serve as a marker for normal liver function. Increases in serum bile acids are seen in patients with acute hepatitis, chronic hepatitis, liver sclerosis, liver cancer, and intrahepatic cholestasis of pregnancy. In Obstetric Cholestasis, concentrations greater than 15 μmol/L usually confirms the diagnosis in the absence of other hepatic disease. Bile acid concentrations greater than 40 μmol/L have been associated with increased fetal risk. |
| 1804 | 9354 | TOTAL GALACTOSE (TGAL)> 1 MONTH | Fluorimetry | Dried blood spots | Ambient | India | Screening for galactosemia |
| 1805 | 7522 | Toxoplasma gondii PCR | NESTED PCR | EDTA WHOLE BLOOD, CSF, AMNIOTIC FLUID, SERUM + CLINICAL HISTORY | A | India | Women infected with toxoplasmosis can transmit the infection across the placenta to their unborn baby. Most babies infected during pregnancy show no sign of toxoplasmosis when they are born, but they may develop learning, visual, and hearing disabilities later in life. This test is useful for the detection of Toxoplama in amniotic fuild and other samples. |
| 1806 | 9433 | TOXOPLASMA IGG AVIDITY | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (4 DAYS); -20°C (>4 DAYS) | India | Avidity test helps in discriminating primary infection & reinfection. Avidity indices less than 30% is an indication of current infection. |
| 1807 | 2233 | TOXORubella PCR (Toxoplasma PCR, Rubella PCR) | POLYMERASE CHAIN REACTION | EDTA PLASMA, CSF, AMNIOTIC FLUID, SERUM, NASOPHARYNGEAL SWAB | F | India | Women infected with toxoplasmosis can transmit the infection across the placenta to their unborn baby. Most babies infected during pregnancy show no sign of toxoplasmosis when they are born, but they may develop learning, visual, and hearing disabilities later in life. This test is useful for the detection of Toxoplama in amniotic fuild and other samples. |
| 1808 | 8030 | TPMT GENOTYPING | PCR SEQUENCING | EDTA WHOLE BLOOD | 2-8°C | India | Measurement of TPMT activity is encouraged prior to commencing the treatment of patients with Thiopurine drugs such as Azathioprine, 6 Mercaptopurine and 6Thioguanine. Patients with low or absent activity are at a heightened risk of druginduced bone marrow toxicity due to accumulation of the unmetabolised drug. |
| 1809 | 9504 | TPMT GENOTYPING+MTHFR MUTATION DETECTION PANEL | PCR SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY | A | India | To detect a thiopurine methyltransferase (TPMT) deficiency and determine your risk of developing severe side effects if treated with the class of immune-suppressing thiopurine drugs that includes azathioprine, mercaptopurine, and thioguanine. This test also looks for mutations in the MTHFR gene |
| 1810 | 1519HD | TRANSFERRIN | NEPHELOMETRY | 10 -12 HRS FASTING SERUM + CLINICAL HISTORY + (AGE & GENDER IS MANDATORY) | 2-8°C (7 DAYS); F (>7 -90 DAYS, IF F WITHIN 24 HRS. OF COLLECTION) | India | Transferrin is an iron binding serum protein which increases in response to iron deficiency in chronic diseases and due to other causes. This assay is useful for workup of patients suspected of having congenital transferrin abnormalities. It is an alternate test to TIBC. |
| 1811 | 9020 | TREPONEMA PALLIDIUM HEMAGGLUTINATION ASSAY (TPHA) | PASSIVE HEMAGGLUTINATION | SERUM | 2-8°C (7 DAYS); -20°C (>7 DAYS) | India | The serological diagnosis of syphilis is classified into two groups: Nontreponemal tests (RPR/VDRL) and Treponemal tests (TPHA/CLIA). Syphilis serology is a treponemal assay for the qualitative determination of antibodies to T. pallidum in human serum or plasma as an aid in the diagnosis of syphilis. Treponemal tests may remain reactive for life, even following adequate therapy thus a positive result suggests infection with Treponema pallidum but does not distinguish between treated and untreated infections. Therefore, the results of a nontreponemal assay, such as rapid plasma reagin, are needed to provide information on a patient’s disease state and history of therapy. Nontreponemal tests lack sensitivity in late stage of infection and screening with these tests alone may yield false positive reactions in various acute and chronic conditions in the absence of syphilis (biological false positive reactions). |
| 1812 | 4115 | Trypanosoma cruzi IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 DAYS) / >2 DAYS -20°C | India | To help diagnose an infection caused by Trypanosoma cruzi |
| 1813 | 3254I | TSH RECEPTOR ANTIBODIES | RADIO IMMUNOASSAY | SERUM | FROZEN: UP TO 2 WEEKS | India | This assay is used as an aid in the differential diagnosis and monitoring of Grave’s disease. Measurement of TSH receptor antibody in the last trimester of pregnancy in a patient with history of thyroid disease helps in assessing the risk of thyroid disease in neonates. |
| 1814 | 5433 | TUMOR NECROSIS FACTOR -ALPHA | ENZYME IMMUNOASSAY | SERUM | AFTER SEPARATION OF SERUM IMMEDIATELY STORE AT -20 °C | India | Evaluation of patients with suspected systemic infection, in particular infection caused by gram-negative bacteria. Evaluation of patients with suspected chronic inflammatory disorders, such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis |
| 1815 | 1215 | U1 snRNP ANTIBODIES | IMMUNOBLOT | SERUM | 2-8°C (14 days); -20°C (>14 days) | India | U1RNP antibody in combination with Smith antibody provides additional support for the diagnosis of SLE. A positive U1RNP antibody alone with the corresponding clinical history supports the diagnosis of Mixed connective tissue disease. |
| 1816 | RD1479 | UGTA1 GENE MUTATION | PCR-SEQUENCING | EDTA WHOLE BLOOD + CLINICAL HISTORY in specified format | A | India | Aids in identifying patients at risk for Irinotecan toxicity. UGT1A1 genotyping is also helpful for the diagnosis of Gilbert syndrome. It is recommended on patients to be treated with chemotherapy regimens including Irinotecan (Camptosar) and for patients with unconjugated hyperbilirubinemia. |
| 1817 | 4332 | URINARY OXALATE | ENZYMATIC SPECTROPHOTOMETRY | URINE -24 HOURS COLLECTED IN 10 ML CONC HCL & REFRIGERATE DURING COLLECTION. ( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY MANDATORY DETAILS.) | F (7 DAYS) | India | This assay is useful for monitoring therapy for kidney stones and identifying increased urinary oxalate as a risk factor for stone formation. It also helps in the diagnosis of Primary or Second ary hyperoxaluria. Ingestion of Ascorbic acid may falsely elevate urinary oxalate excretion. |
| 1818 | 3316U | URINARY VMA (VANILYL MANDELIC ACID) | SPECTROPHOTOMETRIC | 20ML OF URINE ALIQUOT FROM THE COLLECTED 24HRS URINE SPECIMEN TO BE SHIPPED STRICTLY IN FROZEN CONDITION (Do not consume bananas, pineapple, chocolates, coffee, ice creams, high diet in cereals and vanilla, potatoes and B-Complex, Vitamins 48 hours pr | F | India | Elevated values of VMA along with other catecholamine metabolites are suggestive of catecholamine secreting tumor like Neuroblastoma, Pheochromocytom a and other Neural crest tumors. VMA levels may also be useful in monitoring patients who are also treated. Elevated levels are suggestive of Pheochromocytom a but not diagnostic. |
| 1819 | 5002 | URINE SUPERSATURATION PANEL (CALCIUM, MAGNESIUM,OXALATE,URIC ACID AND PHOSPHORUS, FROM 24hrs URINE ) | SPECTROPHOTOMETRY, ENZYMATIC SPECTROPHOTOMETRY | ON 2 DIFFERENT DAYS URINE SAMPLES TO BE COLLECTED. 1- FOR CALCIUM, MAGNESIUM, URIC ACID & PHOSPHORUS 24 HRS URINE COLLECTED WITHOUT PRESERVATIVE & THROUGHOUT COLLECTION REFRIGERATE URINE SPECIMEN & SEND FROZEN ALIQUOTE TO SRL LAB. 2- FOR OXALATE 24 HOURS URINE COLLECTED IN 10 ML CONC HCL & SEND FROZEN ALIQUOTE TO SRL LAB ( MENTION 24 HRS. TOTAL URINE VOLUME ON TRF ALONG WITH PATIENT AGE, GENDER AND CLINICAL HISTORY MANDATORY DETAILS.) | F | India | To help determine the underlying reason for developing a kidney stone |
| 1820 | 5007 | UTI SCREENING PANEL (CBC,ESR,GLUCOSE FASTING, URINALYSIS,URINE CULTURE/SENSITIVITY) | AUTOMATED CELL COUNTER, AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS) / MANUAL (MODIFIED WESTERGREN) /SPECTROPHOTOMETRY/DIPSTICK& MICROSCOPY/CULTURE | EDTA WB/CITRATE WB BLACK TOP /FASTING PLASMA FLOURIDE & URINE + 2-3 SMEARS + (AGE & GENDER IS MANDATORY)/URINE IN STERILE CONTAINER | FLUORIDE PLASMA : 2-8°C (3 DAYS); URINE : 2-8°C(24 HRS) | India | To help diagnose urinary tract infection |
| 1821 | DT3203 | VACCICHEQ (HBsAb, VZV IgG, MUMPS IgG, MEASLES IgG,Rubella IgG) | Chemiluminescent Microparticle Immunoassay (CMIA)/ENZYME IMMUNOASSAY | SERUM | R/F | India | To check the status of mentioned vaccines |
| 1822 | 3360H | VALPROIC ACID | CHEMILUMINESCENCE | SERUM (JUST BEFORE THE NEXT DOSE; USUALLY EARLY IN THE MORNING;TO CONFIRM THAT AN ADEQUATE DOSE IS PRESCRIBED BEFORE BEDTIME) | 2-8°C (48 HRS); F ( >48 HRS) | India | Valproic Acid is used for the treatment of simple and complex absence seizures and in combination with other anticonvulsants for treatment of generalized seizures. This assay is useful for monitoring therapy, assessing compliance and evaluating potential toxicity. |
| 1823 | 4197 | VANCOMYCIN | CHEMILUMINESCENCE | SERUM [IT IS MANDATORY TO MENTION ON THE TRF WHETHER IT IS A TROUGH LEVEL (PRE-DOSE) OR PEAK LEVEL (POST-DOSE) SAMPLE]. | 2-8°C (48 HRS); F (> 48 HRS) | India | Vanconmycin is an antibiotic used to treat infections by Gram Positive organisms resistant to Betalactam antibiotics. Vancomycin is associated with Nephrotoxocity & Ototoxicity, hence therapeutic monitoring is essential specially in patients with reduced renal function, aggressive or prolonged Vancomycin therapy and comedication with other Nephrotoxic agents. Toxic effects have resulted when serum concentrations of vancomycin reach 80 to 100 μg/mL and are rarely seen when serum levels are maintained below 30 μg/mL. If an aminoglycoside is being used concurrently, the potential for toxicity is additive. |
| 1824 | 8125 | VARICELLA (HERPES) ZOSTER IGG ANTIBODIES, CSF | EIA/Biochemical | Serum & CSF | FROZEN | India | To help diagnose an infection caused by VARICELLA (HERPES) ZOSTER |
| 1825 | 9220RFX | VDRL REFLEX TPHA CONFIRMATION | FLOCCULATION & PASSIVE HEMAGGLUTINATION | SERUM | 2-8°C (3 days); -20°C (>3 days) | India | To screen for or diagnose an infection with the bacterium Treponema pallidum, which causes syphilis, a sexually transmitted disease (STD) |
| 1826 | Z047K | VIMENTIN | IMMUNOHISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK+ SITE OF BIOPSY AND CLINICAL DETAILS MANDATORY.IF TISSUE RECEIVED IT WILL BE CHARGED FOR TISSUE PROCESSING | A | India | Vimentin is the major intermediate filament in a variety of mesenchymal cells, including endothelial cells, all fibroblastic cells, macrophages, Sertoli cells, melanocytes, lymphocytes and ovarian granulosa cells. Vimentin is found in all types of sarcomas and lymphomas. Positive staining for vimentin is seen in most cells of fibrosarcomas, liposarcomas, malignant fibrous histocytomas, angiosarcomas, chondrosarcomas and lymphomas. All melanomas and Schwannomas are strongly vimentin-positive. |
| 1827 | 9887 | VIRAL PNEUMONIA PANEL I (Influenza A RNA, Influenza B RNA, Para Influenza, RSV, Enterovirus RNA) | MULTIPLEX POLYMERASE CHAIN REACTION | SWAB (THROAT SWAB, NASOPHARYNGEAL SWAB, RESPIRATORY SECRETIONS, BAL) | F | India | To help diagnose a viral penumonia caused by mentioned virus |
| 1828 | 9888 | VIRAL PNEUMONIA PANEL II (Adenovirus DNA, Cytomegalovirus DNA, HSV 1 & 2) | POLYMERASE CHAIN REACTION | SWAB (THROAT SWAB, NASOPHARYNGEAL SWAB, RESPIRATORY SECRETIONS, BAL) | F | India | To help diagnose a viral penumonia caused by mentioned virus |
| 1829 | 3511 | VITAMIN A, SERUM/EDTA PLASMA | HPLC | 1] Require 12-14 hrs fasting SERUM sample (to be collected in plain tube not in gel tube) or Plasma EDTA. 2] It should be light protected (wrap in aluminum foil) and to be stored to freeze immediately. 3] Doctors Name and Contact details + Clinical history of the patient is mandatory. 4] Patients must have no alcohol and must be without Vitamin A supplement for 24 hrs. |
F [Serum 43 days,EDTA Plasmsa 8 days at -18ºC ] | India | This assay is useful for diagnosing Vitamin A deficiency & toxicity and for monitoring therapy. It evaluates persons with intestinal malabsorption of lipids. Vitamin A deficiency can leads to blindness whereas chronic intoxication can affect several organs. Known HIV positive patients with Vitamin A deficiency show increased disease progression and mortality. |
| 1830 | 3512 | VITAMIN B1, SERUM/EDTA PLASMA | HPLC | 1] Require 12-14 hrs fasting SERUM sample (to be collected in plain tube not in gel tube) or Plasma EDTA. 2] Specimen should be light protected (wrap tube in aluminum foil) and should be stored to freeze immediately. 3] Doctors Name and Contact details+ Clinical history of the patient is mandatory.4] Patients must have no alcohol and must be without Vitamin B1 supplement for 24 hrs. |
F | India | Assessment of thiamine deficiency |
| 1831 | 3513 | VITAMIN B2, SERUM/EDTA PLASMA | HPLC | 1] Require 12-14 hrs fasting SERUM sample (to be collected in plain tube not in gel tube) or Plasma EDTA. 2] Specimen should be light protected (wrap tube in aluminum foil) and should be stored to freeze immediately. 3] Doctors Name and Contact details+ Clinical history of the patient is mandatory. 4] Patients must have no alcohol and must be without Vitamin B2 supplement for 24 hrs. |
F | India | Vitamin B2 is involved in metabolism of fats, carbohydrates and proteins. The clinical manifestations of deficiency are nonspecific and include mucocutaneous lesions of the mouth and skin, corneal vascularization, anemia, and personality changes. |
| 1832 | 3514 | VITAMIN B6, SERUM/EDTA PLASMA | HPLC | 1] Require 12-14 hrs fasting SERUM sample (to be collected in plain tube not in gel tube) or Plasma EDTA. 2] Specimen should be light protected (wrap tube in aluminum foil) and should be stored to freeze immediately. 3] Doctors Name and Contact details+ Clinical history of the patient is mandatory.4] Patients must have no alcohol and must be without Vitamin B6 supplement for 24 hrs. |
F | India | Vitamin B6 is a cofactor in many metabolic pathways including heme synthesis. Vitamin B6 deficiency may be observed in patients with metabolic disorders, secondary to therapeutic drug use, or alcoholism. Deficiency effects the function of the immune system. |
| 1833 | 3516 | VITAMIN C, EDTA Plasma | HPLC | 1] Require 12-14 hrs fasting Plasma EDTA only. 2] Specimen should be light protected (wrap in aluminum foil) and should BE STORED TO FREEZE IMMEDIATELY. 3] Require Doctors Name and Contact details+ Clinical history of the patient is mandatory. 4] Patients must have no alcohol and must be without Vitamin C supplement for 24 hrs. |
F | India | Vitamin C is an antioxidant involved in connective tissue metabolism, drug metabolizing systems and mixed function oxidase systems. Deficiency causes Scurvy. This assay is useful in the diagnosis of Vitamin C deficiency and as an aid to deter excessive intake. |
| 1834 | 3517 | VITAMIN E, SERUM/EDTA PLASMA | HPLC | 1] Require 12-14 hrs fasting sample, if SERUM (to be collected in plain tube not in gel tube) or Plasma EDTA. 2] It should be light protected (wrap in aluminum foil) and should be stored to freeze immediately. 3] Doctors Name and Contact details + Clinical history of the patient is mandatory. 4] Patients must have no alcohol and must be without Vitamin E supplement for 24 hrs. |
[Serum and EDTA Plasmsa, 15 days at -18ºC] | India | Evaluation of individuals with motor and sensory neuropathies. Monitoring vitamin E status of premature infants requiring oxygenation. Evaluation of persons with intestinal malabsorption of lipids. |
| 1835 | 7523 | VITAMIN K1, SERUM | HPLC | 1] Require 3.5mL of 12 hrs fasting SERUM sample (to be collected in plain tube not in gel tube). 2] It should be light protected (wrap in aluminum foil) and should be stored to freeze immediately. 3] Doctors Name and Contact details + Clinical history of the patient is mandatory. |
frozen | India | Vitamin K is required as a cofactor for the synthesis of Factors II, VII, IX & X and protein C & S. Deficiency leads to bleeding. Warfarin acts as an anticoagulant because it is a Vitamin K antagonist. |
| 1836 | 7101 | VITAMIN PLUS XL | CHEMILUMINESCENCE | SERUM ( Age+Gender mandatory) | 2-8°C (48 hrs); F (>48 hrs) | India | Assessment of Vitamins deficiency |
| 1837 | 9050 | VON WILLEBRAND FACTOR ANTIGEN, PLASMA | IMMUNOTURBIDIMETRY-STA COMPACT | FASTING, CITRATED PLATELET POOR PLASMA* – AT MINUS 20° C*(DOUBLE CENTRIFUGED PLASMA)* + CLINICAL HISTORY | F (TO BE F IMMEDIATELY AT -20°C & TRANSPORTED IN DRY ICE) | India | von Willebrand factor is important for plateletplatelet & plateletvessel hemostatic interactions. Decreased vWF antigen is seen in Congenital von Willebrand disease (vWD) and in acquired conditions associated with monocloncal gammopathies, lymphoproliferative disorders and autoimmune diseases. This assay is useful for the diagnosis of vWD and its subtyping. It also helps in differentiating |
| 1838 | 9052 | VON WILLEBRAND FACTOR, PLASMA | ENZYME IMMUNOASSAY | PLASMA (CITRATE) | 20+/-5°C (8 HRS); -20°C (1MONTHS) | India | To diagnose von Willebrand disease (VWD) |
| 1839 | 8762 | VZV PCR | PCR | EDTA WHOLE BLOOD/CSF/VESICLE SWAB IN STERILE SALINE/CSF/AMNIOTIC FLUID/CVS | A | India | Varicellazoster virus (VZV) causes both Varicella (Chickenpox) and Herpes zoster (Shingles). VZV produces a generalized vesicular rash on the dermis (chickenpox) in normal children, usually before 10 years of age. After primary infection with VZV, the virus persists in latent form and may emerge, usually in adults 50 years of age and older clinically to cause a unilateral vesicular eruption, generally in a dermatomal distribution (shingles). VZV DNA is detected in cerebrospinal fluid from patients with central nervous system disease caused by this virus. |
| 1840 | RD1302 | WARFARIN SENSITIVITY BY GENOTYPING | PCR-SEQUENCING | EDTA WHOLE BLOOD | A/R | India | To determine CYP2C9 and/or VKORC1 genetic variations and the dose of warfarin |
| 1841 | 9121 | WEIL FELIX | TUBE AGGLUTINATION | SERUM | 2-8°C (2DAYS); -20°C (>2DAYS) | India | This test detects infection due to Rickettsial organisms. Rickettsiae are fastidious bacterial organisms that are maintained in nature through a cycle involving reservoirs in mammals and insect vectors. A 4 fold rise in titer is diagnostic of infection. |
| 1842 | 9960 | WEST NILE VIRUS IGG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (14 DAYS); -20°C (>14 DAYS) | India | To help diagnose an infection caused by West Nile virus (WNV) |
| 1843 | 9959 | WEST NILE VIRUS IGM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (14 DAYS); -20°C (>14 DAYS) | India | To help diagnose an infection caused by West Nile virus (WNV) |
| 1844 | 3012 | WESTERN BLOT-HIV -1 ANTIBODIES(Confirmation) INDICATES- HIV -2 | IMMUNOBLOT | SERUM / EDTA (PLASMA MAY BE ACCEPTABLE) | 2-8°C (7 DAYS) ,>7 DAYS -20°C | India | This is a confirmatory test for HIV. Specificity when combined with ELISA exceeds 99.9%. Indeterminate results may be seen with early HIV 1/2 infections, Autoimmune diseases, pregnancy and recent Tetanus Toxoid administration |
| 1845 | RD1493 | WHOLE EXOME SEQUENCING – – SOLO | Next Generation Sequencing | EDTA WHOLE BLOOD (PROBAND & PARENT) + CLINICAL HISTORY | A | India | WES is a test that looks at the genetic information contained in all of our 20,000 genes (and their multiple exons) in one single test. |
| 1846 | Z119K | WILM’S TUMOR PROTEIN 1 (WT1) | IMMUNO HISTOCHEMISTRY | TISSUE IN 10%FORMALIN / PARAFFIN BLOCK -SITE OF BIOPSY & CLINICAL DETAILS MANDATORY IF TISSUE RECD. TISSUE PROCESSING WILL BE CHARGED | A | India | Wilms tumor susceptibility gene 1 protein (WT1) has diagnostic utility in the distinction of mesothelioma from adenocarcinoma in tissue sections of pleural tumors. WT1 diffusely stains most ovarian serous carcinomas and all Wilms tumors. |
| 1847 | RD1407 | WT1 MUTATION DETECTION | PCR – Sequencing | EDTA WHOLE BLOOD / EDTA BONE MARROW + CLINICAL HISTORY | A | India | Wilm’s tumour tumor suppressor gene1 (WT1) causes an embryonic malignancy of the kidney. It occurs in both sporadic and hereditary forms. Inactivation of WT1 causes Wilm’s tumour, and DenysDrash syndrome (DDS), leading to nephropathy and genital abnormalities |
| 1848 | RD1324EP | XPERT MTB / RIF ( GENE EXPERT) – EXTRAPULMONARY | REAL TIME PCR ON GENEXPERT PLATFORM | PUS, PLEURAL FLUID , ASITIC FLUID/GASTRIC ASPIRATE, TISSUE, CSF, PERITONEAL FLUID, PERICARDIAL FLUID, SYNOVIAL/KNEE JOINT FLUID, ABSCESS ASPIRATE | A/R | India | To help diagnose an infection caused by Mycobacteria, Extrapulmonary |
| 1849 | 9507UL | XPERT PLUS | Semi nested Real time PCR on GeneXpert platform / FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | SPUTUM / BAL / ENDOMETRIAL TISSUE | A | India | #N/A |
| 1850 | 9507EPUL | XPERT PLUS | Semi nested Real time PCR on GeneXpert platform / FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE | SPUTUM / BAL / ENDOMETRIAL TISSUE | A | India | #N/A |
| 1851 | 7713UL | XPERT TOTAL | Semi nested Real time PCR on GeneXpert platform / FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE /BACTEC MGIT-960 METHOD | SPUTUM / BAL / ENDOMETRIAL TISSUE | A | India | #N/A |
| 1852 | 7713EPUL | XPERT TOTAL – EXTRAPULMONARY | Semi nested Real time PCR on GeneXpert platform / FLUORESCENT STAIN / ZIEHL NEELSEN STAIN & MGIT 960+LJ CULTURE /BACTEC MGIT-960 METHOD | ENDOMETRIAL TISSUE/PUS/CSF | A | India | To help diagnose an infection caused by Mycobacteria, Extrapulmonary |
| 1853 | RD1440 | Y-CHROMOSOME MICRODELETION PCR | MULTIPLEX PCR | EDTA WHOLE BLOOD | A | India | Y chromosome microdeletion (YCM) is a family of genetic disorders caused by missing gene(s) in the Y chromosome. YCM is known to be present in a significant number of men with reduced fertility. In men with reduced sperm production some form of YCM has been detected and varies from oligozoospermia, significant lack of sperm, or azoospermia, complete lack of sperm. |
| 1854 | 5702 | YERSINIA CULTURE | CULTURE | STOOL IN STERILE CONTAINER | R | India | To help diagnose an infection caused by Yersinia enterocolitica |
| 1855 | 3329IG | YERSINIA ENTEROCOLITICA IgG | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 DAYS); -20°C (>2 DAYS) | India | To help diagnose an infection caused by Yersinia enterocolitica |
| 1856 | 3329IM | YERSINIA ENTEROCOLITICA IgM | Enzyme Linked Immnunosorbent assay | SERUM | 2-8°C (2 DAYS); -20°C (>2 DAYS) | India | To help diagnose an infection caused by Yersinia enterocolitica |
| 1857 | 4965 | ZAP-70 | FLOW CYTOMETRY | EDTA WHOLE BLOOD / HEPARIN WHOLE BLOOD + DIRECT SMEARS + CLINICAL HISTORY | A | India | Prognostic marker for CLL |
| 1858 | 9145U24 | ZINC, 24 HR URINE | FAAS WITH D2 CORRECTION | 24 HR URINE IN METAL FREE JERRY CAN AVAILABLE FROM SRL (NO PRESERVATIVE). 24 HRS VOLUME SHOULD BE COMPULSARILY SPECIFIED . FIRST SHAKE THE CAN AND TAKE THE 10-20 ML ALIQUOT. IN METAL FREE SCINTILLATION BOTTLE AVAILABLE FROM SRL (NO PRESERVATIVE)THE MEASUREMENT OF URINE VOLUME SHOULD BE DONE AFTER ALIQUOTING. | 2-8°C (5 DAYS); F ( >5 – 30 DAYS) | India | Zinc is an essential element which acts as a critical cofactor in various enzyme systems and is required for active wound healing. Zinc deficiency occurs due to lack of dietary absorption or loss after absorption. Zinc excess is not a major clinical concern. The only known effect of excessive zinc ingestion is interference with copper absorption leading to hypocupremia. This assay is useful for identifying the cause of abnormal serum zinc. |
| 1859 | 9145 | ZINC, SERUM | FAAS WITH D2 CORRECTION | COLLECT WHOLE BLOOD IN SPECIAL GREINER VACCUTAINER WITH GEL AND YELLOW RING IN THE CAP AVAILABLE FROM SRL CENTRIFUGE DO NOT SEPERATE SERUM. SERUM MORNING FASTING SPECIMEN SHOULD BE COLLECTED. | 2-8°C (7 DAYS); F ( >7 – 30 DAYS) | India | Zinc is an essential element which acts as a critical cofactor in various enzyme systems and is required for active wound healing. Zinc deficiency occurs due to lack of dietary absorption or loss after absorption. Zinc excess is not a major clinical concern. The only known effect of excessive zinc ingestion is interference with copper absorption leading to hypocupremia. This assay helps to detect zinc deficiency. Elevated serum zinc is of minimal clinical interest. |
| 1860 | 9145U | ZINC, URINE SPOT | FAAS WITH D2 CORRECTION | SPOT URINE IN METAL FREE SCINTILLATION BOTTLE AVAILABLE FROM SRL (NO PRESERVATIVE) | 2-8°C (5 DAYS); F ( >5 – 30 DAYS) | India | Zinc is an essential element which acts as a critical cofactor in various enzyme systems and is required for active wound healing. Zinc deficiency occurs due to lack of dietary absorption or loss after absorption. Zinc excess is not a major clinical concern. The only known effect of excessive zinc ingestion is interference with copper absorption leading to hypocupremia. This assay is useful for identifying the cause of abnormal serum zinc. |
| 1861 | 1956 | NSCLC THERAPY PANEL ( RD1405 [EGFR MUTATION DETECTION] + 6028F [ALK (EML4-ALK) FISH] [+] 6032F [ROS1 GENE REARRANGEMENT BY FISH]) |
Pyrosequencing, FISH | TISSUE IN NORMAL SALINE /PARAFFIN BLOCK/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS+ CLINICAL HISTORY | 2, 5:0930 HRS | India | 0 |
| 1862 | RD1421T | ONCOBRCA-NEXT ( BRCA3 [BRCA 1 GENE MUTATIONS] BRCA4 [BRCA2 GENE MUTATIONS ) |
NGS | Paraffin Block | A | India | 0 |
| 1863 | Z412K | PD-L1 (SP 142) | Ventana IHC | FFPE block + CLINICAL HISTORY | A | India | 0 |
| 1864 | 4555 | COLORECTAL CANCER PROFILE | PCR | TISSUE IN FORMALIN/PARAFFIN BLOCK/UNSTAINED SLIDES – 5 NOS/CELL BLOCKS+CLINICAL HISTORY | A | India | 0 |
| 1865 | 8043 | ACUTE LEUKEMIA DIAGNOSTIC & PROGNOSTIC PANEL | Flowcytometry, Cytogenetics, FISH, PCR | BM-Heparin, EDTA WB, Clinical History | A | India | 0 |
| 1866 | 7899 | ALL CYTOGENETICS PANEL | CELL CULTURE/FISH | BONE MARROW/WB WB (≥70% blast cell) SODIUM HEPARIN SPECIMEN TO REACH US WITHIN 48 HRS + CLINICAL HISTORY IN SPECIFIED FORMAT, BLOOD PICTURE(CBC REPORT) AND MEDICATION OF THE PATIENT ON THE TRF IN SPECIMEN COLUMN | A | India | 0 |
| 1867 | 2015 | MINIMAL RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY | Flowcytometry | BM-EDTA + Clinical history (Sample should reach within 24hrs of collection). Sample should reach laboratory preferably within 24 hrs of collection. Filled history sheet, initial Immunophenotyping report/data | Refrigerated (2-8*C) | India | 0 |